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Abstract 
          The N-terminally pyroglutamyl-modified β-amyloid (Aβ) peptides are found in 
abundance in the pathological Alzheimer disease (AD) brain deposits. Such 
modification not only increases the hydrophobic properties of a given molecule, but also 
plays a protecting role against proteolytic degradation. This project involved the study 
of the human type I and type II pyroglutamyl peptidases and their involvement in Aβ 
processing in AD. 
          Human PcpI has been successfully overexpressed in Escherichia coli strain and 
purified to homogeneity. The protein displayed significant instability in vitro.  
To overcome this problem a number of methods were employed such as screening for 
an optimal protein expression system and buffer composition, site-directed mutagenesis 
and chemical modification of selected surface residues. This resulted in the selection of 
the HEPPS buffer system as providing the most stabilising conditions for human PcpI. 
Improvement in the protein stability enabled initial crystallisation experiments and the 
identification of favourable conditions for crystal production. Further optimization of 
this process is needed in order to obtain good quality crystals which are required for 
structural study. 
          The study on human PcpII involved an extensive screening for optimal expression 
conditions in bacterial, baculovirus/insect and mammalian systems. The truncated PcpII 
isoform PcpII/S62-H1024, which lacks the N-terminal transmembrane domain, was 
successfully expressed and secreted from the HEK 293T cell line using three different 
pOPIN-based constructs. Moreover, homology modelling of human PcpII catalytic 
domain was performed, which helped to gain an insight into the three-dimensional 
structure of the protein and its mode of substrate binding. 
          Lastly, immunohistochemical staining of the human AD brain tissue sections was 
performed to compare the level and distribution of PcpI and PcpII enzymes between 
diseased and control cases. The results confirmed that the neurodegenerative conditions 
lead to the increased synthesis of both enzymes in the cortical AD tissues. Additionally 
PcpI was shown to be able to participate in the degradation of pGlu-modified Aβ 
peptides. 
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Chapter 1 – Introduction 
1.1. Introduction to Alzheimer’s disease 
1.1.1. Disease of 20th century 
          Twentieth century brought rapid advances in medicine and an increase in the 
awareness of the beneficial aspects of a hygienic lifestyle, nutrition and prophylaxis. 
Modern diagnostic services and intensive research focused on drug discovery and 
medical treatments, which significantly contributed to human health and longevity.  
In the industrialized countries the average life expectancy has nearly doubled over the 
20
th
 century from 40-45 years to 78 years for both males and females (Kinsella, 1992). 
Extended life time is undoubtedly a priceless value, but unfortunately it has also some 
negative consequences, such as prevalence of different diseases and ailments 
characteristic for the older age.  One of leading death causes is Alzheimer’s disease 
(AD) considered to be the most common type of dementia and often referred as  
a disease of the 20
th
 century (Blennow et al., 2006). Current estimations show that there 
are around 37 million people living with dementia worldwide with the number 
increasing to 66 million by 2030 (ADI, 2010). AD accounts for 50-80% of dementia 
cases in developed countries and it is reported to be a source of massive economic 
burden (Alzheimer's Association, 2010). The disease is often associated with ageing and 
it affects around 12% of people at the age of 65 and then the number increases 
exponentially with women being more likely to develop AD and other dementia types 
(Kawas and Corrada, 2006). Alzheimer’s with lesser frequency is also diagnosed in 
younger individuals before the age of 65 and therefore it is differentiated as a late-onset 
(sporadic) and early-onset (familial, FAD) type (Seltzer and Sherwin, 1983). Both 
forms may have distinct aetiology (1.1.4.1) and display varied clinical features (Seltzer 
and Sherwin, 1983; Koedam et al., 2010). AD sufferers struggle with progressive 
decline in cognitive functions, memory impairment, problems with speech and 
understanding, changes in mood and personality as well as difficulties in basic activities 
of daily living which finally leads to a complete loss of functional independence.  
After diagnosis the clinical duration of the disease takes on average 8 to 10 years (Bird, 
2008). 
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1.1.2. Pathology of Alzheimer’s 
          The disease was named after psychiatrist Alois Alzheimer, who aptly associated 
unusual changes in the brain anatomy with aggressive dementia symptoms in one of his 
patients (Alzheimer, 1907). Alzheimer performed post-mortem brain tissue 
examination, which revealed common symptoms of the disease such as brain atrophy, 
thick neurofibrillary tangles, minute cortical senile plaques and disintegrated neuronal 
cells (Alzheimer, 1907). These structural abnormalities are widespread throughout the 
neocortical and sub-cortical grey matter, hippocampus and amygdala regions (Winkler 
et al., 1998; Murdoch, 2010). Brain neuropathological lesions and processes have 
become indicative of AD and constitute the basis of diagnostic criteria. 
1.1.2.1. Changes to AD brain  
          Accurate diagnosis of Alzheimer’s sometimes may be problematic because some 
neuropathological lesions and processes are similar for a diseased and cognitively 
normal ageing brain (Bancher et al., 1989; Munoz and Feldman, 2000; Guillozet et al., 
2003). One of those common features is whole-brain shrinkage (figure 1.1) which 
accelerates in later adulthood by an average of 0.2% to 0.7% per year in healthy elderly 
patients (Scahill et al., 2003; Enzinger et al., 2005) and from 1% to 4% per year in AD 
patients (Wang et al., 2002a; Schott et al., 2005). Higher brain atrophy rate is related to 
an increased risk of dementia as a result of progressive loss of neurons and supporting 
cells. This phenomenon is thought to be in direct relationship with neurofibrillary 
pathology affecting cellular functioning (1.1.2.2) or as a result of not fully understood 
cellular events leading to apoptotic cell death (Stadelmann et al., 1999; Raina et al., 
2001; Zhao et al., 2003). Neuronal deterioration is thought to start years before the 
symptoms of dementia occur and in the AD case it was observed to be the most 
prominent in limbic system areas such as the medial temporal lobe and neocortex 
(Mungas et al., 2002; Karas et al., 2004). These areas are particularly sensitive as the 
temporal lobe is a home for the hippocampus, which is the region essential for short- 
and long-memory function as well as spatial navigation and behaviour. The neocortex is 
involved in control of conscious thought, language, motor functions and sensory 
perception (figure 1.1).  
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Figure 1.1. Juxtaposition of Alzheimer's disease vs. normal brain. Graphical 
comparison of a vertical slice of an Alzheimer’s (left) and a vertical slice of a normal 
brain (right). The AD brain displays severe atrophy and surface folding due to neuronal 
degradation. Massive ventricular enlargement can be observed as large holes in the 
brain cross-section. Structural damage mainly affects cortical and hippocampal areas 
which are involved in memory, language and behavioural control. Taken from 
www.sciencephoto.com. 
 
 
          Neuronal loss in the pathological brain has rather a focal character and in 
advanced disease stages can reach even 90% of the normal nerve cell population 
(Gomez-Isla et al., 1996). AD brain, due to general shrinkage, has been found to be 
underweight comparing to healthy one and could weigh less than 1 kg (Murdoch, 2010). 
An important pathological phenomenon observable in the early AD phase is an 
enlargement of the ventricular system containing the cerebrospinal fluid (figure 1.1) 
(Thompson et al., 2004). This occurs not only in AD but also in other disorders like 
schizophrenia, mild cognitive impairment, HIV/AIDS as well as to some extent in 
normal ageing brain (Thompson et al., 2004; Styner et al., 2005; Thompson et al., 
2006).  
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          Determination of AD predisposition on the basis of observable brain changes is 
still challenging, however recent discoveries seem to be extremely promising on this 
subject. It has been reported that very subtle cortical thinning may be a premorbid 
biomarker of AD and can be shown in asymptomatic patients even 10 years before the 
appearance of severe neurodegeneration using magnetic resonance imaging (MRI) 
(Dickerson et al., 2011). MRI could be also applied to analyze hippocampal and 
entorhinal cortex morphology or degeneration of basal forebrain in people with mild 
cognitive impairment (MCI) or early dementia symptoms (Teipel et al., 2005; 
Devanand et al., 2007). Moreover, ventricles volume is evaluated using MRI and is 
strongly related to the changes in the surrounding structures. This correlation is 
considered to be indicative for AD tissue deterioration and can provide measures for the 
assessment of the disease progression and therapy effectiveness (Thal et al., 2006; 
Carmichael et al., 2007). Aforementioned examination methods seem particularly worth 
further improvement considering that the diagnosis of AD is usually given too late to 
counteract already advanced neuropathological changes. 
1.1.2.2. Neurofibrillary tangles (NFTs) 
          Specific features accepted as diagnostic criteria in AD determination are known 
as senile plaques (1.1.2.3) and NFTs (figure 1.2). Other often observed findings are 
dystrophic neurites called neuropil threads (NTs) (figure 1.2). Interestingly, both 
neuritic plaques and NFTs can also be observed in young patients with Down syndrome 
(DS) and in marginal amounts in cognitively healthy individuals (Bancher et al., 1989; 
Cork, 1990; Davis et al., 1999; Guillozet et al., 2003). The changes are thought to be  
a natural consequence of ageing and may be responsible for mild memory disturbance. 
Therefore, the level of morphological changes and brain distribution of these 
abnormalities are a sign of pathology and determine the stage of AD (Braak and Braak, 
1991). 
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Figure 1.2. Senile plaques, neuropil threads (NTs) and neurofibrillary tangles (NFTs) in 
AD middle frontal gyrus. The image shows the result of the immunostaining of the tau 
protein revealing its accumulation within neuronal cytoplasm, dendrites (NTs) and in 
the senile plaque halo. Two degenerated neurons containing NFTs are enlarged in the 
bottom insets. Taken from (Munoz et al., 2007). 
 
 
          Progressive deposition of the space-occupying NFTs is considered to be a major 
cause of nerve cells death during AD and other neurodegenerative disorders called 
tauopathies (Gomez-Isla et al., 1997; Tolnay and Probst, 1999). The tangles are the 
aggregates of abnormally hyperphosphorylated tau (P-tau) protein located within the 
neuronal cytoplasm (Bancher et al., 1989). Tau is a natural mediator that stimulates and 
supports the assembly of tubulin in microtubules creating the cellular cytoskeleton.  
If it is aberrantly phosphorylated, it dissociates from the microtubuli and sequesters 
normal tau along with the other microtubule associated proteins (Alonso et al., 1997). 
This leads to disintegration of cellular scaffolding and compromises associated 
biological processes as well as complex axonal transport and structure. P-tau molecules 
self-assemble into paired helical filaments (PHFs) or straight filaments (SFs) (Iqbal et 
al., 1986). PHFs and SFs further accumulate forming NFTs or processes, such as NTs 
and dystrophic neurites (Trojanowski and Lee, 1995). Tau was first isolated from AD 
tangles in 1974 and identified as a microtubule-associated protein in 1986 (Iqbal et al., 
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1974; Grundke-Iqbal et al., 1986). The protein exists in nine isoforms as a result of an 
alternative splicing (Goedert et al., 1989). The level of transcripts encoding the isoforms 
is comparable in normal and AD brain tissues and all of the variants are incorporated 
into NFTs.  
          The reason for an abnormal tau hyperphosphorylation, as many other aspects of 
Alzheimer’s, remains unknown. The level of phosphorylation is three- to four-fold 
higher in AD than in a healthy control brain (Iqbal et al., 2010). So far, a few enzymes 
have been considered to be involved in this modification e.g. glycogen synthase 
kinase-3 (GSK-3) which may be up-regulated in AD by an unknown mechanism 
(Imahori et al., 1998). Moreover, GSK-3 can be induced by amyloid β peptides (Aβ, 
1.1.3) triggering a P-tau increase in embryonic rat hippocampus (Imahori and Uchida, 
1997). Other disregulation observed in AD relates to the cleaved form of protein 
phosphatase 2B (PP2B) the level of which can be three-fold higher than in control brain 
tissues (Qian et al., 2011). Studies show that P-tau also antagonizes neuronal apoptosis 
through inhibition of β-catenin phosphorylation, a protein naturally participating in 
programmed cell-death (Li et al., 2007). This may explain why AD neurons containing 
NFTs rather go through a degeneration process than apoptotic death. The resulting 
neuronal loss preferentially affects brain areas involved in memory creation and storage 
such as the hippocampus or basal forebrain (Munoz and Feldman, 2000). The latter is  
a home for the cholinergic system producing acetylcholine (ACh), an important 
neurotransmitter in the central and peripheral nervous system, which is involved in 
numerous physiological processes. The counteraction of ACh deficiency is currently 
one of the main treatment strategies in mild and moderate AD cases (1.1.4.2).   
          Severe neuronal death, common in AD,  has been initially directly related to the 
number of tangles (Cras et al., 1995). Later findings revealed that nerve cells loss is 
correlated but also far exceeds the level of formed NFTs (Gomez-Isla et al., 1997; Kril 
et al., 2002). Moreover, the density threshold of tangles above which one can determine 
the case with significant neuronal depletion has been estimated for 5/mm
2
 (Grignon et 
al., 1998). In the late AD stage, after cell death released NFTs convert to less condensed 
extracellular tangles that increases their immunoreactivity for astroglial proteins 
(Yamaguchi et al., 1987). NFT protein constituents undergo modifications and probable 
cross-linking which make them resistant to proteolysis and which prevents their 
removal from the brain environment (Cras et al., 1995). Besides, deposition of P-tau in 
the extracellular space stimulates an increase of intraneuronal calcium level and 
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consequent cell death (Gomez-Ramos et al., 2008). Lastly, P-tau mediates aggregation 
of α-synuclein in the form of Lewy bodies, found particularly in individuals with 
familial and sporadic types of AD as well as in DS patients with AD (Lippa et al., 1999; 
Hamilton, 2000; Popescu et al., 2004). This observation is one of many examples of 
aberrant protein fibrillization in synergistic mode and represents an important subject 
for further research (Giasson et al., 2003). Pre-filament tau is considered as an 
interesting target in immunotherapy of Alzheimer’s and tauopathies (Kayed and 
Jackson, 2009). 
1.1.2.3. Senile plaques and congophilic angiopathy 
          The most prominent feature of AD is extracellular accumulation of amyloid β 
(Aβ) peptides in the form of insoluble fibrillary deposits. Limited Aβs deposition also 
occurs in healthy ageing individuals, but in AD as well as in DS the process is 
particularly elevated and leads to acute pathology (Cork, 1990; Davis et al., 1999). Aβ 
is a product of complex proteolytic processing of amyloid precursor protein (APP) 
naturally found in many tissues (1.1.3.1) (Kang et al., 1987). Abnormal build-up is 
considered to be a result of an imbalance in synthesis and clearance of the peptides 
(Mawuenyega et al., 2010). Increased extracellular concentration of Aβ peptides leads 
to their aggregation in brain parenchyma and vessels in the form of plaques and 
cerebrovascular angiopathy, respectively (Duyckaerts et al., 2009).  
          Senile plaques are lesions preferentially found in grey matter and have been first 
mentioned by Blocq and Marinesco and later associated with dementia by Alzheimer 
(Blocq and Marinesco, 1892; Alzheimer, 1907). They are primarily composed of an Aβ 
core, associated molecules, dystrophic neuronal processes and reactive microglia 
(Dickson, 1997). The crucial part of the plaque is its amyloid core of diverse Aβ 
peptides (1.1.3) making abnormal, insoluble fibrillary structure (Castano et al., 1995). 
Some characteristic ultrastructural abnormalities can be identified within surrounding 
dilated neurites that include PHFs, enlarged lysosomes and mitochondria (Selkoe, 
2001). Neuritic plaques are often enveloped by reactive astrocytes and with some of 
their processes reaching the amyloid core (Selkoe, 2001). Importantly, astrocytes are 
partially responsible for persistence of AD as they suppress efficient phagocytosis of 
senile plaques by microglia (DeWitt et al., 1998). It was also discovered that senile 
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plaques contain free cholesterol and apolipoprotein E (ApoE) – a cholesterol 
transporter, which implies that they may be significant in AD progression (Namba et 
al., 1991; Panchal et al., 2010). Aβ peptides accumulate also in a form of diffuse 
plaques displaying amorphous structure and lack of the compacted amyloid centre of the 
classical neuritic plaques. They have no or very little associated molecules and 
deteriorated neurites. ApoE is co-localized with diffuse plaques and probably binds the 
N-terminal parts of Aβs as they display negative immunoreactivity (Uchihara et al., 
1996; Thal et al., 2005). Moreover, the majority of ApoE-positive Aβ deposits were 
noticed in individuals carrying apoϵ4 allele, which is one of the main risk factors in AD 
(1.1.4.1) (Thal et al., 2005). Large representation of these lesions in cognitively normal 
subjects led to the conclusion that their toxic influence may be indirect or negligent 
(Delaere et al., 1990; Dickson et al., 1992). There are also suggestions that Aβ 
aggregation into diffuse/dense core plaques is a protective mechanism for removing 
excess soluble but highly neurotoxic Aβ monomers and oligomers (Poduslo et al., 
2010). It is not known for how long diffuse plaques remain in this state, but they are 
considered being indicative of a preclinical AD stage. Many studies have tried to answer 
the question if diffuse plaques evolve to a neuritic state and which is their mechanism of 
formation (Dickson et al., 1992; Braak and Braak, 1997; D'Andrea et al., 2004). 
Exclusive association of the agglomerates of glial cells with senile plaques led to 
conclusion that microglia may participate in maturation of diffuse plaques to a neuritic 
state (Mackenzie et al., 1995). On the other hand it is hypothesised that different 
amyloid plaques rather originate by distinctive mechanisms explaining their varied 
structure and content (D'Andrea et al., 2004). Popular dogma states that progressive 
extracellular amyloid deposition initiates plaque creation, however growing evidence 
indicates their origin from cerebral blood vessels, neurons, Purkinje cell dendritic 
processes and astrocytes (Miyakawa et al., 1982; D'Andrea et al., 2001; D'Andrea and 
Nagele, 2002; Wang et al., 2002b; Nagele et al., 2003). An interesting proposal for 
plaque origin involves neuronal death, when lysis of the cell filled with Aβs results in 
the deposition of its content in the brain or plaques initiated by astrocytic lysis 
(D'Andrea et al., 2001; D'Andrea and Nagele, 2002; Nagele et al., 2003). The question 
of the existence of unique plaque species may be backed by their distinguished 
morphologies and may be correlated with different dementia types.  
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            Pathological AD plaques vary in density and compaction state. The usual 
spherical size of plaques is 10-160 μm in cross-sectional diameter and they are 
generally abundant in the association and limbic cortices (Armstrong et al., 1991; 
Dickson, 1997). It is difficult to estimate the period of time necessary to develop mature 
plaques, but possibly the whole process can take years and starts long before the actual 
onset of the disease. Interestingly, in normal ageing brains the density of senile plaques 
have been found to stabilize after limited period of accumulation (Mackenzie, 1994). 
Therefore morphological changes within the plaques rather than their amount seem to 
be decisive for their pathological action. 
          Aβs deposition in cerebral vessels is also a common feature of advanced ageing 
and AD brain known as cerebral amyloid (congophilic) angiopathy (CAA). Amyloid 
presence is most prominent in arteries and rarely in veins of the cerebral cortex and the 
leptomeninges (Pezzini et al., 2009).  It has been observed that the distribution of CAA 
and Aβ plaques is correlated (Thal et al., 2002; Thal et al., 2008). However, there is a 
difference in Aβ content of both abnormalities, as the less soluble Aβ42 is generally 
found within brain parenchyma plaques, whereas the more soluble Aβ40 predominates 
in CAA (1.1.3) (Weller et al., 2009). ApoE is co-localized with Aβ of those two distinct 
deposits and again in the case of CAA ApoE ε4 genotype together with ageing is 
considered as a major risk factor (Love et al., 2009; Weller et al., 2009). 
          Positron emission tomography (PET) – one of the neuroimaging techniques – is 
found to be useful in determination of the brain amyloid pathophysiology in vivo 
(Nordberg, 1996; Nordberg et al., 2010). This is particularly promising as so far 
amyloid deposits and other AD brain hallmarks have not been discovered until post 
mortem examination. Currently PET is a subject of an intensive development in order to 
improve its usefulness in the early diagnosis, monitoring and evaluation of anti-amyloid 
treatment in AD (Nordberg et al., 2010). 
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1.1.3. β-amyloid peptides (Aβs)  
1.1.3.1. APP processing and synthesis of Aβ peptides 
          APP is a large protein of 770 amino acids (aa) and 87 kDa with a single 
membrane-spanning domain close to its C-terminal end (Kang et al., 1987). The gene 
encoding APP is located on chromosome 21 and yields three distinct isoforms APP695 
(695 aa), APP751 (751 aa) and APP770 (770 aa) (Goate et al., 1991). APP695 is 
predominantly expressed in nerve cells, whereas two other isoforms are functioning in 
most tissues and contain an additional 56 aa Kunitz Protease Inhibitor (KPI) domain 
(Rohan de Silva et al., 1997). The splicing of APP RNA transcripts can be deregulated 
in AD and shifted towards the production of KPI-containing isoforms APP751 and 
APP770 (Menendez-Gonzalez et al., 2005). This modification was found to be triggered 
by the deregulation of neuronal calcium homeostasis and associated long-time 
activation of the extrasynaptic N-methyl-D-aspartate receptor (NMDAR) which finally 
leads to high increase in neuronal production of Aβ (Waxman and Lynch, 2005; Bordji 
et al., 2010). Although APP has been the subject of extended research regarding its 
involvement in AD, determination of its function in a cell is still unclear. APP is 
believed to play an important role in a few physiological processes, such as 
synaptogenesis or neuronal growth, adhesion and mobility (Moya et al., 1994; Small et 
al., 1999; Soba et al., 2005). It could also be involved in copper homeostasis and 
reduction of oxidative stress as well as cell signalling and apoptosis (Barnham et al., 
2003; Chen, 2004). The conception of the regulatory role of APP in the neuronal copper 
homeostasis has been supported by the observation that the copper level in cerebral 
cortex significantly elevates in transgenic knockout mice and decreases in brain cells 
over-expressing APP (White et al., 1999; Maynard et al., 2002). APP is a type I 
transmembrane glycoprotein and a few reports based on the structural data suggest that 
it may function as a cell surface receptor interacting with a range of biomolecules 
including Aβ as potential ligands (Lorenzo et al., 2000; Lu et al., 2003). It has been 
reported that the protein is produced in the endoplasmic reticulum (ER) and its highest 
concentration is found in the trans-Golgi-network (TGN) of neurons (Greenfield et al., 
1999). From there APP can be shipped in post-TGN secretion vesicles to the cell 
surface where it is proteolytically metabolized or may be re-internalized and degraded 
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following the endosomal/lysosomal pathway (Sisodia, 1992; Caporaso et al., 1994; Koo 
and Squazzo, 1994).  
          APP is processed via a set of proteases yielding different end products through 
non-amyloidogenic or amyloidogenic pathways (figure 1.3). In the first step of the 
non-amyloidogenic processing, APP is digested by α-secretase in the plasma membrane 
(Sisodia, 1992). This liberates a large soluble fragment known as sAPPα, but precludes 
generation of Aβ as the enzyme cuts within the Aβ sequence (between K16 and L17) 
(Sisodia, 1992). The α-secretase was identified as a membrane-bound zinc 
metalloproteinase and probably is a member of a disintegrin and metalloproteinase 
(ADAM) family (Sisodia, 1992; Roberts et al., 1994; Buxbaum et al., 1998). sAPPα has 
been considered to play a significant role in neuronal protection, as it is shown to be 
very potent against Aβ toxicity, excitotoxicity and glucose deprivation and helps in 
sustaining ion homeostasis in hippocampal tissue (Furukawa et al., 1996; Mattson, 
1997). It also participates in an early developmental stage of the central nervous system 
(CNS) and in control of proliferation of neural stem cells (Ohsawa et al., 1999; Caille et 
al., 2004). Interesting observations have been made in APP deficient mice, where sole 
expression of sAPPα successfully rescued appeared abnormalities, implying that sAPPα 
represents an essential part of physiological function of APP (Ring et al., 2007). The 
α-secretase activity is dramatically reduced in platelets, cerebrospinal fluid and the 
temporal cortex of AD patients that correlates with diminished levels of sAPPα and may 
contribute to the disease pathology (Colciaghi et al., 2002; Tyler et al., 2002). 
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Figure 1.3. Schematic diagram of APP processing by α- β- and γ-secretase. Subsequent 
α- and γ-cleavage releases sAPPα and p3 fragments, whereas alternative β- and 
γ-cleavage yields sAPPβ and Aβ peptides. 
 
 
          An alternative APP cleavage is made by β-secretase which is the first step of the 
amyloidogenic pathway (figure 1.3). Potential activity of the enzyme was identified in a 
range of proteases such as BACE1 (β-site APP cleaving enzyme), BACE2 or cathepsin 
B (Vassar et al., 1999; Solans et al., 2000; Hook et al., 2005). Among them BACE1, 
which is a type1 transmembrane protein (also known as memapsin 2 or aspartyl 
protease 2 (Asp2)) is the most efficient in and has been best analyzed so far, therefore it 
is referred as the major β-secretase (Sinha et al., 1999; Vassar et al., 1999). BACE1 
proteolysis of APP takes place via the endosomal/lysosomal pathway, but also the 
potential involvement of ER and the Golgi apparatus has been reported (Koo and 
Squazzo, 1994; Haass et al., 1995; Chyung et al., 1997). The cleavage at the position 1 
of the Aβ sequence leads to liberation of soluble ectodomain sAPPβ (Vassar et al., 
1999). sAPPβ is shorter from sAPPα only by the C-terminal Aβ(1-16) region, but this 
difference makes sAPPβ a mediator in nerve cell death and axon pruning in contrast to 
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the neuroprotective status of sAPPα (Nikolaev et al., 2009). Contribution of BACE1 to 
AD pathology may be significant as the protease activity has been found to be seriously 
elevated in diseased brain areas and the enzyme itself is considered as a rate-limiting 
step in neurotoxic Aβ synthesis (Cai et al., 2001; Yang et al., 2003; Johnston et al., 
2005). On the other hand, deficiency of BACE1 in AD model mice prevents memory 
deficits, cholinergic dysfunction or neuronal atrophy and suppresses generation of Aβ 
peptides (Luo et al., 2001; Ohno et al., 2004; Ohno et al., 2007). BACE2 is a 
homologue of BACE1, but it is expressed at significantly lower level in neurons 
(Bennett et al., 2000). Moreover, the BACE2 predominant cleavage site of APP is 
localized near to the α-secretase site and this protease due to gene location,  is suggested 
to be potentially involved in Aβ accumulation in DS (Solans et al., 2000; Yan et al., 
2001). 
          Apart from soluble ectodomains, α- and β-secretase APP processing generates 
membrane-bound C-terminal fragments of αCTF (C83) and βCTF (C99), respectively, 
which are further cut by γ-secretase (figure 1.3). The cleavage of αCTF yields a p3 
fragment of unknown function, whereas the γ-cleavage of βCTF releases a range of Aβ 
peptides – mostly Aβ(1-40) and Aβ(1-42) (Selkoe, 2001). The Aβ fragment is located 
within an extracellular membrane interface, where the first 28 amino acid residues are 
outside of the cell and the remaining residues reside within the membrane, which 
probably defines Aβ structural properties (1.1.3.3) (Kang et al., 1987). γ-secretase is a 
high molecular weight transmembrane complex including presenilin 1 (PSEN1) and 
presenilin 2 (PSEN2), mutations of which have been found causative in the majority of 
FAD cases (1.1.4.1) (Selkoe, 2001). Interestingly, γ-secretase may also mediate 
additional ζ-cleavage yielding Aβ46 and ε-cleavage yielding Aβ49, which implies a yet 
to be studied, sequential mode of final APP proteolysis (Weidemann et al., 2002; Zhao 
et al., 2004; Zhao et al., 2007).  
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1.1.3.2. Function and neurotoxic effect of Aβ peptides 
          Production of Aβs most likely occurs in subcellular compartments such as the ER 
and Golgi body or the endosome/lysosome complex (Koo and Squazzo, 1994; 
Greenfield et al., 1999). Aβs are later secreted out of the cell in exosomes or may be 
re-internalized for degradation (Rajendran et al., 2006; Mohamed and Posse de Chaves, 
2011).  The peptides were originally identified and purified from meningovascular 
amyloid deposits of AD brains and nearly a decade later they were confirmed as a major 
component of the plaques (Glenner and Wong, 1984; Miller et al., 1993). This implied 
the conception of Aβs as abnormal and toxic species exclusively produced in demented 
and aged brains. However, a discovery of soluble Aβs in normal cultured cells and body 
fluids confirmed their constant synthesis and physiological function (Seubert et al., 
1992; Haass et al., 1993; Selkoe, 1993; Ghiso et al., 1997). There are reports stating that 
low levels of Aβ positively modulate synaptic neurotransmission and potassium ion 
channel work, may rescue neuronal cell death or enhance memory and learning (Plant et 
al., 2003; Plant et al., 2006; Puzzo et al., 2008; Morley et al., 2010). Moreover, an 
example of the Caenorhabditis elegans transgenic model was used to show that 
intracellular Aβ aggregates can entrap excess free copper and support a detoxification 
process in muscle cells (Minniti et al., 2009). It is yet to be investigated whether this 
binding occurs in human peripheral cells.  
          The aspect of Aβ clearance is of much interest as it is considered to be affected in 
AD pathology. The peptides can be normally degraded by enzymes, such as neprilysin 
or insulin degrading enzyme (IDE) (Yasojima et al., 2001; Behl et al., 2009). Other 
possible ways include the removal from the brain parenchyma with interstitial fluid, 
interaction with P-glycoprotein helping to cross the blood-brain barrier or uptake by 
perivascular macrophages and microglia (Yazawa et al., 2001; Cirrito et al., 2005). 
Recent data show that statins – cholesterol lowering drugs – are promising stimulators 
of microglia-mediated degradation of extracellular Aβ (Tamboli et al., 2010). 
          Neurotoxic action of Aβs has been identified as a result of their overproduction 
and assembly leading to substantial dysfunction of nerve cells, their eventual loss and 
general brain pathology (Wisniewski et al., 1997; Selkoe, 2001). In diseased brain Aβs 
are found in soluble monomeric or oligomeric forms as well as in insoluble fibrillary 
aggregates further developing into amyloid plaques (1.1.2.3). There are hypotheses that 
33 
 
the severe neurotoxic effect of Aβ comes from its soluble oligomers, as they are thought 
to disturb structural integrity of the cell membrane and to enhance Aβs uptake into the 
cytosol (Kim et al., 2003; Willliams et al., 2011). Aβ could form ion channel-like 
structures that were shown to facilitate transport through the membrane and destabilize 
calcium homeostasis (Mattson et al., 1992; Lin et al., 2001). Studies consider that a few 
functional domains can be distinguished within the Aβ sequence, such as:  
 KLVFFAEDV – Aβ(16-24) and  IIGLMVGGVV – Aβ(31-40) involved in fibril 
formation, β-strand propensity (Danielsson et al., 2006), 
 HHQK – Aβ(13-16) – suppresses activation and interaction of microglia with Aβ; 
sulfate-binding region for sulfated proteoglycans found in senile plaques (Giulian et 
al., 1998),  
 HH – Aβ(13-14) – neuronal binding (Poduslo et al., 2010) and metal coordination 
(together with H6) (Minicozzi et al., 2008),  
 GSNKGAIIGLM – Aβ(25-35) – biologically active fragment of Aβ, neurotoxic 
(Hughes et al., 2000),  
 VFF – Aβ(18-20) – amnestic effect, affects learning and memory (Flood et al., 
1994)  
 IIGL – Aβ(31-34) – binds to the cell surface (Laskay et al., 1997).  
Identification of these essential Aβ fragments has been proven to be an important step 
towards designing of effective peptide antagonists, which could block physiological 
effects of Aβ species (Tjernberg et al., 1996; Laskay et al., 1997; Harkany et al., 1999; 
Gordon et al., 2001).  
          Intracellularly, Aβs probably form fibrils affecting a variety of organelle 
functions that causes alterations in synaptic transmission and neuronal damage. Dead 
nerve cells are the basis for the production of neuritic plaques characterized by a 
fibrillar amyloid core (1.1.2.3). It is proposed that an alternative protective mechanism 
occurs, where a large amount of extracellular soluble monomers and oligomers as well 
as ultimately insoluble protofibrils and fibrils assemble to form diffuse/dense core 
plaques (1.1.2.3) (Poduslo et al., 2010).  
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          One of the severe neurotoxic effects of Aβ species is the generation of intense 
oxidative stress in AD brain. Experimental evidence suggests that Aβ induces excessive 
production of reactive oxygen species (ROS) and peroxidative injury of membrane 
lipids, proteins and other cell constituents (Butterfield and Boyd-Kimball, 2004; Cetin 
and Dincer, 2007). It has been shown that oligomeric Aβ complex displays 
metalloenzyme-like activity as it shows high affinity for copper binding and catalyzes 
reduction of Cu(II) to Cu(I) liberating H2O2 (Opazo et al., 2002). Aβ-catalyzed 
production of H2O2 employs biological reducing agents which negatively affects the 
brain environment redox state and contributes to the neurotoxicity of Aβs. There are 
also suggestions that ROS may play a role in Aβ-mediated vascular constriction 
affecting cerebral circulation (Niwa et al., 2001).  
          The role of cholesterol is also a subject of extended study in relation to AD 
pathology. Aβ prevents its binding to ApoE and low-density lipoprotein that results in 
increased cholesterol levels in the extracellular space that was proven to be toxic for 
neurons (Yao and Papadopoulos, 2002). Interestingly, cholesterol binds to Aβ at the site 
cleaved by α-secretase, which may imply inhibition of α-cleavage in APP (Yao and 
Papadopoulos, 2002).  
1.1.3.3. Modifications of Aβ peptides 
          Amyloidogenic γ-cleavage of APP yields two main C-terminally varied species 
Aβ(x-40) and Aβ(x-42) (figure 1.4) (Selkoe, 2001). Aβ(1-42) presents only about 10% 
of the produced Aβ pool, however two additional C-terminal residues – Ile41 and Ala42 
– make it more hydrophobic and prone for in vitro oligomerization and fibril assembly 
compared to Aβ(1-40) (Burdick et al., 1992; Jarrett et al., 1993; Kim and Hecht, 2005). 
It seems that Aβ peptides ending at the position 42 or 43 generally can act as nuclei and 
trigger amyloidogenesis of more soluble Aβ40 peptides. An interesting proposal of a 
potential neuroprotective role of Aβ(1-40) came after the observation of its inhibiting 
action on Aβ deposition in a transgenic mouse model, which is opposite to the longer 
peptide (Kim et al., 2007). The increasing Aβ42/Aβ40 ratio and elevated plasma levels 
of Aβ42 are common in FAD that suggests a crucial role of this longer peptide in the 
disease pathogenesis (Borchelt et al., 1996; Scheuner et al., 1996; Mayeux et al., 1999). 
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In fact, the majority of the plaque core of Aβs is represented by the species of Aβ(x-42) 
organized in a fibrillary form (Jarrett et al., 1993).  
 
 
Figure 1.4. Sequence of Aβ(1-42) with marked  N- and C-terminal truncations and 
modifications. Major modifications affect aspartic residues Asp1, Asp7 and Asp23 
(racemisation or isomerisation) as well as glutamic residues Glu3 and Glu11 
(cyclisation to pyroglutamyl form). Different γ-secretase truncation at the C-terminus 
results mostly in generation of Aβ peptides ending at the position 40 and 42. 
 
 
          Apart from the C-terminal heterogeneity (Aβ39 – Aβ43), Aβs display a variety of 
N-terminal modifications (figure 1.4), such as racemisation or isomerisation of Asp1, 
Asp7 and Asp23 residues, or cyclisation of Glu3 and Glu11 into the pyroglutamyl form 
(AβpGlu3 and AβpGlu11, respectively) (Jarrett et al., 1993; Shimizu et al., 2000). In 
1998 Hosoda and co-workers reported the results of the quantification of plaque core 
peptides derived from the AD and DS frontal cortex formic acid extracts using the 
ELISA method (Hosoda et al., 1998). The majority of these were represented by 
AβpGlu(3-42), Aβ(1-42) and Aβ(2-42) but also the small amounts of the L-isoaspartate 
isomers of Aβ – Aβ(1-42/L-isoAsp1) and Aβ(1-42/L-isoAsp7). Multiple studies have 
confirmed that AβpGlu(3-42) is the most prominent N-terminal Aβ variant in amyloid 
plaques, reaching 50-80% depending on the site of deposition (Saido et al., 1995; Saido 
et al., 1996; Hosoda et al., 1998; Harigaya et al., 2000). The level of AβpGlu(11-42), in 
turn, is particularly elevated in some FAD cases with identified PSEN1 mutations 
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(Russo et al., 2000). pGlu-containing Aβ forms are believed to play a crucial role in 
initiation of neuropathogenic diseases. AβpGlu(3-42) deposition was observed to be 
dominant and precede deposition of Aβ(1-40/42) in DS patients and resulting plaques 
exhibit equivalent or higher density (Saido et al., 1995). In addition, AβpGlu(3-40) and 
AβpGlu(3-42) were found to be strongly neurotoxic as they interact with the plasma 
membrane of cultured neurons and glial cells and significantly resist degradation by 
cultured astrocytes (Russo et al., 2002). Intracellular occurrence of N-terminally 
truncated Aβs correlates with neuronal loss in the hippocampus of the transgenic mouse 
model (Casas et al., 2004). Another fact, suggesting the neuropathological role of 
pGlu-modified Aβ peptides in AD, is their absence in brains of cognitively normal 
elderly patients with, nonetheless, observed accumulation of Aβ1-40 and Aβ1-42 
(Piccini et al., 2005). In diseased brain, intraneuronal accumulation of AβpGlu(3-40/42) 
was observed to progress continuously whereas the density of the full-length Aβ 
peptides is declining with age (Wirths et al., 2010). This concludes that the full-length 
Aβs are N-terminally modified with the progression of the disease. 
          The mechanism of production of pyroglutamated Aβs remains poorly understood. 
One of the striking questions is the generation of free N-terminal Glu3 and Glu11 
residues that are required for this reaction. Interesting experimental data show that the 
Swedish mutant APP (K670N/M671L) (1.1.4.1) can be processed by BACE1 in vitro in 
a pH-dependent manner (Sidera et al., 2002). In acidic environment (pH 5) APP is cut 
at both β1-site and β2-site yielding Aβ starting with Asp1 and Glu11, respectively. 
BACE1 was localized in acidic TGN compartments so it has been suggested that β2-site 
cleavage also occurs there (Huse et al., 2000; Sidera et al., 2002). Contrary to that, 
β1-site cleavage is exclusive in neutral and basic pH, characteristic for the ER and early 
Golgi body (Sidera et al., 2002). These data indicate that cellular localisation of APP 
may have profound effects on the production of Aβ species. Report by Creemers et al. 
(2000) shows that β2-cleavage at Glu11 is a function of BACE1 expression level and it 
can be subsequent to the cleavage at Asp1 (Creemers et al., 2001). Glu3, in turn, may 
only become available after the Asp1 and Ala2 removal by exopeptidases, such as 
aminopeptidase A (APA) or N (APN)-like types (Sevalle et al., 2009). The isomeric 
form of Asp1 could be removed by a range of dipeptidyl peptidases or acylamino 
acid-releasing enzyme (Bohme et al., 2008). An interesting alternative mechanism of 
the generation of the free Glu3 N-terminus was proposed by Drew group, which 
considers the involvement of Cu
2+
 (Drew et al., 2010). It is possible that Aβ-coordinated 
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Cu
2+
 polarises the carbonyl moiety between Ala2 and Glu3 promoting subsequent 
amide hydrolysis and peptide bond cleavage which finally results in the generation of 
truncated Aβ(3-40/42) species (Drew et al., 2010). Another important finding was 
reported by Kuda and co-workers (1997) stating significantly lower activity of plasma 
glutamyl aminopeptidase in sporadic AD brains comparing to age-matched controls 
(Kuda et al., 1997). It seems to be clear that this reduction could limit the rate of Aβ 
catabolism and facilitate pyroglutamyl formation and finally accumulation of 
AβpGlu(3-40/42) in pathological brain. Early suggestions that pyroglutamyl and 
aspartate Aβ variants are the result of post-translational modification of Aβ(1-40/42) 
raised from the observation of constantly produced full-length Aβs in cerebrospinal 
fluid and cultured cells (Selkoe, 1993). The levels of racemised AβAsp1 forms, 
AβpGlu3 or AβpGlu11 remain essentially constant and independent that led to the 
conclusion that N-terminal conversions precede aggregation, otherwise their quantity 
would be proportional (Saido et al., 1996). Aβ aggregates exist in solid state, as they 
need to be solubilised with formic acid, and this state may also slow and impair any 
structural modifications (Saido et al., 1996). A recent report presented glutaminyl 
cyclase (QC) as being able to catalyze the conversion of Aβ(3-42) to AβpGlu(3-42) 
after APP processing and is thought to be favoured in the acidic environment of 
endosomal vesicles (Cynis et al., 2008). However, it is unclear whether the cyclisation 
occurs inside the cell, or only later, after the Aβ peptide has been secreted. Interestingly, 
the enzyme removing Asp1, APA, is a metallo-ectopeptidase, which suggests that Aβ 
proteolysis may begin in the extracellular space (Sevalle et al., 2009). This nonetheless 
does not preclude the possibility that truncated Aβ could be turned back into the cell and 
undergo further processing. 
          N-terminal pyroglutamyl modification serves as a protection against the action of 
aminopeptidases with the exception of pyroglutamyl peptidases (1.2). Proteolytic 
degradation of both AβpGlu3 and AβpGlu11 may be only initialized by pyroglutamyl 
specific protease as has been confirmed in previous enzymological studies (Armentrout 
and Doolittle, 1969; Barrett and McDonald, 1986). Therefore, pGlu protection 
contributes to the prolonged in vivo survival of Aβ peptides which increases their 
chances for aggregation (Saido et al., 1996). Experimental data confirmed that Aβs 
contain structural regions potentially responsible for their conformational properties 
(Danielsson et al., 2006; Tomaselli et al., 2006). It was demonstrated that the large 
N-terminal fragment of Aβ 1-15 consists of helical regions, whereas fragments of 16-24 
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and 31-40/42 have β-sheet forming propensities and are separated by another disordered 
region 25-30 (Danielsson et al., 2006). Therefore, a loss of 2 or 10 initial residues in 
case of AβpGlu3 and AβpGlu11, respectively, may significantly reduce helical 
propensity and accelerate the aggregation. Modification of full-length Aβ to AβpGlu3 
results in a deficit of 3 charges (2 negative and 1 positive one) and 1 hydrophobic 
residue, and an increase by 1 polar residue in the N-terminus (D'Arrigo et al., 2009). 
Conversion of full-length Aβ to AβpGlu11, in turn brings a deficit of 6 charges (4 
negative and 2 positive ones) as well as a loss of 2 hydrophobic and 3 polar residues 
(D'Arrigo et al., 2009). The resulting reduction in charge repulsion and the fact that the 
central hydrophobic part remains unaltered, makes the truncated and pyroglutamated 
peptides able to stabilize β-sheet conformation and hydrophobic intermolecular 
interactions that may initialize further Aβ assembly (D'Arrigo et al., 2009; Schlenzig et 
al., 2009). Organization of full-length Aβ fibrils, similarly to other amyloid fibrils, 
display a cross-β pattern, where individual β-strands are vertically orientated in relation 
to the fibrillar axis (Kirschner et al., 1986). The peptide N-terminus in unmodified Aβ 
aggregates is shown to be structurally disordered and solvent-accessible (Balbach et al., 
2002; Petkova et al., 2002). It has been proposed that the introduction of pGlu could 
induce structural changes stiffening the N-terminal part of the peptides (Schlenzig et al., 
2009). These rearrangements along with diminished solvent exposure could constrain 
the N-terminal disordered state, as it was observed in some pGlu-containing proteins 
(Liao et al., 2003; Arnold et al., 2006). Interestingly, the aggregation kinetics of 
AβpGlu3 is higher than that of AβpGlu11 which indicates the contribution of the longer 
N-terminal fragment in faster aggregation (D'Arrigo et al., 2009). The rate of initial 
aggregation of pGlu variants can be up to 250-fold accelerated in comparison to that of 
full-length Aβs, so it has been suggested that they may act as seeding agents driving 
oligomerization and fibrillization processes of the other Aβ species (He and Barrow, 
1999; Schilling et al., 2006; D'Arrigo et al., 2009). Moreover, the levels of the 
pyroglutamyl Aβs that terminate at position 42 in plaques are higher than those 
terminating at 40, and the longer form has also a greater aggregation rate (Iwatsubo et 
al., 1996; Hosoda et al., 1998; He and Barrow, 1999). Studies indicate that the 
differences in hydrophobicity of AβpGlu(3-42) and Aβ(1-42) are minimal, however at 
equimolar quantities the former aggregates more rapidly than the latter one (Kuo et al., 
1997). In the same study Aβ(1-42) was shown to be the most polar peptide succeeded 
by Aβ(1-42/L-isoAsp) variants, AβpGlu(3-42) and the most hydrophobic fragment 
Aβ(17-42) (Kuo et al., 1997). The special role of AβpGlu(3-42) was manifested through 
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the observation that it can inhibit the formation of full-length peptides in fibrils (Quist et 
al., 2005; D'Arrigo et al., 2009). This may in turn favour (toxic for neurons) pre-fibrillar 
aggregation of Aβs that is also believed to influence the progression of AD (D'Arrigo et 
al., 2009). It seems to be obvious that the production of modified Aβs such as 
AβpGlu(3-40/42) and AβpGlu(11-40/42) have pronounced effect on faster aggregation 
and generation of neurotoxic amyloid species found in AD and DS brains. Interestingly, 
inherited neurodegenerative disorders, such as familial British dementia (FBD) and 
familial Danish dementia (FDD) also are characterized by amorphous and fibrillar 
deposits consisting mainly of pGlu-modified amyloid peptides – ABri or ADan, 
respectively that are not related to Aβ (Schlenzig et al., 2009). The pyroglutamyl 
residue is particularly dangerous as it prevents proteolytic degradation and clearance of 
these neurotoxic products from diseased brain. 
1.1.4. Aetiology and treatment strategy of AD  
          AD has been a matter of intensive study for many decades but nonetheless its 
ultimate cause still remains unknown. The major problem lies in the clinical 
heterogeneity of AD and relative inability to determine the onset of the disorder.  
A further complication is a resemblance of AD symptoms to a few other conditions e.g. 
diffuse Lewy body dementia, Parkinson's and Huntington disease, Pick’s disease, 
vascular and frontotemporal dementia (Rogan and Lippa, 2002; Lautenschlager and 
Martins, 2005; von Bernhardi et al., 2010). All of them, for example, exhibit 
progressive and irreversible degeneration of brain cells. So far, many risk factors, such 
as genetic mutations, physiological disturbances or environmental agents have been 
analyzed and became a foundation for development of therapeutic strategies for AD 
treatment.  
1.1.4.1. Factors behind AD pathogenesis 
          The genetic basis of Alzheimer’s has been widely studied since the identification 
of several gene mutations and genotype predispositions underlying some cases of the 
disease. The majority of early-onset dominantly inherited AD cases are known to be 
associated with mutations in APP, PSEN1 or PSEN2 genes (Sandbrink et al., 1996). 
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Many APP point mutations have been identified and associated with AD e.g. Swedish – 
(K670N/M671L) (Mullan et al., 1992), London – V717I (Goate et al., 1991), Dutch – 
E693Q (Levy et al., 1990) or Flemish – A692G (Hendriks et al., 1992). These 
mutations increase selective β-cleavage of APP and overproduction of Aβ(x-42/43) or 
promote its faster aggregation. APP mis-metabolism as a key initiating event and the 
subsequent amyloid deposition is the basis of the amyloid cascade hypothesis, a leading 
theory explaining AD pathogenesis (Hardy and Allsop, 1991; Hardy and Selkoe, 2002). 
Mutations in genes encoding PSEN1 and PSEN2 also result in increased extracellular 
concentration of Aβ42 and are thought to account for the majority of early-onset, 
dominantly inherited FAD cases (Sandbrink et al., 1996; Scheuner et al., 1996). 
          Discovery of ApoE within senile plaques raised an interest in its association with 
AD (Namba et al., 1991). This protein plays an important role in lipid transport and 
patients carrying ε4 allele of the apoε gene are frequent within those affected by 
late-onset familial AD (Strittmatter et al., 1993). On the contrary those possessing allele 
ε2 are potentially protected from the disease (Bickeboller et al., 1997). This relationship 
has been considered to be associated with ApoE isoform-dependent efflux of cholesterol 
and other lipids from cultured neurons and astrocytes, with ApoE2 functioning 
significantly better as the acceptor (Michikawa et al., 2000). A recent report also links 
regulation of synthesis and clearance of Aβs with ApoE isoform prevalence (Castellano 
et al., 2011). 
          One of the potential risk factors, although still not well understood, is a microbial 
infection that can elicit neuropathological disorders. Currently, several important 
pathogens induce infections that appear to be related to sporadic AD and cognitive 
decline. There are reports suggesting the contribution of the organisms, such as Herpes 
simplex virus type 1 (HSV1) (Wozniak et al., 2009), Chlamydophila pneumoniae 
(Hammond et al., 2010), Helicobacter pylori, spirochete, picornavirus or Borna disease 
virus to the AD pathophysiology. Infection with HSV1 is very common and affects 
many people with the symptoms known as cold sores. Recent discoveries strongly link 
HSV1 presence with pathogenic changes in the Alzheimer’s brain. It has been shown 
that infection of neuronal and glial cell cultures with the virus triggers intracellular 
accumulation of Aβ(1-40) and Aβ(1-42), and brain deposition of Aβ(1-42) (Wozniak et 
al., 2007). Interestingly, in the later study HSV1 DNA was detected within 90% and 
associated with 72% of amyloid plaques (Wozniak et al., 2009). This shows the strong 
relationship between the virus and AD pathophysiology. Aforementioned findings 
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determine the HSV1 virus as a one of the initiators of senile plaques formation and 
point to the application of antiviral agents in disease treatment. Antigens of the other 
pathogen, C. pneumoniae, have been immunohistochemically detected in neurons, 
neuroglia, endothelial and peri-endothelial cells (Hammond et al., 2010). Surprisingly, 
there was also strong immunoreactivity of the pathogen in extracellular areas of the 
frontal and temporal cortices of the AD brain. Moreover, the appearance of  
C. pneumoniae is co-localised with amyloid deposits and NFTs in the studied regions of 
the brain. One may assume that the chronic or frequent infections could be considered 
as a potential risk factor in sporadic AD and an early preventative action seems to be 
very important. However, the idea of the pathogenic aetiology of Alzheimer’s needs 
further scientific evidence and study. 
          The contribution of metal ions towards neurological disorders is also being 
debated (Budimir, 2011; Chen et al., 2011). Most important biometals, Zn
2+
, Cu
2+
, and 
Fe
3+
, for example may act as seeding factors for amyloidogenesis as they are found 
abundant in Aβ plaques (Bush et al., 1994; Stoltenberg et al., 2007). A recent report 
also suggests the contribution of iron to Aβs toxicity as it was shown to hinder the 
transition of the peptides from unstructured to ordered cross-β conformation (Liu et al., 
2011). The nonphysiological metal, aluminium, is observed to localize at high 
concentrations in Aβ deposits, although its causative role in neuropathogenesis is still 
being questioned (Drago et al., 2008). Interestingly, accumulation of Aβs can be 
inhibited by a Cu/Zn-selective chelator (clioquinol) both in vitro and in a transgenic 
mouse brain in vivo (Cherny et al., 2001). This indicates that copper also promotes Aβ 
aggregation. Moreover, metal ion imbalance is thought to be associated with oxidative 
stress, another potential cause of AD (1.1.3.2) (Budimir, 2011).    
1.1.4.2. Potential therapeutic strategies 
          Rigorous studies are currently being carried out to develop effective ways to stop 
β-amyloid overproduction, enhance its clearance and aggregation blockage. 
          Therapeutic strategies leading to decrease of Aβ concentration are mainly focused 
on inhibition of APP cleavage by two proteases, β- and γ-secretase releasing Aβ peptide 
(Vassar, 2002). For example, oestrogen was found to reduce the neuronal Aβ level by 
stimulation of the APP α-secretase cleavage and thus preclude Aβ generation (Xu et al., 
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1998; Greenfield et al., 2002). Similarly, testosterone is believed to decrease the level 
and activity of β- and γ-secretases, to lower plaque formation and can have a positive 
influence on cognitive functions (Gouras et al., 2000; Ghosh and Thakur, 2008; 
McAllister et al., 2010). One of the proposed approaches towards AD is also application 
of the four-drug cocktail treatment consisting of nonsteroidal anti-inflammatory drugs 
(NSAIDs), cholesterol-lowering drugs (statins) combined with β- and γ-secretase 
inhibitors, which effectively reduces the synthesis of Aβs in cultured cells (Asai et al., 
2010). Particularly β-secretase is a prime drug target as its level is significantly elevated 
in the AD affected brain regions (Yang et al., 2003; Johnston et al., 2005). However, 
the viability of the protease as a therapeutic object is questioned since many, other than 
APP, physiologically important substrates have been identified (reviewed in (Vassar et 
al., 2009). Moreover, BACE1 knock-out mice have very low life expectancy and 
exhibit severe physiological abnormalities (Dominguez et al., 2005; Hu et al., 2006). 
Lastly, inhibition of pyroglutamyl forming enzyme, QC, results in reduction of the 
AβpGlu(3-42) level, decreased plaque formation and gliosis as well as the improvement 
of cognitive functions in the mouse model that makes the enzyme an interesting 
therapeutic target (Schilling et al., 2008b).  
          Immunotherapy is another area of research shown to be promising in 
decreasing the level of amyloid deposits and hyperphosphorylated tau in APP 
transgenic mouse models (Wilcock et al., 2009). Furthermore, evidenced reductions 
in neuronal loss and cognitive decline as well as full reversion of memory deficit 
have been observed. Preclinical studies indicate that the best effects of Aβ 
immunotherapy might be achieved if it is applied before the disease onset or in its 
very earliest stages (Lemere and Masliah, 2010). Constantly improved diagnostic 
methods are invaluable for identification of presymptomatic, at risk individuals who 
might particularly benefit from early vaccination to prevent AD. There is also a need 
for natural mobilization of the immune system. One such interesting example is the 
observation of immune stimulation of macrophages by the form of vitamin D3 in 
combination with curcumin (Fiala, 2010). 
          Significant attempts have been made to develop strategy preventing Aβ 
fibrillization and deposition (Wisniewski and Sadowski, 2008). In a number of studies 
Aβ homologues have been proven efficient in disrupting β-sheet conformation (Hilbich 
et al., 1992; Soto et al., 1998; Sigurdsson et al., 2000). These β-sheet breakers are 
particularly advantageous as they target only the abnormal conformation of Aβ and do 
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not affect the normal function of the soluble Aβ peptides. A similar concept is found to 
reverse protein disorders caused by prions (Soto et al., 2000). The promising therapeutic 
means represent N-methylated peptides (meptides) that are examples of specially 
designed peptide aggregation inhibitors and are also able to block β-sheet formation 
(Kokkoni et al., 2006). An intriguing concept using the metal-chelating property of Aβ 
has been found effective in order to prevent peptide aggregation. A binuclear 
Ru(II)−Pt(II) complex and Pt(II)-based compounds bind to Aβ42 and effectively inhibit 
its abnormal assembly (Barnham et al., 2008; Kumar et al., 2010). Another approach 
utilizes inhibitors of pathological chaperones, a group of proteins that were found to 
enhance conformational assembly of Aβ to fibrils by increasing their β-sheet content 
that stabilizes their abnormal structure (Wisniewski and Sadowski, 2008).  Key 
examples linked to AD Aβ aggregation include ApoE4, α1-antichymotrypsin and C1q 
complement factor (Ma et al., 1994; Sanan et al., 1994; Wisniewski et al., 1994; Boyett 
et al., 2003). There is also a wide interest in a potent antioxidant, resveratrol, as a 
beneficial compound in reducing the risk of AD. Indeed, this polyphenol has been 
observed to directly bind to Aβ42, attenuate cytotoxicity of Aβ42 oligomers and 
interfere in its fibril assembly (Feng et al., 2009). 
          One of the earliest propositions for AD origin was the cholinergic hypothesis 
(Francis et al., 1999). It assumes that the disease is caused by the brain when the deficit 
of the ACh and ACh-synthesizing enzyme, choline acetyltransferase (ChAT) as well as 
related loss of cholinergic neurons. ACh is crucial for memory formation, reasoning and 
information processing. The majority of the drugs treating mild and moderate AD 
symptoms are cholinesterase inhibitors and aim to counteract ACh deficit (Birks, 2006). 
Apart from ACh also other neurotransmitters, such as noradrenalin, serotonin and 
somatostatin are observed to be unusually low in AD and DS (Mann and Yates, 1986). 
          Numerous AD treatment and prevention strategies are a matter of study and 
development nowadays, but unfortunately nothing has been proven to stop the disease 
so far (Selkoe, 2001). In high income countries the key strategy is to increase the 
awareness of the disease, promote prophylactic care and early diagnosis of dementia. 
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1.2. Pyroglutamyl peptidases 
1.2.1. General characteristics 
          Pyroglutamyl peptidase also known as pyrrolidone carboxyl peptidase (Pcp) is  
an enzyme hydrolytically removing the N-terminal pyroglutamyl residue (pGlu) from 
peptides or proteins (figure 1.5) and is classified as an ω-exopeptidase displaying 
specificity for L-pGlu-L-amino acid optical isomers (Doolittle and Armentrout, 1968; 
Uliana and Doolittle, 1969). Pcp has also been referred to by many other names such as 
pyroglutamate (pyroglutamyl) aminopeptidase, L-pyroglutamyl peptide hydrolase, 
pyrrolidonecarboxylate (pyrrolidonecarboxylyl) peptidase, 5-oxoprolyl peptidase or 
PYRase (Cummins and O'Connor, 1998). 
 
 
 
 
 
 
 
Figure 1.5. The hydrolytic removal of the N-terminal L-pGlu residue catalysed by 
Pcp. The enzymatic reaction liberates pyroglutamic acid (L-pGlu acid) and the 
peptide remnant with a free NH2- terminus. 
 
 
          Pcp activity has been observed in a number of prokaryotic and eukaryotic 
organisms (1.2.3 and 1.2.4) (Haitinger, 1882; Doolittle and Armentrout, 1968). 
Moreover, in mammalian tissues it exists in three distinct enzymatic forms: Pcp type I 
(EC 3.4.19.3), Pcp type II (EC 3.4.19.6) and serum thyroliberinase (EC 3.4.19.-) 
(Cummins and O'Connor, 1998).    
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1.2.2. Role of the pyroglutamyl group 
          Pyroglutamic acid (pGlu), also known as pyrrolidone carboxylic acid (PCA) or 
5-oxo-L-proline, is a product of glutamic acid dehydration (Haitinger, 1882). It can also 
be obtained from glutamine, various glutamate esters and diesters or γ-glutamyl 
derivatives (Sanger et al., 1955; Winstead and Wold, 1964; Orlowski and Meister, 
1971). Biologically N-terminal pGlu formation is a result of post-translational 
cyclisation of glutamyl or the glutaminyl residue catalysed by glutaminyl cyclase (QC) 
(Schilling et al., 2003). Substrate specificity of QC is pH-dependent where conversion 
of Gln to pGlu is favoured at pH 8.0 whereas optimal pH for the conversion of Glu is 
6.0 (figure 1.6) (Schilling et al., 2004). 
          There are also reports on the spontaneous generation of free pyroglutamyl acid. 
For example, glutamine can non-enzymatically degrade to pyroglutamyl acid and 
ammonia during incubation at 37ºC in phosphate or bicarbonate buffer or in cell culture 
media (Gilbert et al., 1949; Tritsch and Moore, 1962). Free pGlu has also been observed 
to be generated from glutamic acid under specific culture conditions (78ºC and pH 3.0) 
(Park et al., 2001). Although spontaneous cyclisation of the N-terminal glutamyl or 
glutaminyl residue in vivo has not been experimentally supported, recent data suggest 
that this could occur in some gluten peptides (Monsuur et al., 2006). There is also no 
evidence so far regarding the catalytic attachment of the pGlu residue to a peptide 
N-terminus. 
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Figure 1.6. The formation of the N-terminal pGlu residue catalysed by glutaminyl 
cyclase (QC). Under mild acidic conditions QC is able to catalyse the cyclisation of 
glutamyl group to pGlu (a), whereas in the basic pH range the enzyme favours the 
glutaminyl group as a substrate (b) (Schilling et al., 2004). 
 
 
          The physiological role of free or N-terminal pGlu has been established in many 
aspects of cellular life. In Pseudomonas fluorescens pGlu was found to act as an 
inductor of the pcp gene expression (Le Saux and Robert-Baudouy, 1997). Studies 
showed that pGlu inhibits the growth of extremophiles e.g. hyperthermophilic archaeon 
Sulfolobus solfataricus in conditions of high temperature and low pH (Park et al., 2001; 
Park et al., 2003). On the other hand it can stimulate the growth of organisms living at 
low temperature and neutral pH (Park et al., 2003). The inhibitory action of pGlu was 
also detected in vitro with hamster tumour cultured cells or on (Na
+
-K
+
) ATPase of the 
small intestine microvilli (Escobedo and Cravioto, 1973; Goetz et al., 1973). The pGlu 
is physiologically metabolised to L-glutamic acid by 5-oxoprolinase as a step in the 
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γ-glutamyl cycle (Van der Werf et al., 1971). In body, elevated levels of pGlu 
(5-oxoproline) are hallmarks of organic acid disorders such as 5-oxoprolinuria 
(pyroglutamic aciduria) and hawkinsinuria (Bachmann et al., 1994). The increase has 
recently been observed in blood plasma samples of individuals with gastric cancer or in 
urine of malnourished rats (Wu et al., 2010; Yu et al., 2011). Prolonged pGlu 
accumulation triggers oxidative stress, causes protein oxidation and production of 
reactive species as well as was shown to impair non-enzymatic antioxidant action, 
energy production and lipid synthesis in cultured rat brain tissues (Silva et al., 2001; 
Pederzolli et al., 2007). In Huntington’s disease patients diminished level of striatum 
pGlu is followed by its increase in the plasma (Uhlhaas and Lange, 1988).  
          The presence of the N-terminal pGlu group often plays a protecting role and its 
removal biologically activates or deactivates a given molecule. This modification can be 
found in many physiological peptides and proteins such as thyrotropin-releasing 
hormone (TRH), luteinizing hormone-releasing hormone (LHRH), neurotensin, gastrin, 
anorexigenic peptide, vasoactive peptide or fibrinopeptide B (reviewed in (Cummins 
and O'Connor, 1998).  Other examples include snake venoms physalaemin (Anastasi et 
al., 1964) eledoisin (Anastasi and Erspamer, 1963) and bradykinin-potentiating peptides 
(Hayashi and Camargo, 2005), honeybee antibacterial hymenoptaecin (Casteels et al., 
1993) phytotoxins (de Lamotte et al., 2007) or light and heavy chains of 
immunoglobulin (Doolittle and Armentrout, 1968). TRH, LHRH or neurotensin 
represent a group called neuropeptides, which are derived from the central and 
peripheral nervous system and play an important role in modulation of functions of 
various cell types (Peillon et al., 1991; Rozengurt, 2002). They are directly involved in 
cell signalling that is crucial for cellular metabolism, growth and differentiation. 
Neuropeptides consist of 3 to 40 amino acids in length and their biological activity is 
physiologically regulated by neuropeptidases, generally found on the neuronal cell 
surface (Isaac et al., 2009). It is clear then that disturbances of their enzymatic activity 
consequently affect biochemical pathways. The example of neuropeptidase is Pcp type 
II (PcpII) which catalyzes degradation of TRH by the removal of the N-terminal pGlu 
group (figure 1.7) (Cummins and O'Connor, 1998). The function of PcpII and 
inactivation of TRH are further discussed in section 1.2.4.2  
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Figure 1.7. The hydrolytic removal of the N-terminal L-pGlu of TRH catalysed by 
PcpII. The reaction yields inactive TRH and free pyroglutamic acid. 
 
 
          In the case of TRH, the pyroglutamyl residue was shown to play an important 
structural role as the lactam ring carbonyl of the pGlu moiety interacts with the tyrosyl 
residue of the TRH receptor (Perlman et al., 1994). Interestingly, it has been 
demonstrated that any structural alterations in the pGlu ring negatively affect hormonal 
efficiency and receptor binding ability (Hinkle and Tashjian, 1973). 
          Pharmacologically pGlu has become very popular since it is a natural component 
of human skin and its salts are found applicable in cosmetology mainly due to 
moisturising benefits (Lin et al., 1995; Marty, 2002; Oshimura et al., 2007). Moreover, 
administration of D,L-pGlu arginine salts prevents both electroconvulsive shock and 
scopolamine-induced amnesia in rats as well as improves cognitive properties (Spignoli 
et al., 1987). Application of synthetic pGlu modifications to therapeutic peptides is 
beneficial for prolongation of their half-life in body. Such an example is 
pGlu-containing glucose-dependent insulinotropic polypeptide (GIP), gastric inhibitory 
polypeptide or glucagon-like peptides which are resistant to degradation by dipeptidyl 
peptidase IV (O'Harte et al., 2002; Green et al., 2004; Irwin et al., 2005). On the other 
hand, presence of pGlu may also be a problem. For example, therapeutic administration 
of glutamine to the gastrointestinal tract may be difficult due to possible conversion to 
pGlu, therefore the N-terminal amino acid modifications, such as Gly-Glu are used to 
overcome this problem (Jiang et al., 2006). Similarly, derivatization of the N-terminal 
pGlu group was shown to be effective protection against drug degradation by Pcps 
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(Moss and Bundgaard, 1992). Importantly, in several neurodegenerative disorders pGlu 
peptides are believed to initialize the formation of toxic deposits and therefore 
contribute to the pathogenesis (Saido, 2000). In Alzheimer’s pGlu modification is found 
in Aβ peptides as a result of cyclisation of glutamic residues at the position 3 and 11. 
This increases the hydrophobic properties of the peptides triggering their aggregation 
that contributes to the disease progression and is discussed in detail in section 1.1.3.3. 
1.2.3. Prokaryotic pyroglutamyl peptidases 
          Pcp activity was first discovered in P. fluorescens in 1968 and has since been 
reported and characterised in a variety of bacterial, plant and animal sources (Doolittle 
and Armentrout, 1968; Cummins and O'Connor, 1998). Biochemical studies resulted in 
this group of enzymes to be subdivided into two classes –type I and type II. The type I 
Pcps (PcpI) are cysteine proteases expressed both in prokaryotic and eukaryotic 
organisms, whereas type II Pcps (PcpII) are large zinc metallopeptidases and so far have 
been found in mammalian cells only (Cummins and O'Connor, 1998). PcpII are 
furthered described in section 1.2.4.2.  
          Bacterial and archaeal Pcps have been most extensively studied. This has resulted 
in the observation that they have high sequence and structural similarity. They all 
function intracellularly in either a dimeric or tetrameric form with an average subunit 
molecular mass of 25 kDa and an average polypeptide chain length of 215 aa.          
Amino acid sequence alignment shows up to 40% identity between respective bacterial 
and archaeal Pcps and up to 76% in the most conserved segments (Cummins and 
O'Connor, 1998). Moreover, there are no significant similarities to other known proteins 
(Awade et al., 1994). Analysis of Bacillus subtilis, Streptococcus pyogenes or  
P. fluorescens genomes revealed that the pcp gene is present in a single copy and low 
transcript levels imply poor mRNA stability or weak protein synthesis (Awade et al., 
1992a; Cleuziat et al., 1992; Gonzales and Robert-Baudouy, 1994). There is also 
suggestion of a possible bacterial mechanism controlling the enzyme expression, which 
may be supported by the identification of putative ferric uptake regulator (FUR) binding 
site within the P. fluorescens pcp gene promoter (Le Saux and Robert-Baudouy, 1997). 
Moreover, the same study demonstrated that Pcp synthesis is induced by pGlu acid and 
down-regulated by iron. As yet, not much is known about the exact physiological role 
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of prokaryotic Pcp. Some suggestions have been made, pointing to a possible 
involvement of the enzyme in protein maturation and degradation, as well as in 
detoxification of the bacterial cell cytoplasm form of pGlu peptides (Awade et al., 
1994). Exogenous pGlu-peptide could also be degraded in order to get essential 
nutrients. However, these suggestions are not conclusive and need further evidence 
since numerous bacterial strains, such as Escherichia coli show a lack of Pcp activity 
(Mulczyk and Szewczuk, 1970).  
          Despite the identification of enzymatic activity in a variety of organisms, to date 
structural information has been gained only from bacterial and archaeal Pcp 
homologues. All Pcp members with characterized protein structure along with source 
organisms and Protein Data Bank (PDB, www.pdb.org) accession codes are listed in 
table 1.1. 
 
SOURCE ORGANISM PDB ID REFERENCE 
b
a
ct
er
ia
 
Bacillus anthracis 3LAC unpublished 
Staphylococcus aureus 3GIU unpublished 
Thermus thermophilus 2EBJ unpublished 
Bacillus amyloliquefaciens 1AUG (Odagaki et al., 1999) 
a
r
c
h
e
a
 
Pyrococcus horikoshii 1IU8 (Sokabe et al., 2002) 
Pyrococcus furiosus 1IOF (Tanaka et al., 2001) 
Thermococcus litoralis 1A2Z (Singleton et al., 1999) 
 
Table 1.1. List of bacterial and archaeal Pcp homologues with known protein structure. 
These prokaryotic peptidases are the only source of structural information concerning 
Pcps so far. 
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          Structural comparison of Pcp homologues shows the high similarity with minor 
differences which, however, are thought to be responsible for their individual 
biochemical properties. A study shows that the enzymes from hyperthermophile 
archaeal sources exhibit higher catalytic activity and elevated protein thermostability 
than their mesophilic counterparts (Ogasahara et al., 2001). For example, Pcp from  
Bacillus amyloliquefaciens denatures at around 50ºC, whereas the P. furiosus 
counterpart and its oxidized form denature at 105ºC and 115ºC, respectively 
(Kabashima et al., 2001; Ogasahara et al., 2001). 
          One of the first solved Pcp structures was archaeal enzyme from Thermococcus 
litoralis, which has been determined to a resolution of 1.7 Å (PDB 1A2Z) 
(Singleton et al., 1999). The native Pcp exists as a homotetramer of 96 kDa with 
overall dimensions of 78 Å x 65 Å x 52 Å and possesses a 222 point symmetry  
(figure 1.8). The centre of the T. litoralis enzyme is hydrophobic and contains  
a unique motif consisted of four β-hairpins, one from each monomer. One of the 
β-strands in each hairpin is build by amino acid residues Phe-Phe-Leu-Leu at 
positions 179 to 182 in the sequence. This highly hydrophobic insertion has been 
considered as a feature that may contribute to protein thermostability, however it 
has not been found in other thermophilic Pcp homologues.  
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Figure 1.8. Cartoon diagram representing the Pcp homotetramer form T. litoralis (PDB 
1A2Z). Each one of the subunits is labelled and shown in different colour. The disulfide 
bond between subunits A and B or C and D is coloured in red. The unique hydrophobic 
core in the centre of the tetramer is created by four β-hairpins from each monomer and 
is thought to significantly contribute to protein stability (Singleton et al., 1999). 
 
 
          The other factor that may enhance protein stability is the presence of 
inter-subunit (A-B and C-D) disulfide bridges between Cys190 residues, which has 
been observed to remain intact even under strongly reducing conditions (Singleton 
et al., 1999). Apart from T. litoralis this interaction appears only in Pcp from P. 
furiosus and is generally uncommon in intracellular enzymes (Tanaka et al., 2001). 
Interestingly, mutagenesis of corresponding Ser185 to cysteine in B. 
amyloliquefaciens enzyme and consequent creation of inter-subunit disulfide 
bridge also greatly increased its thermal stability (Kabashima et al., 2001).   
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          The fact that known hyperthermophilic Pcps differ by some small but 
important structural features led to the conclusion that the origin of high stability 
does not arise from a single factor. In individual proteins enhanced thermostability 
is considered to be a result of increased hydrophobic or ionic interactions, stable 
secondary structure, improved hydrogen bonding, favourable packing and 
advanced oligomerization or their combination (Kumar et al., 2000; Trivedi et al., 
2006).  
          Each 24 kDa T. litoralis Pcp monomer consists of 220 amino acid residues 
creating polypeptide chain folded into a single, ‘comma-shaped’ α/β domain with 
dimensions 40 Å x 36 Å x 23 Å. All of the Pcp structures characterized so far 
share common tertiary organization of the monomer, comprised of a 
seven-stranded β-sheet centre twisted by ~90º and surrounded by five α-helices. 
Structural secondary elements of the T. litoralis Pcp monomer with α-helices and 
β-strands sequentially labelled α1-α5 and βA-βK, respectively, are presented in 
figure 1.9.  
 
 
 
 
 
 
 
 
 
Figure 1.9. Cartoon representation of the Pcp monomer from T. litoralis . Secondary 
structure elements are sequentially labelled α1-α5, 310 and βA-βK, respectively. 
Polypeptide N-terminus is marked as N (blue) and C-terminus is marked as C (red). A 
fragment between strands βE and βG creates small ‘insertion’ subdomain.  
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          A subunit fragment between strands βE and βG (from residues 70 to 138) forms 
small ‘insertion’ subdomain (Singleton et al., 1999). This constitutes one face of the 
Pcp monomer formed by long disordered loop and a double-stranded (βF and βG) 
anti-parallel β-sheet. Another significant structural fragment is two-stranded (βJ and βK) 
anti-parallel β-sheet proceeded by a short 310 helix which participates in the 
formation of the tetrameric hydrophobic centre. Both aforementioned substructures 
also are involved in hydrophobic interactions between respective protein subunits. 
The most disordered part of the polypeptide chain is its C-terminus, which is a 
long loop after α5 helix running back towards the β-sheet centre. 
          Sequential conservation throughout Pcps and mutational analysis led to 
suggestions that the Cys-His-Glu triad is involved in the catalytic mechanism 
(Yoshimoto et al., 1993; Awade et al., 1994). In T.litoralis Pcp the catalytic triad – 
Glu80, Cys143 and His167 – occupies a hydrophobic pocket and is distributed on the 
central β-sheet and one of the α-helices (figure 1.10). The catalytic cysteine resides on 
the N-terminus of helix α4 in opposition to His167 and Glu80 located on βI and βE, 
respectively. The Sγ of Cys143 makes a hydrogen bond of 3.46 Å in length with the Nε 
of His167. The other His167 nitrogen – Nδ is hydrogen-bonded to the Glu80 Oε with a 
distance of 2.86 Å. This suggests the role of Glu80 in stabilization and proper 
orientation of His167 imidazolium ring. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. A diagram representing active site residues of T. litoralis Pcp. Proposed 
catalytic triad – Glu80, Cys143 and His167 are presented in stick mode and distances 
between them are shown in angstroms (Å) (Singleton et al., 1999).  
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          Analysis of the crystal structure of Pcp from B. amyloliquefaciens revealed that 
its active site contains a hydrophobic S1 binding pocket suitable to accommodate the 
pyroglutamyl residue (Ito et al., 2001). This pocket has also been seen in T. litoralis 
enzyme and is lined with well conserved hydrophobic residues Phe9, Phe12, Val44, 
Ile91, Tyr141 and Leu143. There is no other defined main chain substrate-binding areas 
apart from this, which may explain the broad enzyme substrate specificity (Ito et al., 
2001). Co-crystallization of the Bacillus Pcp with the transition state analogue inhibitor 
5-oxo-pyrrolidine-2-carbaldehyde has enabled the analysis of the mechanism of 
substrate recognition by the enzyme active centre (Ito et al., 2001). In the structure, the 
pyrrolidone ring of the inhibitor has been located in the hydrophobic pocket composed 
of Phe10, Phe13, Thr45, Ile92, Phe142 and Val143 whereas the inhibitor has been seen 
to make two hydrogen bonds with the main chain of the enzyme  
(main chain71:O···H-N:Inhibitor and Gln71:N-H···OE:Inhibitor). Interestingly, the 
pyrrolidone ring of the inhibitor and the benzene rings of three Phe residues of the 
pocket appear to be almost parallel and they play a crucial role in proper nesting of the 
substrate. A large movement of Phe142 was observed in the crystal structure with 
bound inhibitor when compared to the unbound form and, together with Phe13, both 
residues were proposed to be involved in an induced fit mechanism. Multiple sequence 
alignments show that three phenylalanines (Phe10, Phe13 and Phe142 – B. 
amyloliquefaciens Pcp numbering) are conserved in all Pcp sequences with rare 
replacements of Phe13 and Phe142 by Tyr residues in some enzymes (Ito et al., 2001). 
This replacement however may not be meaningful as Phe142Tyr mutagenesis 
experiments in B. amyloliquefaciens Pcp resulted in no change of kinetic 
performance of the enzyme. The conservation of Gln71 is not high, but it is the main 
chain that is involved in hydrogen bonding with the substrate, which suggests that the 
residue type may not be important. 
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          Pcp type I enzymes have been assigned to C15 family, which is a single member 
of the CF clan of cysteine peptidases (Rawlings et al., 2010). The primary and tertiary 
structure of PcpI shows no discernable similarity to any other peptidase in the family; 
hence it is associated with the separate clan CF.  
          Cysteine peptidases represent a separate class of enzymes, which have been 
identified in variety of organisms and are distinguished by their characteristic catalytic 
mechanism and active site. The hydrolytic pathway of cysteine peptidase is shown in 
figure 1.11. In the active site the cysteine thiolate is stabilized by the nitrogen of the 
neighbouring histidine imidazolium ring. In some cysteine peptidases containing 
catalytic triad, the imidazolium ring is orientated by the third residue such as 
asparagine, aspartate or glutamate, which helps to charge one of its nitrogen atoms. 
There are many of the enzymes however, which possess only Cys-His dyad. In the first 
step of catalytic pathway, the cysteine thiolate carries out the nucleophilic attack on the 
carbonyl moiety of the peptide bond. This results in the formation of a tetrahedral 
transition state and subsequent release of the acyl-enzyme thioester intermediate and 
amine product. In a second step the thioester intermediate is attacked by a water 
molecule which leads to the formation of second tetrahedral intermediate and finally the 
liberation of carboxylic acid product and regeneration of free enzyme. It is worth noting 
that serine peptidases display similar catalytic mechanism as cysteine peptidases, but in 
former enzymes it is based instead on an active site serine residue, where its hydroxyl 
oxygen functions as a nucleophile.  
          The cysteine thiol group is very reactive and can form complexes with metal ions 
or be rapidly oxidised that can result in the creation of disulfide bonds or higher 
oxidation states such as sulfenic, sulfinic, and sulfonic acids. In order to prevent this 
occuring, type I Pcps strictly require a thiol-reducing agent such as β-mercaptoethanol 
or dithiothreitol (DTT) to maintain catalytic activity (Prasad, 1987). Consequently, 
many sulfhydryl-blocking reagents, such as N-ethylmaleimide or 2-iodoacetamide, 
display strong inhibitory effect towards this class of cysteine peptidases (Bauer and 
Kleinkauf, 1980; Cummins and O'Connor, 1996).  
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Figure 1.11. The catalytic mechanism of cysteine peptidase with the Cys-His dyad. 
Nucleophilic attack of thiolate on the carbonyl group of the peptide bond results in the 
formation of a thioester acyl-enzyme intermediate. In the subsequent step the thioester 
is hydrolysed, which leads to the release of carboxylic acid product and regeneration of 
the catalytic centre.  
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          A particular feature of PcpI enzymes is their broad substrate specificity regarding 
the amino acid following the N-terminal pGlu with the exception when the second 
position is occupied by a proline residue (Mudge and Fellows, 1973; Browne and 
O'Cuinn, 1983). The only exemption from this rule is the Pcp isolated from Klebsiella 
cloacae, which is able to hydrolyse the pGlu-Pro bond (Kwiatkowska et al., 1974). 
Moreover, this homologue is associated with a particulate fraction, unlike the Pcps from 
other sources which have been shown to be soluble proteins (Kwiatkowska et al., 1974; 
Tsuru et al., 1978; Awade et al., 1992a; Awade et al., 1992b). Studies showed that 
prokaryotic Pcps can process a variety of  biologically active peptides as well as 
synthetic substrates such as pGlu-p-nitroanalide or pGlu-β-naphtylamide (pGlu-βNA) 
(Cummins and O'Connor, 1998). Despite that, the enzyme is very sensitive to even 
minor alterations in the pGlu structure, which may significantly impair its ability to 
hydrolyse the peptide bond (Capecchi and Loudon, 1985). This finding is believed to be 
potentially useful in the development of pro-drugs resistant to Pcp degradation.  
          Although Pcps exhibit no discernible structural similarity to any member of 
cysteine protease family, they do, however, resemble other enzyme classes in terms of 
fold or topological features. One example is carboxypeptidase A from Bos taurus (PBD 
2CTB) which was observed to display significant homology to T. litoralis Pcp 
(Singleton et al., 1999). Superimposition of both structures results in 2.0 Å root mean 
square deviation (RMSD) between their Cα atom positions over 100 out of 220 Pcp 
residues. Moreover, the location of the catalytic residues is almost identical and the 
position of catalytic zinc ion in carboxypeptidase A is only 1.2 Å away from Cys143-Sγ 
in Pcp. The other enzyme that also exhibits structural similarity is E. coli purine 
nucleotide phosphorylase (PDB 1A69) (Singleton et al., 1999). Both proteins’ Cα 
backbones superimpose with 1.9 Å RMSD over 119 out of 220 Pcp residues. The high 
structural homology may be considered as evidence that these three enzymes evolved 
from a common ancestor and could be classified in one super-family of enzymes. 
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1.2.4. Eukaryotic pyroglutamyl peptidases 
          Eukaryotic enzymes displaying N-terminal pyroglutamyl removal activity have 
been divided into two types on a mechanistic basis (Szewczuk and Kwiatkowska, 
1970). In mammalian tissues Pcp exist in three distinct enzymatic forms: PcpI (EC 
3.4.19.3), PcpII (EC 3.4.19.6) and serum thyroliberinase (EC 3.4.19.6) (Barrett et al., 
1998; Cummins and O'Connor, 1998). To date the enzyme activity or pcp genes have 
been identified in a range of protozoa, fungi, plant and animal organisms (Rawlings et 
al., 2010). Contrary to archaeal and bacterial homologues, as yet there is no information 
on the PcpI nor PcpII structure from any eukaryotic source.  
1.2.4.1. Pyroglutamyl peptidase type I 
          A eukaryotic PcpI functions intracellularly as a soluble, cytosolic cysteine 
peptidase and is classified, as its prokaryotic counterparts, as a member of C15 family 
(Rawlings et al., 2010). So far it has been reported to occur in various mammalian 
tissues including human cerebral cortex, liver, kidney, pancreas, skeletal muscle and 
semen; rat, bovine and guinea pig brain (Cummins and O'Connor, 1998; Valdivia et al., 
2004). Immunohistochemical studies have helped to localize the enzyme also in the 
pituitary, hypothalamus, adenohypophysis and renal proximal tubules. PcpI activity is 
relatively high in vertebrate liver and kidney when compared to other tissues. There are 
also observed sex differences and age-related changes in the native serum 
pGlu-substrate hydrolyzing activity (Martinez et al., 1999). Non-mammalian type I 
Pcps have been noted in avian, fish and amphibian tissues (Albert and Szewczuk, 1972; 
Tsuru et al., 1982). In a number of plants the enzyme activity has been found in leaves, 
seeds, sprouts and roots (Szewczuk and Kwiatkowska, 1970). The amino acid sequence 
is known amongst others for Pcp homologues from rat (Abe et al., 2003), bovine 
(Kilbane et al., 2007), mouse and human (Dando et al., 2003) sources and with the 
growing genome sequencing data now available this number will increase. 
 
60 
 
          Mammalian enzymes have been identified to be monomers of relatively low 
molecular mass of about 24 kDa (Cummins and O'Connor, 1998; Dando et al., 2003; 
Kilbane et al., 2007). The first report of the cloning and sequencing of a vertebrate 
pyroglutamyl peptidase was published by Dando and co-workers and concerned the 
human (AJ278828) and mouse (AJ278829) PcpI homologues (Dando et al., 2003).  
A biochemical study shows that eukaryotic PcpI enzymes resemble prokaryotic 
counterparts in terms of their broad pyroglutamyl substrate specificity and an absolute 
requirement for thiol-reducing reagents to maintain activity (1.2.3). Moreover, upon 
treatment with micromolar concentrations of thiol-blocking inhibitors, human PcpI 
loses its activity (Dando et al., 2003). This implies that the free cysteine thiol group is 
important for the catalytic reaction. Interestingly, the influence of reducing agents has 
been shown to be tissue specific – inhibitory for brain and serum Pcps and stimulating 
for liver, spinal cord, kidney and adrenal activity (Prasad, 1987). Multiple amino acid 
sequence alignment of human, mouse, B. amyloliquefaciens and T. litoralis Pcp 
representatives shows complete conservation of the catalytical Glu-Cys-His triad 
between the species (figure 1.12).   
 
Figure 1.12. Alignment of human, mouse, B. amyloliquefaciens and T. litoralis Pcp 
amino acid sequences. The sequences were aligned using the ClustalX2 software 
(Larkin et al., 2007). The conserved catalytic triad residues Glu85, Cys149 and His168 
(human PcpI numbering (Dando et al., 2003)) are marked in red. Other conserved 
residues are marked in green and conserved prolines, which tend to occur at the end of 
β-strands, are marked in blue. It is worth noting that T. litoralis Pcp contains 
hydrophobic insertion (marked in yellow) that participates in the formation of the 
tetrameric hydrophobic core (1.2.3) and does not appear in mammalian homologues. 
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          The alignment shows greater sequence conservation between the species within 
the N-terminal region and relatively low similarity in the C-terminal part (figure 1.12). 
The interesting insertion in the T. litoralis Pcp sequence consisted mostly of 
hydrophobic residues 177-182 (marked in yellow in figure 1.12) and is lacking in the 
mammalian homologues. Moreover, Dando and co-workers performed a modelling of 
human PcpI using structures of T. litoralis (PDB 1A2Z) and B. amyloliquefaciens (PDB 
1AUG) enzymes as templates (Dando et al., 2003). The comparison of T. litoralis Pcp 
monomer and the human PcpI model is presented in figure 1.13. Despite the 
evolutionary distance between the species, there is a significant resemblance in the 
organization of secondary structural elements. It is worth noting that among the 
conserved residues there are six prolines which tend to occur at the β-strand end (figure 
1.12).  However, there is a striking difference in the T. litoralis Pcp structure that 
possesses the extended loop (marked with dashed line in figure 1.13). This region is 
involved in formation of the tetramer hydrophobic core (1.2.3) and may contribute to 
protein thermostability. The lack of such a loop in the model has been suggested as an 
explanation why human PcpI physiologically exists as a monomer (Dando et al., 2003). 
 
Figure 1.13. Comparison of T. litoralis Pcp monomer structure (A) with human PcpI 
model (B). Structural α-helices, β-strands and loops are shown in red, yellow and green, 
respectively. The distinctive extended loop in T. litoralis Pcp is marked with dashed line 
rectangle. Based on (Dando et al., 2003). 
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          Extended biochemical studies of human, mouse and bovine PcpI indicated that 
mammalian enzymes are relatively unstable in vitro (Dando et al., 2003; Kilbane et al., 
2007; Mtawae et al., 2008). Both wild-type and recombinant human PcpI have been 
found unstable in most of the water-miscible, hydrophilic solvents. Thermal stability 
analysis showed that enzyme activity rapidly declines above 45ºC and the half-life at 
60ºC was estimated at 15 min. Moreover human PcpI remains active from pH 6.0 to 9.0 
(with maximal activity at pH 7.0-8.5) displaying Michaelis-Menten kinetics with Km 
value of 50 μM (Dando et al., 2003). A range of biologically active peptides such as 
bombesin, neurotensin, LHRH or leukopyrokinin are successfully hydrolysed by 
mammalian PcpI. The only exception is eledoisin possessing a proline residue at the 
second position. This is consistent with substrate specificity of prokaryotic enzymes 
also unable to cleave the pGlu-Pro bond (1.2.3). Other studies analyzing the hydrolysis 
of dipeptides and tripeptides by bovine PcpI showed that the enzyme displays much 
higher affinity for the latter substrates (Cummins and O'Connor, 1996; Kilbane et al., 
2007). Similarly to prokaryotic homologues, mammalian type I Pcps also exhibit 
absolute requirement for thiol-reducing agents (e.g. β-mercaptoethanol, DTT or 
tris(2-carboxyethyl)phosphine (TCEP)) in activity assays. The reducing environment is 
essential for cysteine peptidases to prevent the reactive thiol group of the catalytic 
cysteine from oxidation.  However, higher concentrations of these chemicals have 
inhibitory influence on the enzyme performance. PcpI activity is also diminished in a 
presence of reversible inhibitors such as 2-pyrrolidone and N-ethylmaleimide, 
sulfhydryl-blockers iodoacetate and iodoacetamide or transition metal ions including 
Ni
2+
, Zn
2+
 and Cu
2+
,  (Dando et al., 2003). Consequently, the latter inhibition has been 
seen to be partially recoverable by the addition of chelators such as 
ethylenediaminetetraacetic acid (EDTA) or by protein sample dialysis in order to 
remove the metal ions. 
          The ability of mammalian type I Pcps to process a variety of physiologically 
important molecules suggests its essential but as yet undefined role in peptide 
regulatory and degradation pathways. The possible functions of PcpI in a human body 
are further discussed in section 1.2.4.3. 
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1.2.4.2. Pyroglutamyl peptidase type II and serum thyroliberinase 
          Type II Pcp activity was first observed in synaptosomal membrane preparations 
of guinea pig brain (O'Connor and O'Cuinn, 1984). Since then it has been demonstrated 
in a variety of central nervous system tissues and appears to be preferably associated 
with postsynaptic membranes (Horsthemke et al., 1984; Garat et al., 1985; O'Leary and 
O'Connor, 1995). There are also PcpII activities detected in other body regions such as 
retina, lung or liver but none in heart, kidney and muscle (Vargas et al., 1992). The 
enzyme is wider known as thyrotropin-releasing hormone-degrading ectoenzyme 
(TRHDE) as it displays very narrow substrate specificity restricted to TRH, TRH 
analogues and TRH-like peptides (1.2.2) (Wilk and Wilk, 1989; Gallagher et al., 1997; 
Kelly et al., 1997). The only notable exception was observed for rat and porcine brain 
enzyme to slowly hydrolyze pGlu-βNA, which is a substrate often used in PcpI assays 
(Bauer, 1994). The high degree of TRH specificity led to PcpII being considered as a 
neuropeptide-specific peptidase, which is an important element of the mammalian 
regulatory system of hypothalamic/pituitary/thyroid axis (Jeffcoate and Hutchinson, 
1978; Wilk, 1986). There are reports regarding a stringent control of rat pituitary, 
adenohypophysial, but also liver PcpII and mRNA transcript levels by thyroid 
hormones and consequently the endocrine activity of TRH (Bauer, 1987, 1988; Suen 
and Wilk, 1989; Schomburg and Bauer, 1995).  
          PcpII activity has been identified both as membrane-anchored ectoenzyme, which 
the highest level is found in brain, and soluble serum enzyme originally referred as 
serum thyroliberinase (Taylor and Dixon, 1978; Bauer et al., 1981; O'Connor and 
O'Cuinn, 1984). Concurrent analytical comparison of membrane-bound brain and liver 
type II Pcps with soluble serum thyroliberinase, confirmed that all of them are derived 
from the same gene and exhibit identical enzymatic features (Schmitmeier et al., 2002). 
Moreover serum enzyme is generated via proteolytic processing of the particulate liver 
counterpart. An interesting discovery has been reported by the Chavez-Gutierrez group 
regarding production of truncated PcpII isoform (PPII*) in rat tissues  
(Chavez-Gutierrez et al., 2005). PPII* mRNA species are derived from alternative 
transcript processing resulting in generation of a shorter and inactive enzyme version 
which lacks a part of the C-terminal domain. The formation of covalent PcpII-PcpII* 
heterodimers has been found to reduce peptidase performance and is considered to 
represent a mode of catalytic activity control. 
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          The human enzyme consists of 1024 amino acids and the relatively sparse 
sequence differences between species are localized in a region C-terminal to the 
transmembrane domain (Schomburg et al., 1999). PcpII, like many surface peptidases, 
functions as homodimer of a relatively large molecular mass of subunit of around 
116 kDa (Bauer, 1994). A mutational study showed that the homodimerization occurs 
through the interchain disulfide bridge formed of two Cys68 residues of each subunit, 
located closely to the membrane-spanning domain (Papadopoulos et al., 2000). This 
covalent linkage, however, seems not to be important for enzyme activity and 
trafficking to the cell surface.  
          PcpII is a glycosylated metalloenzyme with a zinc ion being essential for catalytic 
activity and has been classified in M1 family of peptidases (Czekay and Bauer, 1993; 
Rawlings et al., 2010). The extracellular catalytic domain is well conserved among 
mammalian homologues and has been associated with the unusually narrow TRH 
hydrolysis specificity (Schomburg et al., 1999). Isolation of cDNA encoding human 
PcpII and deduction of the amino acid sequence has enabled identification of 12 
putative N-glycosylation sites as well as a characteristic consensus motif of the 
zinc-dependent metallopeptidases HEXXHX18E (Schomburg et al., 1999). This motif 
coordinates the Zn
2+
 ion within the catalytic centre (Vallee and Auld, 1990). 
Additionally the extracellular domain contains eight cysteine residues that are believed 
to be necessary to maintain an active protein structure (Papadopoulos et al., 2000). The 
study showed that PcpII can be inhibited by chelating agents such as 
1,10-phenanthroline, 8-hydroxyquinoline and EDTA, but its activity is not affected by 
specific PcpI inhibitors (Cummins and O'Connor, 1998).  
1.2.4.3. Physiological role of pyroglutamyl peptidase 
          The physiological role of PcpI, mainly due to its broad substrate specificity, still 
remains unclear. Since the enzyme activity is widely distributed and relatively high in 
tissues such as liver, kidney or skeletal muscles, it has been considered to play a 
significant role in peptide catabolism to free amino acids (Awade et al., 1994; Cummins 
and O'Connor, 1998). This may also include the regulation of free cellular pGlu level 
and its consequent biological implications (1.2.2). Awade and co-workers also 
suggested that PcpI could play a detoxification role because high concentrations of 
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pGlu-containing peptides are cytotoxic and could abnormally acidify the cytoplasm 
(Awade et al., 1994). A similar role has been suggested for prokaryotic Pcps in order to 
detoxify and assimilate nutrients from the external environment. PcpI could also 
participate in the absorption of peptides and proteins from the alimentary tract; this may 
be supported by the fact that the enzyme is found in the intestinal mucous membrane, 
duodenum and in small intestine (Albert and Szewczuk, 1972). A recent study showed 
that natural gluten peptides possess an N-terminal pGlu residue (Monsuur et al., 2006). 
Moreover the pcp gene is located in close proximity to the genes associated with coeliac 
disease susceptibility. However, the involvement of the Pcp enzymatic activity in the 
disease aetiology and pathology has been excluded. 
          Analysis of PcpI levels in rat retina and hypothalamus exposed to environmental 
light and dark conditions resulted in observations that the peptidase levels fluctuate 
periodically that implicates a possible association with the daily biological clock 
(Sanchez et al., 1996). Elevated PcpI activity has been observed in the spinal cord of 
patients suffering from motor neuron disease (Shaw et al., 1996). The condition is 
characterised by the deposition of ubiquitinated proteins in degenerating spinal cord 
nerve cells that also implicates a potential role of the peptidase in associated protein 
degradation. Contrary to that, the level of Pcp activity is decreased in human breast 
cancer and dysregulated in N-methyl nitrosourea-induced breast cancer that may 
suggest possible contribution of the enzyme towards initiation and progression of the 
pathology (Carrera et al., 2005).  
          PcpI ability to process a variety of physiologically important peptides suggests its 
potential but as yet undefined role in regulatory and degradation pathways in the central 
nervous system (CNS). The role of PcpI in the TRH degradation process has been 
studied. This showed that treatment of primary hypothalamic cell cultures with PcpI 
inhibitor, Z-Gly-Pro-CHN2, results in elevated levels of TRH (Faivre-Bauman et al., 
1986). Later, however, it was suggested that PcpI involvement may be marginal as the 
enzyme inhibition by pGlu-diazomethylketone does not significantly affect the TRH 
concentration either in vivo or in vitro (Charli et al., 1987). Moreover, immunoblot 
analysis confirmed the cytosolic localization of PcpI in pituitary gland cells, which are 
the target of TRH (Abe et al., 2004). This finding suggests that the enzyme may not 
contribute to TRH hydrolysis since neuropeptides are thought not to access the cytosol. 
Interestingly, studies show that the Km values for TRH hydrolysis are similar for both 
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mammalian PcpI and PcpII which indicates equivalent substrate affinity between both 
enzymes (Gallagher and O'Connor, 1998; Schomburg et al., 1999; Abe et al., 2004). 
          The cytosolic location of PcpI precludes its involvement in extracellular peptide 
catabolism. Cummins and co-workers have suggested therefore that PcpI may be a part 
of the intracellular degradation mechanism which counteracts an excessive production 
and secretion of neuropeptides (Cummins and O'Connor, 1998). This may happen in the 
case of suppression of neuropeptide-synthesising cells. The other proposal assumes that 
such peptides released from ageing or damaged vesicles may be returned back to the 
cell, supply amino acid pool and be re-incorporated into biosynthetic pathways 
(O'Cuinn et al., 1990). Intracellular peptidases have been observed to undergo 
significant changes during brain development and, regarding this, PcpI has also been 
proposed to participate in maturation of the cerebellum and brain cortex (de Gandarias 
et al., 1998). Lastly, a potential involvement of brain pyroglutamyl peptidase activity in 
the propensity of amyloid peptides is a particularly striking matter (He and Barrow, 
1999). The formation of insoluble deposits consisting of pGlu-containing Aβs is a 
prominent feature in Alzheimer’s pathology. Therefore the study of the linkage between 
the disease origin and physiological role of both PcpI and PcpII activities in brain seems 
to be particularly interesting for Alzheimer’s therapy. 
1.2.5. Application of pyroglutamyl peptidases 
          The presence of the N-terminal pGlu group is very problematic during the 
preparation of peptides for sequencing via Edman degradation procedure (Edman and 
Begg, 1967). Therefore, enzyme preparations, such as calf liver PcpI, are found 
commercially useful for peptide and protein unblocking to enable sequencing by this 
method (Leone et al., 2011). Detection of Pcp activity is commercially applied in 
bacterial diagnostic, since the enzyme is not present in all of the strains (Mulczyk and 
Szewczuk, 1970). Analytical tests using chromogenic and fluorogenic pGlu substrates 
have been developed for differentiation of Enterobacteriacea, Staphylococci and other 
species (Mulczyk and Szewczuk, 1970, 1972; Facklam et al., 1995). 
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          Particularly archaeal Pcps seem to be an interesting enzymatic tool due to their 
enhanced thermostability as they could be utilized in reaction conditions that are 
unfavourable for mesophilic homologues. They could be employed in conventional 
chemical synthesis where pGlu is introduced to the peptides and proteins as a protecting 
group and then needs to be specifically removed. Thermostable enzymes are more 
resistant to organic solvents, which are used in such reactions. Contrary to that, in vitro 
instability of wild type mammalian PcpI counterparts is problem, which decreases  their 
potential applicability in peptide processing (Mtawae et al., 2008).  
1.3. Aims of project 
 
The aims of this project included: 
 Stability and structural study on human PcpI 
 Overexpression and structural study on human PcpII 
 Comparative study on localisation and distribution of PcpI and PcpII in human AD 
and normal brain tissues 
 Involvement of PcpI in processing of pGlu-modified Aβ peptides 
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Chapter 2 – General Materials and Methods 
 
2.1. Reagent grade chemicals and equipment 
          All enzymes and reagents used in molecular biology were obtained from Promega 
Ltd, Fermentas or New England BioLabs. General reagents used for the preparation of 
buffers and solutions were obtained from Sigma Aldrich (UK) and Melford 
Laboratories Ltd (unless otherwise stated) and were of the best available quality. 
Double distilled (ddH2O; Neptune, Purite Ltd) and autoclaved (Priorclave Compact 60, 
Priorclave Ltd) water was used for the preparation of the solutions for DNA and enzyme 
reactions. All purification columns employed in chromatography were obtained from 
Amersham Biosciences and were used and stored according to the manufacturer’s 
instructions.  
2.2. Growth media and antibiotics 
2.2.1. Luria-Bertani broth (LB) 
          25 g of LB broth powder (Melford Laboratories Ltd) was dissolved in 1 L of 
ddH2O (Purite Ltd) and sterilized in the autoclave for 20 min at 120ºC and 15 psi 
(Priorclave Compact 60, Prioclave). An appropriate antibiotic (2.2.4) was added to  
the cooled media prior to use. 
 
2.2.2. Selective agar plates 
 
          15 g of bacteriological agar (Agar No.1, Oxoid) was dissolved in 1 L of LB broth 
(2.2.1) and autoclaved for 20 min at 120ºC and 15 psi. An appropriate antibiotic (2.2.4) 
was added to the cooled liquid agar (~50ºC) and it was poured into Petri dishes (90 mm 
diameter) and left until solid. Plates with set agar were stored at 4ºC and warmed up to 
37
o
C prior to use. 
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2.2.3. SOC medium 
          Premade SOC medium was obtained from Invitrogen and was used in the final 
step of cell transformation with DNA substrate (2.7.1). The composition of the 
medium per 1 L was as follows: 
2%  tryptone 
0.5%  yeast extract 
10 mM  NaCl 
2.5 mM  KCl 
10 mM  MgCl2•6H2O 
20 mM  glucose 
2.2.4. Antibiotics and other basic solutions 
          Solutions of the antibiotics, isopropyl-β-D-thiogalactopyranoside (IPTG) and 5-
bromo-4-chloro-3-indolyl-β-D-galacto-pyranoside (X-gal) were prepared using 
autoclaved ddH2O or reagent grade ethanol (Fisher Scientific UK Ltd) and sterilized  
by filtration using Minisart NML syringe filters (Sartorius UK). Next the solutions were 
aliquoted and stored at -20
o
C. Stock concentrations of antibiotics, IPTG and X-gal are 
listed in table 2.1. 
SOLUTION STOCK CONCENTRATION SOLVENT 
Ampicillin 100 mg/ml water 
Carbenicillin 50 mg/ml water 
Chloramphenicol 35 mg/ml ethanol 
Gentamicin 20 mg/ml water 
Kanamycin 50 mg/ml water 
Tetracycline 12.5 mg/ml 70% ethanol 
   
IPTG 1 M water 
X-gal 20 mg/ml DMSO/DMF 
 
Table 2.1. Concentrations of the stock solutions used in the growth media 
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2.3. Buffers and basic solutions 
          All buffers were filtered using a 0.22 μm nylon membrane filter (Whatman) and 
FilterSys™ FilterSystem glassware (Phenomenex). Buffer pH was adjusted at room 
temperature using Whatman PHA 2000 pH meter, which was calibrated immediately 
prior to use. Composition of buffers used in particular procedures and experiments are 
listed below. 
2.3.1. Agarose gel electrophoresis 
TAE Buffer (pH 8.0) 
40 mM Tris acetate 
5 mM sodium acetate 
1 mM EDTA 
2.3.2. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Stacking gel  6.0% 
Acrylamide/Bis-acrylamide (30/0.8% w/v) 2.0 ml 
0.5 M Tris-HCl pH 6.8 2.5 ml 
10% (w/v) SDS water solution 1.0 ml 
10% (w/v) APS water solution 100 µl  
TEMED 10 µl 
ddH2O 4.5 ml 
  
Separating gel 12.5% 8.0% 
Acrylamide/Bis-acrylamide (30/0.8% w/v) 4.2 ml 2.7 ml 
1.5 M Tris-HCl pH 8.8 2.5 ml 2.5 ml 
10% (w/v) SDS water solution 1.0 ml 1.0 ml 
10% (w/v) APS water solution 100 µl 100 µl  
TEMED 10 µl 10 µl 
ddH2O 2.3 ml 3.8 ml 
 
TEMED and APS were added to each gel solution to initiate polymerisation 
immediately before pouring between the glass plates. 
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Running buffer (pH 8.8) Sample loading buffer 
5 mM Tris-HCl 125 mM Tris-HCl pH 6.8 
0.38 M glycine 2% (w/v) SDS 
0.1% (w/v) SDS 20% (v/v) glycerol 
 0.001% (w/v) bromophenol blue 
 0.005% (v/v) β-Me 
 
Coomassie Blue stain 
0.05% (w/v) Coomassie Blue stain 
50% (v/v) methanol 
10% (v/v) acetic acid 
2.3.3. Protein purification  
2.3.3.1. Tris-HCl buffers (pH 7.5) – 6xHis-PcpI purification 
Lysis buffer Buffer A Buffer B Buffer C 
50 mM Tris-HCl 50 mM Tris-HCl 50 mM Tris-HCl 50 mM Tris-HCl 
8 mM β-Me 8 mM β-Me 8 mM β-Me 10 mM DTT 
20 mM Imidazole  1 M Imidazole 0.1 M NaCl 
1 mM PMSF   1 mM EDTA 
2.3.3.2. K2HPO4/KH2PO4 buffers (pH 8.0) 
Lysis buffer Buffer A 
50 mM K2HPO4/KH2PO4 50 mM K2HPO4/KH2PO4 
5 mM β-Me 5 mM β-Me 
20 mM Imidazole  
1 mM PMSF  
  
Buffer B Buffer C 
50 mM K2HPO4/KH2PO4 50 mM K2HPO4/KH2PO4 
5 mM β-Me 10 mM DTT 
1 M Imidazole 0.1 M NaCl 
 1 mM EDTA 
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2.3.3.3. Tris-HCl buffers (pH 7.5) – PcpI-6xHis purification 
Lysis buffer Buffer A Buffer B Buffer C 
50 mM Tris-HCl 50 mM Tris-HCl 50 mM Tris-HCl 50 mM Tris-HCl 
0.15 M NaCl 0.15 M NaCl 0.15 M NaCl 0.15 M NaCl 
5 mM β-Me 5 mM β-Me 5 mM β-Me 10 mM DTT 
20 mM Imidazole  0.5 M Imidazole 1 mM EDTA 
1 mM PMSF    
2.3.3.4. Tris-HCl buffers (pH 7.5) – native PcpI purification 
Lysis buffer Buffer A Buffer B 
50 mM Tris-HCl 50 mM Tris-HCl 50 mM Tris-HCl 
1.5 M (NH4)2SO4 1.5 M (NH4)2SO4 10 mM DTT 
10 mM DTT 10 mM DTT 1 mM EDTA 
1 mM EDTA 1 mM EDTA  
1 mM PMSF   
  
Buffer C Buffer D 
50 mM Tris-HCl 50 mM Tris-HCl 
1.5 M NaCl 0.15 M NaCl 
10 mM DTT 10 mM DTT 
1 mM EDTA 1 mM EDTA 
2.3.3.5. HEPPS buffers (pH 8.0) 
Lysis buffer Buffer A Buffer B Buffer C 
50 mM HEPPS 50 mM HEPPS 50 mM HEPPS 50 mM HEPPS 
0.1 M NaCl 0.1 M NaCl 0.1 M NaCl 0.1 M NaCl 
5 mM β-Me 5 mM β-Me 5 mM β-Me 10 mM DTT 
20 mM Imidazole  0.5 M Imidazole 1 mM EDTA 
1 mM PMSF    
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2.3.4. Activity assay 
Buffer F (pH 8.0) 
50 mM  K2HPO4/KH2PO4 
10 mM DTT 
2 mM   EDTA 
2.3.5. In-Fusion™ cloning 
TE buffer (pH 8.0) 
10 mM  Tris-HCl 
1 mM EDTA 
2.3.6. Phosphate buffered saline (PBS) buffers 
PBS buffer (pH 7.4) PBST buffer (pH 7.4) 
100 mM  Na2HPO4 100 mM  Na2HPO4 
2 mM KH2PO4 2 mM KH2PO4 
137 mM NaCl 137 mM NaCl 
2.7 mM KCl 2.7 mM KCl 
  0.05% Tween 
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2.4. Escherichia coli strains 
 
          The following cloning and expression strains were used in the experimental work 
during this project. 
2.4.1. DNA cloning strains 
a) Nova Blue (Novagen) 
genotype: endA1 hsdR17(rK
–
 mK
+
) supE44 thi-1 recA1 gyrA96 relA1 lac F′[proA+B+ 
lacI
q
ZΔM15::Tn10] (TetR) 
 
b) NEB 5-α (New England BioLabs) 
genotype: fhuA2Δ(argF-lacIqZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 
 
c) XL10-Gold® (Stratagene) 
genotype: Tet
R
 Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac Hte [F′proAB lacIqZΔM15 Tn10 (TetR) Amy CamR] 
 
d) OmniMAX™ 2 (Invitrogen) 
genotype: F′[proAB+ lacIq lacZΔM15 Tn10(TetR) Δ(ccdAB)] mcrA Δ(mrr-hsdRMS-
mcrBC) φ80(lacZ) ΔM15 Δ(lacZYA-argF) U169 endA1 recA1 supE44 thi-1 gyrA96 
relA1 tonA panD 
2.4.2. Protein expression strains 
a) BL21-CodonPlus (DE3)-RIPL (Stratagene) 
genotype: F
-
 ompT hsdS(rB
-
 mB
-
) dcm+ Tet
R
 gal λ(DE3) endA Hte [argU proL (CamR)] 
[argU ileY leuW Strep/Spec
R
] 
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b) ArcticExpress™ (DE3)RIL (Stratagene) 
genotype: F
-
 ompT hsdS(rB
-
 mB
-
) dcm+ Tet
R
 gal λ(DE3) endA Hte [cpn10 cpn60 GentR] 
[argU ileY leuW Str
R
] 
 
c) Rosetta™ 2(DE3) (Novagen) 
genotype: F
-
 ompT hsdSB(rB
-
 mB
-
) gal dcm (DE3) pRARE2 (Cam
R
) 
 
d) Rosetta-gami™ 2(DE3) (Novagen) 
genotype: Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE galK rpsL 
(DE3) F′[lac+ lacIq pro] gor522::Tn10 trxB pRARE (CamR, KanR, StrR, TetR) 
 
e) BL21(DE3)pLysS (Promega) 
genotype: F
-
 ompT hsdSB (rB
-
 mB
-
) dcm gal λ(DE3) pLysS (CamR) 
2.5. Preparation of chemically competent cells 
          Chemically competent cells were prepared  by treating with divalent cations using 
the method described by (Hanahan et al., 1991). A single colony of a given E. coli 
strain was used to inoculate 10 ml of sterile LB broth (2.2.1). The culture was grown 
overnight at 30ºC on a shaking platform at 200 rpm (E25 Temperature-Controlled 
Excella™ Shaker, New Brunswick Scientific Co., Inc.). Fresh LB media (2.2.1) with 
appropriate antibiotic was inoculated with 1/100 v/v overnight culture. This was grown 
at 37ºC until an OD595 of 0.4 was reached. The optical density measurement was carried 
out in WPA Biowave CO8000 Cell Density Meter (Walden Precision Apparatus, UK). 
The cells were pelleted at 3000xg for 10 min at 4ºC (Harrier 18/80, Sanyo). Cells pellets 
were washed with 20 ml of ddH2O to remove any contaminating antibiotics etc. and 
harvested again at 3000xg for 10 min at 4ºC. After that the cell pellet was gently re-
suspended in 20 ml of cold 100 mM MgCl2 (autoclaved stock) per 50 ml of initial 
culture volume and left on ice for 10 min. This was re-centrifuged at 3000xg for 10 min 
at 4ºC and the supernatant was discarded. The cell pellet was re-suspended in 5 ml of 
cold 100 mM CaCl2 (autoclaved stock) per 100 ml of initial culture volume and left on 
ice for 2 h. Alternatively, the cells were incubated overnight which enhanced cell 
competency. The super competent cells were mixed with an equal volume of 40% 
glycerol and left on ice for 15 min. Next 50 μl cell aliquots were transferred into pre-
chilled 1.5 ml tubes, immediately frozen in liquid nitrogen and stored at -80ºC. For 
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concurrent DNA transformations (2.7.1) fresh competent cell aliquot was taken directly 
prior to addition of glycerol. 
2.6. Glycerol stocks 
 
          In order to preserve bacterial cultures for further applications, working glycerol 
stocks of given bacterial strains were prepared. 0.5 ml of 40% v/v glycerol stock 
(autoclaved) was placed in a sterile 1.5 ml tube and mixed with 0.5 ml of the required 
overnight E. coli culture. This was flash frozen in liquid nitrogen and stored at -80ºC. 
Cell glycerol stocks were then directly used   to inoculate liquid LB media (2.2.1). 
2.7. Techniques used during work with DNA samples 
2.7.1. DNA transformation into competent cells 
          An appropriate amount of plasmid DNA was added to 50 μl aliquots of competent 
bacterial cells that were thawed on ice (2.5) (Hanahan, 1983). Competent cell samples 
were incubated on ice for 20 min followed by heat shock treatment at 42ºC for 45 s in a 
bench unstirred water bath (Grant Instruments Ltd) and then further incubated on ice for 
2 min. 150 μl of pre-warmed LB or SOC media (2.2.1 and 2.2.4, respectively) was 
added to each aliquot and incubated at 37ºC for 1 h in a shaking incubator (E25 
Temperature-Controlled Excella™ Shaker, New Brunswick Scientific Co., Inc.). 
Transformed cells were plated out onto Petri dishes containing agar with selective 
antibiotic (2.2.4). This was incubated overnight at 37ºC. 
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2.7.2. Plasmid preparation 
          Overnight E. coli cloning strain cultures harbouring the desired plasmid were 
harvested at 4ºC, 3000xg for 15 min in a cooling centrifuge (Harrier 18/80, Sanyo).  
The cell pellet was further subjected to plasmid extraction using the GeneJET™ 
Plasmid Miniprep kit (Fermentas) and GenElute
TM
 Plasmid Maxiprep (Sigma-Aldrich) 
kit according to the manufacturers’ instructions.  
2.7.3. DNA purification 
          Plasmid DNA obtained from mini- or maxipreparation (2.7.2) or a polymerase 
chain reaction (PCR) product, was purified and concentrated using the SureClean Plus 
kit (Bioline, UK) protocol in order to remove any contaminants such as buffer 
constituents, primers, non-specifics or enzymes. If the sample did not have to be 
quantitated, a pink synthetic polyacrylamide co-precipitant was used in order  
to facilitate visualization of cleaned-up nucleic acids. The SureClean Plus method is 
based on ethanol precipitation and is suitable if purified DNA is required for sequencing 
or cloning.  
2.7.4. DNA quantitation 
          DNA concentration was determined on the basis of absorbance measurement  
at 260 nm using WPA UV-1101 Biotech Photometer (Walden Precision Apparatus, 
UK) or NanoDrop 8000 micro-volume UV-Vis spectrophotometer (Thermo Scientific). 
The protein contamination was estimated according to the absorbance ratio A260/A280. 
A280 was frequently used to measure protein concentration. A ratio of A260/A280 > 1.8 
indicates little protein contamination in a DNA sample (Sambrook et al., 1989). 
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2.7.5. DNA digestion 
          Restriction enzyme cleavage of plasmid or PCR products was conducted  
to confirm the presence of the desired DNA fragments or to prepare DNA for 
subsequent cloning. The technique employs one or more restriction enzymes to 
selectively cut DNA strands into shorter fragments. Two different digestion methods 
were used – slow (2.7.5.1) and fast (2.7.5.2). Composition of the digestion reaction 
mixtures and protocol details are presented below. The results of the digestion were 
analyzed using DNA gel electrophoresis (2.7.8). 
2.7.5.1. Double digestion reaction – slow method 
          A digestion reaction was carried out at 37ºC for 3 h. The suitable buffer was 
chosen according to directions of the 4-CORE
®
 Buffer System (Promega) to maintain 
100% activity for the used restriction enzymes. The reaction mixture composition is 
shown below. 
 
x μl 0.5 μg/μl DNA (plasmid or PCR product) 
1 μl  10 U first restriction enzyme 
1 μl  10 U second restriction enzyme  
2 μl 10x restriction enzyme buffer 
0.2 μl 10 μg/μl BSA (bovine serum albumin)  
to a final volume of 20 μl ddH2O  
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2.7.5.2. Double digestion reaction – fast method 
          The digestion reaction was carried out using the FastDigest® system (Fermentas) 
at 37ºC for 15 min. The reaction mixture composition is shown below. 
 
x μl 0.5 μg/μl DNA (plasmid or PCR product) 
1 μl  10 U first FastDigest® restriction enzyme  
1 μl  10 U second FastDigest® restriction enzyme  
2 μl 10x FastDigest® buffer  
0.2 μl 10 μg/μl BSA   
to a final volume of 20 μl ddH2O  
2.7.6. DNA dephosphorylation 
          Linearized cloning vector (2.7.5) was dephosphorylated at the 5′ end with 
Antarctic Phosphatase (isolated from a recombinant E. coli source, New England 
BioLabs) in order to prevent its recircularization before ligation with insert DNA 
(2.7.7). The composition of the dephosphorylation reaction mixture is presented below. 
 
x μl 1-5 μg/μl plasmid DNA 
1 μl 5 U Antarctic Phosphatase 
1 μl 10x Antarctic Phosphatase reaction buffer 
to a final volume of 10 μl ddH2O 
 
The reaction was carried out for 15 min at 37ºC and heat-inactivated for 5 min at 65ºC. 
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2.7.7. DNA ligation 
          Linearized (2.7.5) and dephosphorylated (2.7.6) plasmid DNA was joined with 
prepared insert DNA using the T4 DNA ligase (isolated from bacteriophage T4, 
Promega). The ratio of plasmid to insert DNA was varied if necessary. The composition 
of ligation reaction mixture is presented below. 
 
1 μl 0.5-1 μg/μl plasmid DNA 
x μl insert DNA 
1 μl 5 U T4 DNA ligase 
1 μl 10x T4 DNA ligase reaction buffer 
to a final volume of 10 μl ddH2O 
 
The reaction was carried out for 1 h at 25°C or overnight at 4°C. The sample was 
heat-inactivated for 10 min at 65ºC and the reaction mixture used for transformation 
into competent cells (2.7.1). 
2.7.8. DNA gel electrophoresis 
2.7.8.1. Agarose gel preparation 
          The required amount of electrophoresis grade agarose (Melford labs, UK) was 
dissolved in TAE buffer (2.3.1) to make a 1% or 2% solution in case of  
an analytical or preparative procedure, respectively. The agarose suspension was heated 
in a microwave until completely melted. The agarose solution was cooled down and 
1 μl of ethidium bromide was added to a final concentration of 0.1 µg/ml. This was 
poured into a horizontal electrophoresis casting plate with a fixed well-forming comb. 
The gel was left to solidify for about 30 min before using. Once set it was immersed 
into TAE buffer in the electrophoresis tank (Mini-Sub
®
 CellGT, Bio-Rad UK). 
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2.7.8.2. Running and visualisation of gels 
          The DNA samples to be analyzed were mixed with 5x DNA loading buffer 
(Bioline, UK) and loaded into the agarose gel wells. To estimate the size of DNA, 
Hyperladder
TM
 I and Hyperladder
TM
 IV DNA markers (Bioline, UK) were applied, 
which allow for quantification of the fragments ranging from 200 bp to 10 kb and 
100 bp – 1 kb, respectively (figure 2.1). The gel was run at 80-100V (PowerPac Basic 
power supply, Bio-Rad UK) for approx. 45 min or until dyes in the gel had reached the 
required distance. Next the gel was removed from the tank, visualized at 312 nm  
and documented using a Bio-Doc-H
TM
 UV transilluminator (UVP). 
 
 
 
 
 
 
 
Figure 2.1. DNA markers Hyperladder
TM
 I and Hyperladder
TM
 IV (Bioline, UK) used 
for the estimation of DNA fragments size. Taken from www.bioline.com. 
2.7.9. DNA gel extraction 
         Gel extraction was carried out as a method of selective DNA isolation. DNA 
samples were run using 2% agarose gel electrophoresis (2.7.8). The extraction was 
performed using the silica-membrane-based DNA purification method with the 
QIAquick Gel Extraction kit (Qiagen UK) following the manufacturer’s instruction. 
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2.7.10. DNA sequencing 
          Standard sequencing of assayed DNA was conducted by Source BioScience UK 
Ltd using vector specific T7 or custom primers. All purified plasmid samples were 
supplied either as 100 ng/µl water solution or 1 μg air dried pellet. 
2.8. Techniques used during work with protein samples 
2.8.1. Protein extraction 
          The method of protein extraction from bacterial cells was chosen depending  
on the overexpression scale.  The detergent-based method (2.8.1.1) was used for small 
volume culture growth (100 ml) designed for qualitative determination of protein 
overexpression. The sonication method (2.8.1.2) was applied for larger culture volumes 
of 1 L and above designed mainly for protein purification. 
2.8.1.1. Detergent-based method 
          In order to extract the desired protein, pelleted bacterial cells were lysed with 
BugBuster
®
 10x Protein Extraction Reagent (Novagen), which was previously diluted  
in a suitable buffer of pH 8.0. The reagent is composed of Tris-buffer based mixture  
of non-ionic and zwitterionic detergents that enhance cell wall perforation with the 
avoidance of protein damage. A 25 U/µl Benzonase®
 
Nuclease (Novagen) was added  
to the cell extract in order to reduce the viscosity. The whole procedure for the protein 
extraction was carried out according to the manufacturer’s instructions.  
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2.8.1.2. Sonication 
          The bacterial cell pellets were carefully resuspended in 10 volumes (w/v) of cold 
lysis buffer (2.3.3) and incubated at room temperature for 30 min. Serine protease 
inhibitor phenylmethylsulfonyl fluoride (PMSF) and 2 μl of 25 U/µl Benzonase® 
Nuclease (Novagen) were added to the lysis buffer immediately before the resuspension 
of the pellet. A beaker containing the bacterial cell suspension was placed on ice and 
kept there during the ultrasound treatment procedure. Sonication was carried out using a 
bench mounted ultrasonic disintegrator (MSE Soniprep 150, Sanyo). A titanium probe 
was immersed in the suspension and the manifold sonication was conducted at a 
frequency of 10 kHz and in ten 10 s blasts. This technique allows for a rapid cell 
disruption and protein liberation by the application of the high frequency sonic energy. 
A disadvantage of the sonication technique is a possibility of protein damage due to its 
oxidation by the free radicals, singlet oxygen species and hydrogen peroxide, which 
may be concomitantly synthesized in the foam bubbles. Therefore, the procedure was 
carried out with high attention to avoid foaming of the protein suspension. In the next 
step the extract was centrifuged at 4ºC, 12000xg and for 20 min (GS-15R Centrifuge, 
Beckman). The supernatant was decanted for further protein purification. 
2.8.2. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
          Protein samples were analysed using SDS-PAGE in denaturating conditions 
(Laemmli, 1970). The purpose of this technique is to separate proteins according to their 
electrophoretic mobility and molecular weight.  
2.8.2.1. Acrylamide gel preparation 
          Two glass plates, combs and a casting frame were fixed into the casting stand 
(Mini-PROTEAN Tetra system, Bio-Rad UK). The separating gel (2.3.2) was poured 
into the casting chamber to about 2 cm below the top of the shorter plate. The desired 
density of separating gel was obtained by varying the concentration of the crosslinking 
acrylamide/bisacrylamide solution. Next, 1 ml of ddH2O was added on top of the gel  
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to prevent drying and it was left to solidify. Once the gel had polymerized, water was 
removed and a 4% stacking gel (2.3.2) was poured on top of the separating gel and left 
to set for 1 h.  
2.8.2.2. Protein samples preparation 
          All protein samples to be analyzed were mixed with sample loading buffer (2.3.2) 
with a 2:1 ratio and then heat-treated at 95ºC for 10 min in a bench Dri-Block
®
 heater 
(DB-2A, Techne) to ensure denaturation of the proteins. The samples were spun down 
for 2 min at room temperature at the maximum speed in a bench microcentrifuge 
(MiniSpin
®
, Eppendorf, UK). 
2.8.2.3. Molecular weight standards 
          Identification of desired protein and assessment of its molecular mass was 
facilitated with Precision Plus Protein
TM
 (Bio-Rad UK) and BenchMark™ His-Tagged 
(Invitrogen) molecular weight markers presented in figure 2.2. 
 
Figure 2.2. Precision Plus Protein
TM
 (Bio-Rad) and BenchMark™ His-Tagged 
(Invitrogen) protein molecular weight standards allowing quantification of protein sizes 
ranging from 10 kDa to 250 kDa and form 10 kDa to 160 kDa, respectively. The figures 
were taken from www3.bio-rad.com and www.invitrogen.com. 
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2.8.2.4. Running and visualisation of gels 
          The gel casting frame was fixed in the electrode assembly and inserted into  
the vertical electrophoresis apparatus (Bio-Rad UK). The internal reservoir was filled 
with running buffer (2.3.2). Gel wells were precisely cleaned of acrylamide remnants 
with the running buffer. Next, prepared protein samples (2.8.2.2) along with molecular 
weight marker were slowly loaded into the wells in predetermined order using a 100 μl 
Hamilton syringe (Hamilton, USA). Then the outer compartments of the casting frame 
were filled up with running buffer. The electrophoresis was run at 30 mA (PowerPac 
300 power supply, Bio-Rad UK) until the dye front reached the bottom of the gel  
(approx. 1 h). When finished the apparatus was disassembled and the gel was 
submerged in Coomassie Blue stain (2.3.2) and heated in a microwave oven for 3 min. 
The stain was replaced with ddH2O and the gel de-staining was continued in  
a microwave for 20 min. The gel was visualized on a bench white light transilluminator 
and documented in Perfection V30 scanner (Epson). 
2.8.3. Determination of protein concentration  
2.8.3.1. Measurement of A280 
          The concentration of purified protein was determined using the standard 
measurement of absorbance at 280 nm (Warburg and Christian, 1942) in WPA UV-
1101 spectrophotometer (Walden Precision Apparatus, UK). The protein extinction 
coefficient was determined with the ProtParam tool using the ExPASy proteomics 
server (Expert Protein Analysis System, www.expasy.org, (Gasteiger et al., 2003))  
on the basis of amino acid sequence.  
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2.8.3.2. The Bradford assay 
          The protein concentration  at all stages of purification was determined using the 
Bradford assay  (Bradford, 1976). In this method Coomassie Brilliant Blue G-250 dye 
binds selectively to arginine and aromatic residues, which has a consequence in a shift 
of absorbance maximum from 470 nm to 595 nm. Protein samples were mixed with 
ready-to-use Bio-Rad Protein Assay (Bio-Rad UK) solution according to the 
manufacturer’s instructions. A linear range of BSA solutions from 0.1 to 2.0 mg/ml 
were used to produce a standard curve. The absorbance at 595 nm was measured using a 
WPA UV-1101 spectrophotometer (Walden Precision Apparatus, UK).   
2.8.4. Fluorometric enzyme activity assay 
          The 6xHis-PcpI activity was assayed on the basis of the modified protocol by 
Browne and O’Cuinn and utilized L-pyroglutamyl-7-amido-4-methylcoumarin  
(L-pGlu-AMC) as the enzyme substrate (figure 2.3) (Browne and O'Cuinn, 1983). For 
the assay each 25 μl protein sample was placed in a separate well of 96-well 
fluorometer microplate and this was done in triplicate. Next, each protein sample was 
mixed with 100 μl of 250 μM pGlu-AMC in buffer F (2.3.4) and incubated at 37ºC for 
30 min. The reaction was terminated by the addition of 100 μl of 1.5 M acetic acid. The 
negative control was prepared by the addition of acetic acid to the protein sample prior 
to mixing with pGlu-AMC. Detection of liberated product (7-amino-4-methylcoumarin, 
AMC, figure 2.3) was analysed in Infinite® 200 microplate reader (TECAN) with 
excitation at 370 nm and emission read at 440 nm. The readings were visualised using 
associated i-control™ software (TECAN). A standard curve was prepared using the 
fluorometric readings from a range of AMC solutions with concentrations between 0 to 
400 μM and is presented in appendix V. 
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Figure 2.3. The reaction of the enzymatic hydrolysis of L-pyroglutamyl-7-amido-4-
methylcoumarin (L-pGlu-AMC) by Pcp liberating free L-pGlu acid and 7-amino-4-
methylcoumarin (AMC). 
2.8.5. Dynamic Light Scattering 
          The polydispersity and aggregation state of the protein in a solution was 
evaluated using the dynamic light scattering (DLS) technique (Proteau et al., 2010).  
The principle of DLS uses the properties of scattered light to measure the rate of 
diffusion of protein particles. This is further processed to establish a size distribution for 
the sample. The molecular weight of a particle is determined from its Stokes radius or a 
hydrodynamic radius (MW-R) which depends on the conformation, size and density. 
This technique shows to be particularly useful in identification of trace amounts of an 
aggregated protein (0.1% estimated % mass). 
          The purified protein sample (~1.0 mg/ml) was centrifuged at 13,400xg at 4ºC and 
then the supernatant was gently pipetted into a UV quartz cuvette and left to incubate 
for 10 min. The measurements were conducted at room temperature in DynaPro™ DLS 
instrument (Wyatt Technology) and ddH2O was used to set solvent parameters. 
Collected data were analysed and viewed using Dynamics 6.7.3 software (Wyatt 
Technology). 
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2.8.6. Western blotting   
          The gel obtained in the SDS-PAGE was transferred to a nitrocellulose membrane 
using iBlotter (Invitrogen) at 100V for 1 h according to the manufacturer’s instructions. 
Next, the membrane was blocked for 30 min in a PBST buffer (2.3.6) containing  
5% milk powder. This was replaced with a 1:500 solution of a mouse anti-His6 Mab 
primary antibody (R&D systems) and incubated for 2 h at room temperature.  
The membrane was washed with PBST buffer (3x 10 min) and subsequently incubated 
in a 1:5000 solution of a goat anti-mouse-horseradish peroxidase-coupled secondary 
antibody (Pierce) for 1 h at room temperature. Next, the membrane was washed with 
PBST buffer (3x 10 min). In order to visualise the protein, the membrane was covered 
with 2 ml of ECL-Plus
TM
 reagent (GE Health care), incubated for 5 min and then 
analysed and documented using a Xograph imaging apparatus (Xograph Healthcare). 
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Chapter 3 – Studies on human pyroglutamyl peptidase I 
 
3.1 Human PcpI         
 
          Human pyroglutamyl peptidase type I is placed in the C15 peptidase family of the 
MEROPS classification (Rawlings et al., 2010). The enzyme functions as a cysteine 
ω-exopeptidase, which specifically removes the N-terminal pyroglutamyl group from 
peptide and protein substrates. It also exhibits a strict requirement for thiol-reducing 
agents in order to maintain its catalytic activity (2.1.3). In vertebrates, the highest level 
of PcpI was found in liver and kidney, but it can be also localised in many other tissues 
such as skeletal muscle, cerebral cortex, pituitary or renal proximal tubules (Cummins 
and O'Connor, 1998). Studies show that the native mammalian enzymes appear to exist 
as soluble monomeric proteins with a low protein sequence similarity (below 30%) to 
their dimeric or tetrameric prokaryotic counterparts. The first X-ray crystal structure of 
a Pcp enzyme was reported for T. litoralis (Singleton et al., 1999) followed by B. 
amyloliquefaciens (Odagaki et al., 1999), P. furiosus (Tanaka et al., 2001) and P. 
horikoshii (Sokabe et al., 2002). However, as yet there is no structural information on 
any eukaryotic PcpI despite the fact that its activity has been demonstrated from a broad 
range of plant and animal sources (Cummins and O'Connor, 1998). No peptidase gene 
sequence has yet been identified in any of the yeast or fungal genomes. Mammalian 
representatives which were purified and characterised so far include human, murine and 
bovine type I Pcps (Dando et al., 2003; Kilbane et al., 2007). Multiple reports indicate 
that mammalian enzymes have comparable biochemical features to other type I Pcps, 
but are relatively unstable in vitro (Dando et al., 2003; Kilbane et al., 2007; Mtawae et 
al., 2008).  
          This chapter presents experimental work on the native and recombinant human 
PcpI enzymes regarding their overexpression, purification and crystallisation trials. 
Site-directed mutagenesis, chemical modification of the protein and screening  
for optimal buffer conditions were additionally conducted towards the improvement of 
human PcpI stability in vitro.  
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3.2. Preparation of human PcpI  
 
          The amino acid sequences of the native and recombinant human PcpI forms were 
used to determine the protein parameters using the bioinformatical tools available on the 
ExPASy server (www.expasy.org, (Gasteiger et al., 2003)). Experimental pI was 
estimated using isoelectric focusing by S. Connelly (Connelly, 2006). The peptidase 
with N-terminal hexahistidine affinity tag, C-terminal tag and native protein are named 
as 6xHis-PcpI, PcpI-6xHis and PcpI, respectively. The amino acid sequence and 
parameters are presented in table 3.1. Although all known mammalian sequences 
contain a putative NAS glycosylation site (table 3.1), to date studies have not 
considered that the active form of the enzyme is glycosylated (Cummins and O'Connor, 
1998). 
PcpI protein sequence: 
 
MGSSHHHHHHSSGLVPRGSH (N-terminal His-tag)  
 
MEQPRKAVVVTGFGPFGEHTVNASWIAVQELEKLGLGDSVDLHVYEIPVE
YQTVQRLIPALWEKHSPQLVVHVGVSGMATTVTLEKCGHNKGYKGLDNC
RFCPGSQCCVEDGPESIDSIIDMDAVCKRVTTLGLDVSVTISQDAGRYLCDF
TYYTSLYQSHGRSAFVHVPPLGKPYNADQLGRALRAIIEEMLDLLEQSEGK
INYCHKH 
 
(C-terminal His-tag) KLAAALQHHHHHH 
 
 6xHis-PcpI native PcpI PcpI-6xHis 
Length (aa) 229 aa 209 aa 222 aa 
Molecular weight 
(Da) 
25301.7 Da 23138.3 Da 24657.0 Da 
Experimental pI 6.30 5.55 not determined 
Theoretical pI 6.12 5.54 6.08 
Extinction 
coefficient  
(M
-1
 cm
-1
) 
24410 24410 24410 
 
Table 3.1. Amino acid sequence and biophysical parameters of human native and 
His-tagged PcpI. The native protein sequence is shown in black font and both  
N-terminal and C-terminal His-tag sequences are shown in blue. The potential 
N-glycosylation motif NAS is highlighted in orange. The parameters were computed 
using bioinformatic tools in the ExPASy server (www. expasy.org, (Gasteiger et al., 
2003)) and the experimental pI was established by S. Connelly within his PhD project 
(Connelly, 2006). 
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3.2.1. Materials and methods  
          The cDNA encoding human PcpI was obtained via PCR amplification from  
a human pituitary gland cDNA library and was previously supplied by Cambridge 
Bioscience Ltd (UK). The re-cloning into a pET-28a(+) (appendix I) expression vector 
and initial work on recombinant human PcpI had been conducted by S. Connelly as a 
part of his PhD project (Connelly, 2006). The E. coli BL21(DE3)pLysS (2.4.2) carrying 
the recombinant vector pET-28a(+)/pcpI had been stored as glycerol stocks at -80ºC and 
were used in further work. The pET-28(+) vectors enable the production of the proteins 
with either an N-terminal or a C-terminal hexahistidine tag, which facilitates their 
selective purification using nickel affinity chromatography. 
          Both recombinant and native PcpI were overexpressed in selected E. coli cells. 
Initial purification procedure of 6xHis-PcpI was based on the protocol applied in  
the PhD project by S. Connelly (Connelly, 2006).  
3.2.1.1. Preparation of pET-28a(+)/pcpI recombinant plasmid 
3.2.1.1.1. Minipreparation of pET-28a(+)/pcpI recombinant plasmid 
          For the plasmid minipreparation procedure 10 ml of fresh LB media containing 
50 μg/ml kanamycin and 30 μg/ml chloramphenicol was inoculated with a glycerol 
stock of the E. coli BL21(DE3)pLysS cells (2.4.2) harbouring the recombinant 
pET-28a/pcpI. This was incubated overnight at 37ºC in a shaking incubator. Next the 
pET-28a(+)/pcpI was extracted according to the protocol of GeneJET™ Plasmid 
Miniprep kit (Fermentas) (2.7.2). The result of the minipreparation was determined by a 
double digestion with NdeI and NotI restriction enzymes (2.7.5.1) followed by agarose 
gel electrophoresis (2.7.8). The recombinant plasmid sample was further purified 
(2.7.3), quantified (2.7.4) and sequenced using standard T7 primers (2.7.10). 
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3.2.1.1.2. Maxipreparation of pET-28a(+)/pcpI recombinant plasmid 
          The E. coli NovaBlue (Novagen) competent cells (2.4.1) were transformed with 
prepared pET-28a(+)/pcpI (2.7.1) in order to obtain a higher quantity of the DNA.  
The cells were plated on the Petri dishes containing agar (2.2.2) with 50 μg/ml 
kanamycin and incubated overnight at 37ºC. A single colony was used to inoculate  
10 ml of LB media containing 50 μg/ml kanamycin and this was grown overnight at 
37ºC in a shaking incubator. Next day 1 ml of the E. coli culture was transferred to 
100 ml of LB media containing 50 μg/ml kanamycin and was grown at 37ºC until  
the OD595 reached 2.0. The pET-28a(+)/pcpI extraction was carried out using the 
GenElute
TM
 Plasmid Maxiprep kit (Sigma-Aldrich) (2.7.2). The result of the 
maxipreparation was determined by a double digestion with NdeI and NotI restriction 
enzymes (2.7.5.1) followed by 1% agarose gel electrophoresis (2.7.8). The recombinant 
plasmid sample was further purified (2.7.3) and quantified (2.7.4). 
3.2.1.2. Overexpression of 6xHis-PcpI 
3.2.1.2.1. Preparation of chemically competent cells  
          Preliminary overexpression of 6xHis-PcpI was performed in the E. coli 
BL21-CodonPlus®(DE3)-RIPL strain (2.4.2) obtained from Stratagene. The strain cells 
are engineered to produce extra copies of argU, ileW, leuY and proL tRNAs that 
recognize rare arginine, isoleucine, leucine and proline codons. This has been designed 
in order to overcome rare E. coli codon bias problems and therefore enable an efficient 
high-level expression of proteins from heterologous organisms compared to 
conventional BL21 strains. Comparison of codon usage in Escherichia coli and Homo 
sapiens is presented in table 3.2. A lack of suitable codons causes depletion of the 
internal host tRNA pools. This can result in delayed translation leading to codon 
substitutions and misincorporations that affect the functional properties of the protein. 
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ORGANISM 
AGG 
arginine 
AGA 
arginine 
CUA 
leucine 
AUA 
isoleucine 
CCC 
proline 
Escherichia coli 1.2 2.1 3.9 4.4 5.5 
Homo sapiens 11.4 11.5 6.5 6.9 20.0 
Table 3.2. Comparison of codon frequencies in Escherichia coli and Homo sapiens. 
The frequency is described as the number of codons per thousand of total. A higher 
number indicates more significant bias between human and E. coli tRNA pools. Based 
on data taken from www.stratagene.com. 
 
          The E. coli BL21-CodonPlus®(DE3)-RIPL cells were made competent according 
to the general chemical procedure described in section 2.5. Competent cell aliquots were 
directly used for the transformation procedure (2.7.1) or stored as glycerol stocks at 
-80ºC (2.6). 
3.2.1.2.2. Screening for optimal overexpression conditions 
          The E. coli BL21-CodonPlus®(DE3)-RIPL competent cells (3.2.1.2.1) were 
transformed with the pET-28a(+)/pcpI plasmid (3.2.1.1) following the protocol 
described in section 2.7.1. The cells were plated on Petri dishes containing 50 μg/ml 
kanamycin and 35 μg/ml chloramphenicol and incubated overnight at 37ºC. Next  
a single colony was used to inoculate 10 ml of LB media supplemented with 50 μg/ml 
kanamycin and 35 μg/ml chloramphenicol and this was grown overnight at 37ºC  
in a shaking incubator. Next day 8 flasks containing 100 ml of LB media with the above 
antibiotics were inoculated each with 1 ml of the overnight culture and grown in  
a shaking incubator at 37ºC. The induction of the protein overexpression was initiated 
by the addition of IPTG (2.2.4) to a final concentration of 1 mM. At this point cultures 
were continued to grow at 25ºC (4 flasks with cultures induced at an OD595 of 0.6, 0.8, 
1.0 and 1.2, respectively) and 37ºC (4 flasks with cultures induced at an OD595 of 0.6, 
0.8, 1.0 and 1.2, respectively). Samples for the protein overexpression analysis were 
collected from each flask prior to induction with IPTG as well as after 4 h, 6 h and 
overnight incubation. Protein isolation was carried out according to the detergent-based 
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procedure (2.8.1.1) and the results of the protein expression were analysed using the 
SDS-PAGE technique with a 12.5% separating gel (2.8.2). 
3.2.1.3. Purification of 6xHis-PcpI       
3.2.1.3.1. Production of 6xHis-PcpI       
          The optimal conditions for 6xHis-PcpI production in BL21-CodonPlus®(DE3)-
RIPL cells were established on the basis of protein overexpression screening in small 
scale culture growth (3.2.1.2.2). The E. coli BL21-CodonPlus®(DE3)-RIPL carrying 
pET-28a(+)/pcpI were grown overnight at 37ºC in 10 ml LB media containing 50 μg/ml 
kanamycin and 35 μg/ml chloramphenicol in a shaking incubator. Next day this was 
used as a starting inoculation culture for six flasks containing 1 L of LB with the above 
antibiotics and was further grown at 37ºC in a shaking incubator until an OD595 of 0.6 
had been reached. At this point the expression of the 6xHis-PcpI was induced by the 
addition of IPTG to a final concentration of 1 mM. The incubation was continued for  
a further 6 h at 25ºC and after that the cells were harvested by centrifugation at 6000xg 
for 20 min. The cell pellet was stored at -20ºC. 
3.2.1.3.2. Protein extraction 
          For protein purification purpose the cell paste (3.2.1.3.1) was resuspended in  
10 volumes of Tris-HCl lysis buffer (2.3.3.1). The cell lysate was subjected to a protein 
extraction procedure using the sonication technique (2.8.1.2). The result of 6xHis-PcpI 
overexpression was analysed by the SDS-PAGE technique using a 12.5% separating gel 
(2.8.2). 
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3.2.1.3.3. Nickel affinity chromatography 
          Immobilized metal-ion affinity chromatography (IMAC) is one of the most 
efficient and popular methods of protein purification. His-tagged protein molecules are 
retained on the resin through the specific coordinative bond between histidines and 
immobilized ions such as nickel, cobalt or copper. Then bound material can be eluted 
by the application of competitive molecules (e.g. imidazole) or a change in pH. 
          The XK 26/20 column packed with the Ni
+
 Sepharose
TM
 resin (Amersham 
Biosciences) was pre-equilibrated with three column volumes of Tris-HCl buffer A 
(2.3.3.1). Then the crude supernatant obtained after protein isolation (3.2.1.3.2) was 
loaded onto the column using an injection superloop (GE Healthcare). This was washed 
with three column volumes of buffer A (2.3.3.1) to remove unbound proteins.  
Next three column volumes of buffer B (2.3.3.1) were introduced over a gradient of 
0-100% to elute remaining, bound proteins. Both buffers A and B contained 
β-mercaptoethanol, as 6xHis-PcpI was reported to exhibit a strong requirement for 
thiol-reducing agents in order to maintain its activity (2.1.3). An elution buffer B also 
contains imidazole, which acts as a binding competitor for nickel ions. During 
purification 5 ml elution fractions were collected over the entire elution volume and the 
whole procedure was carried out at a flow rate of 3 ml/min. On the basis of the elution 
profile appropriate fractions were analysed for protein presence and purity by the 
SDS-PAGE technique using a 12.5% separating gel (2.8.2). Protein samples were stored 
at 4ºC. 
3.2.1.3.4. Gel filtration chromatography 
          All fractions which contained 6xHis-PcpI collected after nickel column 
purification (3.2.1.3.3) were pooled together. The protein solution was concentrated by 
the gradual addition of ammonium sulfate to the saturation of 80%. The mixture was 
stirred gently for 2 h or more at 4ºC and then the precipitated protein was pelleted by 
centrifugation at 13500xg for 30 min. Next the pellet was resuspended in Tris-HCl 
buffer C (2.3.3.1). This was applied onto a Superdex
TM
 200 Hi-load 16/60 gel filtration 
column (Amersham Biosciences) which was pre-equilibrated with buffer C. The protein 
sample was eluted with 120 ml (one column volume) of buffer C at a flow rate of 
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0.5-1.0 ml/min. Over the entire filtration process 1.5 ml fractions were collected and 
later analysed for protein purity using the SDS-PAGE technique using a 12.5% 
separating gel (2.8.2). The concentration of the purified protein sample was determined 
via absorbance measurement at 280 nm as described in section 2.8.3.1. The extinction 
coefficient for 6xHis-PcpI was calculated as 24410 M
-1 
cm
-1
 (ProtParam, 
www.expasy.org). Protein samples were stored at 4ºC. The calibration curve for the 
HiLoad™ 16/60 Superdex™ 200 column is shown in appendix IV. 
3.2.1.3.5. Protein activity 
          The activity of 6xHis-PcpI was assayed after each purification step using the 
fluorometric method described in section 2.8.4. 
3.2.1.3.6. Modifications to the purification procedure of 6xHis-PcpI 
          Significant instability of 6xHis-PcpI in Tris-HCl based purification buffers was  
a serious difficulty as the protein could not be used in subsequent experiments such  
as crystallisation studies. Preliminary attempts to overcome this problem were focused 
on minor alterations in the content of purification buffers and observation how they 
influence the protein’s behaviour. List of applied modifications is presented in  
table 3.3. 
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MODIFICATION PURPOSE 
B
u
ff
er
 a
d
d
it
iv
es
 
0.15 M NaCl 
maintains ionic strength of buffer, improves protein 
solubility (Dominy et al., 2002) 
50 mM L-Arg reduces hydrophobic interactions, improves protein 
solubility and stability (Guilloteau et al., 1996; 
Golovanov et al., 2004) 50 mM L-Glu 
0.5% Triton X-100 improves protein solubility (Choi et al., 2005) 
5% glycerol improves protein stability (Vagenende et al., 2009) 
K2HPO4/KH2PO4 based buffers 
pH 8.0 (2.3.3.2) 
alternative to Tris-HCl buffer, reported to be used in 
purification of human and bovine PcpI (Kilbane et al., 
2007; Mtawae et al., 2008) 
 
Table 3.3. List of additives and modifications used in the buffers for the 6xHis-PcpI 
purification in order to improve protein stability. 
 
3.2.1.4. Cloning of PcpI cDNA for production of PcpI-6xHis and native PcpI 
          The incorporation of a polyhistidine affinity tag has become one of the most 
commonly used methods to facilitate efficient protein purification. Its advantage lies 
mainly in relatively small length, which is believed to have no or little effect on  
a protein’s structure or activity compared to a more bulky appendage, such as GST 
(glutathione S-transferase), CBP (calmodulin-binding protein) or MBP (maltose- 
binding protein). It has applications in experiments requiring high yields of at least 
partially purified material that can be carried out at a low cost. The Ni-NTA 
(nickel-nitrilotriacetic acid) resins used for purification of His-tagged proteins are 
amongst the least expensive ones along with MBP or GST columns (Lichty et al., 
2005).  However, studies show that the potential influence of the His-tag and its 
localisation on the macromolecule folding and purification yield cannot be excluded 
(Woestenenk et al., 2004; Eschenfeldt et al., 2010; Spadiut et al., 2010). Sometimes, if 
experimental work with the protein becomes problematic due to its instability or 
insolubility, it is advisable to remove or shift the tag from one terminus to the other. The 
high instability of 6xHis-PcpI in solution could be a result of the enhanced flexibility of 
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its N-terminus extended by the extra 20 amino acid residues which contribute additional 
8% to the total molecular mass. Homology modelling of human PcpI (figure 1.13) 
showed that its amino terminus is organised in one of the internal β-strands of the 
central β-sheet. The attachment of the His-tag could possibly disturb this arrangement 
and in fact may lead to structural disorder and in result trigger excessive aggregation 
and precipitation. Contrary to that the protein’s C-terminus is organised in α-helix with 
the terminal residues exposed to the surface. Therefore it was decided to overexpress 
both the untagged protein (native PcpI) and the protein with C-terminal His-tag 
(PcpI-6xHis) in order to evaluate if these modifications could contribute to stabilisation 
of PcpI in vitro and facilitate its concentration and crystallisation.  
3.2.1.4.1. PCR amplification of PcpI cDNA 
          PCR amplification of the cDNA encoding PcpI was conducted in the way to 
receive inserts for the production of the native and C-terminally His-tagged PcpI 
variants. Gene primers for the reactions were supplied by Eurofins MWG Operon and 
are listed in table 3.4. 
Primer Sequence 
Restriction 
enzyme 
GC 
content 
Tm 
native PcpIF 
(forward) 
CAGCCATATGGAGCAG 
CCGAGGAAGGCG 
NdeI 64.3% 72.4ºC 
native PcpIR 
(reverse) 
CTCGAATTCTCAGTGTTT 
GTGGCAATAGTTGATTTTG 
EcoRI 37.8% 67.2ºC 
     
PcpI-6xHisF 
(forward) 
CAAACCATGGAGCAGCCGA
G 
NcoI 60% 61.4ºC 
PcpI-6xHisR 
(reverse) 
AGCGCAAGCTTGTG 
TTTGTGGCAATA 
HindIII 46.2% 63.2ºC 
 
Table 3.4. List of PCR primers used for amplification of the PcpI cDNA. 
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The composition of the amplification reaction mixture is presented below. 
1 μl 50 ng/μl pET-28a/pcpI 
1 μl 10 μM forward primer 
1 μl 10 μM reverse primer 
12.5 μl 2x GoTaq® Hot Start Green Master Mix* 
9.5 μl ddH2O 
 
* GoTaq® Hot Start Green Master Mix (Promega) is a ready-to-use solution containing 
optimal concentrations of GoTaq® Hot Start Polymerase, 400 μM dNTPs, 4 mM MgCl2 
and 2x GoTaq® reaction buffer (pH 8.5). The GoTaq® polymerase activity is 
temporary blocked at temperatures below 70°C by being bound to a proprietary 
antibody and it can be restored by the heating for 2 min during the initial denaturation 
step at 94–95°C. The mix also contains blue and yellow dyes that allow monitoring of 
DNA run during electrophoresis. 
          PCR amplification was performed in a Mastercycler
®
 thermal cycler (Eppendorf). 
A range of tubes containing reaction mixture was prepared and each one of them was 
subjected to a different annealing temperature within a set gradient. The individual steps 
of PCR are described in table 3.5. 
Step Temperature Time 
Initial denaturation 96ºC 3 min 
   
Denaturation 96ºC 1 min  
   30x Annealing temperature gradient 55ºC – 68ºC 1 min 
Extension 72ºC 1 min 
   
Final extension 72ºC 7 min 
Cooling 4ºC ----- 
Table 3.5. PCR cycling steps during the reaction of amplification of the PcpI cDNA. 
 
The result of the PCR amplification was checked by 2% agarose gel electrophoresis as 
described in section 2.7.8.  
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3.2.1.4.2. Ligation of PcpI insert with pET-28b(+) and pET-22b(+) 
          The PCR products obtained during the amplification of cDNA encoding human 
PcpI (3.2.1.4.1) were purified using the gel extraction method described in section 2.7.9. 
Next both inserts as well as the pET-28b(+) and pET-22b(+) plasmids were cut with 
suitable restriction enzymes (2.7.5.2):  
- digestion with NdeI and EcoRI for the native PcpI cDNA and pET-22b(+) 
- digestion with NcoI and HindIII for the PcpI-6xHis cDNA and pET-28b(+) 
 
          The linearized pET-28b(+) and pET-22b(+) plasmids were subsequently 
dephosphorylated at the 5′ end (2.7.6) and after that subjected to the ligation reaction 
with the pcpI inserts (2.7.7). Next the ligation reaction mixtures were used for  
transformation into E. coli NovaBlue competent cells (2.7.1). The transformants treated 
with the pET-22b(+) or pET-28b(+) mixtures were incubated overnight at 37ºC, on the 
agar plates (2.2.2) containing 100 μg/ml ampicillin or 50 μg/ml kanamycin, 
respectively. 
3.2.1.4.3. Preparation of pET-28b(+)/pcpI and pET-22b(+)/pcpI recombinant plasmids 
          A few single E. coli NovaBlue colonies, obtained from the transformation with 
the pET-22b(+) or pET-28b(+) ligation reaction mixtures (3.2.1.4.2), were picked and 
used for the inoculation of 10 ml of LB media (2.2.1) containing 100 μg/ml ampicillin 
or 50 μg/ml kanamycin, respectively. This was grown overnight at 37ºC in a shaking 
incubator. Next the cultures were subjected to DNA extraction according to the protocol 
of GeneJET™ Plasmid Miniprep kit (Fermentas) (2.7.2). The result of the 
minipreparation was determined by a double digestion with NdeI and EcoRI for the 
pET-22b(+)/pcpI or with NcoI and HindIII for the pET-28b(+)/pcpI (2.7.5.2). This was 
followed by the agarose gel electrophoresis (2.7.8). The sample containing recombinant 
plasmids with inserts were further purified (2.7.3), quantified (2.7.4) and sequenced 
using standard T7 primers (2.7.10). 
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3.2.1.5. Overexpression of the PcpI-6xHis  
          The protocol of the overexpression of PcpI-6xHis was based on the optimal 
conditions previously obtained for 6xHis-PcpI (3.2.1.3.1). The E. coli BL21- 
CodonPlus®(DE3)-RIPL competent cells (3.2.1.2.1) were transformed with the 
pET-28b(+)/pcpI plasmid (3.2.1.4.3) following the protocol described in section 2.7.1. 
The cells were plated on Petri dishes containing agar with 50 μg/ml kanamycin and 
35 μg/ml chloramphenicol. This was incubated overnight at 37ºC. Next a single colony 
was used to inoculate 10 ml of LB media supplemented with 50 μg/ml kanamycin and 
35 μg/ml chloramphenicol and this was grown overnight at 37ºC in a shaking incubator. 
Next day a flask containing 100 ml of LB media with the above antibiotics was 
inoculated with 1 ml of the overnight culture and grown in a shaking incubator at 37ºC. 
The induction of the protein overexpression was initiated by the addition of IPTG 
(2.2.4) to a final concentration of 1 mM once the culture has reached the OD595 of 0.6. 
The incubation was continued for a further 6 h at 25ºC. Protein isolation was carried out 
according to the detergent-based procedure (2.8.1.1) and the results of the protein 
expression were analysed using the SDS-PAGE technique using a 12.5% separating gel 
(2.8.2). 
3.2.1.6. Overexpression of the native PcpI 
          The protocol for the overexpression of the native PcpI was based on the optimal 
conditions previously obtained for 6xHis-PcpI (3.2.1.3.1). The E. coli BL21- 
CodonPlus®(DE3)-RIPL competent cells (3.2.1.2.1) were transformed with the 
pET-22b(+)/pcpI plasmid (3.2.1.4.3) following the protocol described in section 2.7.1. 
The cells treated with pET-22b(+)/pcpI were plated on Petri dishes containing agar with 
100 μg/ml ampicillin and 35 μg/ml chloramphenicol. This was incubated overnight  
at 37ºC. Next a single colony was used to inoculate 10 ml of LB media supplemented 
with 100 μg/ml ampicillin and 35 μg/ml chloramphenicol and this was grown overnight  
at 37ºC in a shaking incubator. The next day a flask containing 100 ml of LB media 
with the above antibiotics was inoculated with 1 ml of the overnight culture and grown 
in a shaking incubator at 37ºC. The induction of the protein overexpression was initiated 
by the addition of IPTG (2.2.4) to a final concentration of 1 mM once the culture has 
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reached the OD595 of 0.6. The incubation was continued for further 6 h at 25ºC. Protein 
isolation was carried out according to the detergent-based procedure (2.8.1.1) and the 
results of the protein expression were analysed by the SDS-PAGE technique using  
a 12.5% separating gel (2.8.2). 
3.2.1.7. Purification of the PcpI-6xHis 
          The protein production and purification steps for the PcpI-6xHis were exactly the 
same as for 6xHis-PcpI and consisted of nickel affinity chromatography (3.2.1.3.3) and 
gel filtration chromatography (3.2.1.3.4). In this case however, lysis and purification 
buffers were enriched with 0.15 M NaCl as it was observed to improve protein 
solubility. The content of the buffers is presented in section 2.3.3.3. Collected fractions 
were analysed for protein purity by the SDS-PAGE technique using a 12.5% separating 
gel (2.8.2). The concentration of purified protein was determined by the absorbance 
measurement at 280 nm as described in section 2.8.3.1. Extinction coefficient for 
PcpI-6xHis was calculated as 24410 M
-1
cm
-1
 (ProtParam, www.expasy.org).  
The activity of PcpI-6xHis was assayed after each purification step using the 
fluorometric method described in section 2.8.4. Protein samples were stored at 4ºC.           
3.2.1.8. Purification of the native PcpI 
3.2.1.8.1. Production and extraction of the native PcpI 
          The E. coli BL21-CodonPlus®(DE3)-RIPL carrying pET-22b(+)/pcpI were 
grown overnight at 37ºC in 10 ml LB media containing 50 μg/ml ampicillin and 
35 μg/ml chloramphenicol in a shaking incubator. Next day this was used as a starting 
inoculation culture for six flasks containing 1 L of LB with the above antibiotics and 
was further grown at 25ºC in a shaking incubator until OD595 of 0.6 had been reached. 
At this point the expression of PcpI was induced by the addition of IPTG to a final 
concentration of 1 mM. The incubation was continued for 6 h at 25ºC and after that the 
cells were harvested by centrifugation at 6000xg for 20 min. The cell pellet was stored 
at -20ºC. The extraction of the native PcpI was conducted exactly the same way as for 
6xHis-PcpI (3.2.1.3.2). 
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3.2.1.8.2. Phenyl Sepharose chromatography 
          The application of hydrophobic chromatography for purification is very useful 
when dealing with non-tagged proteins. The protein to be purified is brought into a high 
ionic strength (high salt content) buffer, which facilitates binding between the 
hydrophobic protein surface and the column matrix. The bound proteins can be 
gradually eluted using a reverse gradient with a buffer of low ionic strength  
(e.g. lower salt concentration). 
          The XK 26/20 column packed with Phenyl Sepharose
TM
 (Amersham Biosciences) 
was pre-equilibrated with three column volumes of Tris-HCl buffer A (2.3.3.4). Then 
the crude supernatant obtained after protein isolation (3.2.1.8.1) was loaded onto the 
column using an injection superloop (GE Healthcare). The column was washed with 
three column volumes of buffer A (2.3.3.4) to remove unbound material. Next three 
column volumes of buffer B (2.3.3.4) were introduced over a gradient of 100-0% to 
elute remaining, bound proteins. During purification 5 ml elution fractions were 
collected over the entire elution volume and whole procedure was carried out at a flow 
rate of 3 ml/min. On the basis of the elution profile appropriate fractions were analysed 
for the presence of protein and purity by the SDS-PAGE technique using a 12.5% 
separating gel (2.8.2). Protein samples were stored at 4ºC. 
3.2.1.8.3. Ion-exchange chromatography 
          At a pH different from isoelectric point (pI) given proteins become differentially 
charged and this feature is used during ion-exchange chromatography. The purified 
material in low ionic strength buffer can be retained on the column matrix through the 
electrostatic interactions between charged surface residues and the oppositely charged 
matrix in the column. Next the bound proteins can be gradually eluted through  
a gradient with a buffer of an increased ionic strength (e.g. high salt concentration). 
          The XK 26/20 column packed with the FFS-Sepharose
TM
 (cation exchange 
column, Amersham Biosciences) was pre-equilibrated with three column volumes of 
Tris-HCl buffer B (2.3.3.4). Then the pooled fractions containing PcpI, obtained after 
Phenyl Sepharose
TM
 chromatography (3.2.1.8.2) were loaded onto the column using an 
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injection superloop (GE Healthcare). The column was washed with three column 
volumes of buffer B (2.3.3.4) to remove unbound material. Next three column volumes 
of buffer C (2.3.3.4) were introduced over a gradient of 0-100% to elute remaining, 
retained proteins. During purification 5 ml elution fractions were collected over the 
entire elution volume and the whole procedure was carried out at a flow rate of 
3 ml/min. On the basis of elution profile appropriate fractions were analysed for the 
presence of protein and purity by the SDS-PAGE technique using a 12.5% separating 
gel (2.8.2). Protein samples were stored at 4ºC. 
3.2.1.8.4. Gel filtration chromatography 
          All fractions which contained native PcpI collected after cation exchange 
purification (3.2.1.8.3) were pooled together. The protein solution was concentrated by 
the gradual addition of ammonium sulfate to 80% saturation. The mixture was stirred 
gently for 2 h or more at 4ºC and then the precipitated protein was pelleted by 
centrifugation at 13500xg for 30 min. Next the pellet was resuspended in Tris-HCl 
buffer D (2.3.3.4). This was applied onto Superdex
TM
 200 Hi-load 16/60 gel filtration 
column (Amersham Biosciences) which was pre-equilibrated with buffer D. The protein 
sample was eluted with 120 ml (one column volume) of buffer D at a flow rate of 
0.5-1.0 ml/min. Over the entire filtration process 1.5 ml fractions were collected and 
later analysed for protein purity by the SDS-PAGE technique using a 12.5% separating 
gel (2.8.2). The concentration of purified protein sample was determined by the 
absorbance measurement at 280 nm as described in section 2.8.3.1. The extinction 
coefficient for the native PcpI was calculated as 24410 M
-1
cm
-1
 (ProtParam, 
www.expasy.org). Protein samples were stored at 4ºC.           
3.2.1.8.5. Protein activity 
          The activity of the native PcpI was assayed after each purification step using the 
fluorometric method described in section 2.8.4.  
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3.2.1.9. DLS analysis of the native PcpI and PcpI-6xHis 
          The polydispersity and aggregation state of both the native PcpI and PcpI-6xHis 
was assayed directly after gel filtration step using the DLS method as described in 
section 2.8.5. Both samples were centrifuged and kept on ice before the measurement. 
3.2.1.10. NDSB additives 
          Non-detergent sulfobetaines (NDSBs) are zwitterionic compounds containing a 
charged sulfobetaine hydrophilic group and a short hydrophobic group (figure 3.1). An 
important advantage of NDSBs is the fact that they do not possess large hydrophobic 
structures which make them difficult to form micelles and hence they are not classified 
as detergents. They were also shown to have no or little effect on enzymatic activity. 
Multiple reports confirm that the addition of NDSBs can significantly increase protein 
solubility, prevent aggregation and aid in refolding of proteins found in inclusion bodies 
or chemically and thermally denatured proteins (Vuillard et al., 1995; Expert-Bezancon 
et al., 2003; Xiang et al., 2008; D'Amico and Feller, 2009). They are also very popular 
as the additives to assist in protein crystallisation and facilitate purification of integral 
membrane proteins (Willis et al., 2005). However, the molecular mechanisms of their 
protecting action against aggregation remains poorly understood. It has been thought 
that the short hydrophobic chains can interact with the protein’s surface regions. This 
may prevent undesired hydrophobic interactions and therefore aggregation, and also 
would explain the difference in efficiency of individual NDSBs. On the other hand over 
a wide pH range this group of compounds can be differentially charged and 
alternatively create ionic interactions with protein surface residues. Such a phenomenon 
could help to abolish the non-specific ionic or dipole protein-protein interactions 
(Vuillard et al., 1995). 
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Figure 3.1. The range of NDSBs employed to improve solubility and stability of PcpI. 
The number by each individual compound name relates to its molecular weight. 
 
 
          Since there are no strict guidelines pointing to which one of the NDSBs is more 
efficient than the others, in order to observe their influence on the PcpI stability during 
the concentration process, each one of the compounds was individually tested by the 
addition to the purified sample of the native PcpI or PcpI-6xHis. Final concentrations of 
sulfobetaines NDSB-195, NDSB-201, NDSB-211, NDSB-221 or NDSB-256 in the 
protein solution were 0.5 M or 1.0 M. This was incubated at 4ºC for 30 min and the 
sample was then concentrated using a Vivaspin20 centrifugal concentrator with  
a 30 kDa molecular weight cut-off (Sartorius Stedim Biotech S.A.). The intention of 
this process was to obtain a protein concentration suitable for the initial crystallisation 
trials (at least 10 mg/ml).  
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3.2.2. Results and discussion 
3.2.2.1. Preparation of pET-28a(+)/pcpI recombinant plasmid 
          The E. coli BL21(DE3)pLysS culture cells after overnight growth were harvested 
by centrifugation and subjected to pET-28a(+)/pcpI plasmid isolation as described in 
section 3.2.1.1.1. Subsequent restriction enzyme digestion (2.7.5.1) and 1% agarose gel 
electrophoresis (2.7.8) confirmed successful plasmid extraction and a presence of the 
PcpI cDNA insert. The band corresponding to the insert can be observed at approx. 
630 bp as seen on the agarose gel electropherogram (figure 3.2).  
 
 
Figure 3.2. The result of agarose gel electrophoresis of pET-28a(+)/pcpI restriction 
digestion products. Individual lanes represent marker Hyperladder I (M), uncut 
plasmid (1) and cut plasmid (2). The insert band can be observed at approx. 630 bp. 
 
 
          The concentration and purity of the prepared pET-28a(+)/pcpI sample was 
determined by absorbance measurement at 260 nm as described in section 2.7.4. 
Plasmid DNA was sent for sequencing using the standard T7 primers (2.7.10), which 
confirmed the presence of the pcpI insert and its correct nucleotide sequence (appendix 
III). 
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          Next the pET-28a/pcpI sample obtained from the minipreparation (3.2.1.1.1) was 
used for a transformation of E. coli NovaBlue competent cells (3.12). The culture cells 
after overnight growth were harvested by centrifugation and subjected to pET-28a/pcpI 
plasmid isolation as described in section 3.2.1.1.2. The plasmid DNA was cut in  
a double restriction digest reaction (2.7.5.1). Next the analysis by 1% agarose gel 
electrophoresis (2.7.8) confirmed the presence of the 630 bp of pET-28a/pcpI insert 
cDNA. The purified and quantified plasmid sample was subsequently used for the 
protein overexpression study. 
3.2.2.2. Overexpression study of 6xHis-PcpI 
          Recombinant human 6xHis-PcpI was produced in 
BL21-CodonPlus(DE3)-RIPL, which improves the expression of rare E. coli codons 
as described in section 3.2.1.2.1. Screening for the optimal expression conditions 
(3.2.1.2.2) was conducted using different OD595 values of the growth culture before 
the protein synthesis was induced with IPTG, postinductory incubation temperature 
and the time of culture growth. The results of 6xHis-PcpI expression were determined 
by the SDS-PAGE technique using a 12.5% separating gel (2.8.2). Both soluble and 
insoluble fractions were analysed and the resulting gel pictures are presented in 
figures 3.3, 3.4, 3.5 and 3.6 for the induction at OD595 of 0.6, 0.8, 1.0 and 1.2, 
respectively. A calculated molecular weight of human 6xHis-PcpI is 25.3 kDa (3.1). 
 
Figure 3.3. The result of SDS-PAGE analysis of 6xHis-PcpI expression induced at 
OD595 0.6 in BL21-CodonPlus®(DE3)-RIPL cells. The supernatant and pellet 
fractions come from the samples collected prior to induction (0) and after 4 h, 6 h and 
overnight (O/N) incubation.  
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Figure 3.4. The result of SDS-PAGE analysis of 6xHis-PcpI expression induced at 
OD595 0.8 in BL21-CodonPlus®(DE3)-RIPL cells. The supernatant and pellet 
fractions come from the samples collected prior to induction (0) and after 4 h, 6 h and 
overnight (O/N) incubation.  
 
 
Figure 3.5. The result of SDS-PAGE analysis of 6xHis-PcpI expression induced at 
OD595 1.0 in BL21-CodonPlus®(DE3)-RIPL cells. The supernatant and pellet 
fractions come from the samples collected prior to induction (0) and after 4 h, 6 h and 
overnight (O/N) incubation.  
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Figure 3.6. The result of SDS-PAGE analysis of 6xHis-PcpI expression induced at 
OD595 1.2 in BL21-CodonPlus®(DE3)-RIPL cells. The supernatant and pellet 
fractions come from the samples collected prior to induction (0) and after 4 h, 6 h and 
overnight (O/N) incubation.  
 
 
          The overexpression of 6xHis-PcpI in BL21-CodonPlus®(DE3)-RIPL was 
particularly enhanced when IPTG was added at an OD595 of 0.6 or 0.8. In the gel 
representing the result of the protein expression induced at the OD595 of 0.6, a strong 
band of approx. 25 kDa can be observed. When induced at higher OD595 1.0 and 1.2, 
protein synthesis seems to be weaker or the protein was found in the pellet fractions of 
cell lysate. Lower temperature (25C) also positively influences 6xHis-PcpI 
overexpression as it slows down the cellular metabolism and may promote more stable 
protein-folding conformations (Battistoni et al., 1992; Vasina and Baneyx, 1997). 
However, the major drawback of such cultivation at lower temperatures is a slower rate 
of bacterial biomass production, so the higher yield of the desired protein can be 
obtained after longer period of incubation. It was decided to conduct future 6xHis-PcpI 
with an addition of IPTG inducer at OD595 of 0.6 and incubation at 25C for 6 h. 
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3.2.2.3. Purification of 6xHis-PcpI 
3.2.2.3.1. Production and extraction of 6xHis-PcpI 
          The production and extraction of 6xHis-PcpI from BL21-CodonPlus®(DE3)-
RIPL was conducted as described in sections 3.2.1.3.1 and 3.2.1.3.2. After harvesting 
2.5 g of bacterial cell paste was obtained from 1 L of culture. A result of 6xHis-PcpI 
overexpression was confirmed by the SDS-PAGE technique using a 12.5% acrylamide 
gel, which is presented in figure 3.7.  
 
Figure 3.7. The result of SDS-PAGE confirming the overexpression of recombinant 
6xHis-PcpI (approx. 25 kDa). Individual lanes represent sample 6 h after induction 
(6h), before induction (0h) and a protein molecular weight marker (M). 
 
          The successful production of the protein in a soluble form enabled further 
purification procedure using nickel affinity chromatography and gel filtration 
techniques. 
3.2.2.3.2. Nickel affinity chromatography 
          The supernatant obtained after 6xHis-PcpI extraction procedure was applied to 
Ni
+ 
Sepharose column and subjected to protein purification as described in section 
3.2.1.3.3. The elution profile presented in figure 3.8 allowed for determination of 
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fractions containing 6xHis-PcpI, which were further analysed using SDS-PAGE to 
assess the purity of the eluted protein. A result of this analysis is presented in figure 3.9. 
 
Figure 3.8. The nickel affinity protein elution profile of the human recombinant 6xHis-
PcpI. The fractions containing the protein are marked by the red bar. The A280 trace is 
coloured in blue and the imidazole gradient is coloured in pink. 
 
 
 
  M – MW marker 
  1 – crude extract 
  2 – fraction A5 
  3 – fraction B5 
  4 – fraction E12 
  5 – fraction F4 
  6 – fraction F8 
  7 – fraction F11 
  8 – fraction G2 
  9 – fraction G5  
 
Figure 3.9. The result of the SDS-PAGE analysis of the human recombinant  
6xHis-PcpI purified through nickel affinity chromatography.  
 
          As 6xHis-PcpI was not completely purified, fractions with the protein were mixed 
and subjected to subsequent purification steps (3.2.2.3.3). 
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3.2.2.3.3. Gel filtration chromatography 
          A high purity and homogeneity of 6xHis-PcpI was required for the purpose of 
crystallisation trials. In order to achieve this and remove any potential protein 
aggregates, the 6xHis-PcpI fractions from Ni
+ 
Sepharose
TM
 column purification were 
pooled together. The protein sample was further subjected to the precipitation by 80% 
ammonium sulfate as described in section 3.2.1.3.4. A subsequent purification step was 
conducted using gel filtration column (3.2.1.3.4). The resulting elution profile and SDS-
PAGE analysis are presented in figures 3.10 and 3.11, respectively. 
 
Figure 3.10. The gel filtration protein elution profile of the human recombinant 6xHis-
PcpI. The fractions containing the protein are marked by the red bar. The A280 trace is 
coloured in blue. 
 
 
 
 
 
114 
 
 
  M – MW marker 
  1 – fraction 56 
  2 – fraction 57 
  3 – fraction 59 
  4 – fraction 60 
  5 – fraction 62 
  6 – fraction 63 
  7 – fraction 65 
  8 – fraction 66 
 
 
Figure 3.11. The result of SDS-PAGE analysis of the human recombinant 6xHis-PcpI 
purified by gel filtration chromatography.  
 
          The purification of human 6xHis-PcpI from BL21-CodonPlus®(DE3)-RIPL cell 
lysate was successful. As it can be seen in figure 3.11, eluted gel filtration fractions 
contained highly purified 6xHis-PcpI with a lack of any contaminating material. The 
concentration and activity after each purification step was determined using the 
Bradford assay and the fluorometric enzyme activity assay described in sections 2.8.3.2 
and 2.8.4, respectively. The purification result is presented in the table 3.6.     
Fraction 
Total 
Protein 
(mg) 
Total 
Activity (U) 
Specific 
Activity 
(U/mg) 
Purification 
Fold 
% 
Yield 
Crude 
Extract 
783.0 284.5 0.36 1.0 100 
Ni Sepharose 66.7 159.3 2.39 6.6 56 
Superdex
TM
 
200 
29.5 97.7 3.31 9.1 34 
 
Table 3.6. The purification table for human recombinant 6xHis-PcpI. All values are 
presented for purification from 1 L of BL21-CodonPlus®(DE3)-RIPL cell culture. 
 
 
          Although the purification of human recombinant 6xHis-PcpI gives a satisfying 
yield (34%) and purity, the protein was observed to be unstable in vitro. Attempts to 
overcome this issue were conducted and are described in section 3.2.2.3.4.  
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3.2.2.3.4. Modifications to purification procedure of 6xHis-PcpI 
          The 6xHis-PcpI was attempted to be concentrated up to minimum of 10 mg/ml 
necessary for the crystallisation study. This was performed at 4ºC using a Vivaspin20 
centrifugal concentrator with a 30 kDa molecular weight cut-off with regenerating 
polyethersulfone membrane (Sartorius Stedim Biotech S.A.). Unfortunately, it was 
noticed that 6xHis-PcpI was extremely unstable and easily precipitated out of the 
solution and it could not be concentrated beyond ~0.13 mg/ml. This problem was 
attempted to be overcome by the application of various buffer additives known for their 
stabilising properties as described in section 3.2.1.3.6. None of the buffer additives, 
however, significantly helped to improve 6xHis-PcpI stability and the protein still 
appeared to precipitate out of solution. Moreover, the application of K2HPO4/KH2PO4 
based buffers or the addition of Triton X-100 and glycerol resulted in the purification 
yield being much lower than in original buffer system. Minor improvement was 
observed when 0.15 M NaCl was included. Particularly, the yield from the gel filtration 
purification step was increased and the protein was able to be concentrated up to around 
1.0 mg/ml. This has led to a decision to include 0.15 M NaCl in purification buffers for 
PcpI-6xHis (3.2.1.7). 
          The unsuccessful attempts to overcome 6xHis-PcpI instability and obtain  
a concentrated sample to conduct crystallisation studies it was decided to generate  
C-terminally His-tagged PcpI (PcpI-6xHis) and native PcpI (3.2.1.4).     
3.2.2.4. Cloning of PcpI cDNA for production of PcpI-6xHis and native PcpI 
3.2.2.4.1. PCR amplification of PcpI cDNA 
          The amplification of cDNA encoding PcpI (3.2.1.4.1) was successful and was 
confirmed by the 2% agarose gel electrophoresis. The positive result of the reaction was 
obtained over the whole range of the applied annealing temperature gradient. The bands 
corresponding to the inserts of the native PcpI and PcpI-6xHis can be observed at 
approx. 630 bp as seen on figures 3.12 and 3.13, respectively.  
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Figure 3.12. The result of the amplification of cDNA encoding human PcpI (627 bp). 
The insert was flanked with NdeI and EcoRI restriction sites to clone it into pET-22b(+) 
expression vector. M – marker Hyperladder I. 
 
Figure 3.13. The result of the amplification of cDNA encoding human PcpI (627 bp). 
The insert was flanked with NcoI and HindIII restriction sites to clone into pET-28b(+) 
expression vector. M – marker Hyperladder I. 
 
3.2.2.4.2. Ligation of PcpI insert with pET-28b(+) and pET-22b(+)and preparation of 
recombinant plasmids 
          Both ligation reactions of PcpI inserts with pET-28b(+) and pET-22b(+) 
(3.2.1.4.2) were successful and was confirmed by the presence of colonies carrying 
recombinant plasmids. Both recombinant plasmids were isolated as described in section 
3.2.1.4.3. The presence of the desired inserts was shown using a double digestion 
reaction with suitable restriction enzymes and subsequent 1% agarose gel 
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electrophoresis. The results for the pET-28b(+)/pcpI and pET-22b(+)/pcpI are presented 
in figures 3.14 and 3.15, respectively. 
 
Figure 3.14. The result of agarose gel electrophoresis of pET-28b(+)/pcpI restriction 
digestion products. Individual lanes represent marker Hyperladder I (M), uncut 
plasmid (1) and cut plasmid (2). Insert band can be observed at approx. 630 bp. 
 
Figure 3.15. The result of agarose gel electrophoresis of pET-22b(+)/pcpI restriction 
digestion products. Individual lanes represent marker Hyperladder I (M), uncut 
plasmid (1) and cut plasmid (2). Insert band can be observed at approx. 630 bp. 
 
 
          The correct sequence of both inserts was confirmed by DNA sequencing (2.7.10, 
appendix III). The pET-28b(+)/pcpI and pET-22b(+)/pcpI were further used for the 
overexpression of PcpI-6xHis and native PcpI, respectively (3.2.2.5). 
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3.2.2.5. Overexpression of PcpI-6xHis and native PcpI 
          The overexpression of PcpI-6xHis and native PcpI in the BL21-
CodonPlus®(DE3)-RIPL strain was successful and yielded soluble proteins fractions. 
This was confirmed by SDS-PAGE gels presented in figures 3.16 and 3.17, 
respectively.          
 
Figure 3.16. The result of SDS-PAGE confirming the overexpression of PcpI-6xHis 
(approx. 24 kDa). Individual lanes represent sample 6 h after induction (6h), before 
induction (0h) and a protein molecular weight marker (M). 
 
 
Figure 3.17. The result of SDS-PAGE confirming the overexpression of native PcpI 
(approx. 23 kDa). Individual lanes represent sample 6 h after induction (6h), before 
induction (0h) and a protein molecular weight marker (M). 
 
          Both PcpI-6xHis and native PcpI were present in soluble fractions which 
facilitated further protein purification steps (3.2.2.6 and 3.2.2.7, respectively).      
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3.2.2.6. Purification of PcpI-6xHis 
3.2.2.6.1. Nickel affinity chromatography 
          The production and extraction of PcpI-6xHis from BL21-CodonPlus®(DE3)-
RIPL was conducted as described in sections 3.2.1.3.1 and 3.2.1.3.2. Around 2.5 g of 
bacterial cell paste was obtained from 1 L of culture after harvesting. This was used for 
protein extraction and the supernatant, obtained during the procedure, was applied to 
Ni
+ 
Sepharose column and subjected to protein purification as described in section 
3.2.1.7. The elution profile presented in figure 3.18 allowed for determination of 
fractions containing PcpI-6xHis, which were further analysed using SDS-PAGE to 
assess the purity of the eluted protein. A result of this analysis is presented in figure 
3.19. 
 
Figure 3.18. The nickel affinity protein elution profile of the human recombinant PcpI-
6xHis. The fractions containing the protein are marked by the red bar. The A280 trace is 
coloured in blue and imidazole gradient is coloured in pink. 
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M – MW marker 
  1 – crude extract 
  2 – fraction A10 
  3 – fraction E10 
  4 – fraction F1 
  5 – fraction F4 
  6 – fraction F6 
  7 – fraction F8 
  8 – fraction F9 
  9 – fraction G3 
Figure 3.19. The result of SDS-PAGE analysis of the human recombinant PcpI-6xHis 
purified through nickel affinity chromatography.  
 
          As PcpI-6xHis was not totally purified, all fractions with the protein were mixed 
and subjected to subsequent gel filtration step (3.2.2.6.2). 
3.2.2.6.2. Gel filtration chromatography 
          The purpose of PcpI-6xHis purification is to produce a protein sample of high 
purity and homogeneity in order to conduct crystallisation trials. All fractions obtained 
after Ni
+ 
Sepharose
TM
 column purification which contained the protein were pooled 
together and further subjected to precipitation by 80% ammonium sulfate. Next the 
protein precipitate was resuspended in purification buffer and applied to a gel filtration 
column. The resulting elution profile and SDS-PAGE analysis are presented in figures 
3.20 and 3.21, respectively. 
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Figure 3.20. The gel filtration protein elution profile of the human recombinant PcpI-
6xHis. The fractions containing the protein are marked by the red bar. The A280 trace is 
coloured in blue. 
 
  
 
M – MW marker 
  1 – fraction 58  
  2 – fraction 60 
  3 – fraction 61 
  4 – fraction 62 
  5 – fraction 63 
  6 – fraction 64 
  7 – fraction 65 
  8 – fraction 67 
   
Figure 3.21. The result of SDS-PAGE analysis of the human recombinant PcpI-6xHis 
purified by gel filtration chromatography.  
 
          The purification of human recombinant PcpI-6xHis from BL21-
CodonPlus®(DE3)-RIPL cell lysate was successful. The protein concentration and 
activity after each purification step was determined using the Bradford assay and the 
fluorometric enzyme activity assay described in sections 2.8.3.2 and 2.8.4, respectively. 
The purification result is presented in the table 3.7.     
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
1 5 9 13 18 22 26 31 35 39 44 48 52 56 61 65 69 74 
A
b
s
o
rb
a
n
c
e
 a
t 
2
8
0
n
m
 (
A
U
) 
Fraction number 
122 
 
Fraction 
Total 
Protein 
(mg) 
Total 
Activity  
(U) 
Specific 
Activity 
(U/mg) 
Purification 
Fold 
% 
Yield 
Crude Extract 838.0 301.7 0.36 1.0 100 
Ni
+
 Sepharose 199.6 247.0 1.24 3.4 82 
Superdex
TM
 
200 
42.3 186.1 4.40 12.2 62 
 
Table 3.7. The purification table for human recombinant PcpI-6xHis. All values are 
presented for purification from 1 L of BL21-CodonPlus®(DE3)-RIPL cell culture. 
 
 
          The purification of PcpI with the C-terminal His-tag was shown to be more 
effective (62% recovery) when compared to its 6xHis-PcpI yield (34%, section 
3.2.2.3.3). The reason of this improvement may probably be explained by the fact that 
the shift of the tag to protein’s C-terminus could offer better accessibility of the 
histidine residues when binding to Ni
+
 Sepharose. Additionally, there may be  
a difference in the folding process between both recombinant PcpI forms where C-
terminal tag localisation is definitely favourable. The advantage of such a shift can be 
seen in around two-fold better purification recovery of PcpI-6xHis over 6xHis-PcpI as 
well as in observable increase of the in vitro stability of the former form (3.2.2.6.3).  
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3.2.2.6.3. Stability of PcpI-6xHis 
          A centrifuged sample of PcpI-6xHis directly after the gel filtration step was 
analysed for homogeneity using the DLS technique as described in section 2.8.5.  
The result of the analysis was presented in figure 3.22. 
 
 
Figure 3.22. Result of DLS analysis of PcpI-6xHis. Peak no. 2 corresponds to the 
protein with estimated mass MW-R for 24.1 kDa. Polydispersity index was 13.8% 
indicating mostly homogenous state of the protein. 
 
          The DLS experiment indicates that the analysed PcpI-6xHis sample contains  
a single species with a polydispersity index calculated for 13.8% (below 15% 
threshold). Lack of undesired aggregates is significant improvement supporting the fact 
that modification of PcpI would increase its stability. It is worth noting that although 
DLS analysis suggests that PcpI is stable in given conditions this cannot be an 
indication of the general protein stability particularly during a prolonged period and as  
a concentrated protein sample. This result however confirms the purity and 
homogeneity of the sample required for protein crystallisation. 
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           It was reported in section 3.2.2.3.4 that, despite multiple attempts, PcpI with the 
N-terminal His-tag could not be concentrated beyond 1.0 mg/ml. For the case of  
PcpI-6xHis this was increased to ~2.5 mg/ml when concentrated solely in gel filtration 
buffer and reached the desired 5.5 mg/ml when the sample was enriched with NDSB 
additives (3.2.1.10). Above this point the protein was seen to heavily precipitate out of 
solution. All of the available sulfobetaines NDSB-195, NDSB-201, NDSB-211,  
NDSB-221 or NDSB-256 were tested in order to identify their influence on the protein 
behaviour. None of the compounds could be distinguished as the one having the best 
stabilising propensity towards PcpI-6xHis, however the NDSB-195 (figure 3.1) was 
shown to be the most advantageous in this matter. This betaine contains the shortest 
bridge (C2) between N
+
 and SO3
-
 which may offer some positive protein protecting 
features over the other tested chemicals that could adopt a cyclic conformation  
in solution.  Some reports favour NDSB-195 as having the best solubilising properties 
and being the most stable at high pH (Vuillard et al., 1995). 
          PcpI-6xHis concentrated up to ~5.5 mg/ml with NDSB-195 was subjected to 
preliminary crystallisation experiments using the vapour diffusion technique (3.4.2.4.1).  
3.2.2.7. Purification of native PcpI 
3.2.2.7.1. Phenyl sepharose chromatography 
          The production and extraction of native PcpI from BL21-CodonPlus®(DE3)-
RIPL was conducted as described in section 3.2.1.8.1. The harvesting of 1 L of bacterial 
culture yielded around 2.0 g of cell paste. Next this was used for protein extraction and 
the supernatant, obtained during the procedure, was applied to a Phenyl Sepharose™ 
column and subjected to protein purification as described in section 3.2.1.8.2. The 
elution profile presented in figure 3.23 allowed the determination of fractions 
containing native PcpI, which were further analysed using SDS-PAGE to assess the 
purity of the eluted protein. The result of this analysis is presented in figure 3.24. 
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Figure 3.23. The Phenyl Sepharose™ protein elution profile of the human native PcpI. 
The fractions containing the protein are marked by the red bar. The A280 trace is 
coloured in blue and the 1.5 M (NH4)2SO4 gradient is coloured in pink. 
 
 
 
M – MW marker 
  1 – fraction A5 
  2 – fraction A10 
  3 – fraction C11 
  4 – fraction D9 
  5 – fraction D12 
  6 – fraction E2 
  7 – fraction E4 
  8 – fraction E6 
  9 – fraction E8 
Figure 3.24. The result of SDS-PAGE analysis of the human native PcpI purified by 
Phenyl Sepharose™ chromatography.  
 
          As the Phenyl Sepharose™ column only partially purified native PcpI, all 
fractions containing the protein were mixed and subjected to a further ion-exchange 
chromatography step (3.2.2.7.2). 
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3.2.2.7.2. Ion-exchange chromatography 
          Preparation of the native PcpI sample to be purified using FFS-Sepharose
TM
 
cation exchange column was conducted as described in section 3.2.1.8.3. The elution 
profile presented in figure 3.25 allowed for determination of fractions containing native 
PcpI, which were further analysed using SDS-PAGE to assess the purity of the eluted 
protein. A result of this analysis is presented in figure 3.26. 
 
Figure 3.25. The FFS-Sepharose
TM
 cation exchange protein elution profile of the 
human native PcpI. The fractions containing the protein are marked by the red bar. The 
A280 trace is coloured in blue and the 1.5 M NaCl gradient is coloured in pink. 
 
 
 
 
  1 – fraction A5 
  M – MW marker 
  2 – fraction D6 
  3 – fraction E8 
  4 – fraction E10 
  5 – fraction E12 
  6 – fraction F2 
  7 – fraction F5 
  8 – fraction F7 
  9 – fraction F10 
 
 
Figure 3.26. The result of SDS-PAGE analysis of the human native PcpI purified 
through FFS-Sepharose
TM
 cation exchange chromatography.  
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          FFS-Sepharose
TM
 column purification yielded a highly purified native PcpI 
sample as can be seen from the SDS-PAGE analysis (figure 3.26). In order to improve 
the degree of the purity all fractions containing the protein were mixed and subjected to 
a further gel filtration step (3.2.2.7.3). 
3.2.2.7.3. Gel filtration chromatography 
          Purification of native PcpI, as in the case of PcpI-6xHis, is aimed to produce  
a protein sample of high purity and homogeneity required for crystallisation 
experiments. All fractions obtained after FFS-Sepharose
TM
 column purification which 
contained native PcpI were pooled together and further subjected to the precipitation by 
80% ammonium sulfate. Next the protein precipitate was resuspended in purification 
buffer and applied to a gel filtration column. The resulting elution profile and the  
SDS-PAGE analysis are presented in figures 3.27 and 3.28, respectively. 
 
Figure 3.27. The gel filtration protein elution profile of the human native PcpI. The 
fractions containing the protein are marked by the red bar. The A280 trace is coloured in 
blue. 
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M – MW marker 
  1 – fraction 58 
  2 – fraction 59 
  3 – fraction 60 
  4 – fraction 61 
  5 – fraction 63 
  6 – fraction 64 
  7 – fraction 65 
  8 – fraction 66 
 
Figure 3.28. The result of SDS-PAGE analysis of the human native PcpI purified by gel 
filtration chromatography.  
 
          The purification of human native PcpI from BL21-CodonPlus®(DE3)-RIPL cell 
lysate was successful. The protein concentration and activity after each purification step 
was determined using the Bradford assay and the fluorometric enzyme activity assay 
described in sections 2.8.3.2 and 2.8.4, respectively. The purification result is presented 
in the table 3.8.     
Fraction 
Total 
Protein 
(mg) 
Total 
Activity 
(U) 
Specific 
Activity 
(U/mg) 
Purification 
Fold 
% 
Yield 
Crude Extract 874.0 218.1 0.25 1.0 100 
Phenyl 
Sepharose™ 
236.2 168.0 0.71 2.9 77 
FFS-
Sepharose™  
39.7 101.9 2.57 10.3 47 
Superdex
TM
 
200 
15.3 52.4 3.42 13.7 24 
 
Table 3.8. The purification table for human native PcpI. All values are presented for 
purification from 1 L of BL21-CodonPlus®(DE3)-RIPL cell culture. 
 
          The purification of untagged native PcpI showed it to be less effective (24% 
recovery) when compared to 6xHis-PcpI or PcpI-6xHis yield (34%, section 3.2.2.3.3 
and 62%, section 3.2.2.6.2, respectively). This can be understood since the presence of 
any type of affinity tag attached to the protein aims to increase selectivity during its 
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separation from the rest of cellular material. The purification fold is noticeably low for 
the Phenyl Sepharose™ step which may be explained by the fact that hydrophobic 
interactions are very unspecific (hence relatively high total protein mass, table 3.8) so 
typical elution peaks are very broad. Subsequently the FFS-Sepharose™ cation 
exchange step yielded a good level of purification which was improved in gel filtration. 
The resulting 24% yield is low however native PcpI at this stage was reasonably stable 
(3.2.2.7.4) and its total amount was sufficient to concentrate it and prepare initial 
crystallisation screening dishes. 
3.2.2.7.4. Stability of PcpI-6xHis 
          A centrifuged sample of native PcpI directly after gel filtration step was analysed 
for homogeneity using DLS technique as described in section 2.8.5. The result of the 
analysis was presented in figure 3.29. 
 
 
Figure 3.29. Result of DLS analysis of native PcpI. Peak no. 2 corresponds to the 
protein with estimated mass MW-R for 29 kDa. Polydispersity index was 14.9% 
indicating mostly homogenous state of the protein. 
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The DLS experiment indicates that the analysed native PcpI sample contains a single 
species with an acceptable polydispersity index calculated for 14.9%. Returned 
molecular weight of the species is nearly 29 kDa (figure 3.29) and is a bit higher than 
the real one 23.1 kDa. This can be explained by the fact that a particle size is estimated 
on the basis of hydrodynamic (Stokes) radius and depends on both mass and 
conformation. It is possible that untagged PcpI may be less stable than PcpI-6xHis and 
undergoes slow denaturation or an aggregation process. This may explain a slightly 
higher polydispersity index comparing to PcpI-6xHis (13.8% vs. 14.9%, respectively). 
However, this data generally suggests the stability of native PcpI in solution and, at 
least in tested conditions, lack of undesired aggregates. The result also confirms the 
purity and the homogeneity of the protein sample which was subsequently subjected to 
concentration and crystallisation experiments (3.5.3.1). 
          The attempts to concentrate native PcpI were not successful and resulted in  
a maximum of 1.0 mg/ml sample above which a heavy precipitation was observed.  
Therefore, as in case of PcpI-6xHis, native PcpI samples were separately enriched with 
a range of NDSB compounds as described in section 3.2.1.10. In this case the protein 
solubility was slightly improved, however it could not be concentrated beyond  
~2.8 mg/ml even in a presence of NDSB-195. Despite persisting problem with protein 
stability it was decided to prepare the 2.8 mg/ml native PcpI sample (with NDSB-195) 
and subject it to initial crystallisation trials using vapour diffusion technique (3.4.2.4.1). 
 
          The instability of PcpI created a serious problem which, until solved, prevents the 
use of the protein in crystallographic structural studies. An initial study on the untagged 
and C-terminally His-tagged PcpI brought slight improvement to this question and 
enabled at least preliminary crystallisation experiments to be carried out. Therefore it 
was decided to conduct a further study regarding PcpI stability involving site-directed 
mutagenesis, thermofluor shift assay and chemical modification of surface residues 
(3.3)   
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3.3. Stability studies on human PcpI 
          Stability and solubility of proteins are strongly correlated with their ability and 
usefulness for the production of high-quality crystals, therefore any improvement of 
these properties directly influences rates of crystallisation. Therefore, it is understood 
that this question is considered as a one of the most significant in protein science and 
became extensively studied over years. Multiple methods that aim to interfere with  
protein behaviour in vitro have been reported and include screening for optimal 
expression, purification and storage conditions, application of additives and stability 
enhancers, protein engineering or chemical modifications (Richards, 1997; van den 
Burg and Eijsink, 2002; Pace et al., 2004; Littlechild et al., 2007).  
The problems with PcpI instability in solution that were approached in this project, were 
previously often observed during experimental work (Doolittle and Armentrout, 1968; 
Szewczuk and Kwiatkowska, 1970; Connelly, 2006; Mtawae et al., 2008). Interestingly, 
Pcp representatives from extremophilic sources such as T. litoralis,  
P. furiosus and P. horikoshii are recognised as those exhibiting thermostable 
properties (2.1.3). The reason of such a difference lies in the fact that prokaryotic 
peptidases acquire tetrameric structural conformations and some of them possess 
hydrophobic insertions or make disulfide bonds and ionic interactions, which probably 
elevate this unusual stability. There are reports on stabilising effect of thiol-reducing 
agents or, to some degree, EDTA on type I Pcps, so these compounds were included  
in purification buffers. This, however, seems to be insufficient method to overcome  
the problem of excessive precipitation of the protein out of the solution, particularly 
during sample concentration prior to crystallisation trials. Therefore it was  
necessary to attempt other available tools that could help in this matter and these 
include screening for optimal buffer conditions (thermofluor-based thermal shift assay), 
site-directed mutagenesis of cysteine residues or their modification with  
5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) as well as methylation of surface lysine 
residues. 
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3.3.1. Fluorescence-based thermal stability assay 
          In most applications that take longer period of time, protein stability is a decisive 
factor, which influences the effectiveness and the results of a given experiment.  
The environment, which helps to maintain stable protein, is also favourable to decrease 
its tendency to aggregate and prevent its denaturation during analytical and biophysical 
experiments or storage. Analysis of the influence of generic ingredients like buffers, 
salts and detergents as well as protein-ligand interactions as potential protein-stabilisers 
is of high value, particularly in cases of increased protein lability. 
          The fluorescence-based thermal stability (thermofluor shift) assay was developed 
by Pantoliano and co-workers and was originally used for rapid identification of ligands 
for target proteins as a strategy for drug discovery (Pantoliano et al., 2001). The method 
allows for a high-throughput screen of optimal buffer conditions and additives that can 
promote protein stabilisation against thermal denaturation (Ericsson et al., 2006; Niesen 
et al., 2007). It is particularly useful when designing conditions for crystallisation of 
proteins for structural studies. The principle of this method is based on the observation 
that folded and unfolded proteins can be easily distinguished by the interaction with  
a specific fluorescent dye (fluoroprobe). The fluorescence is quenched in aqueous 
solution, but the emission can be readily detected when the dye binds to the protein 
hydrophobic interior which becomes exposed during thermally-induced unfolding. 
Progressive changes in fluorescence intensity as a function of temperature follow  
a typical sigmoidal melting curve with a sharp transition between a folded and unfolded 
state. Transition midpoint (Tm, melting temperature) of the unfolding varies depending 
on the buffer/ligand conditions creating the protein environment and therefore can 
define their influence on its stability when compared to control parameters (e.g. Tm in 
water or in the absence of ligand or buffer). An important advantage of this method is 
its universality as no advanced knowledge on the tested protein is required in order to 
perform the screening for optimal stabilising conditions. 
          The thermofluor shift assay of human PcpI was performed using SYPRO
® 
Orange 
dye (Sigma), which is considered to be the most favoured for its properties for this 
method due to its high signal-to-noise ratio (Niesen et al., 2007). 
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3.3.1.1. Materials and methods 
3.3.1.1.1. Sample preparation 
          Purified PcpI sample was concentrated up to 1.0 mg/ml and mixed with other 
compounds prior to the assay. The mix for 22 reactions consisted of: 
115.5 μl PcpI (0.5-1.0 mg/ml) 
0.578 μl 5000x SYPRO® Orange  
46.2 μl 2x NaCl (double protein concentration) 
45.6 μl ddH2O 
 
          Next 9 μl of the mix was combined with 1 μl of a given buffer solution (table 3.9) 
in 100 μl strip tubes (Qiagen), placed in a Rotor-Gene 6000 real-time PCR cycler 
(Corbett Life Sciences).  
No. Buffer solutions pH 
1. ddH2O (Control)  
2. 100 mM Glycine  10 
3. 100 mM L-Arginine  9.5 
4. 100 mM Bicine  9.0 
5. 100 mM CHES  8.5 
6. 100 mM di-Sodium Tetraborate  8.5 
7. 100 mM HEPPS  8.0 
8. 100 mM Tris-HCl  8.0 
9. 100 mM Imidazole  8.0 
10. 100 mM Ammonium Sulfate  7.5 
11. 100 mM HEPES  7.5 
12. 100 mM MOPS  7.2 
13. 100 mM PIPES  7.0 
14. 100 mM Sodium osate  7.0 
15. 100 mM Bis-Tris Propane  6.7 
16. 100 mM MES  6.5 
17. 100 mM Zinc Acetate  6.5 
18. 100 mM Sodium Citrate  5.6 
19. 100 mM Sodium Acetate  4.6 
20. 50 mM Tris-HCl, 0.15 M NaCl, 5 mM β-Me (buffer A+ β-Me)  7.5 
21. 50 mM Tris-HCl, 0.15 M NaCl (buffer A)  7.5 
 
Table 3.9. List of the buffer solutions tested for PcpI stability in the thermofluor shift 
assay. 
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          Moreover the screening was repeated with the same selection of buffers and with 
addition of the reversible PcpI inhibitors – 2-pyrrolidone or L-pGlu acid. Each of the 
inhibitors was added to the protein sample with 5-fold molar excess and incubated for 
1 h at 4ºC prior to preparation of the master mix.  
3.3.1.1.2. Thermofluor shift assay 
          The assay was performed in the Rotor-Gene 6000 real-time PCR cycler (Corbett 
Life Sciences). All samples with screening conditions were prepared in triplicate and 
heated from 25ºC to 90ºC at a rate of 0.2ºC/min. Fluorescence intensity measurements 
were taken simultaneously and collected by a software package associated with the 
cycler. The excitation and emission wavelengths were 490 nm and 575 nm, 
respectively.  
3.3.1.1.3. Analysis of thermofluor shift data 
          In order to calculate the temperature midpoint values Tm the fluorescence 
intensity data were fitted using Xlfit
TM
 curve-fitting software (ID Business Solutions 
Ltd). Tm which is an inflection point of the transition curve was calculated for each 
sample after fitting to a Boltzmann model using the equation shown in figure 3.30. 
    
   
           
 
Figure 3.30. Boltzmann equation: I stands for a fluorescence intensity at the 
temperature T; A and B are minimum and maximum fluorescence intensities, 
respectively; C is a slope of the transition curve; Tm is the temperature midpoint for the 
unfolding transition. 
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          Individual PcpI Tm values for all tested buffers were compared with the reference 
value T0 which was the protein in ddH2O (control). The change in unfolding 
temperatures – ΔTm=Tm-T0 – was calculated for each sample. Positive ΔTm indicates 
that given conditions prompt stabilising structural changes towards a more ordered and 
less flexible conformation, whereas negative ΔTm can be considered as a sign of protein 
disordered state and misfolding.  
3.3.1.1.4. Optimisation for HEPPS buffer 
          The results of the experiment showed that the highest ΔTm was obtained for the 
PcpI sample containing HEPPS buffer at pH 8.0. Therefore it was decided to carry out 
the optimisation of the thermofluor shift screening with a set of HEPPS buffers where 
the pH was varied: 7.3, 7.5, 7.7, 7.9, 8.1, 8.3, 8.5 and 8.7. Sample preparation and the 
assay performance were conducted as described in sections 3.3.1.1.1 and 3.3.1.1.2, 
respectively. 
3.3.1.2. Results and discussion 
3.3.1.2.1. Thermofluor shift assay 
          Fluorescence intensity data obtained for all PcpI samples containing individual 
buffer components (3.3.1.1.1) were plotted against assayed temperature values and are 
presented in figure 3.31. For all tested conditions the fluorescence intensity function 
acquires a bell-shape-like profile reaching a maximum peak and then gradually 
decreases. This is often observed and may be a result of a probable precipitation or 
aggregation of the denatured protein and fluoroprobe complex (Niesen et al., 2007). 
Therefore the data beyond the maximum were excluded from fitting to the Boltzmann 
model (3.3.1.1.3).  
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Figure 3.31. Thermofluor shift assay results for the set of given buffers reflecting state 
of the protein in each condition. The data after the maximum peak were excluded  
from fitting as these relate to precipitated protein-dye complex and do not fit to the 
Boltzmann model. 
 
 
          The PcpI stability screening was conducted solely with a selection of buffers as 
well as with the buffers individually combined with reversible inhibitors – 2-
pyrrolidone or L-pGlu acid. The protein Tm values were calculated for each condition 
using Xlfit
TM
 curve-fitting software (3.3.1.1.3) and compared with reference T0. 
Comparison of the obtained changes in the unfolding temperature (ΔTm) for each screen 
is presented in figure 3.32. 
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Figure 3.32. Comparison of the changes in ΔTm of PcpI in given buffer conditions (blue 
bars) as well as in presence of reversible inhibitors 2-pyrrolidone (green bars) or L-pGlu 
acid (yellow bars). Negative ΔTm indicate destabilising protein environment, whereas 
positive values indicate that buffer conditions prompt stabilising structural changes of 
the protein. 
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          The condition screening, which consisted of 20 different buffers showed varied 
results in terms of their influence on PcpI stability (figure 3.32). Representative buffers, 
which prompted the most significant positive shift of melting temperature (+ΔTm) were 
HEPPS (pH 8.0), PIPES (pH 7.0), sodium citrate (pH 5.6) and sodium acetate (pH 4.6). 
Both HEPPS and PIPES belong to a specific group of tertiary and secondary 
aminoalkanesulfonic acids also known as Good buffer series (Good et al., 1966). They 
are widely used as biological buffers because of the sufficient coverage of the 
physiological pH range and above, as well as their similarity to amino acids in ability to 
function in multiple ionization states e.g. zwitterionic form. Moreover, their stabilising 
effect may be a result of binding to a protein that has been confirmed by the fact that 
many structures in the PDB contain ordered MES or HEPES (Newman, 2004). This 
finding supports their usefulness in crystallisation experiments. 
          The stabilising influence of sodium citrate and sodium acetate has already been 
observed for the case of a number of proteins (Ericsson et al., 2006). However due to 
acidic pH of these buffers, close to the PcpI pI (theoretical value 6.08) and that they 
create potential problems in some other applications (e.g. nickel affinity purification), 
they were not considered to be used further in this study. 
         Surprisingly the most destabilising effect (negative ΔTm) on PcpI was observed for 
Tris-based buffers used so far in the purification – buffer A (-1.9ºC) and buffer A+β-Me 
(-1.8ºC) (2.3.3.3). Similar but even stronger influence on PcpI disorder was seen for 
ammonium sulfate (-2.2ºC) used for the protein precipitation and concentration prior to 
the gel filtration step (3.2.1.7 and 3.2.1.8.4). Negative ΔTm value (although lower than 
the parameter of buffer A) was also obtained for Tris-HCl (-0.36ºC). Differences 
between both conditions lies in pH (Tris-HCl pH 8.0 vs. buffer A pH 7.5) and the 
presence of 0.15 M NaCl in buffer A. NaCl increases the ionic strength of the solution 
and its inclusion in the purification buffers was due to the observation of its positive 
effect on 6xHis-PcpI solubility (3.2.2.3.4). It may be concluded that the stabilising 
effect of Tris-HCl may be a function of pH where a more alkaline environment has a 
better influence on PcpI. It is worth noting that Tris-HCl has a relatively narrow 
buffering capacity in the 7.5-9.2 range and its pH is strongly temperature-dependent. 
Therefore the buffer at pH 7.5, being at the edge of the buffering range can easily lose 
its properties with insignificant temperature shifts, which may result in the protein being 
exposed to unfavourable conditions. Moreover, the presence of any reducing agents, 
such as β-Me, in unstable buffer may addtionally decrease pH of the solution leading it 
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towards the pI of PcpI and result in a reduction of its solubility. These findings have 
helped to understand why PcpI was extremely unstable and easily precipitated out of 
solution during sample concentration and could not be kept for more than a few days at 
both 4ºC or room temperature. It is worth noting that the other buffer from the Tris 
group – Bis-Tris propane pH 6.7 – surprisingly had a minimal positive effect on PcpI 
conformational order. The reason for this may be explained by the fact that Bis-Tris has 
a wider buffering capacity from pH 6 to 9.5 and its zwitterionic structure precludes 
dramatic pH and ionic strength changes of the solution (Stellwagen et al., 2008). 
          Despite the negative thermal shift values for most of the tested buffers in all the 
cases, with exception of zinc acetate, addition of either of the inhibitors dramatically 
increased protein stability (figure 3.32). This can be observed even for the most 
destabilising buffer A and ammonium sulfate. Such a change is not suprising since 
binding of inhibitor or any other ligand prompts protein towards a less flexible and 
more ordered conformation. Both inhibitors due to their highly stabilising properties 
were included in crystallisation experiments (3.4.2.4.3). 
          The best positive ΔTm result obtained for HEPPS buffer led to the decision to use 
this for further optimisation screening but with varied pH values as described in section 
3.3.1.1.4.  
3.3.1.2.2. Optimisation for HEPPS buffer 
          Investigation for the optimal pH value of HEPPS was performed on the group of 
buffers as described in section 3.3.1.1.4. Comparison of the changes obtained in the 
unfolding temperature (ΔTm) for each pH is presented in figure 3.33.           
140 
 
 
Figure 3.33. Comparison of the changes in ΔTm of PcpI in a set of HEPPS buffers with 
varied pH. 
 
          Results of the optimisation show that all of the tested buffers have a stabilising 
effect on PcpI. The best ΔTm value was obtained in the presence of HEPPS at pH 8.1. 
The shift in transition temperature is very similar for conditions of pH from 7.9 to 8.5 
and starts decreasing beyond this range. This indicates that PcpI stability is pH-sensitive 
and, based on this finding, application of HEPPS buffer at pH 8.0 in the purification 
system seems to be the best solution. 
3.3.1.2.3. Application of HEPPS-based buffers  
          Results obtained from the thermofluor shift assay led to a decision to replace the 
purification buffer system of PcpI from Tris-based to HEPPS-based, the content of 
which is shown in section 2.3.3.5. All Tris-HCl solutions (including buffer A) displayed 
a negative effect on the structural confirmation of human PcpI contrary to the stabilising 
action of HEPPS (figure 3.32). The characteristic properties of HEPPS, as a zwitterionic 
member of Good’s buffer family, are limited effect on biochemical reactions and 
interaction with mineral cations, high solubility and stability, very low sensitivity to 
temperature, concentration or ionic strength of the solution and non-toxicity (Good et 
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al., 1966). The disadvantage of Tris (primary amine) is its ionic character and therefore 
its potential ability to interact with the other compounds in the solution. This may 
seriously affect the buffer properties and have implications on protein behaviour and 
assessment of experimental results. An exemplary phenomenon was reported from 
studies on haemoglobin function, where Tris-HCl buffer interaction with chloride 
anions impeded accurate measurements (Weber, 1992). The replacement of Tris-HCl 
with zwitterionic HEPES (belonging to Good’s buffer series) prevented an occurrence  
of such binding and dramatically improved the protein stability. 
          The protocol for the purification of PcpI-6xHis and native PcpI remained  
the same as in 3.2.1.3 and 3.2.1.8, respectively, only with the omission of the 
ammonium sulfate precipitation step. Instead, concentration of the protein sample prior 
to gel filtration was performed in a Vivaspin20 centrifugal concentrator with a 30 kDa 
molecular weight cut-off (Sartorius Stedim Biotech S.A.). The replacement of  
Tris-based to HEPPS-based buffer system resulted in significant improvement of PcpI 
stability in solution. The purification yield was not much higher than previously 
obtained for PcpI-6xHis (3.2.2.6.2, table 3.7) and was around 65-70% (results not 
shown). However, the protein sample was extremely stable during storage at 4ºC and  
in concentration steps prior to gel filtration and before the crystallisation experiments. 
Both native PcpI and PcpI-6xHis could be surprisingly easily concentrated even up to 
70 mg/ml. This indicates that the problem with the PcpI instability in solution was 
overcome and both protein forms were further subjected to crystallisation experiments 
described in section 3.4. 
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3.3.2. Study on human PcpI cysteine mutants 
          Analysis of the human PcpI sequence indicated a relatively high number of 
cysteine residues (figure 3.34). The peptidase has one cysteine as a part of catalytic triad 
(Cys149, 1.2.4.1) and seven remaining ones, which seems to be unusual for the human 
enzyme when compared to known Pcps from other sources. Only one non-catalytic 
cysteine can be found in homologues from B. amyloliquefaciens, P. furiosus or T. 
litoralis (1.2.3). Moreover, in the latter two tetrameric proteins, this cysteine 
participates in a formation of the inter-subunit disulfide bridge (1.2.3). 
Interestingly, in human PcpI four cysteine residues (Cys99, Cys102, Cys107 and 
Cys108) are found within a disordered, loop region as can be seen in figure 3.34. 
This cluster could potentially work as a regulatory subdomain for the cysteine-based 
control of PcpI activity. Changes in the configuration of the cluster may 
undoubtedly trigger protein conformational changes and, depending on conditions, 
have influence on its stability. Cysteine residues are often referred as redox switches 
of enzymes (Spadaro et al., 2010). The nucleophilic thiol group in the residue is 
known to be very reactive and can be easily oxidised forming disulfide bonds or a 
range of oxidised derivatives such as sulfenic, sulfinic, and sulfonic acids, often having 
important impact on the protein function. This thiol-dependent control of redox state has 
a wider effect on diverse biological processes, such as protein folding, response to stress 
or signal transduction. Exemplary reversible oxidation of mitochondrial protein thiols is 
considered to have protective function against oxidative damage as a part of a biological 
defence system (Costa et al., 2003).  Moreover, any abnormal perturbations in the 
intracellular redox homeostasis, including oxidative stress, can lead to cellular 
dysfunction and subsequent pathological conditions.  
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Figure 3.34. Cartoon representation of the model of human PcpI with marked positions 
of cysteine residues (in red stick mode). The model was created using the homology 
modelling applications in the MOE
TM
 software (Chemical Computing Group Inc.). The 
structure of the B. amyloliquefaciens Pcp (1AUG) was used as a template and the 
output was evaluated using a Ramachandran plot presented in appendix VI. 
Missing from the model are the first 7 N-terminal residues (MEQPRKA) and 10  
C-terminal residues (EGKINYCHKH), owing it to lack of homology between the query 
sequence and the template. Therefore Cys206 cannot be marked as it is outside of 
sequence validated for the generation of the model. The cysteine-rich loop, containing 
Cys99, Cys102, Cys107 and Cys108 tandem, is encircled in green. All of the non-
catalytical cysteine residues were mutated to alanine residues.  
 
          A surprisingly high number of cysteine residues in human PcpI sequence 
implicates their potential influence on the activity and structural stability. All of 
the non-catalytic cysteines shown in figure 3.34 (along with the C-terminal C206 
residue) may probably be surface exposed and therefore can easily participate in a 
range of intermolecular interactions (such as disulfide bridging) and be a target for 
chemical modifications. In order to assess their significance for the protein 
performance it was decided to conduct a study on the range of single and multiple 
PcpI cysteine mutants.  
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3.3.2.1. Materials and methods 
3.3.2.1.1. Site-directed mutagenesis of cysteine residues 
          The pET-28b(+)/pcpI plasmid construct (3.2.1.4.3) was used as a PCR template to 
conduct a series of mutations switching cysteine residues with alanine residues in the 
human PcpI. This was performed using QuikChange® Lightning Site-Directed 
Mutagenesis kit (Stratagene) according to manufacturer’s instruction. The basic 
protocol employs high fidelity PfuUltra HF DNA polymerase, which extends 
oligonucleotide primers containing the desired mutation and in result producing mutated 
plasmid construct. The product sample is treated with the DpnI endonuclease, which is 
specific for methylated and hemi-methylated substrates. This helps to digest the parental 
DNA template and separate the mutated constructs, which are unmethylated.  
 
The composition of the site-directed mutagenesis reaction mixture is presented below. 
50 ng/μl pET-28b(+)/pcpI 1 μl  
forward primer ~125 ng/μl  
reverse primer ~125 ng/μl  
10x reaction buffer* 5 μl  
dNTP mix* 1 μl  
QuikSolution
TM
 reagent* 1.5 μl  
PfuUltra HF DNA polymerase* 1 μl  
ddH2O to a final volume of 50 μl  
 
*composition is proprietary, provided with the QuikChange® Lightning kit (Stratagene)  
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All primers used for cysteine to alanine mutations were supplied by Eurofins MWG 
Operon and are listed in tables 3.10 (single mutations) and 3.11 (multiple mutations). 
Primer Sequence 
GC 
content 
Tm 
C87A 
(forward) 
GTCACACTGGAGAAAGCCGGACAC 
AACAAGG 
54.8% 70.8ºC 
C87A 
(reverse) 
CCTTGTTGTGTCCGGCTTTCTCCAG 
TGTGAC 
54.8% 70.8ºC 
C99A 
(forward) 
GGGCTGGACAACGCCCGCTTTTGCC 68.0% 71.2ºC 
C99A 
(reverse) 
GGCAAAAGCGGGCGTTGTCCAGCCC 68.0% 71.2ºC 
C102A 
(forward) 
CAACTGCCGCTTTGCCCCCGGCTCC 72.0% 72.8ºC 
C102A 
(reverse) 
GGAGCCGGGGGCAAAGCGGCAGTTG 72.0% 72.8ºC 
C107A 
(forward) 
CGGCTCCCAGGCCTGCGTGGAGGAC 76.0% 74.5ºC 
C107A 
(reverse) 
GTCCTCCACGCAGGCCTGGGAGCCG 76.0% 74.5ºC 
C108A 
(forward) 
CGGCTCCCAGTGCGCCGTGGAGGAC 76.0% 74.5ºC 
C108A 
(reverse) 
GTCCTCCACGGCGCACTGGGAGCCG 76.0% 74.5ºC 
C126A 
(forward) 
CATGGATGCTGTGGCCAAGCGAGTCACC 60.7% 71.0ºC 
C126A 
(reverse) 
GGTGACTCGCTTGGCCACAGCATCCATG 60.7% 71.0ºC 
C206A 
(forward) 
CAGAGGGCAAAATCAACTATGCCCAC 
AAACACTGA 
45.7% 69.5ºC 
C206A 
(reverse) 
TCAGTGTTTGTGGGCATAGTTGATTTTG 
CCCTCTG 
45.7% 69.5ºC 
 
Table 3.10. List of the primers used for site-directed mutagenesis to produce the PcpI 
derivatives with single cysteine mutations. 
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Primer Sequence 
GC 
content 
Tm 
C99/102A 
(forward) 
GACAACGCCCGCTTTGCCCCCGGCTC 73.1% 74.3ºC 
C99/102A 
(reverse) 
GAGCCGGGGGCAAAGCGGGCGTTGTC 73.1% 74.3ºC 
C107/108A 
(forward) 
GCTCCCAGGCCGCCGTGGAGGACGG 80.0% 75º.0C 
C107/108A 
(reverse) 
CCGTCCTCCACGGCGGCCTGGGAGC 80.0% 75.0ºC 
 
C99/102/107/108A  
sequential mutagenesis using C99/102A  
and C107/108A primers 
C87/99/102/107/108/126/206A 
(CtA) 
sequential mutagenesis using C87A, C99/102A, 
C107/108A, C126A and C206A primers 
 
Table 3.11. List of the primers used for site-directed mutagenesis to produce PcpI 
derivatives with multiple cysteine mutations. Multiple mutants C99/102/107/108A and 
C87/99/102/107/108/126/206A (CtA) were produced via multi-step mutagenesis using 
suitable primers. 
 
The reactions were carried out in the Piko
® 
thermal cycler (Finnzymes) and the cycling 
parameters are outlined in table 3.12. 
Step Temperature Time 
Initial denaturation 95ºC 2 min 
   
Denaturation 95ºC 20 s  
 18x 
Annealing 60ºC 10 s 
Extension 68ºC 2,5 min 
   
Final extension 68ºC 5 min 
Cooling 4ºC ----- 
                     
Table 3.12. Thermal cycling parameters for the site-directed mutagenesis. 
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         Next, 2 μl of the DpnI restriction enzyme solution was added directly to each 
amplification reaction, which was briefly spun down and further incubated at 37°C for 
5 min in order to digest the parental, non-mutated DNA template. All reactions were 
subjected to a plasmid transformation into XL10-Gold® ultracompetent cells (2.4.1) 
according to a protocol described in section 2.7.1. 
3.3.2.1.2. Preparation of recombinant plasmid constructs 
          Random single E. coli XL10-Gold® colonies, obtained from the transformation 
with the site-directed mutagenesis reaction mixtures (3.3.2.1.1), were picked and used 
for the inoculation of 10 ml of LB media (2.2.1) containing 50 μg/ml kanamycin. This 
was grown overnight at 37ºC in a shaking incubator. Next the cultures were subjected to 
DNA extraction according to the protocol of GeneJET™ Plasmid Miniprep kit 
(Fermentas) (2.7.2). The result of the minipreparation was analysed by 1% agarose gel 
electrophoresis (2.7.8). The obtained mutated plasmid constructs were further purified 
(2.7.3), quantified (2.7.4) and the results of the mutagenesis experiments were checked 
by DNA sequencing using standard T7 primers (2.7.10). 
3.3.2.1.3. Overexpression of PcpI cysteine mutants 
          The protocol of the overexpression of 11 cysteine mutants: C87A, C99A, C102A, 
C107A, C108A, C126A, C206A, C99/102A, C107/108A, C99/102/107/108A and CtA 
(all non-catalytic cysteines mutated to alanines), was based on the one established for 
the synthesis of PcpI-6xHis (3.2.1.5). The BL21-CodonPlus®(DE3)-RIPL (3.2.1.2.1) 
were transformed with the cysteine-mutated pET-28b(+)/pcpI plasmid constructs 
following the protocol described in section 2.7.1. The cells were plated on Petri dishes 
containing agar with 50 μg/ml kanamycin and 35 μg/ml chloramphenicol. This was 
incubated overnight at 37ºC. Next a single colony from each transformation was used to 
inoculate 10 ml of LB media supplemented with 50 μg/ml kanamycin and 35 μg/ml 
chloramphenicol and this was grown overnight at 37ºC in a shaking incubator. Next day 
a flask containing 100 ml of LB media with the above antibiotics was inoculated with 
1 ml of the overnight culture and grown in a shaking incubator at 37ºC. The induction 
of the protein overexpression was initiated by the addition of IPTG (2.2.4) to a final 
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concentration of 1 mM once the culture had reached an OD595 of 0.6. The incubation 
was continued for a further 6 h at 25ºC. Protein isolation was carried out according to 
the detergent-based procedure (2.8.1.1) and the results of the protein expression were 
analysed by the SDS-PAGE technique using a 12.5% separating gel (2.8.2). 
3.3.2.1.4. Purification and crystallisation trials of PcpI cysteine mutants 
          All 11 PcpI cysteine mutants were designed to contain a C-terminal His-tag in 
order to facilitate their purification using nickel affinity chromatography (3.2, 3.3.2.1.1). 
The production and purification steps followed the protocol set for the non-mutated 
PcpI-6xHis using the nickel affinity column (3.2.1.3.3) and the gel filtration column 
(3.2.1.3.4). The thermofluor shift assay performed on PcpI-6xHis showed that 
application of HEPPS buffer can provide the best stabilising environment for the 
protein. Therefore the HEPPS-based buffer system was used for the purification and 
storage of all PcpI cysteine mutants and composition of which is presented in section 
2.3.3.5. Fractions collected during the purification procedure were analysed for protein 
purity by the SDS-PAGE technique using a 12.5% separating gel (2.8.2).  
The concentration of the purified protein samples was determined by absorbance 
measurement at 280 nm (2.8.3.1, extinction coefficient 24410 M
-1
cm
-1
 (ProtParam, 
www.expasy.org)). The activity of the mutated variants was assayed using the 
fluorometric method described in section 2.8.4. Protein samples were stored at 4ºC.   
          All cysteine-mutated PcpI-6xHis isoforms were tested for enzymatic activity 
using the fluorimetric activity assay utilising L-pGlu-AMC as the substrate as described 
in section 2.8.4. 
          Purified samples of PcpI cysteine mutants were concentrated in Vivaspin20 
centrifugal concentrators (Sartorius Stedim Biotech S.A.) and further subjected to 
crystallisation trials using the microbatch technique as described in section 3.4.3.2.       
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3.3.2.2. Results and discussion 
3.3.2.2.1. Mutated pET-28b(+)/pcpI derivatives 
          Site-directed mutagenesis of the pET-28b(+)/pcpI (3.3.2.1.1) resulted in obtaining 
mutated plasmid variants as designed for the 11 PcpI-6xHis cysteine mutants: C87A, 
C99A, C102A, C107A, C108A, C126A, C206A, C99/102A, C107/108A, 
C99/102/107/108A and CtA. All pET-28b(+)/pcpI derivatives were prepared as 
described in 3.3.2.1.2 and analysed by DNA sequencing (2.7.10). The results confirmed 
the correct mutation had taken place for all of the selected cysteine residues, which had 
been replaced by alanines (appendix VII). 
3.3.2.2.2. Overexpression of PcpI cysteine mutants 
          The PcpI-6xHis cysteine mutants: C87A, C99A, C102A, C107A, C108A, 
C126A, C206A, C99/102A, C107/108A, C99/102/107/108A and CtA were 
successfully produced in BL21-CodonPlus(DE3)-RIPL cells, facilitating the 
production of the rare E. coli codons as described in section 3.2.1.2.1. All mutant 
enzymes were overexpressed from the mutated derivatives of pET-28b(+)/pcpI, in 
order to incorporate the C-terminal His-tag. The results were analysed by the SDS-
PAGE technique using  
a 12.5% separating gel and the results for the PcpI-6xHis C107A, C107/108A and 
CtA are shown in figure 3.35.  
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Figure 3.35. The result of the SDS-PAGE analysis confirming the overexpression of 
the mutated forms of PcpI-6xHis: C107A, C107/108A and CtA. Individual lanes 
represent a sample 6 h after induction (6h), before induction (0h) and a protein 
molecular weight marker (M). 
 
 
          All mutated enzymes were overexpressed successsfully in a soluble form and 
were further subjected to protein purification (3.3.2.2.3). 
3.3.2.2.3. Purification of PcpI cysteine mutants 
          The purification of the PcpI cysteine mutants was performed following the 
protocol established for PcpI-6xHis as described in section 3.2.1.7. On average 2.5 g of 
cell paste was obtained per 1 L of bacterial culture. This was used for protein extraction 
and the supernatant, obtained during the procedure, was applied to a Ni
+ 
Sepharose 
column and subjected to protein purification as described in section 3.2.1.7.  
The representative elution profile for C107/108A, shown in figure 3.36, allowed for 
determination of fractions containing the PcpI-6xHis cysteine mutant, which were 
further analysed using the SDS-PAGE to assess the purity of the eluted protein. A result 
of this analysis is presented in figure 3.37. 
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Figure 3.36. The nickel affinity protein elution profile of the C107/108A PcpI-6xHis 
mutant. The fractions containing the protein are marked by the red bar. The A280 trace is 
coloured in blue and the imidazole gradient is coloured in pink. 
 
 
M – MW marker 
  1 – fraction A10 
  2 – fraction C5 
  3 – fraction E12 
  4 – fraction F3 
  5 – fraction F6 
  6 – fraction F8 
  7 – fraction 10 
  8 – fraction F12 
  9 – fraction G2 
 
 
Figure 3.37. The result of the SDS-PAGE analysis of the C107/108A PcpI-6xHis 
mutant purified by nickel affinity chromatography.  
 
 
          All cysteine-mutated PcpI-6xHis variants were observed to have a similar elution 
profile from the nickel affinity purification step and were found in fractions eluted with 
the same concentration of imidazole.  
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          The mutated isoforms were intended to be used in crystallisation trials, therefore 
their samples were required to be of the high purity and homogeneity. In order to 
achieve this and remove any undesired contaminants, the fractions collected from Ni
+ 
Sepharose
TM
 column purification, which contained the desired protein were pooled 
together, concentrated using Vivaspin20 centrifugal concentrators and run through the 
gel filtration column (3.2.1.3.4). The resulting representative elution profile and the 
SDS-PAGE analysis for C107/108A mutant are presented in figures 3.38 and 3.39, 
respectively. 
 
 
Figure 3.38. The gel filtration protein elution profile of the C107/108A PcpI-6xHis 
mutant. The fractions containing the protein are marked by the red bar. The A280 trace is 
coloured in blue. 
 
M – MW marker 
  1 – fraction 60 
  2 – fraction 62 
  3 – fraction 64 
  4 – fraction 65 
  5 – fraction 66 
  6 – fraction 68 
  7 – fraction 69 
  8 – fraction 70 
  9 – fraction 71 
 
Figure 3.39. The result of the SDS-PAGE analysis of the C107/108A PcpI-6xHis 
mutant purified by gel filtration chromatography.  
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          The cysteine-mutated isoforms were generally found to be eluted in the fractions 
typical for proteins of around 25 kDa (appendix IV) and the position of the peak was the 
same as previously observed for all non-mutated PcpI forms (3.2.2.3.3, 3.2.2.6.2 and 
3.2.2.7.3). The only surprising phenomenon was observed for the C107A mutant (figure 
3.40), which eluted in the fractions typical for a protein with a mass between 43 and 
75 kDa (appendix IV).  
 
Figure 3.40. The gel filtration protein elution profile of the C107A PcpI-6xHis mutant. 
The fractions containing the protein are marked by the red bar. The A280 trace is 
coloured in blue. 
 
          Analysis of the eluted fractions by the SDS-PAGE technique revealed that the 
presence of a protein of around 45 kDa which may suggest that C107A exists in a 
dimeric form (figure 3.41).  
 
M – MW marker 
  1 – fraction 50 
  2 – fraction 52 
  3 – fraction 54 
  4 – fraction 55 
  5 – fraction 56 
  6 – fraction 58 
  7 – fraction 60 
 
Figure 3.41. The result of the SDS-PAGE analysis of the C107A PcpI-6xHis mutant 
purified by gel filtration chromatography.  
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          Additionally, the results of the fluorimetric activity assay (2.8.4) showed that all 
of the mutated proteins were enzymatically active, with an exemption of C107A. These 
results for C107 PcpI mutant may implicate an important role of this residue in the 
human PcpI. The adjacent C107 and C108 residues are believed to be located within a 
flexible, cysteine-rich loop (figure 3.34) and may possibly undergo an oxidation to 
cystine creating a strained 8-membered intramolecular ring. The disulfide bridge 
between neighbouring cysteines (vicinal disulfide) is a rare structural element resulting 
in the formation of a tight turn of the polypeptide backbone. Studies on small model 
peptides showed that the side chains of the ring-forming cysteines exist in the 
equilibrium of the cis-trans conformation (Kim et al., 1999). Such a formed peptide 
units show frequent  deviation from planarity with a torsion angle ranging from 159 to –
131º (Carugo et al., 2003). The polypeptide segments containing a vicinal cystine 
bridge are found to be significantly bent with the two side chains protruding on the 
same (cis) side of the backbone. On the contrary, in reduced state cysteine side chains 
are located on the opposite (trans) positions and the lack of backbone constraints makes 
it more extended and flexible.  
          Vicinal disulfides have been reported and characterised in a range of enzymes, 
receptors and toxins (reviewed in (Carugo et al., 2003). The biological function of this 
interaction is not fully understood and it is considered to have both roles in the 
regulation of redox homeostasis (e.g. participation in electron exchange) as well as in 
the control of the structural conformation of the protein backbone. Formation and 
decomposition of the vicinal disulfide has been observed to have an impact on the 
protein performance and structural conformation. Such a regulatory effect is thought to 
occur in the nicotinic receptor which is unable to bind ACh when its intramolecular 
Cys-Cys bridge is unformed (Czajkowski and Karlin, 1995). Similarly, the reduction of 
the cystine ring found within an active site of the methanol dehydrogenase from 
Methylophilus sp. has been seen to cause its rapid inactivation (Blake et al., 1994). The 
vicinal disulfide is also thought to play an important role in binding and cation 
reduction in mercuric ion reductase, which activity has been seen to be abolished as a 
result of the oxidation of the adjacent active site C558 and C559 residues (Engst and 
Miller, 1999). Interestingly, the disulfide ring is more resistant to reduction than the 
disulfide bond between two cysteines separated by another amino acid (CXC motif) 
(Zhang and Snyder, 1989). 
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          In some cases the oxidation of adjacent cysteine residues may destabilise 
structural conformation of a given protein. For example, the reduction of a vicinal 
disulfide bond seems to be necessary to maintain structural stability of a Janus-faced 
atracotoxin despite the complete loss of its neurotoxic activity (Wang et al., 2000). 
Similarly, the alternative formation of two possible cystine rings inactivates human 
ribonuclease inhibitor (Kim et al., 1999).  
          An interesting role of this kind of interaction between adjacent cysteine residues 
was proposed in the report by Cemazar and co-workers after the observation of the non-
native vicinal disulfide bridge in the transient intermediates of the Amaranthus α-
amylase inhibitor during its oxidative folding (Cemazar et al., 2003). Molecular 
modelling analysis led to the suggestion that the cystine ring is created within a flexible 
loop region and it may impose structural constraints on the folding intermediates. This 
formation of the transient vicinal disulfides is believed to govern the protein folding 
process by creating a compact fold and facilitating the reshuffling to native disulfide 
bridges by the positioning of the cysteine residues in close proximity.  
          The presence of the adjacent C107 and C108 residues and their localisation 
within a flexible cysteine-rich loop can be seen in the human PcpI structure model 
(figure 3.34), and may have a significant impact on the protein behaviour and stability. 
Potential formation of the C107-C108 ring could provide conformational constraints on 
the polypeptide backbone necessary for proper folding, structure stability and activity as 
it was observed in the aforementioned studies. Therefore observed existence of C107A 
in a dimeric form (and a lack of higher oligomers) may be explained by the possible 
intermolecular disulfide bridge between unbound C108 residues. Since the C107A 
mutant was seen to be inactive one may suggest that the C107-C108 tandem may serve 
as an artificial redox switch, which regulates enzymatic activity. Such an observation, 
however, has not been made for the C108A mutant, which retained all of the properties 
of the native PcpI and was enzymatically active. This finding implies that in the native 
protein C108 may be more reactive than C107 residue or its side chain is better exposed 
to participate in the dimerization. The study on the thimet oligopeptidase showed that 
the dimer formation by intermolecular disulfide bond could inactivate the protein due to 
blocking of the opening of the substrate channel (Sigman et al., 2003). Other 
explanation suggests the induction of structural changes preventing substrate binding or 
hindering conformational changes required for enzymatic activity (Ray et al., 2002). 
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         It is difficult to determine at this point if a formation of dimer is forced due to the 
C107A mutation and a probable interaction between C108 residues or it can appear 
naturally as a control of the protein behaviour. Studies showed that eukaryotic type I 
Pcps exist in a soluble monomeric form (1.2.4.1). On the contrary, Pcps from bacterial 
and archaeal sources are known to function as dimers or tetramers and in the cases of  
P. furiosus and T. litoralis representatives, formation of the inter-subunit disulfide 
bridge is thought to have a stabilising effect on the protein (1.2.3). Although the 
cysteine residue involved in this disulfide Cys190 (T. litoralis numbering) does not 
have an equivalent cysteine residue in the human PcpI sequence, one may suggest that 
an unusually high and odd number of cysteines in the latter one potentially gives  
an opportunity for the formation of similar dimer or oligomer.  
          Finally, it is worth noting that four cysteines in the flexible loop in the human 
PcpI could be involved in the coordination of a metal ion. The presence of such a cluster 
is typical for metal binding domains, where the metal ion plays an important structural 
function (Berg, 1990). However, previous reports on the incubation of human PcpI with 
EDTA resulted in no change in activity, which could indicate an absence of any metal 
ion of structural or activity-related importance (Dando et al., 2003). Nonetheless, one of 
the approaches, as a part of the PcpI stabilisation study, was the addition of  
50 μM ZnCl2 to the E. coli culture prior to induction with IPTG (3.2.1.5). This is  
a common procedure for the expression of proteins containing zinc-binding motifs 
(Niedziela-Majka et al., 1998). The presence of the structural zinc has been shown to 
stabilise protein domains (Guy et al., 2003), however in this case it was not observed to 
improve PcpI stability. 
          All studied cysteine mutated variants PcpI-6xHis were purified, concentrated and 
used in a microbatch crystallisation procedure 3.4.2.4.2. The trial was performed using  
a variety of the commercially available screens (3.4.2.3). The results of these 
experiments were discussed in section 3.4.3.2. 
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3.3.3. Modification of the surface residues 
          Chemical modifications of protein residues in order to improve crystallisability 
are relatively less often used approaches. Frequently problems with obtaining good 
quality crystals are related to the difficult properties of the protein molecule arising 
from disorder fragments of the polypeptide chain such as extended surface loops.  
In other cases flexible, solvent-exposed amino acid side chains can also be problematic 
in crystallisation experiments. To overcome this, these residues can be suitably mutated 
or chemically modified. The important advantages of chemical modification are the 
elimination of repeated procedures beginning with re-cloning and finishing with 
purification, avoidance of the possibility of protein misfolding and, finally, 
manipulation of only surface residues (Walter et al., 2006). Currently, the best known 
and used methods include modification of cysteine residues with DTNB, iodoacetate or 
N-ethylmaleimide as well as reductive methylation of the exposed amino groups 
resulting in conversion of primary amines to tertiary amines (Ellman, 1959; Rayment, 
1997). 
3.3.3.1. Materials and methods 
3.3.3.1.1. Modification of surface cysteines with DTNB 
          Exposed thiol groups in the protein can be modified with DTNB also known as 
Ellman's reagent (Ellman, 1959). The method is based on the reaction of protein thiols 
with DTNB, which results in the production of the intermolecular disulfide bond and  
a release of the 2-nitro-5-thiobenzoate (NTB
-
) (figure 3.42). In aqueous solution at 
neutral or alkaline pH NTB
-
 is subsequently ionized to the NTB
2-
 anion which produces 
a yellow color. This reaction is stoichiometric, therefore spectrophotometrical 
quantification of the NTB
2-
 helps to determine the amount of thiol groups that were 
modified by the DTNB.  
158 
 
 
Figure 3.42. Reaction of a thiol group with DTNB. 
          The modification of PcpI cysteine residues was conducted according to the 
protocol described by Mi and co-workers (Mi et al., 2008). DTNB powder was 
dissolved in dilution buffer (20 mM Tris-HCl pH 8.0 and 200 mM NaCl) to 2.0 mM and 
this was added to the purified PcpI-6xHis solution at a 5-fold molar excess. This was 
further incubated on ice for 30 min in order to complete the reaction. Next the mixture 
was purified by gel filtration chromatography as described in section 3.2.1.7 to remove 
excess DTNB and the reaction products. The pre-equilibration of the column and 
elution were performed using dilution buffer. Purified and modified PcpI-6xHis was 
concentrated in Vivaspin20 centrifugal concentrators (Sartorius Stedim Biotech S.A.) 
and further subjected to crystallisation trials using the microbatch technique as 
described in section 3.4.3.2.       
3.3.3.1.2. Methylation of the surface lysines 
          Some of the amino acid residues found on the surface of the proteins, such as 
lysine or glutamic acid possess long and flexible side chains, which are often thought to 
hinder the process of crystallisation. Methylation of the side chain amines of the surface 
lysines has been shown to promote the process of formation of a crystal lattice 
presumably by immobilization of this mobile region. 
          The protocol of the methylation was taken from the report by Rayment and  
co-workers (Rayment, 1997). A purified sample of PcpI-6xHis (3.2.1.7) in HEPPS 
buffer C (2.3.3.5) was enriched with NaCl in order to obtain final volume of 250 mM. 
The sample was brought to a concentration of 0.5 mg/ml and after that it was mixed 
with 20 μl of the freshly prepared 1 M dimethylamine-borane complex (ABC; Fluka) 
and 40 μl of 1 M formaldehyde (from 37% stock) per 1 ml of the protein solution.  
This was gently mixed and incubated for 2 h at 4ºC. After that the next portion of 20 μl 
of ABC and 40 μl of 1 M formaldehyde was added per 1 ml of the original protein 
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sample, and this was continued to incubate for another 2 h at 4ºC. Next 10 μl of the 
ABC was added to the mixture and left for overnight incubation at 4ºC. After incubation 
any potential protein aggregates and contaminants were removed by centrifugation of 
the treated PcpI-6xHis sample. The protein was further purified using the gel filtration 
method. Pre-equilibration of the column and protein elution were performed using  
Tris-HCl buffer (20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM DTT). Appropriate 
fractions containing PcpI-6xHis were pooled together and subjected to buffer exchange 
(HEPPS buffer C, 2.3.3.5) using Vivaspin20 centrifugal concentrators (Sartorius Stedim 
Biotech S.A.). Then the protein sample was concentrated to the required concentration 
and subjected to crystallisation experiments using microbatch technique as described in 
section 3.4.3.2.              
3.3.3.2. Results and discussion 
          The human PcpI-6xHis was subjected to the modification of exposed cysteine 
residues with DTNB (3.3.3.1.1) and lysine methylation (3.3.3.1.2). Significant 
aggregation of the protein was observed during the lysine methylation procedure, 
formation of which was concluded from the gel filtration elution profile (figure 3.43). 
This is however often observed as the reaction with ABC can cause significant protein 
precipitation (up to 50%) (Walter et al., 2006). Although the aggregation was not seen 
on the SDS-PAGE gel (not shown), only the fractions collected during monomer elution 
were used for further applications. 
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Figure 3.43. The gel filtration protein elution profile of the lysine-methylated PcpI-
6xHis. The fractions containing the protein are marked by the red bar. Probable protein 
aggregates were eluted in a broad peak in the fractions 38-55. The A280 trace is coloured 
in blue. 
Modified protein sample was concentrated up to 10 mg/ml and used in a microbatch 
crystallisation procedure 3.4.2.4.2. The trial was performed using a variety of the 
commercially available screens (3.4.2.3). The results of these experiments were 
discussed in section 3.4.3.2. 
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3.4. Crystallisation study on human PcpI 
3.4.1. Introduction to protein crystallisation 
          X-ray crystallography and Nuclear Magnetic Resonance (NMR) spectroscopy are 
currently the most effective and popular methods to resolve three-dimensional protein 
structure. The goal of protein crystallisation is to produce well-ordered crystals suitable 
for X-ray diffraction that would result in good quality analytical data. The development 
of this technique has significantly accelerated since the first generation of earthworm 
hemoglobin crystals by Hünefeld in 1840 and the pioneering studies on the X-ray 
crystal structure of myoglobin in 1950. Nowadays it is widely used in a range of life 
science areas. Crystallisation itself is considered to be inherently difficult mainly due to 
the frequent problems with finding optimal and sometimes unique conditions to enhance 
protein crystal nucleation and growth. Moreover, the fragile nature of protein crystals 
and the fact that they disintegrate easily due change in temperature, pH, ionic strength 
or by dehydration often requires time-consuming optimisation of those parameters. The 
successful production of diffracting crystals is governed by a number of environmental 
factors such as protein purity (at least 97% pure) and concentration, pH, temperature, 
and precipitants. The values of all these parameters are usually unique for different 
proteins so their estimation can be facilitated by a high-throughput screening for 
optimal conditions or investigated through more time-consuming “trial and error” 
process.  
          The process of crystallisation can be differentiated into two stages: nucleation and 
crystal growth. First the purified and concentrated protein must undergo slow reduction 
of solubility to reach supersaturation. Very often this would result in the formation of an 
amorphous protein precipitate. However, in appropriate conditions, protein molecules 
can create non-covalent interactions, adopt proper geometrical orientation and align in 
an ordered crystalline aggregate. The aggregated state also must be more energetically 
favourable than the soluble one in order to allow for the crystal growth. Both crystal 
nucleation and growth can occur within the protein supersaturation region of the phase 
diagram (figure 3.44). 
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Figure 3.44. A schematic phase diagram of protein crystallisation. The different routes 
to reach the solubility curve are represented for four most popular methods of 
crystallisation: (i) microbatch, (ii) vapour diffusion, (iii) dialysis and (iv) free-interface 
diffusion (FID). Adjustable parameters refer to the concentration of precipitant or 
additive, pH and temperature. Taken from (Chayen and Saridakis, 2008). 
 
 
          The phase diagram (figure 3.44) indicates the relation between the protein 
concentration and the range of parameters that create the environment of crystallisation. 
The initial protein-precipitant solution first needs to reach the nucleation zone (labile 
zone), where the generation of the nuclei commences, and further progress to the 
metastable zone and solubility curve in order to produce crystals. The diagram presents 
different methods of crystallisation and the routes which given solutions follow to reach 
the destination point. It is worth noting that both dialysis and free-interface diffusion 
require much more concentrated protein solution than the remaining two methods and 
the process can start at two alternative points. In both cases the undersaturated solution 
may contain protein only or protein with a relatively low precipitant concentration. 
Many difficulties regarding the crystallisation process can be approached by the 
manoeuvres within the phase diagram. For example the transition from an 
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undersaturated to a supersaturated solution can be achieved by the proper combination 
of protein and precipitating agent or other influencing parameters. Another problem 
may be addressed when the system is maintained for too long within a nucleation zone. 
This usually results in rapid formation of a great number of nuclei and excessive 
production of small crystals. In order to overcome this, the system must be adjusted in 
the way so it could approach the nucleation zone slowly enough to allow the developing 
nuclei sufficient time to grow. 
          The two most popular techniques – vapour diffusion and microbatch 
crystallisation, were used in the study of human PcpI.  
          The principle of the vapour diffusion relies on process leading to equilibration 
between a droplet of purified protein mixed with precipitant solution and a larger 
reservoir containing the same precipitant solution but in higher concentrations. Over the 
course of time in a closed system water evaporates from the droplet, leading to the 
increase of precipitant concentration which can provide optimal conditions for 
crystallisation (Chayen, 1998). The technique can be performed in two variants known 
as the hanging drop and sitting drop methods, which differ in the shape and vertical 
orientation of the droplet in the setup. This may potentially have a small influence on 
the equilibration process. 
          Crystallisation under oil, widely known as microbatch crystallisation is 
particularly useful for high-throughput, automated screening for optimal conditions.  
The technique combines a small drop of a concentrated protein sample with the 
precipitant solution and this is further incubated under a small layer of the paraffin oil 
and silicon oil mixture (Chayen, 1997; D'Arcy et al., 2003). Application of the oil 
allows for a slow diffusion of water from the droplet and a concentration of the 
sample and the reagents. 
          Human native PcpI, C-terminally His-tagged PcpI, cysteine mutants and PcpI 
with surface-modified residues were purified to homogeneity, concentrated and 
subjected to crystallisation trials using vapour diffusion and microbatch techniques.  
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3.4.2. Materials and methods 
3.4.2.1. Protein sample preparation 
          The purified protein samples were quantified using absorbance measurement at 
280 nm (2.8.3.1) and concentrated in a suitable purification gel filtration buffer (2.3.3). 
Protein concentration was conducted at 4ºC using a Vivaspin20 centrifugal concentrator 
with a 30 kDa molecular weight cut-off and regenerating polyethersulfone membrane 
(Sartorius Stedim Biotech S.A.). Immediately prior to crystallisation experiments the 
protein sample was centrifuged at 13,400xg for 5 min at 4ºC to pellet any possible 
aggregates. 
3.4.2.2. Vapour diffusion technique 
          Crystallisation experiments employing the vapour diffusion technique (sitting and 
hanging drop methods) were conducted in 24 well ComboPlate™ plates (Greiner Bio-
One) with CrystalClene
TM
 cover slides (Molecular Dimensions Ltd). Additionally,  
in the sitting drop method trial Micro-Bridge® inserts were employed (PSR1000, 
Crystal Microsystems). Typically, 0.5 or 1.0 ml of precipitant solution (reservoir) was 
pipetted into a well. A 1 μl (or more) of concentrated protein solution was mixed with 
reservoir solution in a desired ratio on a cover slide (hanging drop method) or 
microbridge (sitting drop method). The cover slides were sealed to the upper edge of the 
plate using Dow Corning high vacuum grease (Molecular Dimensions Ltd). Plates were 
then incubated at 4ºC or 18ºC and examined for crystal growth under a light 
microscope. 
3.4.2.3. Microbatch screening technique 
          Crystallisation experiments employing the microbatch screening technique were 
conducted in Hampton 96 well plates using an Oryx6 crystallisation robot according to 
the manufacturer’s instructions (Douglas Instruments Ltd).  
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Commercial screening kits of precipitation solutions used in this method included: 
 Crystallization Basic Kit for Proteins 82009 (Sigma) 
 Crystallization Extension Kit for Proteins 70437 (Sigma) 
 JCSG-plus™ (Molecular Dimensions Ltd) 
 PACT-premier™ (Molecular Dimensions Ltd) 
 Structure Screen 1 and Structure Screen 2 (Molecular Dimensions Ltd) 
 pHClear and pHClear II (Qiagen) 
The Oryx6 robot was set up to dispense equal volumes (0.5-1.0 μl) of the concentrated 
protein solution and precipitation solution in the bottom of each well. This was 
immediately covered with 1:1 (v/v) mixture of paraffin oil and silicon oil to prevent 
excessive evaporation of the well content. Plates were then incubated at 18ºC and 
controlled for crystal growth under a light microscope.         
3.4.2.4. Crystallisation experiments  
3.4.2.4.1. Vapour diffusion crystallisation trials  
          Preliminary purifications of PcpI-6xHis and native PcpI in Tris-HCl based buffer 
system (2.3.3.3 and 2.3.3.4, respectively) resulted in the observation that both enzyme 
forms are extremely unstable and began precipitating out of solution during sample 
preparation procedure (3.4.2.1), when concentrated in the presence of NDSB-195 
(3.2.2.6.3 and 3.2.2.7.4) above ~5.5 mg/ml and ~2.8 mg/ml, respectively. Various 
attempts were made in order to overcome the instability problem as described in section 
3.4. Concentrating to at least 10 mg/ml is necessary to obtain a supersaturated protein 
solution facilitating its progress into the metastable zone (figure 3.39). Nonetheless, 
despite a relatively low protein concentration it was decided to perform a preliminary 
condition screening employing the vapour diffusion technique (3.4.2.2).  Prior to the 
experiment a PcpI-6xHis and native PcpI samples were also assessed for homogeneity 
using DLS (3.2.2.6.3 and 3.2.2.7.4) in order to evaluate a possible aggregation state.  
A range of ammonium sulfate solutions (5-100% with 5% increments) were used in the 
reservoir as a precipitating reagent. In the case of both native PcpI and PcpI-6xHis, 
samples were mixed with reservoir solution in varied ratios such as 9:1, 8:2, 7:3 and 5:5 
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(protein:reservoir) to make up to 10 μl of a final droplet volume. The principle of the 
vapour diffusion crystallisation technique is a change of the droplet composition as it 
aims to reach equilibrium with the reservoir solution. This, in consequence, leads to the 
increase of protein concentration and its eventual supersaturation. The trials were 
performed using both sitting and hanging drop methods for native and recombinant 
PcpI-6xHis. Two sets of crystallisation plates were prepared, which were incubated both 
at 4ºC and 18ºC. 
3.4.2.4.2. Microbatch crystallisation trials  
          The samples of the native PcpI, PcpI-6xHis, 11 cysteine mutants of PcpI-6xHis 
(3.3.2) as well as DTNB-modified and lysine-methylated PcpI-6xHis variants were 
purified in HEPPS based gel filtration buffer (2.3.3.5) and concentrated to a minimum 
of 10 mg/ml (3.4.2.1). Biochemical modification of the protein has often proved to 
improve crystallisation or enhance crystal quality (Rayment et al., 1993; Oubridge et 
al., 1995). Individual mutations of cysteines to alanines in this case reduce surface 
charge quantity and alter its distribution that may be important for generation of protein 
crystals. A search for crystallisation conditions was conducted using the microbatch 
screening technique and commercial kits as described in section 3.4.2.3. All plates were 
incubated at 18ºC. 
3.4.2.4.3. Co-crystallisation trials  
           The presence of an inhibitor, co-factor or substrate transition state analogue in 
the active site often makes the protein less flexible and hence may facilitate its 
crystallisation (Hassell et al., 2007). The choice of the inhibitor for PcpI was based on 
the results of thermofluor assay (3.3.1), which showed that the addition of the 
2-pyrrolidone or L-pGlu acid increases the Tm of the protein by around 1.5ºC or 1.1ºC  
(for HEPPS buffer). 2-pyrrolidone is a reversible inhibitor being a pyroglutamate 
analogue and has been previously used to stabilise PcpI during purification and 
storage (Armentrout and Doolittle, 1969; Mudge and Fellows, 1973). Quantified 
native PcpI and PcpI-6xHis were enriched with a 5-fold molar excess of either 
2-pyrrolidone or L-pGlu acid, incubated for 1 h at 4ºC and then subjected to the 
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standard sample preparation (3.4.2.1). Both protein samples were concentrated to 
around 15 mg/ml in HEPPS gel filtration buffer (2.3.3.4) and the crystallisation 
experiments were conducted using the microbatch technique as described in section 
3.4.2.3. All plates were incubated at 18ºC. 
3.4.2.4.4. Optimisation of crystallisation conditions  
          The optimisation of crystallisation conditions for PcpI-6xHis+2-pyrrolidone and 
native PcpI+2-pyrrolidone was conducted using the microbatch screening technique 
(3.4.2.3). The inhibitor was added in a 5-fold molar excess in relation to PcpI-6xHis and 
native PcpI prior to sample preparation as described in 3.4.2.4.3. A range of 
optimisation conditions was designed using XSTEP Optimization software provided 
with Oryx 6 crystallisation robot (Douglas Instruments Ltd). Varied condition 
parameters including pH, precipitant concentration and protein concentration were 
combined and are presented in table 3.13. All crystal plates were incubated at 18°C. 
Varied parameter Range Increment 
PcpI-6xHis/native PcpI concentration 5 – 25 mg/ml  5  mg/ml  
pH 4.5 – 7.5 0.5 
PEG 3350 concentration 7.5% – 25% 2.5% 
 
Table 3.13. Parameters for the crystallisation conditions used during the optimisation 
procedure. 
3.4.2.4.5. Crystal microseeding 
          The vapour diffusion technique (hanging drop) was employed to conduct the 
crystal streak microseeding procedure. The principle of this method is to use the  
pre-formed protein crystal nuclei in new crystallisation solutions in order to determine 
the optimal conditions for crystal growth. A droplet with PcpI-6xHis+2-pyrrolidone 
crystals and mother liquor was transferred to a small plastic tube containing 10 μl of the 
condition solution that they were produced in. Next the crystals were crushed using a 
needle, pipetting and vortexed to generate microcrystalline powder. Then individual 
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1:100 and 1:1000 dilutions of the microseed stock were prepared in a precipitant 
solution. A clean cat whisker was dipped into the diluted solution and ran through the 
pre-equilibrated drop consisting of the equal volumes of concentrated protein and 
chosen precipitant condition. The parameters of conditions used during microseeding 
are presented in table 3.14. All plates were treated as described in section 3.4.2.2 and 
incubated at 18ºC. 
 
Varied parameter Range Increment 
PcpI-6xHis/native PcpI concentration 10 – 50 mg/ml  5 mg/ml 
pH 5.1 – 5.9 0.2 
PEG 3350 concentration 10% – 20% 2% 
 
Table 3.14. Parameters for the crystallisation conditions used during the microseeding 
procedure. 
3.4.2.4.6. Preparation of crystals and X-ray data collection 
           The crystals of PcpI-6xHis+2-pyrrolidone were prepared for X-ray data 
collection by two methods depending on their quality and quantity. A small nylon loop 
was used to pick up a crystal which was immediately immersed in prepared cryo-
protectant solution and then plunged in liquid nitrogen. Alternatively a crystal was flash 
frozen in liquid nitrogen directly from the droplet. X-ray diffraction of the crystals was 
analysed at Diamond Light Source synchrotron on I03 beamline using the Pilatus 6M 
detector. 
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3.4.3. Results and discussion 
3.4.3.1. Vapour diffusion crystallisation trials  
          Concentrated protein samples of the native PcpI (approx. 2.8 mg/ml) and  
PcpI-6xHis (approx. 5.5 mg/ml) were subjected to crystallization trials using vapour 
diffusion technique as described in section 3.4.2.4.1. Prior to this, samples of both 
proteins were assessed using DLS measurement which returned a small polydispersity 
value and showed their homogeneity (3.2.2.6.3 and 3.2.2.7.4). Analysed proteins came 
directly from the gel filtration purification step in Tris-HCl buffer (2.3.3.3 and 2.3.3.4). 
A range of ammonium sulfate solutions (5-100% with 5% increments) were used in the 
reservoir. The use of simple single salt solutions was aimed to identify a protein 
precipitation point in initial crystallisation trials. This, if successful, could be further 
used as a starting point for optimization screening. Unfortunately, for both PcpI variants 
immediate precipitation was observed in a droplet upon mixing with a higher 
concentration of ammonium sulfate solutions (35% and above). The precipitation turned 
brown within a few days which indicates that this precipitant is unfavoured in 
crystallization conditions and causes protein denaturation. A few reports and experience 
using human PcpI showed the enzyme to be extremely unstable at room temperature 
after extended period of time. However, concurrent incubation at 4ºC, which should 
help to stabilize the protein and slow the equilibration process between a drop and  
a well, did not significantly improve precipitation. The observations were consistent for 
both hanging and sitting drop method. Moreover, both native PcpI and PcpI-6xHis were 
also noticed to progressively precipitate in conditions of lower ammonium sulfate 
concentration. This can be explained by the increase of precipitant concentration in  
a droplet with time which aims to reach equilibrium with reservoir solution. The other 
possibility is negative influence of ammonium sulfate on the stability of both proteins. 
This was later confirmed by the thermofluor shift assay (3.3.1) which showed that 
ammonium sulfate (pH 7.5) decreases Tm by 2.17ºC in case of PcpI-6xHis. It was 
decided therefore to search firstly the conditions that would stabilize the enzyme in 
solution and help to obtain a higher protein concentration to carry on further 
crystallisation trials. 
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3.4.3.2. Microbatch crystallisation trials  
          The thermofluor shift assay resulted in identification of HEPPS buffer as the most 
stabilizing for PcpI-6xHis of all tested conditions (3.3.1). The subsequent application of 
this buffer system (2.3.3.4) for purification of the native PcpI, PcpI-6xHis and cysteine 
mutants of PcpI-6xHis helped to stabilise the proteins particularly during the 
concentration step. Concentrated protein samples of the native PcpI (~12 mg/ml),  
PcpI-6xHis (~15 mg/ml), all cysteine mutants (concentrated to 10-15 mg/ml) and  
PcpI-6xHis derivatives subjected to lysine methylation and cysteine DTNB-
modification (~10 mg/ml), were subjected to crystallization trials using the microbatch 
technique as described in section 3.4.2.4.2. The screening yielded very few results and 
in most of the cases immediate protein precipitation was observed upon mixing with the 
condition solution. Despite a number of wells staying clear for an initial few days no 
protein crystals were observed even after longer period of incubation. Additional 
difficulty was found in some cases with an early appearance of salt and polyethylene 
glycol (PEG) crystals. This was problematic in the analysis of the experimental results 
and is undesirable if in a given condition the protein requires longer time for crystal 
growth. Despite a broad screening for crystallisation conditions for all PcpI forms it 
brought no positive results. Therefore it was decided to additionally enhance the protein 
stability using its inhibitors.           
3.4.3.3. Co-crystallisation trials  
          Concentrated samples of the native PcpI (~12 mg/ml) and PcpI-6xHis 
(~15 mg/ml), both mixed with a 5-fold molar excess of either 2-pyrrolidone or L-pGlu 
acid, were subjected to crystallisation experiment using the microbatch technique as 
described in section 3.4.2.4.3. This time the level of protein precipitation was much 
slower comparing to trials without inhibitors. Numerous wells stayed clear for a few 
days indicating improved protein stabilisation, where previously fast precipitation had 
occurred. After 2 weeks many of the wells contained small crystalline particles, which 
were soft by crushing with a fine needle that is an indication of protein crystals.  
Most of these were too small however to test them. Only small plate crystals found for  
PcpI-6xHis+2-pyrrolidone mixture in a condition of 0.1 M Bis-Tris pH 5.5 and  
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15% PEG3350 were confirmed as protein using X-ray diffraction screening (3.4.2.4.6).  
A cryo-protectant solution consisted of 0.1 M Bis-Tris pH 5.5, 15% PEG 3350 and 30% 
PEG400 was used. The crystals and resultant diffraction pattern are presented in figures 
3.45 and 3.46, respectively.  
 
 
 
 
 
 
 
Figure 3.45. Crystals of human recombinant PcpI-6xHis+2-pyrrolidone obtained from 
incubation with 0.1 M Bis-Tris pH 5.5 and 15% w/v PEG3350. 
 
Figure 3.46. An X-ray diffraction pattern of a PcpI-6xHis+2-pyrrolidone crystal.  
The fragment with a regular reflection arrangement is zoomed in and the spots are found 
at the resolution of 28 Å. 
 
          The crystals were not of a good quality; too small and diffracting to around 28 Å. 
This however helped to establish a starting crystallisation condition for a further 
optimisation process.   
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3.4.3.4. Optimisation of crystallisation conditions  
           The precipitant solution 0.1 M Bis-Tris pH 5.5 and 15% PEG 3350, which PcpI-
6xHis crystals were found at, was used as a starting point for optimisation of the 
crystallisation conditions. Although the crystals were only found for PcpI-6xHis mixed 
with 2-pyrrolidone, it was decided to conduct the experiment also for native  
PcpI+2-pyrrolidone. The optimisation procedure was performed as described in section 
3.4.2.4.4. Unfortunately, the designed conditions did not yield any good quality crystals 
although they were frequently checked over a 2 months period. In wells where higher 
protein concentrations were used (~15-25 mg/ml) immediate precipitation was 
observed. Many wells returned small crystalline particles for PcpI-6xHis+2-pyrrolidone, 
similar to those obtained in co-crystallisation trials (3.4.3.2) however they did not 
follow any pattern in relation to pH or precipitant concentration. There was no such 
crystallisation observed in the plates with the native PcpI indicating that it is less stable 
than its C-terminally His-tagged form.  
3.4.3.5. Crystal microseeding 
          The microseeding procedure was conducted using PcpI-6xHis crystals resulted 
from co-crystallisation trials in 0.1 M Bis-Tris pH 5.5 and 15% PEG 3350 (3.4.3.3). 
This condition was used as a basis for a design of new reservoir solutions as described 
in section 3.4.2.4.5. Unfortunately, the conditions used also did not yield any good 
quality crystals. The plates were frequently checked over a 2 months period, however 
within this time most of the protein precipitated in droplets. Similarly to microbatch 
optimisation (3.4.3.4), wells where higher protein concentrations were used (up to 
50 mg/ml) immediate precipitation was observed.  
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          Crystallisation experiments on human PcpI did not yield good quality crystals that 
could provide data for structural study of the protein. However, they helped to establish 
conditions suitable for nucleation. These parameters were further used for a design of 
optimisation and microseeding conditions. Unfortunately, neither of those promoted 
crystal growth so far. Human PcpI is known to be very unstable protein and may be 
sensitive for even minor changes in the content of precipitating solutions. This could 
 in turn affect crystallisation ability and therefore it is necessary to continue 
optimisation screening over a narrow range of condition parameters with minor 
increments.  
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Chapter 4 – Studies on human pyroglutamyl peptidase II 
4.1. Human PcpII 
 
          Human pyroglutamyl peptidase type II, better known as thyrotropin-releasing 
hormone-degrading enzyme (TRH-DE), is a member of the M1 family of Zn-dependent 
metallopeptidases in the MEROPS classification (Rawlings et al., 2010). The enzyme 
catalytic activity is highly specific towards a degradation of TRH and TRH-like 
neurohormones, important for physiological regulation of the multiple functions within 
the central nervous system. Analysis of PcpII distribution in primary murine cultures 
showed that it can be exclusively found on the surface of neurons (but not on glial 
cells), which facilitates its regulating function in quenching of the neurotropic TRH 
signal (Bauer et al., 1990; Cruz et al., 1991). Initial reports regarding Pcp did not 
differentiate the type I (3.1) and type II form of the peptidase until the study by the 
O’Connor group, which proposed the existence of two pGlu-removing activities 
displaying distinct biochemical properties (O'Connor and O'Cuinn, 1984). One of them 
was the inhibition of PcpII activity by chelating agents such as 1,10-phenanthroline, 8-
hydroxyquinoline and EDTA, but its activity is not affected by specific PcpI inhibitors 
(Cummins and O'Connor, 1998). 
          PcpII is a large glycoprotein of liver origin and can be found in the body as  
a brain and liver enzyme (both membrane-bound) or as a soluble serum enzyme, which 
is thought to be generated by an alternative post-translational proteolytic cleavage 
(Schmitmeier et al., 2002). The different homologues have 12 potential N-glycosylation 
sites and differ only in their glycostructures. The brain enzyme possesses an 
oligomannose moiety, whereas the two remaining ones contain, typical for serum, 
terminal α(2-6)-sialic acid units linked to galactose (Schmitmeier et al., 2002). All PcpII 
variants, like many surface peptidases, function as homodimers of a relatively large 
molecular mass of 230 kDa (brain enzyme) or 250 kDa (liver and serum enzymes). The 
amino acid sequence of the extracellular catalytic domain is well conserved among 
mammalian homologues and contains a characteristic exopeptidase (G/A)(A/G)MEN 
motif and a catalytic consensus HEXXHX18E motif, which coordinates the Zn
2+
 ion 
within the active centre of the zinc-dependent metallopeptidases (Vallee and Auld, 
1990; Schomburg et al., 1999). Additionally the extracellular domain contains eight 
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cysteine residues that are believed to be necessary to maintain an active protein 
structure and are involved in homodimerization (Cys68, human protein numbering) 
(Papadopoulos et al., 2000). To date there is no published structural data on any PcpII 
protein. 
          This chapter presents experimental work on the human PcpII enzyme including  
a screening for the optimal overexpression conditions in bacterial, baculovirus/insect 
and mammalian systems. Apart from the protein expression study, preliminary 
homology modelling of the protein three-dimensional structure was conducted,  
in the absence of any crystallographic structural information on any type II Pcp 
representative. This could provide some idea about the protein conformation and would 
help to investigate how the substrate binds in the active site.  
4.2. Preparation of human PcpII 
4.2.1. Materials and methods 
4.2.1.1. Prediction of structural domains and conserved regions  
          Due to the fact that PcpII is a large membrane-anchored ectoenzyme preliminary 
amino acid sequence analysis was performed in order to identify potential domain 
boundaries and functionally important regions of the protein. The query sequence was 
submitted to the GlobPlot protein disorder, domain and globularity prediction server 
(Linding et al., 2003) and searched against the Pfam protein database 
(pfam.sanger.ac.uk). The results returned by Globplot (not shown) predicted  
the existence of 3 putative PcpII domains separated by short low-complexity fragments: 
an N-terminal domain (transmembrane, 1-61), a middle domain (catalytic, 130-793) and 
a C-terminal domain (801-1024). The search against the Pfam collection resulted in the 
identification of the region (141-530) conserved in protein members of the M1 family of 
peptidases (Rawlings and Barrett, 1995). Initial overexpression experiments of the full 
protein in the bacterial cells may be problematic. Therefore on the basis of the presented 
domain predictions it was decided to perform an expression study of chosen PcpII 
fragments: PcpII/L141-M541, PcpII/S62-G793 and PcpII/L141-H1024 (figure 4.1). All 
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of the truncated PcpII fragments cover the catalytic domain region with the consensus 
HEXXHX18E motif. The longest PcpII/S62-H1024 and PcpII/L141-H1024 variants 
consist of the catalytic and C-terminal domains. The expression of such a long fragment 
(901 aa) may be more difficult than the synthesis of the complete catalytic domain. 
However, the structural study on some metallopeptidases, such as aminopeptidase A, 
neprilysin or perfringolysin O, resulted in the observation that the presence of the C-
terminal domain or its specific residues may be essential for the correct folding and 
function of whole protein (Shimada et al., 1999; Navarrete Santos et al., 2002; 
Rozenfeld et al., 2004). 
 
Figure 4.1. Schematic representation of the full-length PcpII (PcpIIFL) and truncated 
PcpII fragments: PcpII/L141-M541 (blue), PcpII/S62-G793 (yellow), PcpII/L141-
H1024 (green) and PcpII/S62-H1024 (orange). The position of the individual domains, 
the consensus HEXXHX18E motif and the catalytic triad residues are marked in the 
diagram representing the full-length protein. 
 
          The amino acid sequences of the native and truncated isoforms of human PcpII 
were used to determine the protein parameters using the bioinformatic tools available  
on the ExPASy server (www.expasy.org, (Gasteiger et al., 2003)). The expression 
studies were conducted for a range of the protein variants such as full-length PcpII 
(referred further as PcpIIFL), PcpII/L141-M541, PcpII/S62-G793, PcpII/L141-H1024 
and PcpII/S62-H1024. The amino acid sequence of PcPIIFL with predicted domain 
boundaries and potential N-glycosylation sites as well as parameters for the relevant 
177 
 
PcpII isoforms are presented in table 4.1. The nucleotide and amino acid sequences  
of the individual proteins are found in appendices VIII-XI. 
PcpII protein sequence: 
 
MGEDDAALRAGSRGLSDPWADSVGVRPRTTERHIAVHKRL (1-40 cytoplasmic) 
VLAFAVSLVALLAVTMLAVLL (41-61 transmembrane) 
SLRFDECGASATPGADGGPSGFPERGGNGSLPGSARRNHHAGGDSWQPEAGGVASPGTT
SAQPPSEEEREPWEPWTQLRLSGHLKPLHYNLMLTAFMENFTFSGEVNVEIACRNATRY
VVLHASRVAVEKVQLAEDRAFGAVPVAGFFLYPQTQVLVVVLNRTLDAQRNYNLKIIYN
ALIENELLGFFRSSYVLHGERRFLGVTQFSPTHARKAFPCFDEPIYKATFKISIKHQAT
YLSLSNMPVETSVFEEDGWVTDHFSQTPLMSTYYLAWAICNFTYRETTTKSGVVVRLYA
RPDAIRRGSGDYALHITKRLIEFYEDYFKVPYSLPKLDLLAVPKHPYAAMENWGLSIFV
EQRILLDPSVSSISYLLDVTMVIVHEICHQWFGDLVTPVWWEDVWLKEGFAHYFEFVGT
DYLYPGWNMEKQRFLTDVLHEVMLLDGLASSHPVSQEVLQATDIDRVFDWIAYKKGAAL
IRMLANFMGHSVFQRGLQDYLTIHKYGNAARNDLWNTLSEALKRNGKYVNIQEVMDQWT
LQMGYPVITILGNTTAENRIIITQQHFIYDISAKTKALKLQNNSYLWQIPLTIVVGNRS
HVSSEAIIWVSNKSEHHRITYLDKGSWLLGNINQTGYFRVNYDLRNWRLLIDQLIRNHE
VLSVSNRAGLIDDAFSLARAGYLPQNIPLEIIRYLSEEKDFLPWHAASRALYPLDKLLD
RMENYNIFNEYILKQVATTYIKLGWPKNNFNGSLVQASYQHEELRREVIMLACSFGNKH
CHQQASTLISDWISSNRNRIPLNVRDIVYCTGVSLLDEDVWEFIWMKFHSTTAVSEKKI
LLEALTCSDDRNLLNRLLNLSLNSEVVLDQDAIDVIIHVARNPHGRDLAWKFFRDKWKI
LNTRYGEALFMNSKLISGVTEFLNTEGELKELKNFMKNYDGVAAASFSRAVETVEANVR
WKMLYQDELFQWLGKALRH  
 
 PcpIIFL 
PcpII/ 
L141-M541 
PcpII/ 
S62-G793 
PcpII/ 
L141-
H1024 
PcpII/ 
S62-H1024 
cDNA length 
(bp) 
3072 1203 2196 2652  2889  
Protein length 
(aa) 
1024  401  732  884  963  
Molecular 
weight (Da) 
116999.6  46285.3 83702.3 102399.4 109657.0 
Theoretical pI 6.50 6.07 6.32 6.78 6.41 
Extinction 
coefficient  
(M
-1
 cm
-1
) 
217080  82530  159880  195080  211580 
 
Table 4.1. Amino acid sequence and biophysical parameters of human PcpII and its 
truncated isoforms. The amino acid sequence of the protein is presented with marked 
predicted cytoplasmic (blue), transmembrane (yellow) and extracellular domains. 
Disordered fragments, which separate structural domains, are highlighted in grey. 
Potential N-glycosylation sites are marked in red font and the consensus catalytic 
HEXXHX18E motif is highlighted in green. The parameters were computed using  
the bioinformatic tools in the ExPASy server (www. expasy.org, (Gasteiger et al., 
2003)). 
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4.2.1.2. Cloning and expression of PcpII in bacterial cells 
          The expression screening in the bacterial system was conducted for three protein 
variants: PcpII/L141-M541, PcpII/S62-G793 and PcpII/L141-H1024. The cloning 
experiment employed pET-28a(+) vector (appendix I) in order to incorporate  
an N-terminal His-tag in all proteins. Additionally, PCR amplification of PcpII/L141-
M541 insert was designed to enable the expression of the protein with the pelB leader 
sequence utilizing the pET-22b(+) vector (appendix II). The pelB is an N-terminal,  
22 aa signal sequence of the pectate lyase B from Erwinia carotovora (Lei et al., 1987). 
The fusion of this leader with a protein of interest enables its secretion to the bacterial 
periplasmic space, where it is subsequently cleaved off by a signal peptidase.  
          The cDNA encoding human PcpII was supplied as the pCMV-SPORT6/trhde 
construct from Open Biosystems Ltd. The clone was provided as E. coli DH5α in LB 
broth with 8% glycerol and 100 μg/ml ampicillin.  
4.2.1.2.1. Preparation of the pCMV-SPORT6/trhde plasmid 
          In order to obtain a higher amount of the pCMV-SPORT6/trhde construct,  
the E. coli DH5α strain glycerol stock was used to inoculate 10 ml of LB media (2.2.1) 
containing 100 μg/ml ampicillin. This was grown overnight at 37ºC in a shaking 
incubator. Next the culture was subjected to DNA extraction according to the protocol 
of the GeneJET™ Plasmid Miniprep kit (Fermentas) (2.7.2). The result of  
the minipreparation was determined by a double digestion with NotI and EcoRV 
restriction enzymes (2.7.5.2). This was followed by 1% agarose gel electrophoresis 
(2.7.8). The samples containing the recombinant plasmids with inserts were further 
purified (2.7.3), quantified (2.7.4) and sequenced using the T7 (forward) and M13 
(reverse) primers (2.7.10). Next pCMV-SPORT6/trhde was used as a template for  
the PCR amplification of the desired PcpII fragments. 
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4.2.1.2.2. PCR amplification of cDNA of PcpII fragments 
          PCR amplification of the cDNA fragments encoding PcpII/L141-M541, 
PcpII/S62-G793 and PcpII/L141-H1024 was conducted to obtain the inserts suitable for 
cloning into pET-28a(+) and the production of N-terminally His-tagged proteins. 
Additional amplification was conducted for PcpII/L141-M541 cDNA (PCR product 
referred as pcpII/L141-M541-pelB) to allow its cloning into pET-22b(+) in order  
to obtain a protein with N-terminal pelB leader sequence. Gene primers for the reactions 
were supplied by Eurofins MWG Operon and are listed in table 4.2. 
Primer Sequence 
Restriction 
enzyme 
GC 
content 
Tm 
L141-M541F 
(forward) 
CAGCCATATGCTGTCGGG 
CCACCTGAAG 
NdeI 60.7% 71.0ºC 
L141-M541R 
(reverse) 
CTCGAATTCTCACATAAA 
ATTAGCCAGCATTCTT 
EcoRI 35.3% 64.7ºC 
S62-G793F 
(forward) 
AGCCATATGAGCCTGCGC 
TTC 
NdeI 57.1% 61.8ºC 
S62-G793R 
(reverse) 
CTCGAATTCTTACCCAAG
CTTG 
EcoRI 45.5% 58.4ºC 
L141-H1024F 
(forward) 
CAGCGCTAGCCTGTCGGG 
CCACCTGAAG 
NheI 67.9% 73.9ºC 
L141-H1024R 
(reverse) 
TCTGCGGCCGCTTAGTGT
CTTAGAGCTTTTCCTAAC 
NotI 37.9% 62.4ºC 
L141-
M541pelBF 
(forward) 
GATGGCCATGGCACTGT 
CGG 
NcoI 65.5% 72.7ºC 
L141-
M541pelBR 
(reverse) 
CTCGAATTCTCACATAAA 
ATTAGCCAGCATTCTT 
EcoRI 35.3% 64.7ºC 
 
Table 4.2. List of PCR primers used for amplification of the PcpII cDNA fragments. 
L141-M541pelBF and L141-M541pelBR (identical with L141-M541R) were used for 
production of the insert enabling incorporation into the pET-22b(+) expression vector. 
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The composition of the amplification reaction mixture is presented below. 
1 μl 50 ng/μl pCMV-SPORT6/trhde 
1 μl 10 μM forward primer 
1 μl 10 μM reverse primer 
12.5 μl 2x GoTaq® Hot Start Green Master Mix* 
9.5 μl ddH2O 
 
* The specification and properties of the GoTaq® Hot Start Green Master Mix 
(Promega) were outlined in section 3.2.1.4.1. 
          PCR amplification was performed in a Mastercycler
®
 thermal cycler (Eppendorf). 
A range of tubes containing reaction mixture were prepared and each one of these was 
subjected to a different annealing temperature within a set gradient. The individual steps 
of PCR are described in table 4.3. 
Step Temperature Time 
Initial denaturation 96ºC 3 min 
   
Denaturation 96ºC 1 min  
   30x Annealing temperature gradient 55ºC – 68ºC 1 min 
Extension 72ºC 1 min/1kb 
   
Final extension 72ºC 7 min 
Cooling 4ºC ----- 
Table 4.3. Thermal cycling steps during the reaction of amplification of the PcpII 
cDNA fragments. 
 
The result of the PCR amplification was checked by 2% agarose gel electrophoresis as 
described in section 2.7.8.  
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4.2.1.2.3. Ligation of PcpII cDNA fragments with pET-28a(+) and pET-22b(+)  
          The PCR products obtained during the amplification of cDNA encoding human 
PcpII (4.2.1.2.2) were purified using the gel extraction method described in section 
2.7.9. Next all inserts as well as the pET-28a(+) and pET-22b(+) plasmids were 
digested with suitable restriction enzymes (2.7.5.2):  
- digestion with NdeI and EcoRI of the pcpII/L141-M541, pcpII/S62-G793 inserts  
and pET-28a(+) 
- digestion with NheI and NotI of the pcpII/L141-H1024 insert and pET-28a(+) 
- digestion with NcoI and EcoRI of the pcpII/L141-M541-pelB insert and pET-22b(+)  
 
          The linearized pET-28a(+) and pET-22b(+) plasmids were subsequently 
dephosphorylated at the 5′ end (2.7.6) and after that subjected to the ligation reaction 
with each of the pcpII insert variants (2.7.7). Next the ligation reaction mixtures were 
used for transformation into E. coli NEB 5-α competent cells (2.7.1). The transformants 
treated with the pET-28a(+) or pET-22b(+) mixtures were incubated overnight at 37ºC, 
on the agar plates (2.2.2) containing 50 μg/ml kanamycin or 100 μg/ml ampicillin, 
respectively. 
4.2.1.2.4. Preparation of pET-28a(+)/pcpII and pET-22b(+)/pcpII recombinant 
plasmids 
          A few single E. coli NEB 5-α colonies, obtained from the transformation with the 
pET-28a(+) or pET-22b(+) ligation reaction mixtures (4.2.1.2.3), were picked and used 
for the inoculation of 10 ml of LB media (2.2.1) containing 50 μg/ml kanamycin  
or 100 μg/ml ampicillin, respectively. This was grown overnight at 37ºC in a shaking 
incubator. Next the cultures were subjected to DNA extraction according to the protocol 
of the GeneJET™ Plasmid Miniprep kit (Fermentas) (2.7.2). The result was determined 
by a double digestion of the plasmid preparations (2.7.5.2): 
- digestion with NdeI and EcoRI of the pET-28a(+)/pcpII/L141-M541 and 
pET-28a(+)/pcpII/S62-G793  
- digestion with NheI and NotI of the pET-28a(+)/pcpII/L141-H1024 
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- digestion with NcoI and EcoRI of the pET-22b(+)/pcpII/L141-M541-pelB  
This was followed by the agarose gel electrophoresis (2.7.8). The sample containing 
recombinant plasmids with inserts were further purified (2.7.3), quantified (2.7.4) and 
sequenced using standard T7 primers (2.7.10). 
4.2.1.2.5. Protein overexpression in E. coli strains 
          Preliminary overexpression trials of PcpII/L141-M541, PcpII/S62-G793 and 
PcpII/L141-H1024 variants were performed in a range of commercially available E. coli 
strains designed to facilitate protein production. The tested strains included (2.4.2): 
 BL21-CodonPlus®(DE3)-RIPL (alleviates rare E. coli codon bias, 3.2.1.2.1) 
 ArcticExpress™ (DE3)RIL (alleviates rare E. coli codon bias and produces 
chaperonins facilitating protein expression at lower temperatures) 
 Rosetta™ 2(DE3) (alleviates rare E. coli codon bias) 
 Rosetta-gami™ 2(DE3) (alleviates rare E. coli codon bias and enhances disulfide 
bond formation) 
 BL21(DE3)pLysS (enable expression of a protein toxic to the host cell) 
 
          All of the E. coli cells intended for the overexpression of PcpII fragments were 
made competent according to general chemical procedure described in section 2.5. 
Aliquots of the competent cells were directly used for the transformation procedure 
(2.7.1) or stored as glycerol stocks at -80ºC (2.6). 
4.2.1.2.6. Screening for optimal overexpression conditions 
          The E. coli competent cells of each protein expression strain (4.2.1.2.5) were 
individually transformed with previously prepared recombinant constructs: 
pET-28a(+)/pcpII/L141-M541, pET-28a(+)/pcpII/S62-G793, pET-28a(+)/pcpII/L141-
H1024 and pET-22b(+)/pcpII/L141-M541-pelB (4.2.1.2.4). The transformation was 
conducted following the protocol described in section 2.7.1. All transformants were 
plated on Petri dishes containing 50 μg/ml kanamycin (pET-28a(+)) or 100 μg/ml 
ampicillin (pET-22b(+)) and 35 μg/ml chloramphenicol and incubated overnight  
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at 37ºC. Next day a random colony from each was used to inoculate 10 ml of LB media 
supplemented with selected antibiotics as above. This was grown overnight  
at 37ºC in a shaking incubator. Next day 5 flasks (per each tested strain) containing 
100 ml of LB media with the above antibiotics were inoculated each with 1 ml of the 
overnight culture and grown in a shaking incubator at 37ºC. The induction of the protein 
overexpression was initiated by the addition of IPTG (2.2.3) to the final concentration 
of 1 mM. At this point cultures were continued to grow at 25ºC (5 flasks with cultures 
induced at an OD595 of 0.4, 0.6, 0.8, 1.0 and 1.2, respectively) and 37ºC (5 flasks with 
cultures induced at an OD595 of 0.4, 0.6, 0.8, 1.0 and 1.2, respectively). The exception 
from this rule was made for the ArcticExpress™ (DE3)RIL strain which after addition 
of IPTG was incubated at 12ºC. Samples for the protein overexpression analysis were 
collected from each flask prior to induction with IPTG and then every 5 h over a 30 h 
period.  In the case of the ArcticExpress™ (DE3)RIL the culture sample was collected 
prior to induction with IPTG and after 24 h incubation. Protein isolation was carried out 
according to the detergent-based procedure (2.8.1.1) and the results of the protein 
expression were analysed using the SDS-PAGE technique with an 8% separating gel 
(2.8.2). 
4.2.1.3. Cloning and expression of PcpII in insect and mammalian cells 
          The use of bacterial cells for heterologous expression of large, multi-domain 
mammalian or viral proteins often can be difficult or impossible. The production of 
proteins in the E. coli system is rapid and uncomplicated but it does not provide many 
of the post-translational modifications occurring in eukaryotic cells. This can often 
result in a misfolded protein, which is targeted to inclusion bodies or the yield of the 
production can be insufficient for subsequent applications. Therefore it is advisable to 
consider an expression screening in a more advanced host type such as mammalian or 
insect cells. Eukaryotic cell-based protein production generally requires more time and 
labour; however the popularization of these methods has significantly increased over the 
last decade and nowadays they are routinely used for basic research and large-scale 
commercial applications.  
          A key factor for the popularity of the insect cell system is its effectiveness in 
high-yield production of post-translationally modified eukaryotic proteins in a relatively 
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short period of time. This can be achieved by employing the specifically designed 
baculovirus vector expression system (BEVS) which is widely used to express foreign 
proteins (Mirzaei et al., 2008; Shrestha et al., 2008). Baculoviruses are a family of 
large, rod-shaped viruses infecting the insect population (Summers and Anderson, 
1972). The most common expression system is based on Autographa californica 
nuclear polyhedrosis virus (AcNPV), where heterologous genes are introduced into a 
region of the genome that is not essential for viral replication and is under the control of 
the strong polyhedrin promoter, which drives expression in the last stages of the virus 
cycle (Kochan et al., 1993). Such a construct is further transfected and propagated in 
cultured insect cells and insect larvae. The most popular host lines used for transfection 
are derived from Spodoptera frugiperda (Sf9 or Sf21) or Trichoplusia ni (High Five) 
species (Vadakkadathmeethal et al., 2005). A prominent advantage of the 
baculovirus-mediated expression is the relatively large size of the viral genome, which 
enables the introduction of larger cDNA fragments and therefore expression of larger or 
multi-domain proteins. Moreover, if needed, a production of multi-protein complexes 
can be achieved by a simultaneous transfection with multiple constructs or by 
introduction of two or more expression cassettes in a single baculovirus (Berger et al., 
2004). 
          Mammalian cell lines represent an alternative for insect cell-based protein 
expression. They are most often used for secreted and membrane proteins or in cases 
where the most authentic post-translational modifications are essential for protein 
function.  Several cell lines are commonly used as hosts for gene transfection and 
expression, such as COS (CV-1 cells of simian origin), CHO (chinese hamster ovary 
cells), HeLa (immortal human cells) and HEK (human embryonic kidney cells). A 
HEK293 is one of the most extensively used for the expression of a variety of 
recombinant proteins and was obtained by the exposure of HEK cell cultures to sheared 
DNA fragments of human adenovirus type 5 (Ad5)  (Graham et al., 1977; Thomas and 
Smart, 2005). The cells are transfected with a plasmid vector carrying  
a cDNA insert under control of different constitutive (e.g. CMV or SV40) or inducible 
promoters which force the expression of the desired gene products. An important 
variant of this cell line is the HEK 293T containing the SV40 large T-antigen, which 
facilitates episomal amplification of plasmids with the SV40 origin of replication. This 
in result increases a number of plasmid copies to persist in the transfected cells and the 
level of the desired protein expression (Van Craenenbroeck et al., 2000). 
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          This part of the experimental work involving cloning and expression of PcpII  
in eukaryotic cell systems was entirely conducted in the Oxford Protein Production 
Facility (OPPF, Research Complex at Harwell).  
4.2.1.3.1. Expression vector constructs 
          A series of versatile pOPIN-based vectors was used to screen expression 
conditions for human PcpII (table 4.4). The pOPIN constructs were developed in OPPF 
on the basis of the parent pTriEx2 vector (Novagen) as described by Berrow and 
co-workers, and enable rapid high-throughput screening for protein expression in E. 
coli, mammalian and baculovirus-infected insect cells (Berrow et al., 2007). The 
detailed characteristics and maps of the pOPIN series are available from Addgene 
plasmid repository (www.addgene.org) and their preparation procedure was described 
in the report by Berrow and co-workers (Berrow et al., 2007). This set of vectors 
facilitates ligation-independent incorporation of a desired cDNA insert within the 
commercial In-Fusion
TM
 PCR cloning system (Clontech), which allows for the precise 
engineering of His-tagged protein constructs. The principle of this method relies on the 
generation of the 15 bp 5′ and 3′ extensions in the PCR product, which can be 
subsequently fused to the homologous ends of a linearized vector. The joining is 
catalysed by the In-Fusion
TM
 proof-reading exonuclease, which digests the 
double-stranded extensions and generates single-stranded DNA overhangs enabling the 
annealing between a vector and insert. The assembled construct further undergoes final 
repair within the E. coli host cell. The method was shown to be suitable for the cloning 
of large PCR fragments (3-11kb) over a wide range of DNA concentration (Marsischky 
and LaBaer, 2004; Berrow et al., 2009). 
          All pOPIN-based vectors developed in the OPPF contain the lacZ insert encoding 
β-galactosidase that makes them suitable for the blue-white colony screening technique 
(Berrow et al., 2007). The linearization of each vector with two restriction enzymes 
results in releasing of the lacZ cassette and incorporation of the desired insert DNA 
(Maas, 1999). In case this process is not successful, an intact gene expresses the active 
β-galactosidase, which cleaves colourless X-gal giving a bright blue insoluble product. 
The characteristic blue colour of colonies therefore is an indication of the presence of 
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non-recombinant vector, whereas a white colony is a sign of the successful ligation with 
the insert of interest. 
Vector Fusion Tag Tag Sequence 
pOPINE C-terminal His-tag      -KHHHHHH 
pOPINF N-terminal His-tag     MAHHHHHHSSGLEVLFQGP- 
pOPING 
cleavable secretion leader 
MGILPSPGMPALLSLVSLLSV 
LLMGCVAETG-  
C-terminal His-tag      -KHHHHHH 
pOPINH 
cleavable secretion leader, 
N-terminal His-tag 
MGILPSPGMPALLSLVSLLSV 
LLMGCVAETMAHHHHHHSS 
GLEVLFQGP- 
pOPINI N-terminal His-tag MAHHHHHHSSG- 
pOPINTTG 
cleavable secretion leader  
MGILPSPGMPALLSLVSLLSV 
LLMGCVAETG-  
C-terminal His-tag -KHHHHHH 
pOPINTTGNeo- 
3C-GFP-His 
cleavable secretion leader,  
N-terminal His-tag 
MGILPSPGMPALLSLVSLLSV 
LLMGCVAETMAHHHHHHSS 
GLEVLFQGP- 
 C-terminal GFP  
(green fluorescent protein) 
----- 
pOPINTTGNeo- 
3C-Halo7-His 
cleavable secretion leader,  
N-terminal His-tag  
MGILPSPGMPALLSLVSLLSV 
LLMGCVAETMAHHHHHHSS 
GLEVLFQGP- 
C-terminal HaloTag  ----- 
pOPINTTGNeo- 
3C-CD4-His 
cleavable secretion leader,  
N-terminal His-tag  
MGILPSPGMPALLSLVSLLSV 
LLMGCVAETMAHHHHHHSS 
GLEVLFQGP- 
C-terminal CD4 tag ----- 
pOPINE-3C- 
GFP-His 
cleavable secretion leader,  
N-terminal His-tag  
MGILPSPGMPALLSLVSLLSV 
LLMGCVAETMAHHHHHHSS 
GLEVLFQGP- 
C-terminal GFP  
(green fluorescent protein) 
----- 
pOPINE-3C- 
Halo7-His 
N-terminal His-tag  MAHHHHHHSSGLEVLFQGP-  
C-terminal HaloTag  ----- 
 
Table 4.4. The series of the pOPIN vectors used in the human PcpII expression study. 
Individual vectors differ with the type and position of a fusion tag, which is later 
incorporated in the recombinant protein. The N-terminal His-tags, with the exception of 
that from pOPINI, are cleavable from the protein with human rhinovirus 3C protease 
and all of the C-terminal His-tags are removable by carboxypeptidase A (Berrow et al., 
2007).  
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4.2.1.3.2. PCR amplification of PcpII fragments 
          On the basis of previous structural predictions of PcpII domain boundaries, PCR 
amplification was designed to obtain cDNA fragments encoding PcpIIFL as well as for 
its N-terminally truncated variants PcpII/S62-H1024 (no transmembrane domain) and 
PcpII/L141-H1024 (structured region). List of PCR inserts generated for cloning  
in appropriate pOPIN-based vectors is presented in table 4.5. Forward and reverse 
primer extensions, which were designed to facilitate the In-Fusion
TM
 cloning, are listed 
in appendix XII. 
The composition of the master mix (44 μl/reaction) for a single PCR reaction mixture: 
2  μl 100ng/µl pCMV-SPORT6/trhde 
25  μl 2x KOD Hot Start Buffer* 
10  μl 2 mM dNTP mix 
1  μl 2.5 U/ μl KOD Xtreme™ Hot Start DNA Polymerase* 
6  μl ddH2O 
 
* The KOD Xtreme™ Hot Start PCR system (Novagen) is optimized for the 
amplification of GC-rich (up to 90%) and long templates. The high fidelity KOD 
Xtreme™ DNA polymerase produces blunt-ended DNA products and is combined with 
two monoclonal antibodies, which permit hot start thermocycling. 
 
          PCR amplification was conducted in a 96-well plate. The master mix solution was 
dispensed into each well (44 μl/reaction) using a multi-channel pipette followed  
by the addition of 3 μl of each forward and reverse primer (10 μM). The plate was 
sealed with an adhesive film and placed in the Veriti® 96-Well Thermal Cycler 
(Applied Biosystems). The thermal cycling procedure was run according to the 
parameters listed in table 4.6. 
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VECTOR PCR INSERT OPPF NUMBER 
pOPINE PcpII/S62-H1024 8979 
pOPINE PcpII/L141-H1024 8981 
pOPINF PcpII 7468 
pOPINF PcpII/S62-H1024 8983 
pOPINF PcpII/L141-H1024 9076 
pOPING PcpII/S62-H1024 7465 
pOPING PcpII/L141-H1024 7211 
pOPINH PcpII/S62-H1024 7467 
pOPINH PcpII/L141-H1024 7210 
pOPINI PcpII 7469 
pOPINTTG PcpII/S62-H1024 7466 
pOPINTTG PcpII/L141-H1024 7212 
pOPINTTGNeo-3C- 
GFP-His 
PcpII/S62-H1024 8984 
pOPINTTGNeo-3C-Halo7-His PcpII/S62-H1024 8708 
pOPINTTGNeo-3C-CD4-His PcpII/S62-H1024 8709 
pOPINE-3C-GFP-His PcpII/S62-H1024 8980G 
pOPINE-3C-GFP-His PcpII/L141-H1024 8982G 
pOPINE-3C-Halo7-His PcpII/S62-H1024 8980 
pOPINE-3C-Halo7-His PcpII/L141-H1024 8982 
 
Table 4.5. List of PCR inserts generated for cloning in the pOPIN-based vectors. Each 
construct is referred to by its individual number in the OPPF target database.  
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Step Temperature Time 
Initial denaturation 94ºC 2 min 
   
Denaturation 98ºC 10 s   
     30x Annealing 60ºC 30 s 
Extension 68ºC 2 min 30 s 
   
Final extension 68ºC 2 min 
Cooling 4ºC ----- 
 
Table 4.6. The thermal cycling steps used during the reaction of amplification of the 
PcpII cDNA fragments. 
 
          Next 2 μl of the DpnI restriction enzyme solution was added directly to each 
amplification reaction, which was briefly centrifuged and further incubated at 37°C for 
1 h in order to digest the parental, non-methylated DNA template. The result of the PCR 
reaction was checked by 1% agarose gel electrophoresis as described in section 2.7.8. 
The less hazardous SYBR® Safe gel stain (Invitrogen) was used in place of ethidium 
bromide, which enables DNA visualisation using a blue or UV light illuminator. 
4.2.1.3.3. In-Fusion™ cloning of PCR products 
          The pOPIN-based expression vectors produced in OPPF were digested with  
the appropriate restriction enzymes and subsequently subjected to DNA electrophoresis 
(2.7.8), gel extraction (2.7.9) and purification (2.7.3) procedures (Berrow et al., 2007). 
Linearized vectors were stored at -20°C in 10 mM Tris-HCl buffer (pH 8.0) as 10 µg 
aliquots, which were ready to use for In-Fusion™ reactions in a 96-well plate 
(100 ng/well).  
          The PCR products obtained during the amplification of cDNA encoding human 
PcpII (4.2.1.3.2) were purified using a silica-membrane-based DNA purification method 
with a NucleoSpinR Extract II kit (Invitrogen) according to the manufacturer’s 
instructions. The purified cDNA inserts of the PcpIIFL, PcpII/S62-H1024 and 
PcpII/L141-H1024 were combined with the appropriate, linearized pOPIN-based 
vectors (table 4.5) using the In-Fusion™ PCR cloning system (Clontech). The cloning 
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kit was supplied in In-Fusion™ Dry-Down mix format containing lyophilized 
ready-to-use reaction components including proprietary In-Fusion™ exonuclease. For 
each reaction, the lyophilized reaction pellet was resuspended in a microtube with 10 μl 
of mixed solution containing 1  μl (100 ng) of the linearized pOPIN-based vector, 
100 ng of a purified PCR insert and the required amount of ddH2O (to total up to 10  μl 
volume). This was briefly mixed and transferred to a PCR 96-well plate, which was 
sealed with an adhesive film. The reaction was carried out for 30 min at 42ºC in a 
Veriti® 96-Well Thermal Cycler (Applied Biosystems). Next the plate was placed on 
ice and each reaction was diluted with 40 μl of TE buffer (2.3.5).  
All of the reaction mixtures were subjected to a transformation into E. coli 
OmniMAX
TM
2 T1-phage resistant competent cells (Invitrogen) (2.7.1). 10 μl of cell 
suspension was plated on 6-well Corning
®
 Costar
®
 cell culture plates (Sigma-Aldrich) 
containing LB agar with 50 μg/ml carbenicillin, 20 μg/ml X-gal and 1 mM IPTG and 
incubated overnight at 37ºC. 
4.2.1.3.4. Preparation of recombinant pOPIN/pcpII plasmid constructs 
            The identification of colonies carrying recombinant pOPIN-based plasmids with  
an appropriate pcpII insert (pOPIN/pcpII) was enabled by the application of blue-white 
colony screening (4.2.1.3.1). Random white colonies (2 per each pOPIN/pcpII 
construct) were picked to inoculate 1.5  ml of LB with 50 μg/ml carbenicillin in a 96 
deep-well block. The block was sealed with gas-permeable adhesive film and incubated 
overnight at 37°C in a shaking incubator. Next the cultures were pelleted by 
centrifugation at 5000xg for 15 min at 4°C (Avanti® HP-26 XP with AllSpin JS-5.3 
rotor, Beckman).  Cell pellets were subjected to automated, 96-well format plasmid 
preparation using a QIAgen BioRobot 8000, Wizard SV96 kit (Promega) and a 
QiaVAC96 manifold (Qiagen) according to the manufacturer's instructions.  
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4.2.1.3.5. Verification of recombinant pOPIN/pcpII plasmid constructs 
          All prepared pOPIN/pcpII constructs (4.2.1.3.4) were verified using the 
PCR-based method as described in section 4.2.1.3.2., except that the gene-specific 
forward primer was replaced by a standard T7 forward primer 
(5′-TAATACGACTCACTATAGGG-3′), which is present in all pOPIN-based vectors.  
The following composition of the master mix (22 μl/reaction) was prepared for a single 
PCR reaction: 
2.5 μl 2x KOD Hot Start Buffer 
2.5 μl 2 mM dNTP mix 
1 μl 25 mM MgCl2 
1.5 μl 10 μM T7 forward primer 
0.5 μl 2.5 U/μl KOD Xtreme™ Hot Start DNA Polymerase 
14 μl ddH2O 
           
          PCR amplification was conducted in a 96-well plate. The master mix solution was 
dispensed into each well (22 μl/reaction) using a multi-channel pipette followed by  
the addition of 1.5 μl of reverse primer (10 μM) and 1.5 μl of the appropriate 
pOPIN/pcpII construct sample. The plate was sealed with an adhesive film and placed 
in the Veriti® 96-Well Thermal Cycler (Applied Biosystems). The thermal cycling 
procedure was run according to parameters listed in table 4.7. 
Step Temperature Time 
Initial denaturation 94ºC 2 min 
   
Denaturation 94ºC 30 s   
     30x Annealing 60ºC 30 s 
Extension 68ºC 2 min 30 s 
   
Final extension 68ºC 4 min 
Cooling 4ºC ----- 
 
Table 4.7. Thermal cycling steps during the PCR-based verification of pOPIN/pcpII 
constructs. 
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          The result of the PCR was analysed by 1% agarose gel electrophoresis as 
described in section 2.7.8 with SYBR® Safe gel stain (Invitrogen) used for DNA 
visualisation of the pOPIN/pcpII constructs which were subjected for DNA sequencing 
(2.7.10). The purified plasmid samples were subsequently used for transfection into 
either insect Sf9 cells or mammalian HEK 293T cells. 
4.2.1.3.6. Construction of baculoviruses and expression in insect cell lines 
          The production of recombinant baculoviruses and insect cell expression screening 
for a range of pOPIN/pcpII preparations, which included 7210, 7211, 7212, 7465, 7466, 
7467, 7468, 7469 constructs (OPPF reference number, table 4.4) was conducted solely 
by Dr J.E. Nettleship (OPPF). The cell lines that were tested as expression hosts 
included Sf9 and VE-Sf9 (vankyrin enhanced Sf9), which were co-transfected with each 
pOPIN/pcpII plasmid preparation and linearized A. californica bacmid. The procedures 
of the baculovirus construction and transfection are presented in detail in reports 
published by the OPPF group (Berrow et al., 2007; Nettleship et al., 2010).  
4.2.1.3.7. Preparation and transfection of HEK 293T cells 
          The expression screening for all pOPIN/pcpII constructs in HEK 293T cells was 
conducted according to a protocol by Nettleship and co-workers (Nettleship et al., 
2009). HEK 293T cells were maintained in DMEM  ((Dulbecco's modified Eagle's 
medium, (Dulbecco and Freeman, 1959)) supplemented with 10% foetal calf serum 
(FCS, Sigma), non-essential amino acids (1:100) and L-glutamine (1:100) (Invitrogen), 
and incubated in a 5% CO2/95% air environment. All work involving cell manipulation 
and preparation of transfection reactions was carried out under a Class 2 laminar flow 
cabinet.  
          Before transfection the HEK 293T cells were seeded in 24-well plates at a density 
sufficient to give 75–80% confluency after 24 h growth (around 1.5-2x105 cells/ml). For 
each well to be used, a 60  μl of serum-free DMEM, supplemented with non-essential 
amino acids (1:100) and L-glutamine (1:100), was mixed with a 2µl of 1.33 mg/ml 
GeneJuice™ transfection reagent (Novagen). Next ~1 μg of each pOPIN/pcpII construct 
193 
 
(table 4.5) was added to the above mix, stirred thoroughly and incubated for 10 min at 
room temperature. Meanwhile, the media from the HEK 293T cell layer in the 24-well 
plate was carefully aspirated and immediately replaced with 1 ml of DMEM with 2% 
FCS, non-essential amino acids (1:100) and L-glutamine (1:100). Then the 
DNA/GeneJuice
TM
 cocktail was added to the cells and these were incubated for 3 days 
at 37°C in a 5% CO2/95% air environment. 
4.2.1.3.8. Verification of protein expression 
          The analysis of the PcpIIFL, PcpII/S62-H1024 and PcpII/L141-H1024 expression  
in HEK 293T cells involved separated screening for secreted and intracellular products.  
In order to analyse the secretion of proteins into the media, the culture supernatant  
3 days post transfection was transferred into a 24 deep-well block and harvested for  
10 min at 17000xg at 4ºC (Avanti® HP-26 XP with AllSpin JS-5.3 rotor, Beckman) . 
The adherent cells, which remained after aspiration of the supernatant, were subjected 
for analysis of intracellular expression of the desired proteins. The plate with cells was 
frozen at -80°C for at least 30 min. Next it was defrosted and the cells were washed 
with 100 μl of PBS buffer (2.3.6). A 10 μl aliquot of the supernatant from either the 
secretory or intracellular expression preparation was mixed with 10 μl of sample 
loading buffer (2.3.2) and heated at 95°C for 3 min. The expression yield was analysed 
by SDS-PAGE (2.8.2) using pre-cast Novex® 4-12% gel in NuPAGE® MOPS running 
buffer (Invitrogen). In the next step the His-tagged proteins were detected by Western 
blotting as described in section 2.8.6. 
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4.2.2. Results and discussion 
4.2.2.1. Cloning and expression of PcpII in bacterial cells 
4.2.2.1.1. Preparation of pCMV-SPORT6/trhde plasmid 
          The E. coli DH5α culture cells after overnight growth were harvested by 
centrifugation and subjected to pCMV-SPORT6/trhde plasmid isolation as described in 
section 4.2.1.2.1. Subsequent restriction enzyme digestion (2.7.5.1) and 1% agarose gel 
electrophoresis (2.7.8) confirmed successful plasmid extraction and a presence of the 
PcpII cDNA insert. The band corresponding to the insert can be observed at approx. 
3000 bp as seen on the agarose gel electropherogram (figure 4.2).  
 
Figure 4.2. The result of agarose gel electrophoresis of pCMV-SPORT6/trhde 
restriction digestion products. Individual lanes represent marker Hyperladder I (M), 
uncut plasmid (1) and cut plasmid (2). Insert band can be observed at approx. 3000 bp. 
 
          The concentration and purity of the prepared pCMV-SPORT6/trhde sample was 
determined by the absorbance measurement at 260 nm as described in section 2.7.4. 
Plasmid DNA was sent for sequencing using T7 (forward) and M13 (reverse) primer 
(2.7.10), which confirmed the presence of the PcpII cDNA insert and its correct 
nucleotide sequence (appendix VIII). Next the purified and quantified plasmid sample 
was subsequently used for the PCR amplification of cDNA encoding the desired PcpII 
fragments. 
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4.2.2.1.2. PCR amplification of cDNA of PcpII fragments 
          The amplification of cDNA encoding the PcpII fragments (4.2.1.2.2) appeared to 
be very difficult, probably because of the relatively long fragments to be amplified and 
the possibility of the formation of secondary DNA structures. However, after a few 
attempts the desired PCR products were obtained, which were confirmed by 2% agarose 
gel electrophoresis. The positive result of the reaction was seen over the whole range  
of the applied annealing temperature gradient. The bands corresponding to the inserts  
of the PcpII/L141-M541, PcpII/S62-G793 and PcpII/L141-H1024 can be observed  
at approx. 1200 bp, 2200 bp and 2500 bp, respectively (figure 4.3). The result of PCR 
amplification for PcpII/L141-M541 cDNA to clone into pET-22b(+) is presented  
in figure 4.4. 
 
Figure 4.3. The result of the amplification of cDNA encoding (1) PcpII/L141-H1024 
(~2500 bp), (2) PcpII/L141-M541 (~1200 bp) and (3) PcpII/S62-G793 (~2200 bp) and 
M – marker Hyperladder I. 
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Figure 4.4. The result of the amplification of cDNA encoding PcpII/L141-M541 
(~1200 bp) designed to be cloned into pET-22b(+). M – marker Hyperladder I. 
4.2.2.1.3. Preparation of pET-28a(+)/pcpII and pET-22b(+)/pcpII recombinant 
plasmids 
          The ligation reactions of all PcpII inserts with pET-28a(+) or pET-22b(+) vectors  
(4.2.1.2.3) were successful and confirmed by the obtaining of colonies carrying the 
recombinant plasmids. The pET-28a(+)/pcpII/L141-M541, pET-28a(+)/pcpII/S62-G793, 
pET-28a(+)/pcpII/L141-H1024 and pET-22b(+)/pcpII/L141-M541-pelB constructs were 
isolated and the presence of the desired inserts was shown using a double digestion 
reaction with suitable restriction enzymes and subsequent 1% agarose gel 
electrophoresis as described in section 4.2.1.2.4. The correct sequence of all inserts was 
confirmed by DNA sequencing (2.7.10, appendices IX, X an XI). All constructs were 
further used in an attempt to overexpress given PcpII fragments in a range  
of E. coli expression strains (4.2.1.2.5). 
4.2.2.1.4. Overexpression trials of PcpII fragments 
          Screening for the optimal expression conditions was conducted using a variety  
of E. coli strains (4.2.1.2.5) at different growth temperatures and the process was 
monitored over a prolonged period of time. The results of the overexpression were 
determined using the SDS-PAGE technique with an 8% separating gel (2.8.2). 
Unfortunately none of the PcpII truncated variants was found to be expressed  
197 
 
in the soluble or insoluble fractions. Individual expression strains, which were used  
for the screening, are specifically designed to overcome potential problems associated 
with the synthesis of the human protein in the E.coli-based system, such as rare codon 
bias, insufficient disulfide formation, structural misfolding or protein toxicity for the 
host cell (4.2.1.2.5). PcpII is a large, multi-domain glycoprotein, therefore it seems to be 
understood that its production (even in a truncated version) as a correctly folded protein 
may be hindered by the inability of the E. coli cell-based expression system to provide 
the essential post-translational modifications. The unsuccessful result of these 
experiments led to the decision to attempt alternative protein production possibilities  
in more advanced eukaryotic systems, such as these utilizing insect or mammalian host 
cells, which could provide better conditions for PcpII expression (4.2.1.3). 
4.2.2.2. Cloning and expression of PcpII in insect and mammalian cells 
4.2.2.2.1. PCR amplification of PcpII fragments 
          The amplification of cDNA encoding all desired PcpII fragments (4.2.1.3.2) was 
successful and was confirmed by the 1% agarose gel electrophoresis. The bands 
corresponding to the representative inserts of the PcpIIFL, PcpII/S62-H1024 and 
PcpII/L141-H1024 can be observed at approx. 3000 bp, 2900 bp and 2700 bp, 
respectively (figure 4.5).  
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Figure 4.5. The result of the amplification of the representative PCR products. Each 
fragment was amplified using a different set of forward and reverse primers in order to 
facilitate cloning into the appropriate pOPIN-based vector (table 4.4). The individual 
lanes represent PCR inserts designed for different cloning constructs: 1 – 
PcpII/L141-H1024 (~2700 bp, OPPF No: 8981); 2,3 – PcpII/S62-H1024 (~2900 bp, 
OPPF No: 8979 and 8980, respectively) and 4 – PcpIIFL (~3000 bp, OPPF No: 7468); 
M – marker HyperladderI.  
4.2.2.2.2. Preparation of recombinant pOPIN/pcpII plasmid constructs 
          Successfully amplified cDNA fragments encoding PcpIIFL, PcpII/S62-H1024  
and PcpII/L141-H1024 proteins (4.2.2.2.1) were subjected to In-Fusion™ cloning as 
described in section 4.2.1.3.3. Each PCR product contained an additional 5′ and 3′ 
flanking sequence to enable the annealing with the homologous fragment of the target 
pOPIN-based vector (table 4.5). A range of created pOPIN/pcpII constructs underwent a 
successful PCR-based verification, which showed that all of them carried the desired 
insert. This was additionally confirmed by DNA sequencing. All recombinant 
constructs were further tested for protein expression in insect and mammalian cell lines. 
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4.2.2.2.3. Expression in insect cell lines 
          The screening utilizing the baculovirus-mediated expression vector system in Sf9  
and VE-Sf9 was conducted for three PcpII variants: PcpIIFL, PcpII/S62-H1024 and 
PcpII/L141-H1024 from the range of pOPIN-based constructs listed in table 4.8. 
CONSTRUCT OPPF NUMBER 
pOPINH/pcpII/L141-H1024 7210 
pOPING/pcpII/L141-H1024 7211 
pOPINTTG/pcpII/L141-H1024 7212 
pOPING/pcpII/S62-H1024 7465 
pOPINTTG/pcpII/S62-H1024 7466 
pOPINH/pcpII/S62-H1024 7467 
pOPINF/pcpII 7468 
pOPINI/pcpII 7469 
 
Table 4.8. List of recombinant constructs used for the screening expression conditions  
in the baculovirus-mediated insect cell system. 
 
          The total protein samples were evaluated by Western blotting technique 
employing an anti-His primary antibody (2.8.6). However, the result showed no 
detectable secreted, soluble or cell-associated expression for any of the above PcpII 
variants neither in the Sf9 nor VE-Sf9 tested host cell line. The VE-Sf9 is a genetically 
engineered version of the Sf9, which produces vankyrin displaying a positive influence 
on the cell longevity and the level of recombinant protein expression (Fath-Goodin et 
al., 2006).  
          There may be diverse reasons behind the lack of expression of neither of PcpII 
forms in baculovirus/insect cell system; however it is worth noting that only a selected 
range of the prepared pOPIN-based constructs was screened using this method. All of 
the tested constructs were designed to produce recombinant proteins with the N-
terminal signal sequence facilitating secretion into the growth media. The exemption are 
7468 (pOPINF/pcpII) and 7469 (pOPINH/pcpII) variants, which allow for the 
expression of the full-length PcpII with its native signal sequence. It is difficult to 
predict a result of the utilisation of an alternative vector or expression system. Many 
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proteins have been observed to be expressed and secreted at a comparable level in both 
insect and mammalian systems (Dr J.E. Nettleship, personal communication). 
Nonetheless, it would be advisable in this case to attempt PcpII expression, particularly 
of its truncated variants, using not tested pOPINH/pcpII variants as well as evaluate 
their effectiveness when in mammalian cell lines. Most of the created pOPIN-based 
vectors (table 4.5) do not incorporate the secretion leader and allow for synthesis of 
His-tagged protein remaining in the intracellular fraction. This may appear to be more 
suitable for finding the optimal conditions for the protein production. Another 
explanation of the problem may be the fact that human PcpII functions as  
a glycoprotein and the full-length form is thought to possesses 12 potential 
N-glycosylation sites (table 4.1) (Schmitmeier et al., 2002). There are reports indicating 
that insect cells lack several of the enzymes essential for synthesis of mammalian-type 
N-glycans (Yun et al., 2005; Harrison and Jarvis, 2006). Therefore it is possible that 
PcpII may not be properly N-glycosylated during post-translational processing, which 
may in turn affect its structural folding and stability or compromise its activity. Such a 
limitation of the insect cell system can be potentially considered as one of the reasons 
behind the unsuccessful PcpII expression.        
4.2.2.2.4. Expression in HEK 293T cells 
          The expression screening in HEK 293T cell line was conducted for a total of  
19 different pOPIN-based constructs carrying cDNA inserts encoding PcpIIFL, 
PcpII/S62-H1024 and PcpII/L141-H1024 which are listed in table 4.9. 
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CONSTRUCT OPPF NUMBER 
pOPINE/pcpII/S62-H1024 8979 
pOPINE/pcpII/L141-H1024 8981 
pOPINF/pcpII 7468 
pOPINF/pcpII/S62-H1024 8983 
pOPINF/pcpII/L141-H1024 9076 
pOPING/pcpII/S62-H1024 7465 
pOPING/pcpII/L141-H1024 7211 
pOPINH/pcpII/S62-H1024 7467 
pOPINH/pcpII/L141-H1024 7210 
pOPINI/pcpII 7469 
pOPINTTG/pcpII/S62-H1024 7466 
pOPINTTG/pcpII/L141-H1024 7212 
pOPINTTGNeo-3C-GFP-His/pcpII/S62-H1024 8984 
pOPINTTGNeo-3C-Halo7-His/pcpII/S62-H1024 8708 
pOPINTTGNeo-3C-CD4-His/pcpII/S62-H1024 8709 
pOPINE-3C-GFP-His/pcpII/S62-H1024 8980G 
pOPINE-3C-GFP-His/pcpII/L141-H1024 8982G 
pOPINE-3C-Halo7-His/pcpII/S62-H1024 8980 
pOPINE-3C-Halo7-His/pcpII/L141-H1024 8982 
 
Table 4.9. List of the recombinant constructs used for the screening of expression 
conditions in the mammalian cell system. 
 
          The results of the expression from screened constructs (table 4.8) in both secreted  
and intracellular fractions were verified using the SDS-PAGE and Western blotting  
as described in section 4.2.1.3.8 and are presented in figure 4.6. 
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Figure 4.6. The result of the expression screening of PcpII proteins in HEK 293T cells 
from a range of the pOPIN-based vectors. The SDS-PAGE and Western blotting 
analysis of the supernatant fractions with secreted proteins is shown and indicates the 
presence of secreted, His-tagged proteins expressed from constructs 8708, 8984 and 
7465. All of these constructs were designed to produce PcpII/S62-H1024 protein 
(approx. 109 kDa), which is a truncated version of PcpII without the transmembrane 
domain. The lanes are labelled with corresponding OPPF identifiers (table 4.8), control 
(positive) – control His-tagged protein and BM – BenchMarkTM His-tagged protein 
standard (2.8.2.3, Invitrogen). 
 
          Western blotting analysis of the supernatant fraction confirmed the presence of 
the His-tagged protein corresponding to the given constructs: 
8708 – pOPINTTGNeo-3C-Halo7-His/pcpII/S62-H1024 
8984 – pOPINTTGNeo-3C-GFP-His/pcpII/S62-H1024  
7465 –  pOPING/pcpII/S62-H1024 
          The staining related to 8984 and 7465 products is very faint and may be a sign of 
very low expression level. All of the above recombinant vectors were designed to allow 
synthesis of PcpII/S62-H1024 protein with a leader signal sequence and either an 
N-terminal (8708 and 8984) or C-terminal (7465) His-tag. Moreover, 8708 and 8984 
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allow for production of protein coupled with HaloTag or GFP, respectively. The former 
tag is a product of commercial technology, which was reported to facilitate effective 
purification even at low protein levels and, along with GFP, is widely used for 
verification of expression yield using fluorescent imaging, respectively (Ebe, 2007; Los 
and Wood, 2007). There was no detectable expression for any of the PcpII variants in 
the intracellular fraction. It must be noted that PcpII/S62-H1024 is a truncated version 
of PcpIIFL without its N-terminal part containing the transmembrane domain. It may be 
concluded that in this case the removal of the partially hydrophobic N-terminus could 
prevent global protein misfolding and thus promote protein stability and secretion. Such 
a deletion was reported to greatly improve secretion level of the N-terminally truncated 
human Fas ligand, which is a transmembrane glycoprotein, or increase surface 
expression of Parkin-associated endothelin-like receptor (Muraki, 2008; Dunham et al., 
2009). The successful production of PcpII/S62-H1024 from the 
pOPINTTGNeo-3C-Halo7-His/pcpII/S62-H1024, pOPING/pcpII/S62-H1024 and 
pOPINTTGNeo-3C-GFP-His/pcpII/S62-H1024 constructs in HEK 293T cells, although 
at a very low level, helped to establish preliminary conditions for the protein expression. 
This system however requires further optimisation in order to obtain higher amounts of 
active protein to conduct a structural study on human PcpII. 
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4.3. Homology modelling of human PcpII 
          Information on the three-dimensional structure of a protein is often essential to 
understand its function and interaction with other molecules as well as a prerequisite 
for rational drug design or site-directed mutagenesis. Many proteins fail to crystallize 
or cannot be produced in sufficient amounts to conduct a structural study using X-ray 
crystallography or NMR spectroscopy. In such cases homology model-building using 
bioinformatic tools and a solved protein structure of greater than 30% sequence 
identity as a model is an alternative and reliable method to obtain structural 
information (Krieger et al., 2003). Although this approach may not be as accurate as 
obtaining experimental data, it has proved to be useful to provide a preliminary 
structure of the growing number of the proteins identified in genomic sequencing.  
          Human PcpII belongs to the M1 family of Zn-dependent aminopeptidases 
(Rawlings et al., 2010). Although this group of enzymes plays an important role in  
a variety of the cellular and cell signalling pathways, their structural characteristics, 
related to the exopeptidase performance, remains poorly explored. Only 7 out of 55  
M1 metallopeptidases have solved protein structures including leukotriene A4 
hydrolase (Rudberg et al., 2004), alanyl aminopeptidase (Kochan et al., 2011), 
endoplasmic reticulum aminopeptidase 1 (ERAP1) (Ito et al., 2006) or tricorn 
interacting factor F3 (Rudberg et al., 2004; Kyrieleis et al., 2005; Ito et al., 2006; 
Kochan et al., 2011)All of them were observed to share a common three-domain 
protein (apart from the unique four-domain structure of tricorn interacting factor F3) 
architecture of a saddle-like N-terminal domain and thermolysin-like catalytic 
domain. The latter feature placed the M1 family in clan MA (Rawlings et al., 2010). 
PcpII seems to be a specific enzyme, as it exclusively releases the N-terminal pGlu 
group from TRH peptide, therefore it is the only ω-peptidase within the M1 family. 
Moreover, PcpII  and aminopeptidase N are both anchored in a cell membrane with 
an N-terminal cytoplasmic/transmembrane domain, and the bulk of the protein being 
localised in the extracellular space (Chavez-Gutierrez et al., 2006).  Ectoenzymes are 
also recognized as surface antigens, where for example aminopeptidase N functions 
as the myeloid leukaemia marker CD13 (Razak and Newland, 1992). 
          The protein sequence of human PcpII was used for homology modelling 
procedure in order to generate a three-dimensional model and perform docking 
simulations of TRH into the enzyme’s active site. 
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4.3.1. Materials and methods 
4.3.1.1. Search for a homologous PDB structure 
          The PcpII amino acid sequence was subjected to BLAST (Basic Local Alignment 
Search Tool, blast.ncbi.nlm.nih.gov) online homology search engine utilizing the blastp 
algorithm (BLOSUM62 matrix, gap penalties: existence 11 and extension 1) in order to 
find similar proteins with solved PDB structure. Predictions of structural domains and 
search for conserved regions were conducted using online servers for the purpose of the 
protein expression study as described in section 4.2.1.1. 
4.3.1.2. Modelling of the PcpII catalytic domain 
          The three-dimensional model building was conducted using MOE
TM
 molecular 
modelling tool (Chemical Computing Group). The PcpII query sequence (appendix 
VIII) was aligned with the human endoplasmic reticulum aminopeptidase 1 (ERAP1) 
sequence and subsequently it was modelled on this template. The preliminary backbone 
generation resulted in 100 intermediate models, which were evaluated using the in-built 
residue packing quality function. The best-scored intermediate model was subjected to 
energy minimization using the Amber99 force field within 9 Å radius from the central 
Zn atom and until a 0.01 RMS gradient. The zinc ion was manually added to the model 
using coordinates from the ERAP1 template. The backbone beyond 9 Å radius was 
fixed. In order to understand the structural basis of TRH recognition by the enzyme, the 
docking simulation in the PcpII active site was conducted. The hormone structure was 
created using the MOE
TM
 molecular builder application and the Monte Carlo docking 
simulation method was applied yielding 150 intermediate models. Next, the energy of 
the best ranked PcpII-TRH complex was minimized using the MMFF94X force field 
and evaluated with the Affinity dG scoring algorithm, whereas hydrogen-bonding 
energy was refined using the LigX application. The quality of the PcpII homology 
model was assessed with Ramachandran plot generated in MOE
TM
 and the RAMPAGE 
server (Lovell et al., 2003). 
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4.3.2. Results and discussion 
4.3.2.1. Search for a homologous PDB structure 
          The BLAST search of the PcpII amino acid sequence against the PDB database 
returned the group of enzymes belonging to the M1 family of metallopeptidases.  
The structures with the top scoring are presented in table 4.10. 
PROTEIN PDB ID REFERENCE 
human ERAP1 
(soluble domain) 
2XDT (Kochan et al., 2011) 
Thermoplasma acidophilum  
Tricorn protease-interacting factor F3 
3Q7J (Kyrieleis et al., 2005) 
Colwellia psychrerythraea 
Cold-active aminopeptidase 
3CIA (Bauvois et al., 2008) 
human  
Leukotriene A4 hydrolase (LTA4H) 
3CHO (Kirkland et al., 2008) 
Escherichia coli 
Aminopeptidase N  
2HPO (Addlagatta et al., 2006) 
Plasmodium falciparum 
M1 neutral aminopeptidase 
3EBG (McGowan et al., 2009) 
 
Table 4.10. List of the PDB structures of the proteins displaying the highest homology 
to human PcpII returned during the BLAST search against PDB database. 
 
          The sequential alignment of the above proteins and human PcpII was conducted 
to study the conservation level within this M1 family representatives. Surprisingly, none 
of the aligned sequences covered the N-terminal domain of PcpII, therefore it was 
decided to conduct the modelling of the most conserved central catalytic region (L141-
M541). The alignment of the sequences of human ERAP1 soluble domain with 
PcpII/L141-M541 revealed their 98% coverage as well as 40% identity and 56% 
similarity. Therefore ERAP1 structure (2XDT) was used as a template to generate three-
dimensional model of the catalytic domain of PcpII. 
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4.3.2.2. PcpII catalytic domain model 
          Three-dimensional model of the PcpII catalytic domain was constructed using  
a structure of the soluble domain of human ERAP1 (2XDT) as a template for homology 
modelling. The ERAP1, similarly to human PcpII, belongs to the gluzincin family of 
zinc-dependent metalloproteases sharing the consensus HEXXHX18E motif (Kochan et 
al., 2011). It acts as a multi-functional enzyme participating in maturation of a variety 
of antigenic peptides from N-terminally extended peptide precursors necessary for 
presentation by the class I major histocompatibility complex (MHC). Contrary to PcpII, 
this peptidase exhibits wider substrate specificity dictated, surprisingly by strong 
preferences to positively charged internal residues rather than to peptide N- or  
C-termini, due to large active site cavity, which carries a strong negative electrostatic 
potential  (Evnouchidou et al., 2008).   
          The L141-M541 residues used  for this procedure, were shown to be conserved in 
protein members of M1 family of peptidases as was revealed in a result of the search 
against the Pfam collection (Rawlings and Barrett, 1995). It is worth noting that the 
BLAST search of the sole N-terminal cytoplasmic/transmembrane domain did not 
return any homologous proteins or protein fragments that may suggest that this part is 
unique for human PcpII. The overlay of the model and template Cα backbones is 
presented in figure 4.7 with a RMSD of 1.33 Å. The catalytic domain is composed of an 
α-helical region and a β-sheet region, which forms a narrow but solvent accessible 
active site containing a zinc atom. In the model, active site triad of His440, His444 and 
Glu463 (PcpII numbering) superimpose relatively well with the corresponding residues 
in the template as was shown in figure 4.8. Within a consensus HEXXHX18E motif 
most of the residues were highly conserved between the query and subject sequence and 
only 5 residues showed lack of similarity. A Ramachandran plot for the model was 
generated at 2 Å (appendix XIII) with a calculation of 84.5% of residues being in 
favoured and 14.0% in allowed regions. This would suggest relatively good quality of 
the homology model of PcpII catalytic domain. 
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Figure 4.7. A superposition of the Cα backbones of ERAP1 template (white) and PcpII 
model (green). The catalytic zinc atom is shown as a grey sphere. The organization of 
the catalytic domain relies on the two α-helical (left) and β-sheet (right) regions, which 
form the active site of the enzyme. 
 
 
Figure 4.8. A superposition of the active site residues of ERAP1 (purple) and PcpII 
model (green). The residues superimposed at RMSD 1.33 Å and are labelled according 
to the human PcpII numbering and two spheres in the centre represent the catalytic zinc 
atoms. 
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4.3.2.3. Docking of TRH in PcpII active site 
          The TRH docking simulations were performed with generation of 150 potential 
arrangements in the active site. The analysis of the obtained variants of the peptide 
positioning, which were also supported by the knowledge about the catalytically 
important residues gained from previous study on human PcpII, helped to identify the 
most probable substrate binding mode (Papadopoulos et al., 2001; Chavez-Gutierrez et 
al., 2006). The two-dimensional depiction of the docked TRH conformation in the 
active site moiety was generated in MOE
TM
 and is shown in figure 4.9. This helped to 
identify some of the surrounding, potentially important residues in a corresponding 3D 
representation (figure 4.10). 
 
Figure 4.9. The two-dimensional depiction of the docked TRH conformation within the 
human PcpII active site. The residues that were found in close proximity to the peptide 
are presented (numbering was shifted according to their position in PcpII/L141-M541 
sequence). It is worth noting that carbonyl group of the N-terminal pGlu interacts with 
the catalytic Zn atom, where the distance was calculated for 2.5 Å. Two aromatic 
residues, Tyr263 (Tyr403 in full-length PcpII) and Phe382 (Phe522) are shown to be 
involved in hydrogen bonding with the pGlu moiety and possibly may orientate it to 
facilitate the interaction with catalytic Zn and active site triad. 
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Figure 4.10. Two views of the TRH peptide docked into the active site of the human 
PcpII model. The TRH structure is presented in white with red oxygen and blue 
nitrogen atoms, whereas the zinc ion is shown as a grey sphere. Important amino acid 
residues lining the active site are displayed and coloured (numbering as in full-length 
PcpII sequence). The pyrrolidone ring of TRH and the benzene rings of Tyr403 and Phe 
522 are organised in stacked parallel fashion (A) and Lys462 creates a salt bridge with 
Glu407 of 2.8 Å (B). 
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          The active site moiety of the PcpII catalytic domain model was seen to be created 
by three α-helices and two loops, which carry the residues of the HEXXHX18E motif 
participating in zinc-binding, such as His440, Glu441, His444, Glu463 or Tyr527 
residue known to be involved in a stabilisation of the substrate. The interesting parallel 
organisation of the Tyr403 and Phe 522 aliphatic side chains with the N-terminal 
pyrrolidone ring stacked in between is probably necessary for the proper orientation of 
the pGlu. The distance of pGlu from both residues was calculated to be are around 
4.5 Å and it can form strong hydrogen bonds as shown in figure 4.9. The pyrrolidone 
carbonyl group interacts with catalytic zinc atom at 2.5 Å distance and can create a 
hydrogen bond with the hydroxyl group of Ser268 that was suggested in previous rat 
PcpII modelling study (Chavez-Gutierrez et al., 2006). This serine residue is also 
thought to be involved in the recognition of the pGlu of TRH. Similar hydrogen 
bonding occurs between a TRH histidine and Tyr527 as well as TRH proline and 
Asp519 (figure 4.10). Both of these interactions probably have a substrate stabilising 
function and are necessary for proper orientation of the rest of TRH in relation to the 
catalytic triad of PcpII. In the modelled PcpII active site the carboxylate group of 
Glu407 forms a strong salt bridge interaction with the amine group of Lys462 at a 2.8 Å 
distance. A similar observation was made for the homology model of the rat PcpII, 
which was generated using LTA4H as a template, however at around 3.1 Å distance 
(Chavez-Gutierrez et al., 2006).  
          The position of the human PcpII active site was seen to be buried but allowing an 
accessible channel suitable to accommodate a TRH molecule (figure 4.11). 
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Figure 4.11. The surface presentation of the PcpII active site pocket with the 
accommodated TRH molecule. The TRH is shown in a stick mode and the zinc ion as 
grey sphere. 
 
          The generation of the human PcpII catalytic domain model has enabled a closer 
insight into the structure of this protein domain. Additional docking studies have helped 
to identify catalytically important residues and suggest the interaction involved in 
substrate binding and recognition. Structural information gained from the homology 
model could prove useful in design of further experimental work on PcpII including 
site-directed mutagenesis and identification of potential enzyme inhibitors. This may 
also have further implications for the comparative study of the functional and 
physiological properties of the other enzymes from the M1 metallopeptidase family.  
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Chapter 5 – Study on the role of pyroglutamyl 
peptidases in Alzheimer’s disease pathology 
 
5.1. Pyroglutamyl modifications in AD pathology 
          The association of the pGlu-modified Aβ peptides with AD aetiology has been 
intensively studied since the observation of their abundant deposition in amyloid 
plaques found in the diseased brain tissues (He and Barrow, 1999; Larner, 1999).  
A proteolytic truncation and modification of APP precursor yielding various Aβ 
derivatives commonly occurs under physiological conditions and was described in 
detail in section 1.1.3. The pGlu cap is known to play a protective role against the 
degradation by most of the proteases in the body. The enzymes, QC and Pcp, are 
directly involved in the processing of the N-terminal pGlu residue in peptides and 
proteins (1.1.3). The former enzyme is able to convert N-terminal glutamic acid or  
a glutamine residue to pGlu, which can be later exclusively removed by the latter 
peptidase, which is often an introduction to proteolytic catabolism of a given substrate. 
An excessive formation of a range of pGlu-modified Aβs, namely AβpGlu(3-40/42) and 
AβpGlu(11-40/42), may therefore imply possible imbalance between QC and Pcp 
activities as one of the reasons associated with the development of AD. There are, 
however, only a few reports published so far which could support this implication. The 
involvement of QC was already confirmed to be of importance, after a series of 
observations of a significantly suppressed AβpGlu(3-40/42) formation in transgenic 
mouse and rat models, which were treated with the inhibitors of the enzyme (Cynis et 
al., 2006; Schilling et al., 2008a; Schilling et al., 2008b). Moreover, the analysis of the 
QC distribution in transgenic mice hippocampus indicated that the enzyme contributes 
to the formation of both focal and diffuse (soluble) pGlu-Aβ derivatives (Hartlage-
Rubsamen et al., 2011). These findings have come into focus as a new potential 
therapeutic option for AD treatment. On the contrary to QC, the role of the Pcp enzymes 
remains to be investigated and, as yet, there are no published studies regarding the 
relationship between the activity of these peptidases and the accumulation of pGlu-Aβ 
peptides in the diseased tissues. This chapter presents experimental work on the human 
PcpI and PcpII enzymes and their potential involvement in Alzheimer’s pathology.  
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This includes immunohistochemical staining of the AD and control brain tissues as well 
as qualitative assessment of the processing of pGlu-Aβ peptides by the human PcpI.  
5.2. Immunostaining of AD brain tissue sections 
5.2.1. Introduction to immunohistochemistry 
          The beginning of immunohistochemistry (IHC) is linked with the first report on 
the fluorescent-based detection of the specific cellular components in analysed tissue 
material (Coons et al., 1941). Over the last decades IHC has become a routine research 
and diagnostic tool, which bridges immunological, histological and chemical 
disciplines. The principle of this technique is the identification of target antigen using 
specific antibody, which is suitably labelled with a reporter molecule to facilitate its 
visualisation. This further helps to determine the distribution and localization of the 
desired components in the cellular or tissue context and to compare it with a control 
material. Nowadays, IHC methods are widely applied in detection of the physiological 
disease markers or in drug development to investigate drug effectiveness on the target 
disorder.  
          The development of immunohistochemical methods generally aims to improve 
sensitivity and specificity of the detection of target antigens. In order to meet these 
requirements, different aspects of the IHC are constantly being improved and mainly 
consider the methods of sample preparation, antigen retrieval or production of specific 
antibodies and their effective labelling.  
           Antibodies are the Y-shaped immunoglobulin (Ig) proteins consisting of two 
identical light chains and two identical heavy chains. The heavy chains are different and 
can be divided into a few subtypes, which determine the class of the antibodies  
(Polak and Van Noorden, 2003). The arm of the molecule, which contains variable and 
constant fragments belonging to both chains, is known as Fab (fragment antigen-
binding) region and participates in binding to an appropriate antigen (protein, peptides, 
nucleic acids, carbohydrates etc.). There has been a successful trend to employ the Fab 
fragment only for IHC experiments, however the remaining portion of Ig, known  
as Fc (fragment constant), is required for interaction with other (secondary) antibodies, 
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which is a principle of the multistep staining procedure. The Fc was also found to 
stabilise the overall binding of the molecule to solid substrates such as tissue material 
(Ramos-Vara, 2005). The antibody is designed to specifically recognise and bind to the 
unique site of the antigen called epitope, which is usually 5-21 aa long (Roitt and 
Delves, 2001). The production of a desired antibody is based on the immunization of 
animals triggered by the introduction of a specific antigen. There are two types of 
commercially available antibodies, monoclonal and polyclonal. Monoclonal antibodies 
are obtained by fusing the immortal myeloma cells with lymphocytes raised against 
desired antigen. The lymphocytes are isolated from a single animal source (mostly 
mice) which had been earlier immunised with that antigen. The fusion results in 
creation of hybrydoma (hybrid myeloma) cells that produce desired immunoglobulin. 
Monoclonal antibodies display much higher specificity when compared to those of 
polyclonal origin, which are produced in multiple species such as rabbit, goat, horse and 
chicken (Roitt and Delves, 2001). Polyclonal antibodies have the advantage for the 
potential recognition of different isoforms of a given epitope, but at the same time they 
may bind to unspecific molecules, which could generate undesired background staining. 
Therefore the choice between both variants depends on the purpose of their application 
and desired specificity of the interaction with the target antigen.  
          The proper interaction between the antibody and the antigen absolutely requires 
the latter one to maintain its tertiary structure. However, normal cell morphology, tissue 
architecture and the conformation of target epitopes can be compromised by an 
improper fixation of the sample material to be analysed. Fixation of tissues is necessary 
in order to preserve the cellular components and prevent them from disintegration prior 
to subsequent procedures (Ramos-Vara, 2005). The most common fixative is 
formaldehyde, mainly due to its reliability and low cost, and despite of its potential 
influence on the conformation of proteins or interaction with nucleic acids, which may 
significantly affect their antigenic properties. Sometimes the compromised antigenicity 
can be restored through a range of antigen retrieval methods, e.g. proteolytic digestion, 
heat or chemical treatment (Ramos-Vara, 2005). Nonetheless, this aspect of IHC is 
considered as one of the most challenging and it requires a precise optimisation of the 
fixation conditions for every individual specimen. In order to maintain a rigid structure 
of the fixed material and to enable its long-term storage, it is embedded in a support 
medium such as paraffin wax. Alternatively, if given tissue is too sensitive for  
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de-waxing reagents, it can be covered with cryo-embedding media and then flash-frozen 
in liquid nitrogen. 
          The interaction of an antigen with antibody can be detected using a conjugated 
fluorochrome, enzyme reaction, radioactive element or colloidal gold and documented 
using light and electron microscopy or autoradiography techniques (Polak and Van 
Noorden, 2003). The detection system can be direct, which means that the primary 
antibody is labelled and the reaction can be relatively quick. An alternative method is 
indirect, more time-consuming and is generally suitable for more sensitive detection. It 
is a two-step procedure, where the target epitope is bound by a primary native antibody 
(first layer) being itself an antigen for a secondary antibody (second layer), which is 
conjugated with a desired reporter agent. The most commonly employed detection 
systems are based on enzyme activities, such as peroxidase, alkaline phosphatase or 
glucose oxidase, which catalyse the formation of a coloured or fluorescent product 
visible under a light microscope or UV light (Davey and Busch, 1970). Alternatively, 
the antibody can be tagged with a fluorochrome, such as fluorescein or rhodamine, and 
its localisation can be detected by UV light (Haaijman et al., 1986). The choice of the 
best detection method to use is related to the expression and availability of the target 
antigen and the desired amplification of the signal.  
          The obtaining of the satisfactory results using IHC method sometimes may be 
difficult and can be achieved by the optimal combination of a variety of factors such as 
the preparation and treatment of tissue sample to be analysed, selection of antibodies 
and the detection system.  
           This part of the experimental work involving immunostaining of human PcpI and 
PcpII in the AD and control brain cortex tissue sections was entirely conducted in the 
Peninsula Medical School (PMS, Exeter).  
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5.2.2. Materials and methods 
5.2.2.1. AD brain tissue sections 
          The frozen tissue sections of the post mortem superior temporal gyrus of the 
temporal cortex were acquired from the London Brain Bank for Neurodegenerative 
Diseases, the Newcastle Brain Tissue Resource and the Manchester Brain Bank.  
The control samples came from 10 different subjects (5 male and 5 female) with the age 
range of 54 to 95 years and post mortem delay range of 17 to 50 h. The specification of 
the sporadic and familial AD tissue samples is presented in table 5.1. 
          The tissue samples had been cryogenically frozen in liquid nitrogen, cut into  
10 µm sections and mounted (two sections per slide) onto SuperFrost Ultra Plus® 
adhesive slides (VWR). The sections were kept at -80ºC until use.  
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Autopsy 
Number 
Age Sex 
PMD 
(h) 
PATHOLOGICAL DIAGNOSIS 
Sporadic AD 
A108/09 84 F 24 
AD BNE Braak stage IV (Limbic stage AD)  
with focal amyloid angiopathy 
A087/09 82 M 20 AD Braak stage VI  BNE 5 
A062/09 94 M 40 
AD Braak/HP-tau stage V  
with mild amyloid angiopathy 
A061/09 103 F 12 
AD modified Braak stage V  
with mild focal amyloid angiopathy 
A052/09 84 M 33 
AD modified Braak stage V 
with early amyloid angiopathy  
A050/09 81 F 21 
AD BNE modified Braak stage VI with focal 
amyloid angiopathy & localised limbic pathology 
A031/09 80 M 15 AD Braak stage VI 
A034/08 74 M 51 AD Braak stage VI with mild amyloid angiopathy 
A332/07 87 F 48 
AD Braak stage VI with moderate amyloid 
angiopathy 
A331/07 80 F 13 AD Braak stage V with mild amyloid angiopathy 
Familial AD 
A211/95 61 M 15 FAD APP(Val717Gly) 
A238/96 69 F 10 FAD APP(Val717Ile) 
A051/97 62 F 23 FAD APP(Val717Ile) 
A029/98 42 M 6 FAD PSEN1(delta 4) 
A188/98 72 F 3 FAD APP(Val717Ile) 
A148/99 65 F 22 FAD PSEN1(Glu280Gly) 
N79/95 41 F 63 FAD PSEN1(Thr113-114ins) 
N46/93 64 M 24 FAD PSEN1(Ala246Glu) 
N5/93 46 M 24 FAD PSEN1(Thr113-114ins) 
M 04/13 63 M 11 FAD APP(Gly692Ala) 
M 99/06 57 F 48 FAD PSEN1(Met139Val) 
Table 5.1. List of AD tissue samples used for immunostaining. PMD column contains 
post mortem delay time of sample collection, BNE – BrainNet Europe,  
HP-tau – hyperphosphorylated tau, APP – amyloid precursor protein, PSEN1 – 
presenilin1. 
5.2.2.2. Staining of PcpI and PcpII 
          The immunohistochemical staining of human PcpI and PcpII was performed 
according to a modified method by (Gutowski et al., 1999). The procedure was carried 
out using Vectastain Elite ABC kits (Vector Laboratories) with an anti-rabbit secondary 
antibody for PcpI and an anti-goat secondary antibody for PcpII staining. For the 
experiment, one slide with two sections was used from each control and AD specimen. 
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All samples were thawed at room temperature, fixed in acetone for 10 min at 4C and 
next they were washed 2x 5 min in freshly prepared PBS buffer (2.3.6). Appropriate 
blocking serum (Elite ABC kits) was diluted 1:40 in PBS and 75 μl was placed on each 
section. This was incubated for 30 min at room temperature. The primary antibody 
solution for PcpI (polyclonal rabbit Anti-PGPEP1 (Sigma-Aldrich)) was prepared at the 
dilution of 1:40 and 1:100 in PBS. Concurrently, the primary antibody solution for 
PcpII (polyclonal goat TRH-DE (K-15 (Santa Cruz Biotechnology)) was prepared at the 
dilution of 1:50, 1:100 and 1:200 in PBS. In sections destined for a negative control 
(A149/01, table 5.1), the treatment with primary antibodies was replaced by the addition 
of PBS. Next, 75 μl of each primary antibody dilution was applied to the appropriate 
sections and incubated for 45 min at room temperature. All slides were subsequently 
washed with PBS (3x 5 min) and then treated with 75 μl of the appropriate biotinylated 
secondary antibody (Elite ABC kits), which was previously diluted 1:200 in PBS.  
This was further incubated for 30 min at room temperature and then washed again with 
PBS (3x 5 min). The A (avidin) and B (biotinylated peroxidase) solutions (Elite ABC 
kits) were 1:100 diluted and mixed in PBS, and then 75 μl of the mixture was applied to 
each section,  which was followed by 45 min incubation at room temperature and  
3x 5 min PBS wash. The slides were placed under a fume hood in a solution of PBS 
containing 0.05% (w/v) 3,3′-diaminobenzidine tetrahydrochloride (DAB), 0.04% (w/v) 
NiCl2 and 0.04% (v/v) H2O2 and kept for 5 min to develop a black staining.  
Such colouration is a result of the activity of peroxidase, which in the presence of H2O2 
catalyses the oxidation of the DAB substrate to an intense brown precipitated product, 
which by addition of NiCl2 changes the colour to black or blue black (Hsu and Soban, 
1982). The sections were washed in running water and gradually dehydrated by the 
multi-step immersing in industrial methylated spirit and xylene. Next, all slides were 
mounted using DPX (dibutyl phthalate xylene, Sigma-Aldrich) and left overnight to dry. 
The results of the staining were visualised under Olympus BX60 light microscope and 
documented using mounted digital camera (Nikon). 
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5.2.2.3. Co-staining of PcpI and PcpII with Aβs or neurofilaments 
          The double staining of the control and AD sections from each case was performed 
in two stages. First all sections were subjected to the staining with primary antibodies of 
PcpI or PcpII at the dilutions of 1:100 or 1:50, respectively. Negative control slides 
(A149/01, table 5.1) were consequently prepared by replacement of the primary 
antibody solutions with PBS. The immunostaining procedure was the same as described 
in section 5.2.2.2, with exception of the final step, where NiCl2 was omitted in the 
staining solution to enable a development of the brown colouration. The second staining 
was conducted as described in 5.2.2.2 with the primary antibodies for neurofilaments 
(polyclonal rabbit anti-neurofilament 200 (Sigma-Aldrich)) or Aβ (polyclonal rabbit 
anti-Aβ(22-35)) being separately applied at the dilutions of 1:150 both. This was 
conducted in such a way that one section from each slide pretreated with either anti-
PcpI or anti-PcpII antibody was subjected to anti-Aβ staining and the other one to anti-
neurofilament staining. The Vectastain Elite ABC kit (Vector Laboratories) with anti-
rabbit secondary antibody was utilised in conjugation with the above primary 
antibodies. In this step the colour development was performed using the Vector
®
 VIP 
Peroxidase Substrate kit (Vector Laboratories) according to the manufacturer’s 
instructions. The peroxidase reaction produces an intense, pink/purple precipitate. The 
slides were washed under running water, dehydrated and mounted as in 5.2.2.2.  The 
results of the staining were visualised under an Olympus BX60 light microscope and 
documented using a mounted digital camera (Nikon). 
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5.2.3. Results and discussion 
5.2.3.1. Comparison of PcpI and PcpII level in control and diseased sections 
          The comparison of the individual sections treated with a range of diluted 
solutions of primary antibodies (5.2.2.2), indicated that the optimal detection was 
achieved for dilutions 1:40 for PcpI and 1:50 for PcpII immunostaining. Negative 
control sections of the A149/01 specimen (normal adult brain), which were treated 
solely with the appropriate secondary antibodies, showed very pale, negligible 
background staining (figure 5.1). This may indicate rather high specificity of the applied 
primary anti-PcpI and anti-PcpII antibodies.  
 
   Figure 5.1. Negative control sections for PcpI (left) and PcpII (right) immunostaining.     
 
 
          The immunostaining results for all AD cases obtained for both PcpI and PcpII, 
were compared with the corresponding control normal adult brain sections.  
Representative results for the control A149/01 (normal adult brain) and sporadic AD 
A332/07 (Braak stage VI with moderate amyloid angiopathy) samples are presented in 
figures 5.2 (PcpI) and 5.3 (PcpII).  
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Figure 5.2. Comparison of the immunostaining results of PcpI in control (A) and 
sporadic AD (B and C) cortical tissue sections. Magnification of each picture is shown 
in its heading. Black colouration, marked with white arrows, indicates localisation of 
PcpI and white rectangle in picture B demonstrates a magnified area, which was shown 
in picture C.  
 
          The detection of PcpI antigen can be observed in both the control and AD tissue 
section (figure 5.2). In the diseased sample the staining is much stronger and 
focused that indicates an increased level of the protein when compared to normal brain. 
There is a noticeable difference between a texture of control and diseased sections, with 
the latter one being significantly disintegrated. This was seen in all of the tested samples 
and may be explained by the profound tissue loss and general brain shrinkage 
commonly observed in AD (1.1.2.1). For the case of normal brain sections the natural 
tissue loss may have also occurred due to the age of the patient (95 years, male) or this 
may be due to potential damage made during sample preparation. At this stage it may be 
difficult to associate the up-regulated PcpI synthesis with any particular cell activity. 
However, the amorphous shape of the colouration (figure 5.2, picture C) and a relatively 
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high number of the diffused clusters in the AD tissue may suggest that the peptidase can 
be overexpressed in activated microglial cells. Microglia are resident phagocytic cells 
acting in all tissues of the CNS, which provide early defence against a variety of the 
infectious agents (Graeber and Streit, 1990). They account for around 5% of the total 
cerebral cortex cell population and play a variety of physiological roles (Lawson et al., 
1990). In the normal state microglial secretory proteases participate in processes such as 
the regulation of neuronal growth, neuronal function and regenerative stages of the CNS 
(Kohsaka et al., 1996). Upon injury, inflammatory activation of microglia induces 
production and secretion of a number of proteolytic enzymes involved in the 
degradation of extracellular matrix, damaged neuronal cells, toxic deposits, etc. 
Chronically activated microglial cells are common in progressive neurodegenerative 
disorders including AD and are known to be involved in amyloid uptake from the 
immediate environment and its proteolytic clearance (Rogers et al., 2002). Moreover, 
the microglia activation in Alzheimer’s pathology is associated with an increased level 
of numerous proteases such as neprilysin, insulin-degrading enzyme, cathepsin B or 
matrix metalloproteinases MMP-1 and MMP-3 (Wood, 2003; De Strooper, 2010).  
          There are few reports determining a potential influence of PcpI in AD 
pathogenesis and development. One of the studies, regarding this matter, resulted in the 
observation that the oral administration of rivastigmine up-regulates basal and 
potassium ion-stimulated Pcp activity by 18% in the frontal cortex of transgenic mice 
(Ramirez-Exposito et al., 2001). This drug is an acetylcholinesterase inhibitor widely 
used for AD treatment, but a relationship between both enzymes remains unclear.  
In turn comparative analysis of the alanyl, arginyl, pyroglutamyl and leucyl peptidase 
activity in the cerebral cortex of the AD and normal brain did not confirm their 
association with the characteristic changes of the pathology (Mantle et al., 1989). 
However, the observation of a prominent elevation of PcpI synthesis in AD tissue 
(figure 5.2) and the fact that N-terminal pGlu-modified molecules cannot be degraded 
by any other enzyme, may imply that the peptidase indeed is necessary for the clearance 
of the biological material affected by the neurodegeneration. This question is 
particularly interesting since the substantial group of Aβ species found in AD is 
represented by AβpGlu(3-40/42) and AβpGlu(11-40/42) peptides (1.1.3.3), therefore 
their uptake and degradation by microglia would require Pcp activity. An expression 
level of the enzyme could be determined by the co-staining of PcpI and microglia 
antigens and a subsequent comparative analysis of control and diseased tissues. 
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Figure 5.3. Comparison of the immunostaining results of PcpII in control (A) and 
sporadic AD (B, C and D) cortical tissue sections. Magnification of each picture is 
shown in its heading. Black colouration, marked with white arrows, indicates 
localisation of PcpII, bv stands for blood vessel and white rectangle in picture B 
demonstrates magnified area, which was shown in picture D.  
 
 
          Immunostaining of PcpII (figure 5.3) showed slightly higher level of the protein 
in AD sections than in control, but the accurate comparative analysis is hindered by the 
background staining in the latter one. The increase in PcpII amount seems to be lower to 
than that observed for PcpI. Both control and diseased sections came from the same 
samples as those used for PcpI staining, hence there is similar tissue disintegration.  
The localisation of PcpII is also focused and may reflect the position of neuronal cell 
bodies (visible in horizontal and cross section in picture C) as presented sections 
demonstrate the area of the grey matter. The report by Cruz and co-workers showed that 
PcpII is predominantly localized in neuronal cells, which is consistent with its role in 
TRH-mediated synaptic transmission (Cruz et al., 1991). Moreover, the same study 
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confirmed that glial cell cultures display PcpI but not PcpII activity. There are no 
reports regarding PcpII status in AD, apart from the study indicating the trhde gene, 
encoding PcpII, as being one of a number of genes up-regulated in human 
neuroblastoma cultured cells exposed to a toxic Aβ(1-42)-Aluminium complex (Gatta et 
al., 2011). The direct physiological consequences of this up-regulation for AD 
pathogenesis remain unclear, however the authors pointed to the fact that key protein 
activities affected by the above complex are linked either to regulation of neuronal 
apoptosis or to maintenance of the structural and functional integrity of synapses.  
Due to the fact that neurons undergo progressive deterioration during AD development, 
it would be advisable to conduct co-staining of PcpII and hyperphosphorylated tau or 
the antigens associated with neuroapoptosis. The comparative analysis with a normal 
tissue could, for example, help to determine if PcpII synthesis becomes up-regulated in 
normal or compromised neuronal cells. 
5.2.3.2. Immunostaining of PcpI and PcpII with Aβs or neurofilaments 
          The double-staining experiment was conducted in order to investigate the 
localisation and distribution of both PcpI and PcpII in relation to potential amyloid 
deposits, which are the key hallmarks of AD. The results showing co-staining of human 
PcpI and Aβ or neurofilaments are presented in figure 5.4. Consequently, the results 
showing co-staining of human PcpII and Aβ or neurofilaments are presented in figure 
5.5. The representative sections of the A136/01 specimen of a normal adult brain with 
amyloid angiopathy (age 89, female) were used as the control. The staining of the 
A238/96 specimen from the familial AD case with APP Val717Ile mutation was shown 
as an exemplary result. 
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Figure 5.4. Double-immunostaining results of PcpI with Aβs (A – control, B and C – 
familial AD) and PcpI with neurofilaments (Nfil) (D – control, E and F – familial AD) 
in the cortical tissue sections. Magnification of each picture is shown in its heading. 
Dark brown or black colouration indicates localisation of PcpI and purple staining 
indicates localisation of Aβs or neurofilaments, respectively. White arrows point to the 
areas of the intense stainings, suggesting potential co-localisation of PcpI with either 
Aβs or neurofilaments, whereas arrows marked as bv or n point to blood vessel or 
neurites, respectively.  
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          The results presented for both PcpI and PcpII IHC experiments were difficult to 
analyse due to a strong background colouration obtained from second staining step 
using Vector
®
 VIP Peroxidase Substrate kit (Vector Laboratories) (5.2.2.3). 
Nonetheless, it was possible to detect areas of more intense colour related to PcpI (dark 
brown/black) and Aβ (purple, figure 5.4 A,B,C) or neurofilaments (purple, figure 5.4 
D,E,F).  
The staining of the control section with anti-PcpI and anti-Aβ antibodies revealed  
a presence of the cross-sections of two blood vessels (figure 5.4/A) with visible vascular 
amyloid deposits. This finding agrees with the characteristics of the sample, which was 
taken from a normal brain with amyloid angiopathy. Black stains around the vessels 
may also indicate a strong accumulation of PcpI, which seems to be interesting as the 
studies show that AβpGlu(3-40) accounts for around 11% of total vascular amyloid 
(Kuo et al., 1997; Harigaya et al., 2000). This may suggest a potential up-regulation  
of the peptidase in order to counteract the deposition of these highly hydrophobic 
species. The staining also revealed significant tissue shrinkage in AD sections and  
a presence of clusters detecting PcpI and Aβ (figure 5.4 B,C) or PcpI and neurofilament 
(figure 5.4 E,F) antigens. As it was mentioned above (5.2.3.1), PcpI could be possibly 
localised in microglia, since this type of cell becomes activated during 
neurodegenerative diseases mainly through increased synthesis of the proteolytic 
enzymes. Numerous studies showed that reactive microglia can be embedded in the core 
of senile plaques and that amyloid deposition may precede the activation of these cells 
(reviewed in (Lee and Landreth, 2010). Senile plaques are lesions preferentially found 
in grey matter and are key hallmarks associated with dementia by Alzheimer 
(Alzheimer, 1907). They are primarily composed of an Aβ core, associated molecules, 
dystrophic neuronal processes and reactive microglia (Dickson, 1997). The co-
localisation of PcpI with both Aβs and neurofilaments may indicate their presence 
within senile plaques as it can be seen in pictures C and F, respectively. The elevated 
levels and deposition of pGlu-modified Aβs in AD may suggest an imbalance between 
production and catabolism of the peptides, which could be a result of inactivation or 
decreased production of the pGlu-removing activity. Surprisingly, the results obtained 
for immunostaining of PcpI showed that this level is increased when compared to the 
level in control tissues. Up-regulation of PcpI in diseased brain may indicate its 
essential participation in microglia-mediated clearance of neurodegenerative damage. 
Moreover, the ability of the enzyme to degrade AβpGlu(3-40/42) or AβpGlu(11-40/42) 
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peptides (1.1.3.3) is worth investigating as it could verify its effectiveness as a tool in 
AD treatment strategy.  
 
Figure 5.5. Double-immunostaining results of PcpII with Aβs (A – control, B and C – 
familial AD) and PcpII with neurofilaments (Nfil) (D – control, E and F – familial AD) 
in the cortical tissue sections. Magnification of each picture is shown in its heading. 
Dark brown or black colouration indicates localisation of PcpII and purple staining 
indicates localisation of Aβs or neurofilaments, respectively. White arrows point to the 
areas of the intense stainings, suggesting potential co-localisation of PcpII with either 
Aβs or neurofilaments; n stands for neurites.  
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        The PcpII (dark brown or black) IHC co-staining results obtained for control 
sections for either Aβ (purple, figure 5.5 A,B,C) or neurofilaments (purple, figure 5.5 
D,E,F) showed neglible level of the peptidase expression. Similarly to PcpI IHC results, 
a strong background staining was observed in all of the sections that hindered an 
accurate analysis, particularly for the Aβ and neurofilament antigens. There was  
a slightly higher level of black staining in AD sections in some patches overlaping with 
purple staining, which may suggest co-localisation of PcpII with amyloid peptides or, 
which is understood for this membrane-anchored ectoenzyme, with neurites. 
Concentrated and uneven distribution of the staining could suggest that all analysed 
antigens, as in case of PcpI, may be located within senile plaques, which are known to 
be composed of amyloid core, reactive microglia and dystrophic neuronal processes 
(Dickson, 1997). The increased level of PcpII in AD tissues is surprising, due to the fact 
that progressive neuronal loss and deterioration, observed in acute stages of the 
disorder, should rather result in down-regulation of the synthesis of this peptidase.  
This however, was not noticed in any of the analysed AD samples. The potential 
involvement of PcpII in degradation of the AβpGlu(3-40/42) or AβpGlu(11-40/42) 
peptides (1.1.3.3) still needs to be determined. Nonetheless, its narrow substrate 
specificity, which is limited to TRH, can be considered as a barrier preventing above 
peptides from being processed by this enzyme. The elevated level of PcpII in AD may 
have other implications. Studies showed that a depletion of TRH up-regulates the 
activity of glycogen synthetase kinase-3 (GSK-3β), which is essential for the 
phosphorylation of tau (Luo et al., 2002). The tau hyperphosphorylation in turn was 
observed to trigger axonal retraction in cultured neurons and gradual cell loss. 
Moreover, PcpII is an important control element of the mammalian regulatory system of 
hypothalamic/pituitary/thyroid axis, therefore uncontrolled activity of the enzyme could 
lead to deregulation of this pathway (Jeffcoate and Hutchinson, 1978; Wilk, 1986). 
Indeed clinical hypo- and hyperthyroidism are associated with an increased risk of AD 
(Tan et al., 2008).   
          The increased level of PcpI and, in lower degree, PcpII was observed in AD brain 
cortex tissue sections when compared with the control samples. This experiment 
however needs further optimisation mainly in the aspect of signal detection in order  
to prevent excessive background staining. It would be also advisable to employ an 
alternative immunofluorescence technique, where fluorescent labelling is used as a basis 
of the antigen detection and compare the results with those obtained for chromogenic 
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IHC.  The role of both enzymes in the pathology is not well understood and still needs 
to be determined. PcpI in particular seems to be a good candidate for a study regarding 
its potential involvement in the degradation of pGlu-modified amyloid peptides, which 
were found in abundance in toxic AD lesions. PcpII in turn functions as a regulator of 
the TRH-mediated signalling system and is so far unknown in which way it is 
associated with Alzheimer’s pathogenesis.  A range of amyloid-degrading enzymes, 
such as neprilysin, endothelin converting enzyme or insulin-degrading enzyme are 
considered as therapeutic targets in neurodegeneration (Turner et al., 2004; Nalivaeva et 
al., 2008). The significance of both Pcp activities as tools for AD treatment is high due 
to the exceptional physiological properties of both enzymes.  
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5.3. Processing of pGlu-Aβ peptides by human PcpI 
 
          The abundance of the pGlu-modified Aβ peptides, being a major component of 
senile plaques found in AD brain, namely AβpGlu(3-40/42) and AβpGlu(11-40/42), 
may lead to the suggestion that a mechanism of their exposure to proteolytic 
degradation can be compromised. The Pcp activity, as yet, is the only identified means 
capable of the removal of the N-terminal pGlu protection from physiologically 
important biomolecules (1.2). Although numerous assays were conducted in order to 
determine substrate specificity of both PcpI and PcpII towards processing of the 
biologically important peptides, such as bombesin, neurotensin or LHRH, there is no 
reported study regarding its potential ability to degrade toxic pGlu-modified Aβs. The 
association of the progressive deposition of these peptides in AD brain and Pcp activity 
still needs to be investigated, nonetheless it was decided to qualitatively analyse if the 
AβpGlu(3-40/42) and AβpGlu(11-40/42) species can undergo proteolytic processing by 
human PcpI. 
5.3.1. Materials and methods 
          The human PcpI activity towards degradation of pGlu-modified Aβs was assayed 
on the basis of the modified protocol by Dando and co-workers (Dando et al., 2003). 
Synthetic AβpGlu(3-40), AβpGlu(3-42), AβpGlu(11-40)  and AβpGlu(11-42) peptides 
were purchased from AnaSpec in a form of lyophilized material in serum vials. This 
was resuspended in 5% DMSO solution, according to manufacturer’s instructions, in 
order to obtain a 10 mM final concentration and stored at -20°C. For the qualitative 
study, 25 μl of the 10 ng/μl PcpI in activity assay buffer (2.3.4) was individually mixed 
with 20 μM (final concentration) of each peptide in a total volume of 100 μl. Each of 
the reactions was conducted in triplicate and incubated at 37ºC for 1 hour. The negative 
control was prepared by the addition of acetic acid to the protein sample prior to mixing 
with the peptide solutions. The reaction was terminated by the addition of 10 μl of 
1.5 M acetic acid. Analysis of the results was performed by mass spectrometry using a 
Q-TOF 6520 (Agilent) coupled to a HPLC-Chip 1200 interface system. The samples 
were loaded onto a micro C18 reverse phase analytical column (Agilent Protein 
Identification Chip) and eluted over 20 min using a methanol/water gradient with 0.1% 
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formic acid solution. Next monoisotopic masses of each individual substrate and 
product were calculated and used to obtain extracted ion chromatograms (EIC) to 
determine their presence in the sample solutions.   
5.3.2. Results and discussion 
5.3.2.1. Degradation of pGlu-modified Aβs by human PcpI 
          The mass spec analysis of the proteolytic cleavage of AβpGlu(3-40), AβpGlu(3-
42), AβpGlu(11-40) and AβpGlu(11-42) peptides by PcpI showed that the desired 
product was only obtained for a degradation of the AβpGlu(3-40) variant (figure 5.6). 
 
 
Figure 5.6. Mass spectrum for the proteolytic cleavage of AβpGlu(3-40) by PcpI.  
A top diagram (A) shows the characteristic spectrum obtained for the substrate and 
bottom one (B) – for product Aβ(4-40).  
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          The spectra obtained for the other reactions – AβpGlu(3-42), AβpGlu(11-40) and 
AβpGlu(11-42) – did not confirm the presence of the desired cleavage products. 
However, the subsequent control analysis of the stock solutions of all of the above 
peptides revealed the charge state peaks characteristic for the product of the AβpGlu(3-
40) degradation – Aβ(4-40) to be present in AβpGlu(3-42) and AβpGlu(11-42). 
Moreover, both stocks were cross-contaminated with AβGlu(3-40), which contains an 
N-terminal glutamic acid instead of pyroglutamyl group. There was no AβGlu(3-40) 
contamination and no Aβ(4-40) product in a stock of AβpGlu(3-40) or in a related 
negative control reaction sample, which could confirm that its degradation was 
catalysed by PcpI. Such findings may suggest that the peptides could undergo some 
kind of unspecific spontaneous disintegration or their synthesis was incomplete, hence 
the presence of a Aβ(4-40) contaminant, which lacks protecting N-terminal pGlu 
residue. It is also possible that the cyclisation of the N-terminal glutamic acid to pGlu 
was insufficient explaining the presence of AβGlu(3-40).  
         The unsuccessful processing of the shorter forms of Aβ, AβpGlu(11-40) and 
AβpGlu(11-42), may also lead to the conclusion that the peptides, due to their highly 
hydrophobic properties, can undergo a change in conformation or oligomerization. This 
in turn could hinder the access of the PcpI enzyme to the pGlu residue and thus prevent 
its removal. Such phenomenon can take place in the organisation of amyloid deposits, 
where the pGlu group may be not available for the enzymatic processing. Nonetheless 
positive results obtained for AβpGlu(3-40) confirmed the substrate specificity of the 
PcpI towards this group of peptides. It would be advisable to further optimize this assay 
as well as conduct similar qualitative analysis with PcpII, which was impossible here 
due to the lack of the enzyme preparation. The comparison of the results obtained for 
both enzymes could give an insight on their capability and effectiveness in degradation 
of pGlu-modified Aβs in vivo in AD pathology. 
.  
 
 
 
 
234 
 
Chapter 6 – Summary, conclusions and future work 
 
                      The experimental work conducted within this project was focused around 
the study of human PcpI, human PcpII and their potential relationship with an excessive 
production and deposition of the N-terminally pGlu-modified Aβ species in AD. 
          Human PcpI was successfully overexpressed in E. coli cells in the native and the 
recombinant form carrying N- or C-terminal His-tag. The production of these different 
enzyme variants was part of stability studies on the protein, which was observed to be 
extremely unstable in vitro. The initial approach, which aimed to overcome this 
problem, involved a variety of chemical additives or a change from Tris-HCl to 
K2HPO4/KH2PO4 based buffer in order to investigate how these alterations affect the 
protein behaviour (3.2.1.3.6). None of the above factors proved to be stabilising for the 
N-terminally His-tagged PcpI. The minor improvement in solubility was observed for 
0.15 M NaCl and therefore it was included in purification buffers that were further used.  
          Due to the fact that the N-terminal His-tagged PcpI (6xHis-PcpI) was shown to be 
unstable in solution, two alternative variants of the enzyme were produced – native and 
C-terminally His-tagged (PcpI-6xHis). Several studies on the other proteins have been 
reported where the position of the affinity tag had an influence on protein folding and 
resulted in improved purification yields (3.2.1.4). The PcpI-6xHis variant was showed 
to be more stable than its N-terminally tagged counterpart, this was particularly 
observed during the protein concentration procedure. Additional work which aimed to 
identify the reasons of PcpI instability included performance of a thermofluor shift 
assay, site-directed mutagenesis of the non-catalytic cysteine residues and  chemical 
modification of surface cysteines and lysines (3.3). The results of the screening for 
optimal buffer conditions using the thermofluor shift assay revealed a very destabilising 
effect of the Tris-HCl buffer used initially for PcpI. The Tris-HCl buffer was 
subsequently replaced by a zwitteronic HEPPS buffer, which provided the most 
stabilising environment for the peptidase as confirmed by the increased shift in melting 
temperature (3.3.1.2). The use of HEPPS buffer significantly improved the protein 
stability during the purification and concentration steps. This enabled both native PcpI 
and PcpI-6xHis proteins to be concentrated up to 50 mg/ml and used in crystallisation 
trials.  
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          The site-directed mutagenesis study on all of the non-catalytic cysteine residues 
in human PcpI (3.3.2), suggested that at least some of these residues may have an 
important influence on protein function. Interesting results were obtained for the C107A 
variant, which was observed to be inactive and prone to dimerization. The C107 
probably participates in the formation of a vicinal disulfide bridge with an adjacent 
C108 residue. Therefore, the above mutation could lead to an intermolecular cystine 
formation between the reactive C108 sulfhydryls. Moreover both residues with C99 and 
C102 are located within a Cys-rich loop, which could work as a functional subdomain. 
Such dense localisation of cysteines is typical for Zn-binding motifs. However the 
addition of ZnCl2 to the protein-expressing culture (3.3.2.1.4) or the analysis of  zinc 
acetate in the thermofluor shift assay (3.3.5.1) did not confirm any stabilising effect on 
the protein. Moreover, previous reports on the incubation of human PcpI with EDTA 
resulted in no change in activity, which indicates the absence of any metal ion being 
important for the protein function (Dando et al., 2003).  
          Both native PcpI and PcpI-6xHis were subjected to an extensive crystallisation 
study in order to find optimal conditions for crystal nucleation and growth (3.4).  
The crystallisation experiments were conducted for all PcpI cysteine mutants as well as 
for the protein containing DTNB-modified surface cysteines or methylated surface 
lysines (3.3.3). This part of experimental studies proved to be extremely difficult with a 
few conditions that produced tiny crystals or crystalline precipitate. Nonetheless, small 
plate like crystals were produced for the PcpI-6xHis in the presence of the 2-pyrrolidone 
inhibitor in 0.1 M Bis-Tris pH 5.5 and 15% PEG3350. These crystals were shown to be 
protein and diffracted at a low resolution. This condition is useful as a starting point for 
a crystallisation optimisation procedure. The small crystals were also used for 
microseeding experiments. To date, these attempts have not yielded good quality 
crystals and further optimisation is necessary. 
          The part of the study on human PcpII involved attempts to express the protein in 
bacterial, insect and mammalian systems (4.2.1.2 and 4.2.1.3). The protein sequence 
was submitted to an online prediction server in order to identify putative disordered and 
globular regions that would help to establish domain boundaries. On the basis of this a 
series of truncated protein variants were cloned and tested for expression in specialised 
E. coli strains. However, an overexpression in the bacterial system was unsuccessful 
and this lead to subsequent overexpression trials which were conducted in insect Sf9 and 
VE-Sf9 and mammalian HEK 293T cells. This part of experimental work was 
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conducted in the OPPF laboratory (Research Complex at Harwell) and involved 
preparation of a range of pOPIN-based constructs, which allow for parallel protein 
expression screening in bacterial, insect and mammalian cell lines.  The utilisation of 
baculovirus-mediated insect system was unsuccessful, however three of the constructs 
8708, 8984 and 7465 (table 4.9) which were expressed in mammalian cell line yielded 
small levels of secreted PcpII/S62-H1024 protein. This result may be considered as a 
starting point for further optimisation of the overexpression conditions in order to obtain 
sufficient amount of the protein for structural studies and other applications. 
          Due to the lack of the structural information regarding PcpII, basic homology 
modelling of the putative catalytic domain was conducted using the structure of human 
ERAP1 as a template sharing 40% identity and 56% similarity (4.3.2.1). Additionally, 
docking simulations of TRH in the active site of the enzyme were performed to gain an 
insight into its probable binding mode. The modelling was successful, with the resulting 
structure having an RMSD of 1.33 Å to the template which indicates that the obtained 
structural fold is similar to that of ERAP1 conformation. The TRH docking results 
revealed the specific orientation of Tyr403 and Phe522 residues, which entrap the pGlu 
moiety through complex hydrogen bonding and hydrophobic interactions, and may be 
necessary for the proper orientation of the substrate in the active site. This experiment 
also showed the close interaction of the pGlu carbonyl oxygen with the catalytic Zn 
atom and important residues such as Ser268, Tyr527or Asp519, which may create 
hydrogen bonding with TRH residues . This could be essential for substrate recognition 
and correct orientation in relation to the catalytic moiety. Structural information gained 
from the three-dimensional PcpII model and, in particular, the structure of the active site 
could provide useful information which can be used to design further experiments such 
as site-directed mutagenesis and could aid in the search for potential enzyme inhibitors. 
          The final stage of this project was focused on the investigation of the involvement 
of PcpI and PcpII to AD pathogenesis. The IHC staining of both proteins was conducted 
in order to investigate any potential differences in their localisation and distribution 
between control and diseased cortical tissue sections (5.2). It could be suggested that the 
abundance of pGlu-modified Aβ species in AD brain may be a result of the decreased 
level of Pcp activity. Surprisingly, the immunostaining results indicated that the level of 
both PcpI and PcpII is increased in neurodegenerated tissue when compare to normal 
adult brain sections. Moreover the areas of stainings of both peptidases with either Aβ 
or neurofilaments showed their co-localisation in AD tissue, which probably is a result 
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of senile plaque deposition, where all four antigens could be detected. The distribution 
and amorphous staining of PcpI indicated that the protein may be over-expressed in 
reactive microglia, which were also found within amyloid plaques. The elevated level of 
PcpI may be associated with extensive proteolytic activity of microglial cells acting as 
macrophages and removing damaged biological material from the surrounding 
environment. In turn the increase in PcpII appearance could be a result of a deregulated 
hypothalamic/pituitary/thyroid system. A specific function of this peptidase relies on the 
regulation of the TRH neurotransmitter, therefore its up-regulated activity may 
subsequently have an effect on endocrine homeostasis and cell signalling. The IHC also 
revealed significant shrinkage of the cortical tissues progressing during AD 
development.  
          PcpI substrate specificity was tested against common pGlu-modified peptides, 
which were found in abundance in AD tissues as well as vascular and amyloid deposits 
(5.3). The AβpGlu(3-40), AβpGlu(3-42), AβpGlu(11-40)  and AβpGlu(11-42) peptides 
were used as a substrates for PcpI in order to evaluate if they can be degraded by the 
enzyme. Positive results were obtained for AβpGlu(3-40) and the desired Aβ(4-40) 
product was confirmed by mass spectrometry analysis. The three other peptides failed 
the pGlu removal. However, analysis of the original stock material showed that all of 
them were contaminated with either Aβ(4-40) or AβGlu(3-40) species which may 
indicate spontaneous disintegration or incomplete synthesis. Therefore to analyse 
enzyme affinity towards the degradation of the remaining substrates, the procedure 
needs to be repeated on pure homogenous peptide samples. The other aspect of the 
possible failure in these reactions may also be due to the hydrophobic nature of all the 
peptides, which could spontaneously oligomerise or change conformation in a way that 
hinders accessibility of the pGlu residue for PcpI binding. 
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          Future work on human PcpI should include further optimisation of crystallisation 
conditions already identified in initial screening, in order to yield good quality crystals 
for structural studies. Moreover, site-directed mutagenesis of chosen residues could 
prove to have a stabilising effect on the protein. Such an approach proved to be 
successful in the case of B. amyloliquefaciens PcpI, where artificial generation of 
the inter-subunit disulfide bridge in the position corresponding to the native 
bridges in T. litoralis and P. furiosus homologues, greatly increased its thermal 
stability (Kabashima et al., 2001). Similarly, many prokaryotic Pcps possess Phe 
residue in a position of the conserved Tyr147 in the human enzyme. Interestingly, 
the residue is located in the substrate binding site and studies on human PcpI 
Y147F mutant confirmed it to be more thermostable (Mtawae et al., 2008). It is 
worth investigating this and similar mutants in the context of their stability that 
could be also advantageous for structural studies.  
          Further study on human PcpII will include optimisation of its overexpression 
conditions in the mammalian cell system in order to produce sufficient amounts of the 
protein for a structural study. The full-length protein and its functional domains could 
also be tested for expression in alternative hosts such as COS or CHO cell lines. 
Consequently, new pOPIN-based constructs will be produced and used for expression 
screening of all PcpII variants. It would be advisable to conduct a wider study on the 
potential structural similarities between PcpI and PcpII.  
          An interesting observation is the potential structural and functional similarity 
between PcpI and PcpII. Correlations between both peptidases could be significant, for 
example the finding that  PcpII is the only member of M1 metallopeptidase family, 
which possesses Cys in the conserved HEXXHX18E motif or that PcpI, in turn, contains 
a Cys-rich loop potentially able for Zn coordination. Moreover, prokaryotic Pcps 
display a different structure than that observed for other members of the C15 family. 
One  example is the T. litoralis Pcp, which was observed to display similar scaffold to a 
zinc-dependent carboxypeptidase A from Bos taurus (PBD 2CTB) (Singleton et al., 
1999).  
          The IHC study on PcpI and PcpII level in AD tissues showed their up-regulated 
synthesis. Further studies of this phenomenon is of great interest as it may provide more 
information on the role of both enzymes in this neurodegenerative disorder and evaluate 
their potential use as a drug targets in AD treatment. An alternative 
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immunofluorescence staining method could result in better detection and help with the 
undesired background staining observed in the study. In order to confirm the exact 
localisation of both enzymes in tissue compartments, it is necessary to conduct  
a concurrent detection of antigens associated with microglia or neuronal loss. For the 
improvement of specificity and signal detection, it could be also advantageous to 
employ other anti-PcpI and anti-PcpII antibodies, when they become commercially 
available. Moreover, due to the fact that Pcp activity was seen to decrease with age in 
human cerebrospinal fluid (1.2.4.3) it is understood that any comparative staining 
should be conducted using age-matched controls. 
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Appendices 
Appendix I. The map and cloning/expression region of pET-28a(+) 
vector  
pET-28b(+) vector differs only by 1bp subtracted at position198 beyond BamHI 
restriction site. Taken from www.merck-chemicals.co.uk. 
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Appendix II. The map and cloning/expression region of pET-22b(+) 
vector  
Taken from www.merck-chemicals.co.uk. 
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Appendix III. DNA sequencing results of PcpI 
 
 the N-terminal His-tag motif is highlighted in green and the C-terminal His-tag 
motif is highlighted in orange 
 TGA stop codon is highlighted in blue 
 
DNA sequence: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCAT 
ATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGA
ACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCA
TGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAG
CACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGA
AATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTG
CTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGA
GTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCG
ACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCC
ACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATG
TTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACACTGA 
AAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA 
 
 
 
Amino acid sequence: 
MGSSHHHHHHSSGLVPRGSHMEQPRKAVVVTGFGPFGEHTVNASWIAVQELEKLGLGDS
VDLHVYEIPVEYQTVQRLIPALWEKHSPQLVVHVGVSGMATTVTLEKCGHNKGYKGLDN
CRFCPGSQCCVEDGPESIDSIIDMDAVCKRVTTLGLDVSVTISQDAGRYLCDFTYYTSL
YQSHGRSAFVHVPPLGKPYNADQLGRALRAIIEEMLDLLEQSEGKINYCHKH 
                                              KLAAALQHHHHHH 
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Appendix IV. Calibration curve and chromatographic separation of 
the standard proteins on HiLoad™ 16/60 Superdex™ 200 column.  
 
Taken from www.gelifesciences.com 
 
 
 
 
Protein standard Abbr. Molecular weight (kDa) 
Aprotinin Apr 6500 
Ribonuclease A R 13 700 
Carbonic anhydrase CA 29 000 
Ovalbumin O 43 000 
Conalbumin C 75 000 
Aldolase Ald 158 000 
Ferritin F 440 000 
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Appendix V. Standard curve for 7-amino-4-methyl coumarin (AMC) 
concentration.  
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Appendix VI. A Ramachandran plot of the human PcpI model. 
 
The plot was generated in RAMPAGE Ramachandran Plot server (Lovell et al., 2003). 
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Appendix VII. Sequencing results of the PcpI cysteine mutants 
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Appendix VIII. DNA sequencing results of PcpII 
 
DNA sequence: 
ATGGGGGAAGACGACGCCGCGCTTCGGGCTGGCAGCAGGGGGCTCTCCGACCCGTGGGCAGACT
CAGTGGGAGTGCGACCCCGCACCACGGAGCGCCACATCGCCGTACACAAGCGGCTTGTGCTGGC
CTTCGCTGTGTCCCTCGTGGCATTGCTCGCGGTCACAATGCTCGCTGTGCTGCTCAGCCTGCGC
TTCGACGAGTGCGGGGCGAGTGCCACGCCAGGCGCCGACGGTGGCCCCTCAGGCTTTCCGGAGC
GCGGCGGCAACGGGAGCCTCCCTGGATCGGCCCGGCGCAACCACCACGCAGGCGGGGACTCCTG
GCAGCCCGAGGCGGGTGGGGTGGCCAGTCCGGGGACCACGTCGGCCCAGCCGCCGTCGGAGGAG
GAGCGGGAGCCGTGGGAGCCGTGGACGCAGCTGCGCCTGTCGGGCCACCTGAAGCCGCTGCACT
ACAATCTGATGCTCACCGCCTTCATGGAGAACTTCACCTTCTCCGGGGAGGTCAACGTGGAGAT
CGCGTGCCGGAACGCCACCCGCTACGTAGTGCTGCACGCTTCCCGAGTGGCGGTGGAGAAAGTG
CAGCTGGCCGAGGACCGGGCGTTCGGGGCTGTCCCTGTAGCCGGTTTTTTCCTCTACCCGCAAA
CCCAGGTCTTAGTGGTGGTGCTGAATAGGACACTGGACGCGCAGAGGAATTACAATCTGAAGAT
TATCTACAACGCGCTCATCGAGAATGAGCTCCTGGGCTTCTTCCGCAGCTCCTATGTGCTCCAC
GGGGAGAGAAGATTCCTTGGTGTTACTCAGTTTTCGCCTACACATGCCAGAAAGGCATTTCCTT
GTTTTGATGAGCCAATCTACAAGGCTACTTTCAAAATCAGCATCAAGCATCAAGCAACCTATTT
ATCTTTATCTAATATGCCAGTGGAAACTTCCGTGTTTGAGGAAGATGGATGGGTTACGGATCAC
TTTTCACAGACCCCTCTCATGTCCACATATTATTTAGCCTGGGCAATTTGCAACTTCACATACA
GAGAAACTACCACCAAGAGTGGGGTTGTAGTACGATTATATGCAAGACCTGATGCTATCAGAAG
AGGATCCGGGGACTATGCTCTCCATATAACAAAGAGATTAATAGAATTTTATGAAGACTACTTT
AAAGTGCCCTATTCCTTGCCAAAACTAGATCTTTTAGCTGTGCCTAAGCATCCGTATGCTGCTA
TGGAGAACTGGGGACTAAGTATTTTTGTGGAACAAAGAATACTGCTGGATCCCAGTGTTTCATC
TATTTCTTATTTGCTGGATGTCACCATGGTCATTGTTCATGAGATATGTCACCAGTGGTTTGGT
GACCTTGTGACGCCTGTGTGGTGGGAAGACGTGTGGCTGAAGGAAGGGTTTGCTCACTACTTTG
AATTTGTTGGTACAGACTACCTCTATCCTGGCTGGAACATGGAAAAGCAGAGGTTTCTGACCGA
TGTTCTGCATGAAGTGATGCTGCTGGACGGTTTGGCCAGTTCCCATCCAGTATCACAGGAAGTG
CTGCAGGCAACAGATATTGACAGGGTGTTTGACTGGATCGCATATAAAAAGGGTGCTGCTTTAA
TAAGAATGCTGGCTAATTTTATGGGCCATTCAGTTTTCCAGAGGGGTTTGCAAGATTATTTAAC
CATTCATAAGTATGGTAATGCAGCCAGAAATGATCTCTGGAATACATTATCGGAGGCTTTAAAA
AGAAATGGGAAATATGTAAATATACAAGAAGTAATGGATCAGTGGACACTCCAGATGGGTTATC
CTGTTATCACCATCTTGGGAAACACAACAGCAGAAAATAGAATAATAATTACCCAACAGCATTT
TATCTATGATATCAGTGCTAAAACTAAAGCACTTAAACTTCAGAATAACAGTTACCTGTGGCAG
ATTCCATTAACTATTGTGGTAGGAAATAGAAGCCATGTGTCTTCAGAAGCAATTATTTGGGTGT
CTAACAAATCAGAGCACCACAGAATAACTTATTTGGACAAAGGAAGCTGGCTGCTGGGGAACAT
CAATCAAACTGGCTATTTTAGAGTCAACTATGACCTAAGGAACTGGAGATTATTAATTGATCAA
TTAATCCGGAATCATGAGGTTCTTTCTGTCAGTAACCGAGCGGGCTTGATCGATGATGCCTTCA
GCCTAGCCAGGGCTGGCTATTTGCCTCAGAATATTCCTCTGGAGATTATCAGATACCTGTCTGA
GGAGAAGGATTTTCTTCCTTGGCATGCTGCCAGCCGAGCTCTTTATCCTCTAGATAAATTACTG
GACCGCATGGAAAACTACAACATTTTCAATGAATATATTTTAAAGCAAGTTGCAACAACATATA
TCAAGCTTGGGTGGCCGAAAAATAATTTTAATGGATCTCTTGTTCAAGCATCCTACCAACATGA
AGAACTACGTAGAGAAGTTATAATGCTGGCCTGCAGTTTTGGCAACAAGCACTGTCACCAACAG
GCATCAACACTTATTTCAGATTGGATTTCCAGCAACAGGAACAGAATACCACTAAATGTTAGAG
ACATCGTATACTGTACAGGAGTGTCACTACTGGATGAGGATGTCTGGGAATTCATATGGATGAA
ATTCCATTCCACCACAGCAGTTTCTGAGAAGAAAATATTATTGGAAGCCTTAACTTGCAGTGAT
GACAGGAATTTATTAAACAGGCTTCTAAATCTGTCACTGAATTCTGAGGTGGTGCTGGATCAAG
ATGCAATTGATGTCATAATCCATGTAGCTCGAAATCCACATGGTCGAGACCTTGCCTGGAAGTT
TTTCAGGGATAAATGGAAGATATTAAATACCAGGTATGGAGAAGCATTGTTTATGAATTCCAAA
CTCATCAGTGGTGTCACAGAATTTCTTAATACTGAAGGTGAACTCAAAGAGCTCAAGAACTTCA
TGAAAAACTATGATGGGGTAGCTGCTGCTTCTTTCTCACGAGCTGTGGAAACTGTCGAAGCCAA
TGTGCGCTGGAAAATGCTTTACCAAGACGAGCTTTTCCAATGGTTAGGAAAAGCTCTAAGACAC
TAA  
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Appendix VIII. DNA sequencing results of PcpII 
 
Amino acid sequence: 
MGEDDAALRAGSRGLSDPWADSVGVRPRTTERHIAVHKRLVLAFAVSLVALLAVTMLAV
LLSLRFDECGASATPGADGGPSGFPERGGNGSLPGSARRNHHAGGDSWQPEAGGVASPG
TTSAQPPSEEEREPWEPWTQLRLSGHLKPLHYNLMLTAFMENFTFSGEVNVEIACRNAT
RYVVLHASRVAVEKVQLAEDRAFGAVPVAGFFLYPQTQVLVVVLNRTLDAQRNYNLKII
YNALIENELLGFFRSSYVLHGERRFLGVTQFSPTHARKAFPCFDEPIYKATFKISIKHQ
ATYLSLSNMPVETSVFEEDGWVTDHFSQTPLMSTYYLAWAICNFTYRETTTKSGVVVRL
YARPDAIRRGSGDYALHITKRLIEFYEDYFKVPYSLPKLDLLAVPKHPYAAMENWGLSI
FVEQRILLDPSVSSISYLLDVTMVIVHEICHQWFGDLVTPVWWEDVWLKEGFAHYFEFV
GTDYLYPGWNMEKQRFLTDVLHEVMLLDGLASSHPVSQEVLQATDIDRVFDWIAYKKGA
ALIRMLANFMGHSVFQRGLQDYLTIHKYGNAARNDLWNTLSEALKRNGKYVNIQEVMDQ
WTLQMGYPVITILGNTTAENRIIITQQHFIYDISAKTKALKLQNNSYLWQIPLTIVVGN
RSHVSSEAIIWVSNKSEHHRITYLDKGSWLLGNINQTGYFRVNYDLRNWRLLIDQLIRN
HEVLSVSNRAGLIDDAFSLARAGYLPQNIPLEIIRYLSEEKDFLPWHAASRALYPLDKL
LDRMENYNIFNEYILKQVATTYIKLGWPKNNFNGSLVQASYQHEELRREVIMLACSFGN
KHCHQQASTLISDWISSNRNRIPLNVRDIVYCTGVSLLDEDVWEFIWMKFHSTTAVSEK
KILLEALTCSDDRNLLNRLLNLSLNSEVVLDQDAIDVIIHVARNPHGRDLAWKFFRDKW
KILNTRYGEALFMNSKLISGVTEFLNTEGELKELKNFMKNYDGVAAASFSRAVETVEAN
VRWKMLYQDELFQWLGKALRH 
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Appendix IX. DNA sequencing results of PcpII/L141-M541  
 
 the N-terminal His-tag motif is highlighted in green 
 
DNA sequence: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATCTGT
CGGGCCACCTGAAGCCGCTGCACTACAATCTGATGCTCACCGCCTTCATGGAGAACTTCACCTT
CTCCGGGGAGGTCAACGTGGAGATCGCGTGCCGGAACGCCACCCGCTACGTAGTGCTGCACGCT
TCCCGAGTGGCGGTGGAGAAAGTGCAGCTGGCCGAGGACCGGGCGTTCGGGGCTGTCCCTGTAG
CCGGTTTTTTCCTCTACCCGCAAACCCAGGTCTTAGTGGTGGTGCTGAATAGGACACTGGACGC
GCAGAGGAATTACAATCTGAAGATTATCTACAACGCGCTCATCGAGAATGAGCTCCTGGGCTTC
TTCCGCAGCTCCTATGTGCTCCACGGGGAGAGAAGATTCCTTGGTGTTACTCAGTTTTCGCCTA
CACATGCCAGAAAGGCATTTCCTTGTTTTGATGAGCCAATCTACAAGGCTACTTTCAAAATCAG
CATCAAGCATCAAGCAACCTATTTATCTTTATCTAATATGCCAGTGGAAACTTCCGTGTTTGAG
GAAGATGGATGGGTTACGGATCACTTTTCACAGACCCCTCTCATGTCCACATATTATTTAGCCT
GGGCAATTTGCAACTTCACATACAGAGAAACTACCACCAAGAGTGGGGTTGTAGTACGATTATA
TGCAAGACCTGATGCTATCAGAAGAGGATCCGGGGACTATGCTCTCCATATAACAAAGAGATTA
ATAGAATTTTATGAAGACTACTTTAAAGTGCCCTATTCCTTGCCAAAACTAGATCTTTTAGCTG
TGCCTAAGCATCCGTATGCTGCTATGGAGAACTGGGGACTAAGTATTTTTGTGGAACAAAGAAT
ACTGCTGGATCCCAGTGTTTCATCTATTTCTTATTTGCTGGATGTCACCATGGTCATTGTTCAT
GAGATATGTCACCAGTGGTTTGGTGACCTTGTGACGCCTGTGTGGTGGGAAGACGTGTGGCTGA
AGGAAGGGTTTGCTCACTACTTTGAATTTGTTGGTACAGACTACCTCTATCCTGGCTGGAACAT
GGAAAAGCAGAGGTTTCTGACCGATGTTCTGCATGAAGTGATGCTGCTGGACGGTTTGGCCAGT
TCCCATCCAGTATCACAGGAAGTGCTGCAGGCAACAGATATTGACAGGGTGTTTGACTGGATCG
CATATAAAAAGGGTGCTGCTTTAATAAGAATGCTGGCTAATTTTATGTGA 
 
Amino acid sequence: 
MGSSHHHHHHSSGLVPRGSHMLSGHLKPLHYNLMLTAFMENFTFSGEVNVEIACRNATR
YVVLHASRVAVEKVQLAEDRAFGAVPVAGFFLYPQTQVLVVVLNRTLDAQRNYNLKIIY
NALIENELLGFFRSSYVLHGERRFLGVTQFSPTHARKAFPCFDEPIYKATFKISIKHQA
TYLSLSNMPVETSVFEEDGWVTDHFSQTPLMSTYYLAWAICNFTYRETTTKSGVVVRLY
ARPDAIRRGSGDYALHITKRLIEFYEDYFKVPYSLPKLDLLAVPKHPYAAMENWGLSIF
VEQRILLDPSVSSISYLLDVTMVIVHEICHQWFGDLVTPVWWEDVWLKEGFAHYFEFVG
TDYLYPGWNMEKQRFLTDVLHEVMLLDGLASSHPVSQEVLQATDIDRVFDWIAYKKGAA
LIRMLANFM 
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Appendix X. DNA sequencing results of PcpII/S62-G793 
 
 the N-terminal His-tag motif is highlighted in green 
 
DNA sequence: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATAGCC
TGCGCTTCGACGAGTGCGGGGCGAGTGCCACGCCAGGCGCCGACGGTGGCCCCTCAGGCTTTCC
GGAGCGCGGCGGCAACGGGAGCCTCCCTGGATCGGCCCGGCGCAACCACCACGCAGGCGGGGAC
TCCTGGCAGCCCGAGGCGGGTGGGGTGGCCAGTCCGGGGACCACGTCGGCCCAGCCGCCGTCGG
AGGAGGAGCGGGAGCCGTGGGAGCCGTGGACGCAGCTGCGCCTGTCGGGCCACCTGAAGCCGCT
GCACTACAATCTGATGCTCACCGCCTTCATGGAGAACTTCACCTTCTCCGGGGAGGTCAACGTG
GAGATCGCGTGCCGGAACGCCACCCGCTACGTAGTGCTGCACGCTTCCCGAGTGGCGGTGGAGA
AAGTGCAGCTGGCCGAGGACCGGGCGTTCGGGGCTGTCCCTGTAGCCGGTTTTTTCCTCTACCC
GCAAACCCAGGTCTTAGTGGTGGTGCTGAATAGGACACTGGACGCGCAGAGGAATTACAATCTG
AAGATTATCTACAACGCGCTCATCGAGAATGAGCTCCTGGGCTTCTTCCGCAGCTCCTATGTGC
TCCACGGGGAGAGAAGATTCCTTGGTGTTACTCAGTTTTCGCCTACACATGCCAGAAAGGCATT
TCCTTGTTTTGATGAGCCAATCTACAAGGCTACTTTCAAAATCAGCATCAAGCATCAAGCAACC
TATTTATCTTTATCTAATATGCCAGTGGAAACTTCCGTGTTTGAGGAAGATGGATGGGTTACGG
ATCACTTTTCACAGACCCCTCTCATGTCCACATATTATTTAGCCTGGGCAATTTGCAACTTCAC
ATACAGAGAAACTACCACCAAGAGTGGGGTTGTAGTACGATTATATGCAAGACCTGATGCTATC
AGAAGAGGATCCGGGGACTATGCTCTCCATATAACAAAGAGATTAATAGAATTTTATGAAGACT
ACTTTAAAGTGCCCTATTCCTTGCCAAAACTAGATCTTTTAGCTGTGCCTAAGCATCCGTATGC
TGCTATGGAGAACTGGGGACTAAGTATTTTTGTGGAACAAAGAATACTGCTGGATCCCAGTGTT
TCATCTATTTCTTATTTGCTGGATGTCACCATGGTCATTGTTCATGAGATATGTCACCAGTGGT
TTGGTGACCTTGTGACGCCTGTGTGGTGGGAAGACGTGTGGCTGAAGGAAGGGTTTGCTCACTA
CTTTGAATTTGTTGGTACAGACTACCTCTATCCTGGCTGGAACATGGAAAAGCAGAGGTTTCTG
ACCGATGTTCTGCATGAAGTGATGCTGCTGGACGGTTTGGCCAGTTCCCATCCAGTATCACAGG
AAGTGCTGCAGGCAACAGATATTGACAGGGTGTTTGACTGGATCGCATATAAAAAGGGTGCTGC
TTTAATAAGAATGCTGGCTAATTTTATGGGCCATTCAGTTTTCCAGAGGGGTTTGCAAGATTAT
TTAACCATTCATAAGTATGGTAATGCAGCCAGAAATGATCTCTGGAATACATTATCGGAGGCTT
TAAAAAGAAATGGGAAATATGTAAATATACAAGAAGTAATGGATCAGTGGACACTCCAGATGGG
TTATCCTGTTATCACCATCTTGGGAAACACAACAGCAGAAAATAGAATAATAATTACCCAACAG
CATTTTATCTATGATATCAGTGCTAAAACTAAAGCACTTAAACTTCAGAATAACAGTTACCTGT
GGCAGATTCCATTAACTATTGTGGTAGGAAATAGAAGCCATGTGTCTTCAGAAGCAATTATTTG
GGTGTCTAACAAATCAGAGCACCACAGAATAACTTATTTGGACAAAGGAAGCTGGCTGCTGGGG
AACATCAATCAAACTGGCTATTTTAGAGTCAACTATGACCTAAGGAACTGGAGATTATTAATTG
ATCAATTAATCCGGAATCATGAGGTTCTTTCTGTCAGTAACCGAGCGGGCTTGATCGATGATGC
CTTCAGCCTAGCCAGGGCTGGCTATTTGCCTCAGAATATTCCTCTGGAGATTATCAGATACCTG
TCTGAGGAGAAGGATTTTCTTCCTTGGCATGCTGCCAGCCGAGCTCTTTATCCTCTAGATAAAT
TACTGGACCGCATGGAAAACTACAACATTTTCAATGAATATATTTTAAAGCAAGTTGCAACAAC
ATATATCAAGCTTGGGTAA 
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Appendix X. DNA sequencing results of PcpII/S62-G793 
 
 
Amino acid sequence: 
MGSSHHHHHHSSGLVPRGSHMSLRFDECGASATPGADGGPSGFPERGGNGSLPGSARRN
HHAGGDSWQPEAGGVASPGTTSAQPPSEEEREPWEPWTQLRLSGHLKPLHYNLMLTAFM
ENFTFSGEVNVEIACRNATRYVVLHASRVAVEKVQLAEDRAFGAVPVAGFFLYPQTQVL
VVVLNRTLDAQRNYNLKIIYNALIENELLGFFRSSYVLHGERRFLGVTQFSPTHARKAF
PCFDEPIYKATFKISIKHQATYLSLSNMPVETSVFEEDGWVTDHFSQTPLMSTYYLAWA
ICNFTYRETTTKSGVVVRLYARPDAIRRGSGDYALHITKRLIEFYEDYFKVPYSLPKLD
LLAVPKHPYAAMENWGLSIFVEQRILLDPSVSSISYLLDVTMVIVHEICHQWFGDLVTP
VWWEDVWLKEGFAHYFEFVGTDYLYPGWNMEKQRFLTDVLHEVMLLDGLASSHPVSQEV
LQATDIDRVFDWIAYKKGAALIRMLANFMGHSVFQRGLQDYLTIHKYGNAARNDLWNTL
SEALKRNGKYVNIQEVMDQWTLQMGYPVITILGNTTAENRIIITQQHFIYDISAKTKAL
KLQNNSYLWQIPLTIVVGNRSHVSSEAIIWVSNKSEHHRITYLDKGSWLLGNINQTGYF
RVNYDLRNWRLLIDQLIRNHEVLSVSNRAGLIDDAFSLARAGYLPQNIPLEIIRYLSEE
KDFLPWHAASRALYPLDKLLDRMENYNIFNEYILKQVATTYIKLG 
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Appendix XI. DNA sequencing results of PcpII/L141-H1024   
 
 the N-terminal His-tag motif is highlighted in green 
 
DNA sequence: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATCTGT
CGGGCCACCTGAAGCCGCTGCACTACAATCTGATGCTCACCGCCTTCATGGAGAACTTCACCTT
CTCCGGGGAGGTCAACGTGGAGATCGCGTGCCGGAACGCCACCCGCTACGTAGTGCTGCACGCT
TCCCGAGTGGCGGTGGAGAAAGTGCAGCTGGCCGAGGACCGGGCGTTCGGGGCTGTCCCTGTAG
CCGGTTTTTTCCTCTACCCGCAAACCCAGGTCTTAGTGGTGGTGCTGAATAGGACACTGGACGC
GCAGAGGAATTACAATCTGAAGATTATCTACAACGCGCTCATCGAGAATGAGCTCCTGGGCTTC
TTCCGCAGCTCCTATGTGCTCCACGGGGAGAGAAGATTCCTTGGTGTTACTCAGTTTTCGCCTA
CACATGCCAGAAAGGCATTTCCTTGTTTTGATGAGCCAATCTACAAGGCTACTTTCAAAATCAG
CATCAAGCATCAAGCAACCTATTTATCTTTATCTAATATGCCAGTGGAAACTTCCGTGTTTGAG
GAAGATGGATGGGTTACGGATCACTTTTCACAGACCCCTCTCATGTCCACATATTATTTAGCCT
GGGCAATTTGCAACTTCACATACAGAGAAACTACCACCAAGAGTGGGGTTGTAGTACGATTATA
TGCAAGACCTGATGCTATCAGAAGAGGATCCGGGGACTATGCTCTCCATATAACAAAGAGATTA
ATAGAATTTTATGAAGACTACTTTAAAGTGCCCTATTCCTTGCCAAAACTAGATCTTTTAGCTG
TGCCTAAGCATCCGTATGCTGCTATGGAGAACTGGGGACTAAGTATTTTTGTGGAACAAAGAAT
ACTGCTGGATCCCAGTGTTTCATCTATTTCTTATTTGCTGGATGTCACCATGGTCATTGTTCAT
GAGATATGTCACCAGTGGTTTGGTGACCTTGTGACGCCTGTGTGGTGGGAAGACGTGTGGCTGA
AGGAAGGGTTTGCTCACTACTTTGAATTTGTTGGTACAGACTACCTCTATCCTGGCTGGAACAT
GGAAAAGCAGAGGTTTCTGACCGATGTTCTGCATGAAGTGATGCTGCTGGACGGTTTGGCCAGT
TCCCATCCAGTATCACAGGAAGTGCTGCAGGCAACAGATATTGACAGGGTGTTTGACTGGATCG
CATATAAAAAGGGTGCTGCTTTAATAAGAATGCTGGCTAATTTTATGGGCCATTCAGTTTTCCA
GAGGGGTTTGCAAGATTATTTAACCATTCATAAGTATGGTAATGCAGCCAGAAATGATCTCTGG
AATACATTATCGGAGGCTTTAAAAAGAAATGGGAAATATGTAAATATACAAGAAGTAATGGATC
AGTGGACACTCCAGATGGGTTATCCTGTTATCACCATCTTGGGAAACACAACAGCAGAAAATAG
AATAATAATTACCCAACAGCATTTTATCTATGATATCAGTGCTAAAACTAAAGCACTTAAACTT
CAGAATAACAGTTACCTGTGGCAGATTCCATTAACTATTGTGGTAGGAAATAGAAGCCATGTGT
CTTCAGAAGCAATTATTTGGGTGTCTAACAAATCAGAGCACCACAGAATAACTTATTTGGACAA
AGGAAGCTGGCTGCTGGGGAACATCAATCAAACTGGCTATTTTAGAGTCAACTATGACCTAAGG
AACTGGAGATTATTAATTGATCAATTAATCCGGAATCATGAGGTTCTTTCTGTCAGTAACCGAG
CGGGCTTGATCGATGATGCCTTCAGCCTAGCCAGGGCTGGCTATTTGCCTCAGAATATTCCTCT
GGAGATTATCAGATACCTGTCTGAGGAGAAGGATTTTCTTCCTTGGCATGCTGCCAGCCGAGCT
CTTTATCCTCTAGATAAATTACTGGACCGCATGGAAAACTACAACATTTTCAATGAATATATTT
TAAAGCAAGTTGCAACAACATATATCAAGCTTGGGTGGCCGAAAAATAATTTTAATGGATCTCT
TGTTCAAGCATCCTACCAACATGAAGAACTACGTAGAGAAGTTATAATGCTGGCCTGCAGTTTT
GGCAACAAGCACTGTCACCAACAGGCATCAACACTTATTTCAGATTGGATTTCCAGCAACAGGA
ACAGAATACCACTAAATGTTAGAGACATCGTATACTGTACAGGAGTGTCACTACTGGATGAGGA
TGTCTGGGAATTCATATGGATGAAATTCCATTCCACCACAGCAGTTTCTGAGAAGAAAATATTA
TTGGAAGCCTTAACTTGCAGTGATGACAGGAATTTATTAAACAGGCTTCTAAATCTGTCACTGA
ATTCTGAGGTGGTGCTGGATCAAGATGCAATTGATGTCATAATCCATGTAGCTCGAAATCCACA
TGGTCGAGACCTTGCCTGGAAGTTTTTCAGGGATAAATGGAAGATATTAAATACCAGGTATGGA
GAAGCATTGTTTATGAATTCCAAACTCATCAGTGGTGTCACAGAATTTCTTAATACTGAAGGTG
AACTCAAAGAGCTCAAGAACTTCATGAAAAACTATGATGGGGTAGCTGCTGCTTCTTTCTCACG
AGCTGTGGAAACTGTCGAAGCCAATGTGCGCTGGAAAATGCTTTACCAAGACGAGCTTTTCCAA
TGGTTAGGAAAAGCTCTAAGACACTAA 
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 Appendix XI. DNA sequencing results of PcpII/L141-H1024   
 
Amino acid sequence: 
MGSSHHHHHHSSGLVPRGSHMASLSGHLKPLHYNLMLTAFMENFTFSGEVNVEIACRNA
TRYVVLHASRVAVEKVQLAEDRAFGAVPVAGFFLYPQTQVLVVVLNRTLDAQRNYNLKI
IYNALIENELLGFFRSSYVLHGERRFLGVTQFSPTHARKAFPCFDEPIYKATFKISIKH
QATYLSLSNMPVETSVFEEDGWVTDHFSQTPLMSTYYLAWAICNFTYRETTTKSGVVVR
LYARPDAIRRGSGDYALHITKRLIEFYEDYFKVPYSLPKLDLLAVPKHPYAAMENWGLS
IFVEQRILLDPSVSSISYLLDVTMVIVHEICHQWFGDLVTPVWWEDVWLKEGFAHYFEF
VGTDYLYPGWNMEKQRFLTDVLHEVMLLDGLASSHPVSQEVLQATDIDRVFDWIAYKKG
AALIRMLANFMGHSVFQRGLQDYLTIHKYGNAARNDLWNTLSEALKRNGKYVNIQEVMD
QWTLQMGYPVITILGNTTAENRIIITQQHFIYDISAKTKALKLQNNSYLWQIPLTIVVG
NRSHVSSEAIIWVSNKSEHHRITYLDKGSWLLGNINQTGYFRVNYDLRNWRLLIDQLIR
NHEVLSVSNRAGLIDDAFSLARAGYLPQNIPLEIIRYLSEEKDFLPWHAASRALYPLDK
LLDRMENYNIFNEYILKQVATTYIKLGWPKNNFNGSLVQASYQHEELRREVIMLACSFG
NKHCHQQASTLISDWISSNRNRIPLNVRDIVYCTGVSLLDEDVWEFIWMKFHSTTAVSE
KKILLEALTCSDDRNLLNRLLNLSLNSEVVLDQDAIDVIIHVARNPHGRDLAWKFFRDK
WKILNTRYGEALFMNSKLISGVTEFLNTEGELKELKNFMKNYDGVAAASFSRAVETVEA
NVRWKMLYQDELFQWLGKALRH 
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Appendix XII. List of pOPIN-based constructs and corresponding 
forward and reverse primer extensions for the In-Fusion
TM
 cloning.  
 
Vector PCR insert 
Forward primer 
extension 
Reverse primer 
extension 
pOPINE PcpII/S62-H1024 
AGGAGATATACCA
TG 
GTGATGGTGATGTTT 
pOPINE 
PcpII/L141-
H1024 
AGGAGATATACCA
TG 
GTGATGGTGATGTTT 
pOPINF PcpII 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINF PcpII/S62-H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINF 
PcpII/L141-
H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPING PcpII/S62-H1024 
GCGTAGCTGAAAC
CGGC 
GTGATGGTGATGTTT 
pOPING 
PcpII/L141-
H1024 
GCGTAGCTGAAAC
CGGC 
GTGATGGTGATGTTT 
pOPINH PcpII/S62-H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINH 
PcpII/L141-
H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINI PcpII 
ACCATCACAGCAG
CGGC 
ATGGTCTAGAAAGC 
TTTA 
pOPINTTG PcpII/S62-H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINTTG 
PcpII/L141-
H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINTTGNeo-3C- 
GFP-His 
PcpII/S62-H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINTTGNeo-3C-
Halo7-His 
PcpII/S62-H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINTTGNeo-3C- 
CD4-His 
PcpII/S62-H1024 
GCGAACAGATCGG
TGGT 
ATGGTCTAGAAAGC 
TTTA 
pOPINE-3C-GFP-His PcpII/S62-H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINE-3C-GFP-His 
PcpII/L141-
H1024 
AAGTTCTGTTTCAG
GGCCCG 
ATGGTCTAGAAAGC 
TTTA 
pOPINE-3C-Halo7-
His 
PcpII/S62-H1024 
AGGAGATATACCA
TG 
GTGATGGTGATGTT 
pOPINE-3C-Halo7-
His 
PcpII/L141-
H1024 
AGGAGATATACCA
TG 
GTGATGGTGATGTTT 
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Appendix XIII. A Ramachandran plot of the human PcpII model. 
 
The plot was generated in RAMPAGE Ramachandran Plot server (Lovell et al., 2003). 
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